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Introduction:	   	   Idiopathic	   pulmonary	   fibrosis	   (IPF)	   is	   characterised	   by	   excessive	   deposition	   of	  
extracellular	  matrix	  proteins	  and	  destruction	  of	   the	   lung	  architecture.	  The	  aetiology	  of	   this	  disorder	   is	  
unknown	  and	  few	  effective	  therapies	  are	  available.	  Several	  models	  have	  been	  established	  to	  identify	  key	  
pathological	  cells	  and	  mediators	  that	  may	  be	  important	  in	  IPF,	  however	  these	  models	  lack	  the	  classical	  
histopathological	   features	   seen	   in	   IPF,	   such	   as	   fibrotic	   foci.	   The	   aim	   of	   this	   project	  was	   to	   develop	   a	  
novel	   3-­‐D	   in	   vitro	   assay	   system	   which	   more	   closely	   mimics	   a	   fibrotic	   focus,	   for	   pre-­‐clinical	   drug	  
evaluation.	  
Methods:	   	   Primary	   human	   lung	   fibroblasts	   were	   isolated	   as	   outgrowths	   from	   small	   (<1	   mm3)	   lung	  
explants	  (non-­‐IPF	  and	  IPF	  patients).	  Non-­‐IPF	  (n	  =	  10)	  and	  IPF	  (n	  =	  10)	  fibroblasts	  were	  cultured	  in	  non-­‐
adherent	  96-­‐well	  plates	  to	  generate	  fibroblastic	  spheroids.	  Spheroid	  formation	  and	  phenotypic	  features	  
were	  characterised	  using	  time-­‐lapse	  videomicroscopy,	  histological	  analysis,	  (including	  TUNEL	  assay)	  and,	  
electron	  microscopy.	  RNA	  was	  extracted	  from	  the	  spheroids	  and	  microarray	  analysis	  and	  qRT-­‐PCR	  were	  
used	  to	  analyse	  mRNA	  levels.	  Total	  collagen	  was	  measured	  using	  HPLC	  analysis	  of	  hydroxyproline	  levels	  
while	   active	   TGFβ	   within	   the	   spheroid	   homogenates	   and	   supernatants	   were	   measured	   using	   the	  
transformed	  mink	   lung	   epithelial	   cell	   bioassay.	   A	  medium-­‐throughput	   screen	   of	   potential	   anti-­‐fibrotic	  
compounds	  (using	  a	  focused	  GSK	  compound	  library	  known	  as	  the	  fibrosis	  toolbox)	  was	  also	  performed,	  
using	  hydroxyproline	  levels	  as	  the	  endpoint	  measure.	  
Results:	   	  Non-­‐IPF	  and	   IPF	  fibroblasts	  were	  able	  to	  form	  non-­‐proliferating	  spheroids	  within	  24	  hours	  of	  
incubation,	   with	   clear	   organisation	   and	   orientation	   of	   cells	   within	   the	   spheroid.	   IPF	   spheroids	   had	   a	  
myofibroblastic	   phenotype	   with	   increase	   expression	   of	   αSMA.	   TUNEL	   assay	   identified	   increased	  
numbers	  of	  apoptotic	  cells	   in	  non-­‐IPF	  spheroids	   in	  comparison	  to	   IPF	  spheroids,	  which	  may	  be	  due,	   in	  
part,	   to	   autocrine/paracrine	   COX1-­‐mediated	   PGE2	   generation.	   The	  mink	   lung	   cell	   assay	   demonstrated	  
that	  non-­‐IPF	  and	  IPF	  spheroids	  spontaneously	  produced	  high	  levels	  of	  active	  TGFβ, which	  was	  partially	  
dependent	   on	   β3	   and	   β8	   integrins.	   Antagonising	   TGFβ	   signalling	   did	   not	   however	   affect	   spheroid	  
collagen	   production.	  Microarray	   data	   analysis	   illustrated	   a	   limited	   number	   of	   differentially	   expressed	  
genes,	  with	  the	  majority	  involved	  in	  encoding	  proteins	  that	  play	  a	  key	  role	  in	  metabolic	  pathways.	  The	  
fibrosis	   toolbox	   identified	   potential	   target	   molecules	   that	   impact	   on	   collagen	   biosynthesis	   including	  
EP2/4	   compounds,	   an	   integrin	   αv	   inhibitor,	   Smo	   antagonists,	   MCP-­‐1	   inhibitor,	   and	   mTORC	   1/2	  
inhibitors.	  
Conclusions:	  	  Fibrotic	  fibroblast	  spheroids	  mimic	  some	  of	  the	  key	  characteristics	  of	  fibroblasts	  in	  fibrotic	  
foci	   of	   IPF	   lungs	   (i.e.	   increased	   collagen	   production,	   elevated	   levels	   of	   active	   TGFβ	   and	   resistance	   to	  
apoptosis).	   In	   addition,	   microarray	   and	   medium-­‐throughput	   screening	   identified	   several	   potential	  
targets.	  Therefore,	  fibrotic	  fibroblast	  spheroids	  may	  represent	  a	  novel	  assay	  system	  for	  pre-­‐clinical	  drug	  
evaluation,	  and	  warrant	  further	  investigation.	  	   	  






3-­‐Hyp	   3(S)-­‐hydroxy-­‐L-­‐proline	  
4-­‐Hyp	   4(R)-­‐hydroxy-­‐L-­‐proline	  
5-­‐LOX	   5-­‐lipoxygenase	  
6MWT	   6	  minute	  walk	  test	  
AA	   Arachidonic	  acid	  
ACE	   Angiotensin	  converting	  enzyme	  
AEC	   Alveolar	  epithelial	  cells	  
ALK	   Activin-­‐like	  kinase	  
ANG	   Angiotensin	  
ATI	   Alveolar	  epithelial	  cells	  type	  I	  
ATII	   Alveolar	  epithelial	  cells	  type	  II	  
ATP	   Adenosine	  triphosphate	  
ATS	   American	  Thoracic	  Society	  
αSMA Alpha	  smooth	  muscle	  actin	  
BALF	   Bronchoalveolar	  lavage	  fluid	  
BCA	   Bicinchoninic	  acid	  
BM	   Basement	  membrane	  
BMP	   Bone	  morphogenetic	  protein	  
BSA	   Bovine	  serum	  albumin	  
CAD	   Caspase-­‐activate	  DNase	  
cAMP	   Cyclic	  adenosine	  monophosphate	  
CASP1	   Caspase	  1	  
CCL	   Chemokine	  (C-­‐C	  motif)	  ligand	  
CCR	   Chemokine	  (C-­‐C	  motif)	  ligand	  receptor	  




COMP	   Collagen	  and	  cartilage	  oligomeric	  matrix	  
protein	  
COX	   Cyclooxygenase	  	  
CS	   Citrate	  synthase	  
Ct	   Threshold	  cycle	  
CTGF	   Connective	  tissue	  growth	  factor	  
DAB	   3,3’-­‐diaminobenzdine	  
DAPI	   4’,6-­‐diamidino-­‐2-­‐phenylindole	  
DDR	   Discoidin	  domain	  receptor	  
DLCO	   Diffusing	  capacity	  of	  the	  lung	  for	  carbon	  
monoxide	  
DMEM	   Dulbecco’s	  modified	  eagle’s	  medium	  
DMSO	   Dimtheyl	  sulfoxide	  
DNA	   Deoxyribonucleic	  acid	  
DNMT	   DNA	  methyltransferase	  
DPBS	   Dulbecco’s	  phosphate-­‐buffered	  saline	  
DTT	   Dithiothreitol	  
ECL	   Enhanced	  chemiluminescence	  
ECM	   Extracellular	  matrix	  
EDTA	   Ethylenediaminetetracetic	  acid	  
EIF4A2	   Eukaryotic	  translation	  initiation	  factor	  4A2	  
 
ELISA	   Enzyme-­‐linked	  immunoassay	  
EM	   Electron	  microscopy	  	  
EMT	   Epithelial-­‐mesenchymal	  transition	  
EP	   Prostaglandin	  E	  receptor	  
ER	   Endoplasmic	  reticulum	  
ERK	   Extracellular	  signal-­‐regulated	  kinase	  




ERS	   European	  Respiratory	  Society	  
ET	   Endothelin	  	  
FACIT	   Fibril-­‐associated	  collagens	  with	  interrupted	  
triple	  	  helices	  
FasL	   Fas	  ligand	  
FBS	   Foetal	  bovine	  serum	  
FC	   Fold	  change	  
FDR	   False	  discovery	  rate	  
FGF	   Fibroblast	  growth	  factor	  
FP	   Prostaglandin	  F	  receptor	  
FVC	   Forced	  vital	  capacity	  
GAG	   Glycosaminoglycan	  
GDF	   Growth	  and	  differentiation	  factors	  
GLI	   Glioma-­‐associated	  oncogene	  homolog	  
GPCR	   G-­‐protein	  coupled	  receptor	  
HAT	   Histone	  acetyletransferase	  
HBEC	   Human	  bronchial	  epithelial	  cells	  
HDAC	   Histone	  deacetylase	  
HLF	   Human	  lung	  fibroblast	  
HPLC	   High	  pressure	  liquid	  chromatography	  	  
HRCT	   High	  resolution	  computed	  tomography	  
HSP47	   Heat	  shock	  protein	  47	  
IFN	   Interferon	  
IIP	   Idiopathic	  interstitial	  pneumonia	  
IL	   Interleukin	  
ILD	   Interstitial	  ling	  disease	  
IMPDH2	   Inosine-­‐5’-­‐monophosphate	  2	  




IPF	   Idiopathic	  pulmonary	  fibrosis	  
JAK	   Janus	  kinase	  
JNK	   c-­‐Jun	  amino-­‐terminal	  kinase	  
kDa	   Kilodalton	  
LAP	   Latency-­‐associated	  peptide	  
LLC	   Large	  latency	  complex	  
LOX	   Lysyl	  oxidase	  
LOXL	   Lysy	  oxidase	  like	  protein	  
LTGF	   Latent	  TGFβ	  binding	  protein	  
MACIT	   Membrane-­‐associated	  collagens	  with	  
interrupted	  triple	  helices	  
MAPK	   Mitogen	  activated	  protein	  kinase	  
MCP1	   Monocyte	  chemotactic	  protein	  1	  
MEK	   Mitogen	  activated	  protein	  kinase	  kinase	  
MHC	   Major	  histocompatibility	  complex	  
MIF	   Macrophage	  migration	  inhibitory	  factor	  
MM	   Mismatch	  probe	  
MMP	   Matrix	  metalloproteinases	  	  
MSB	   Martius	  scarlet	  blue	  
MTHFR	   Methylenetetrahydrofolate	  reductase	  
MT-­‐MMP	   Membrane-­‐type	  metalloproteinases	  
mTOR	   Mammalian	  target	  of	  rapamycin	  
mTORC	   Mammalian	  target	  of	  rapamycin	  complex	  
NAC	   N-­‐acetylcysteine	  
NBD-­‐Cl	   4-­‐Chloro-­‐7-­‐nitrobenzofurazan	  	  
NCS	   Neonatal	  calf	  serum	  
NSB	   Non-­‐specific	  binding	  




NSIP	   Non-­‐specific	  interstitial	  pneumonia	  
OD	   Optical	  density	  
P3H	   Prolyl	  3-­‐hydroxylase	  
P4H	   Prolyl	  4-­‐hydroxylase	  
P4HA1	   Prolyl	  4-­‐hydroxylase	  subunit	  alpha	  1	  
PAI	   Plasminogen	  activator	  inhibitor	  
PAR	   Proteinase	  activated	  receptor	  
PBS	   Phosphate	  buffered	  saline	  
PCA	   Principle	  component	  analysis	  
PCP	   Procollagen	  carboxy	  terminal	  proteinase	  
PDE	   Phosphodiesterase	  
PDGF	   Platelet	  derived	  growth	  factor	  
PDI	   Protein	  disulphide	  isomerase	  
PDK1	   Phosphoinositide	  dependent	  protein	  kinase	  1	  
PF	   Pulmonary	  fibrosis	  
PFA	   Paraformaldehyde	  	  
PG	   Prostaglandin	  
PGE2	   Prostaglandin	  E2	  
PGES	   Prostglandin	  E2	  synthase	  
pHLF-­‐Di	   Primary	  human	  lung	  fibroblasts	  isolated	  from	  
digested	  lungs	  
pHLF-­‐Ex	   Primary	  human	  lung	  fibroblasts	  isolated	  from	  
lung	  explants	  
PI3K	   Phosphatidylinositol-­‐3	  kinase	  
PICP	   Procollagen	  type	  I	  carboxy-­‐terminal	  pro-­‐
peptide	  
PIIICP	   Procollagen	  type	  III	  carboxy-­‐terminal	  pro-­‐
peptide	  




PIP2	   Phosphatidylinositol	  4,5-­‐bisphosphate	  
PIP3	   Phosphatidylinositol	  3,4,5-­‐trisphosphate	  
PKB	   Protein	  kinase	  B	  
PLA2	   Prospholipase	  A2	  
PM	   Perfect	  match	  probe	  
PTEN	   Phosphatase	  and	  tensin	  homolog	  
QC	   Quality	  control	  
qRT-­‐PCR	   Real	  time	  quantitative	  reverse	  transcription	  
polymerase	  chain	  reaction	  
RAPTOR	   Regulatory-­‐associated	  protein	  of	  mTOR	  
RAS	   Renin-­‐angiotensin	  system	  
RGD	   Arg-­‐Gly-­‐Asp	  sequence	  
RICTOR	   Rapamycin-­‐insensitive	  companion	  of	  mTOR	  
RIN	   RNA	  integrity	  number	  
RMA	   Robust	  multi-­‐array	  average	  
RNA	   Ribonucleic	  acid	  
RTK	   Receptor	  tyrosine	  kinase	  
RT-­‐PCR	   Reverse	  transcription	  polymerase	  chain	  
reaction	  
ROS	   Reactive	  oxygen	  species	  
SDS-­‐PAGE	   Sodium	  dodecyl	  sulphate	  polyacrylamide	  gel	  
electrophoresis	  
SEM	   Scanning	  electron	  microscopy	  
SFTA2	   Surfactant	  protein	  A2	  
Shh	   Sonic	  hedgehog	  
SLC	   Small	  latency	  complex	  
Smo	   Smoothelin	  
SPTLC2	   Serine	  palmitoyltransferase	  




SYNJ2	   Synaptojanin	  2	  
TβR	   TGF-­‐beta	  receptor	  
TBS	   Tris-­‐buffered	  saline	  
TBST	   Tris-­‐buffered	  saline	  tween	  
TdT	   Terminal	  deoxynucleotidyl	  transferase	  
TEM	   Transmission	  electron	  microscopy	  
TGFβ	   Transforming	  growth	  factor	  beta	  
TIMP	   Tissue	  inhibitors	  of	  metalloproteinase	  
TLC	   Total	  lung	  capacity	  
TMLEC	   Transformed	  mink	  lung	  epithelial	  cell	  
TNF-­‐α	   Tumour	  necrosis	  factor	  alpha	  
TOP1	   Topoisomerase	  1	  
tPA	   Tissue	  plasminogen	  activator	  
TSP-­‐1	   Thrombospondin-­‐1	  
TUNEL	   Terminal	  deoxynucleotidyl	  transferase	  dUTP	  
nick	  ended	  labelling	  
UIP	   Usual	  interstitial	  pneumonia	  
uPA	   Urokinase	  plasminogen	  activator	  
UPR	   Unfolded	  protein	  response	  
UBC	   Ubiquitin	  C	  
VEGF	   Vascular	  endothelial	  growth	  factor	  
XDH	   Xanthine	  dehydrogenase	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Figure	  1.	  1:	  Basic	  schematic	  of	  human	  lung	  structure.	  
	  
	  
1.1.	   Anatomy	  and	  Physiology	  of	  Normal	  Lungs	  
	  
1.1.1.	   Lung	  structure	  and	  function	  
Lungs	  are	  the	  sole	  respiratory	  organs	  found	  in	  mammals	  and	  their	  principal	  function	  involves	  
the	  transport	  of	  atmospheric	  oxygen	  into	  the	  bloodstream	  and	  removal	  of	  carbon	  dioxide	  via	  
diffusion.	  The	  basic	  structure	  of	  the	  lung	  is	  shown	  in	  Figure	  1.1,	  illustrating	  a	  branching	  system	  
composed	  of	  the	  trachea,	  bronchi,	  bronchioles,	  and	  alveoli.	  However,	  several	  cells	  play	  critical	  
roles	   in	   maintaining	   its	   structure	   and	   function	   including	   epithelial	   cells,	   endothelial	   cells,	  
smooth	  muscle	  cells,	  stem	  and	  progenitor	  cells,	  macrophages,	  and	  fibroblasts.	  Thus	  lungs	  are	  





















Reproduced	  from	  (Winslow,	  2006)	  with	  the	  permission	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  Winslow,	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  National	  Cancer	  
Institute	  ©	  2006.	  
	  
Gas	   exchange	   takes	   place	   at	   the	   alveoli.	   Each	   alveolus	   is	   approximately	   200µm	   in	   diameter,	  
composed	   of	   a	   simple	   epithelium	   which	   is	   surrounded	   by	   a	   network	   of	   capillaries.	   To	  
appreciate	   the	   efficiency	   of	   the	   gas	   exchange	   it	   is	   important	   to	   note	   that	   respiratory	   gases	  
need	  to	  pass	  through	  the	  microvascular	  endothelium	  (0.04-­‐0.2µm),	  interstitial	  space	  (0.02-­‐0.2	  




µm),	  alveolar	  epithelium	   (0.05-­‐0.3	  µm),	  and	   the	  surface	   lining	  of	   surfactant	   (0.01	  µm).	  Thus,	  
the	   total	  distance	  between	   the	  airspace	  and	   the	  microvasculature	   is	   approximately	  between	  
0.2	  and	  0.6	  µm	  (Adds	  et	  al.,	  2001).	  Epithelial	  and	  endothelial	  cells	  share	  the	  same	  basement	  
membrane	  and	  together	  they	  form	  a	  total	  gas	  exchange	  surface	  of	  ~70	  m2	  (Selman	  and	  Pardo,	  
2006).	  	  	  
Since	  there	  is	  a	  direct	  contact	  between	  the	  lungs	  and	  the	  external	  environment,	  the	  lungs	  are	  
constantly	   exposed	   to	   several	   noxious	   substances	   such	   as	   pollutants,	   microorganisms,	  
cigarette	   smoke,	  and	  dust.	   Thus,	   it	   is	   vital	   that	   the	   structure	  and	  defence	  mechanism	  of	   the	  
lungs	   remain	   robust	   enough	   to	   withstand	   the	   effects	   of	   such	   contaminants	   in	   order	   to	  
maintain	   its	   respiratory	   function.	   Any	   alterations	   in	   the	   lung	   architecture,	   such	   as	   excessive	  
deposition	  of	  extracellular	  matrix	  (ECM)	  in	  the	  pulmonary	  interstitium,	  can	  reduce	  the	  efficacy	  
of	  gas	  exchange	  (Laurent	  and	  Shapiro,	  2006)	  leading	  to	  severe	  pathological	  conditions	  such	  as	  
pulmonary	  fibrosis	  (PF;	  discussed	  in	  detail	  in	  Section	  1.2).	  	  	  
1.1.2.	   Normal	  pulmonary	  extracellular	  matrix	  
ECM	   encompasses	   components	   of	   the	   interstitial	   connective	   tissue	   and	   the	   basement	  
membrane	  (Dunsmore	  and	  Rannels,	  1996)	  which	  play	  a	  key	  role	  in	  the	  physical	  and	  mechanical	  
properties	  of	  all	  organs	   including	  the	   lungs.	  The	  tensile	  strength	   in	  the	   large	  airways	  and	  the	  
trachea	   is	   achieved	   by	   the	   cartilage	  which	   is	   composed	   of	   collagen	   and	   cartilage	   oligomeric	  
matrix	   protein	   (COMP)	   (Vuga	   et	   al.,	   2013).	   Furthermore,	   the	   basement	   membrane	   in	   the	  
airways	   (located	   beneath	   the	   alveolar	   epithelial	   layer)	   consists	   of	   several	   ECM	   proteins	  
including	   collagen	   type	   IV,	   laminin,	   fibronectin,	   and	   entactin	   all	   of	   which	   are	   involved	   in	  
regulating	  the	  diffusion	  of	  gases	  across	  the	  epithelial	   layer.	  Moreover,	  ECM	  in	  the	  pulmonary	  
interstitium	  (predominately	  composed	  of	   fibrillar	  collagens,	  elastic	   fibres,	  and	  proteoglycans)	  
acts	  as	  a	  spatiotemporal	  natural	  scaffold	  which	   is	  able	   to	  modulate	  several	  cellular	   functions	  
including	   cell	   migration,	   proliferation,	   and	   differentiation	   (Dunsmore	   and	   Rannels,	   1996;	  
Mammoto	  et	  al.,	  2013).	  Thus,	  ECM	  proteins	  play	  essential	  roles	   in	  normal	   lung	  structure	  and	  
function.	  Although	  there	  are	  several	  ECM	  components	  in	  the	  lung	  this	  thesis	  will	  mainly	  focus	  
on	   the	  most	   abundant	   ECM	   constituent,	   collagen,	   and	   its	   effects	   on	   pathological	   conditions	  
(i.e.	  idiopathic	  pulmonary	  fibrosis,	  IPF,	  discussed	  in	  detail	  in	  Section	  1.2.1).	  
	  
	  




1.1.3.	   Collagens,	  the	  most	  abundant	  ECM	  proteins	  
Structure	  and	  collagen	  types	  
Collagens	  are	  characterised	  by	  a	  unique	  triple	  helical	  structure	  composed	  of	  three	  alpha	  chains	  
each	  containing	  domains	  with	  repeats	  of	  an	  amino	  acid	  sequence,	  Gly-­‐X-­‐Y,	  where	  positions	  X	  
and	  Y	  are	  usually	  composed	  of	   lysine	  and	  L-­‐proline	  residues	  of	  which	  some	  are	  hydroxylated	  
during	   posttranslational	   processes	   (Schegg	   et	   al.,	   2009).	   Maintenance	   of	   this	   triple	   helical	  
structure	  is	  vital	  for	  several	  biological	  functions	  including	  adhesion,	  collagen-­‐mediated	  cellular	  
and/or	   enzymatic	   function,	   and	   ECM	   assembly	   (Travis	   et	   al.,	   2013).	   Currently	   28	   types	   of	  
collagens	  have	  been	   identified	   (Table	   1.1)	  which	   are	   encoded	  by	   at	   least	   44	  different	   genes	  
(Schegg	   et	   al.,	   2009),	   giving	   each	   type	   a	   distinctive	   amino	   acid	   sequence	   and	   molecular	  
structure.	   Collagen	   types	   can	   be	   categorised	   into	   two	   groups	   based	   on	   their	   biochemical	  
properties:	   neutral-­‐salt	   soluble	   collagen	   (composed	   of	   immature	   precursor	   with	   very	   few	  
crosslinks)	  and	  acid–soluble	  collagen	  (composed	  of	  mature	  fibres	  with	  several	  intra-­‐molecular	  
crosslinks).	   Approximately,	   1-­‐5	   %	   of	   adult	   lung	   collagen	   is	   considered	   to	   be	   neutral	   salt	  
collagen	  (Last	  and	  Reiser,	  1984;	  Kliment	  et	  al.,	  2011).	  Thus,	  in	  order	  to	  determine	  the	  majority	  
of	  collagen	  content	  in	  the	  lung	  a	  harsh	  technique	  (e.g.	  acid	  hydrolysis)	  is	  required.	  In	  our	  lab,	  
this	  is	  done	  by	  incubating	  tissues/cells	  at	  110	  oC	  overnight	  in	  6	  M	  hydrochloric	  acid	  (HCl;	  details	  
of	  this	  method	  are	  described	  later	  in	  Section	  2.12).	  	  
Nevertheless,	   collagens	   may	   also	   be	   categorised	   into	   seven	   groups	   based	   on	   their	   domain	  
structure:	   fibrillar	   collagen	   (main	   structural	   components	  of	   connective	   tissues),	  FACITs	   (fibril-­‐
associated	   collagens	   with	   interrupted	   triple	   helices),	   network-­‐forming	   collagens,	  
transmembrane	   collagens	   also	   known	   as	   MACITs	   (membrane-­‐associated	   collagens	   with	  
interrupted	   triple	   helices),	   MULTIPLEXINs	   (multiple	   triple-­‐helix	   domains	   and	   interruptions),	  
anchoring	  fibrils,	  and	  beaded-­‐filament	  forming	  collagens	  (Figure	  1.2;	  Table	  1.1).	  Approximately	  
90	  %	  of	  the	  collagens	  in	  the	  human	  body	  are	  fibrillar	  collagen	  types	  I,	   II,	  and	  III	  (Lodish	  et	  al.,	  
2000),	  and	  more	  than	  95	  %	  of	  the	  total	  lung	  parenchymal	  collagen	  is	  type	  I	  and	  III	  with	  a	  ratio	  
of	   2:1	   (Last	   and	  Reiser,	   1984).	   These	   are	   synthesised	  by	   fibroblasts	   and	  distributed	   in	   blood	  
vessels,	  the	  tracheobronchial	  tree,	  and	  alveolar	  interstitium.	  The	  amount	  of	  collagen	  deposited	  
by	   fibroblasts	   in	   the	   lung	   is	   regulated	   by	   a	   carefully	   controlled	   process	   which	   affects	   the	  
balance	   between	   collagen	   synthesis	   and	   degradation.	   During	   a	   pathological	  maturation	   and	  
remodelling	   phase	   the	   process	   of	   collagen	   synthesised	   is	   greater	   in	   comparison	   to	   its	  
degradation	  causing	  an	  elevation	  in	  the	  net	  collagen	  level.	  





Figure	  1.	  2:	  Collagen	  types	  based	  on	  domain	  structure.	  
	  	  
Collagens	   are	   categorised	   into	   seven	   groups	   based	   on	   their	   domain	   structures.	   1)	  
Fibril-­‐forming	  collagens	  are	   initially	  synthesised	  as	  procollagens	  which	  contain	  C-­‐	  and	  
N-­‐terminal	   propeptides	   which	   are	   eventually	   cleaved	   off;	   2)	   FACIT	   (fibril-­‐associated	  
collagens	   with	   interrupted	   triple);	   3)	   Network-­‐forming	   collagens	   which	   form	   an	  
interlaced	  network	  in	  the	  basement	  membrane;	  4)	  MACIT	  (transmembrane-­‐associated	  
collagens	  with	  interrupted	  triple	  helices)	  which	  are	  also	  referred	  to	  as	  transmembrane	  
collagens	  composed	  of	  long	  interrupted	  triple	  helical	  extracellular	  domains	  and	  a	  short	  
cytosolic	   N-­‐terminal	   domain;	   5)	   Multiplexins,	   also	   known	   as	   endostatin	   producing	  
collagens;	   6)	   Anchoring	   fibrils,	   which	   contain	   collagen	   VII	   as	   a	  major	   component;	   7)	  
Beaded-­‐filament-­‐forming	  collagens.	  NC1	   refers	   to	  a	  non-­‐collagenous	  domain	  1	  which	  
does	  not	  contain	  the	  original	  triple	  helical	  structure.	  
	  





























Table	  1.	  1:	  Collagen	  types	  and	  distributions	  
	  
	   Class	   Molecular	  Composition	   Distribution	  
I	   Fibrillar	   [α1(I)]2,	  [α2(I)]	   Abundant;	  widespread	  in	  connective	  
tissues	  
II	   Fibrillar	   [α1(II)]3	   Cartilage,	  vitreous	  humor	  
III	   Fibrillar	   [α1(III)]3	   Skin,	  muscle,	  blood	  vessels	  
IV	   Network	   [α1(IV)]2,	  [α2(IV)]	   Basement	  membrane	  
	  




[α1(VI)],	  [α2(VI)],	  [α3(VI)]	   Widespread,	  especially	  muscles	  
VII	   Anchoring	  
fibrils	  
[α1(VII)]2,	  [α2(VII)]	   Basement	  membrane	  
VIII	   Network	   [α1(VIII)]3	   Descement’s	  membrane	  
IX	   FACIT	   [α1(IX)],	  [α2(IX)],	  [α3(IX)]	   Co-­‐distributes	  with	  collagen	  II	  
X	   Network	   [α1(X)]3	   Hypertrophic	  cartilage	  
XI	   Fibrillar	   [α1(XI)],	  [α2(XI)],	  [α3(XI)]	   Co-­‐distributes	  with	  collagen	  II	  
XII	   FACIT	   [α1(XII)]3	   Found	  with	  collagen	  I	  
XIII	   MACIT	   -­‐	   Neuromuscular	  junctions,	  skin	  
XIV	   FACIT	   [α1{XIV)]3	   Found	  with	  collagen	  I	  
XV	   MULTIPLEXIN	   -­‐	   Located	  between	  collagen	  fibrils	  close	  to	  
the	  basement	  membrane;	  eyes,	  muscles.	  
XVI	   FACIT	   -­‐	   Integrated	  into	  collagen	  fibrils	  
XVII	   MACIT	   [α1(XVII)]3	   Localised	  to	  epithelia	  
XVIII	   MULTIPLEXIN	   -­‐	   Associated	  with	  basement	  membranes	  
XIX	   FACIT	   -­‐	   Rare;	  localised	  to	  basement	  membrane	  
zones;	  
XX	   FACIT	   -­‐	   Widespread	  distribution	  
XXI	   FACIT	   -­‐	   Widespread	  distribution	  
XXII	   FACIT	   -­‐	   Localised	  at	  tissue	  junctions	  
XXIII	   MACIT	   -­‐	   Limited	  tissue	  distribution;	  exists	  as	  a	  
transmembrane	  and	  shed	  form	  
XXIV	   Fibrillar	   -­‐	   Selective	  expression	  in	  developing	  cornea	  
and	  bones	  
XXV	   MACIT	   -­‐	   Precursor	  protein	  for	  CLAC	  
XXVI	   FACIT	   -­‐	   -­‐	  
XXVII	   Fibrillar	   -­‐	   Embryonic	  cartilage,	  developing	  dermis,	  
cornea,	  retina,	  arteries;	  restricted	  to	  
cartilage	  found	  in	  adults	  
XXVIII	   -­‐	   -­‐	   Basement	  membrane	  around	  Schwann	  cells	  
	  




	   	  





The	   biosynthetic	   pathway	   for	   collagen	   type	   I	   has	   been	  most	   intensively	   studied.	   Figure	   1.3	  
illustrates	   a	   simplified	   schematic	   for	   collagen	   synthesis.	   Following	   transcription	   and	  
translation,	   precursor	   collagen	   chains	   known	   as	   nascent	   procollagens	   are	   synthesised	   in	   the	  
endoplasmic	  reticulum	  (ER).	  These	  chains	  then	  undergo	  several	  posttranslational	  modifications	  
including	   hydroxylation	   of	   L-­‐proline	   (Mizuno	   et	   al.,	   2003)	   and	   lysine	   residues	   (Risteli	   et	   al.,	  
2004).	   Two	   enzymes	   play	   a	   vital	   role	   in	   this	   process.	   These	   are	   prolyl	   4-­‐hydroxylase	   (P4H)	  
(Kukkola	   et	   al.,	   2003)	   and	   prolyl	   3-­‐hydroxylase	   (P3H)	   (Vranka	   et	   al.,	   2004)	  which	   require	   an	  
essential	   co-­‐factor	   (ascorbic	   acid,	   vitamin	   C)	   to	   result	   in	   the	   formation	   of	   4(R)-­‐hydroxy-­‐L-­‐
proline	  (4-­‐Hyp)	  and	  3(S)-­‐hydroxy-­‐L-­‐proline	  (3-­‐Hyp),	  respectively.	  4-­‐Hyp	  is	  the	  main	  component	  
of	  all	  collagen	  types,	  comprising	  around	  13.5	  %	  of	  its	  amino	  acid	  composition;	  thus	  the	  amount	  
of	  4-­‐Hyp	  is	  used	  as	  a	  measure	  of	  total	  collagen	  content	  in	  tissue	  samples	  (Kliment	  et	  al.,	  2011).	  
Hydroxylation	   of	   lysine	   residues	   occurs	   via	   the	   activity	   of	   lysyl	   hydroxylases.	   Both	  
hydroxyproline	  and	  hydroxylysine	  contribute	  to	  the	  stability	  of	  the	  triple	  helix	  structure	  where	  
hydroxylysine	  is	  vital	  for	  cross-­‐linking	  of	  collagen	  molecules	  (Reiser	  et	  al.,	  1992).	  	  
Further	  modifications	  to	  the	  procollagen	  chains	  include	  glycosylation	  of	  hydroxylysine	  residues	  
which	   involves	   the	   addition	   of	   the	   monosaccharide	   Gal(β1-­‐O)	   or	   the	   disaccharide	   Glc(α1-­‐
2)Gal(β1-­‐O)	   via	   the	   activity	   of	   galactosyltransferase	   and	   glucosyltransferase	   (Spiro,	   1969).	  
Some	  studies	  have	  demonstrated	  that	  lysyl	  hydroxylase	  3	  may	  also	  catalyse	  a	  modest	  glucosyl	  
and	  galactosyltransferase	  activity,	  supporting	  that	  this	  enzyme	  is	  multifunctional	  (Heikkinen	  et	  
al.,	  2000).	  In	  addition,	  oligosaccharide	  chains	  are	  added	  to	  certain	  asparagine	  residues	  in	  the	  C-­‐
terminal	  propeptide	  (segment	  located	  at	  the	  C-­‐terminus	  of	  the	  procollagen).	  
Several	  folding	  proteins	  and/or	  chaperones	  in	  the	  ER	  also	  play	  a	  role	  in	  collagen	  synthesis.	  For	  
example,	  protein	  disulphide	  isomerase	  (PDI)	  associates	  with	  the	  C-­‐propeptides	  on	  procollagen	  
and	  catalyses	   the	   formation	  of	  disulphide	  bonds	  which	  proceed	   towards	   the	  N-­‐terminus	  and	  
facilitates	  trimer	  formation	  (Wilson	  et	  al.,	  1998).	  PDI	  is	  considered	  as	  a	  multifactorial	  protein	  as	  
it	   not	   only	   catalyses	   the	   formation	   of	   disulphide	   bonds	   but	   also	   acts	   as	   a	   subunit	   for	   P4H	  
during	  proline	  hydroxylation,	  and	  behaves	  as	  a	  molecular	  chaperone	  during	  procollagen	  chain	  
assembly	  (Wilson	  et	  al.,	  1998).	  Another	  protein	  chaperone	  essential	  for	  correct	  folding	  of	  the	  
triple	  helix	  is	  heat	  shock	  protein	  (HSP)-­‐47	  (Nagata,	  1996;	  Lamande	  and	  Bateman,	  1999;	  Sauk	  et	  
al.,	  2005;	  Taguchi	  and	  Razzaque,	  2007).	  	  
	  





Figure	  1.	  3:	  Collagen	  synthesis.	  
Collagen	   genes	   are	   transcribed	   and	   mRNA	   is	   transported	   from	   the	   nucleus	   to	   the	  
ribosomes	  of	  the	  rough	  endoplasmic	  reticulum.	  2)	  Procollagen	  chains	  are	  synthesised.	  
3)	  Procollagen	  chains	  undergo	  posttranslational	  modifications	  including	  hydroxylation,	  
glycosylation,	   and	   disulphide	   bond	   formation.	   4)	   Heat	   shock	   protein	   47	   (HSP47)	  
chaperone	  associates	  with	   the	  chains	  to	  allow	   correct	   folding	  of	   the	   triple	  helix	   (pink	  
crescent	  symbol).	  5)	  Procollagen	  secreted	  into	  the	  extracellular	  matix	  (ECM).	  C-­‐	  and	  N-­‐
propeptidases	   cleave	   the	   C-­‐	   and	   N-­‐terminals	   of	   the	   procollagen	   chains.	   6)	   Lysyl	  
oxidases	   (LOX)	   catalyse	   the	   formation	   of	   crosslinks	   between	   collagen	   molecules.	   7)	  
Matrix	   metalloproteinases	   (MMPs)	   promote	   the	   degradation	   of	   collagen	   (orange	  
Pacman	  symbol).	  	  
	  
Obtained	  from	  an	  Open	  Access	  article	  (Chen	  and	  Raghunath,	  2009)	  distributed	  under	  the	  terms	  









































	   	  




Following	   posttranslational	   modifications	   in	   the	   ER	   and	   Golgi	   apparatus,	   the	   triple	   helix	  
procollagen	  is	  secreted	  into	  the	  extracellular	  space,	  whereby	  proteolytic	  enzymes	  cleave	  the	  C-­‐	  
and	   N-­‐terminal	   propeptides	   resulting	   in	   the	   formation	   of	   collagen	   (also	   referred	   to	   as	  
tropocollagen).	   This	   cleavage	   allows	   the	   collagen	  molecules	   to	   polymerise	   into	   fibrils	   in	   the	  
ECM.	   Furthermore,	   lysyl	   oxidases	   (LOX;	   copper	   dependent	   enzyme)	   in	   the	   ECM	   catalyse	   the	  
formation	  of	   reactive	  aldehydes,	   spontaneously	   forming	   crosslinks	  between	   the	   triple-­‐helical	  
collagen	  molecules	   and	   stabilises	   the	   collagen	   fibrils	   (Lodish	   et	   al.,	   2000;	  Maki	   et	   al.,	   2005).	  
Currently,	  five	  LOX	  enzymes	  have	  been	  identified	  of	  which	  LOXL2	  has	  shown	  to	  be	  associated	  
with	  lung	  fibrosis	  (Barry-­‐Hamilton	  et	  al.,	  2010).	  
Signal	  transduction	  processes	  in	  the	  pulmonary	  ECM	  
The	   pulmonary	   ECM	   is	   able	   to	   interact	   dynamically	   with	   its	   surrounding	   cells,	   activating	   a	  
variety	   of	   signalling	   pathways	   which	   influence	   cell	   morphology	   and	   behaviour	   (e.g.	  
proliferation,	   migration,	   differentiation,	   and	   adhesion).	   In	   addition,	   the	   intracellular	  
cytoskeleton	  may	   exert	   forces	  which	   affect	   the	   orientation	   of	  matrix	  macromolecules.	   Thus,	  
the	   communication	   between	   cells	   and	   ECM	   is	   bi-­‐directional	   which	   is	   essential	   for	   several	  
biological	  processes,	  epitomised	  by	  efficient	  gaseous	  exchange.	  This	  bi-­‐directional	  signalling	  is	  
regulated	  via	  the	  activation	  of	  transmembrane	  linker	  cell	  surface	  receptors	  known	  as	  integrins.	  
These	  are	  able	  to	  associate	  with	  most	  ECM	  proteins	  as	  well	  as	  mediate	  cell-­‐to-­‐cell	  interaction.	  	  
Structurally,	  integrins	  are	  composed	  of	  noncovalently-­‐associated	  alpha	  and	  beta	  subunits.	  The	  
molecular	   interactions	   between	   integrin	   receptors	   and	   their	   respective	   ligands	   involves	   the	  
recognition	  of	  the	  Arg-­‐Gly-­‐Asp	  (RGD)	  sequence,	  which	  is	  known	  to	  be	  present	  in	  several	  ECM	  
components	   including	   collagen,	   fibronectin,	   fibrinogen,	   and	   vitronectin.	   Integrins	   αvβ3	   and	  
αvβ5	  are	  receptors	  for	  vitronectin	  (Horton,	  1997),	  thrombin,	  fibronectin,	  thrombospondin,	  and	  
fibrinogen.	   Furthermore,	   within	   the	   integrin	   family	   four	   collagen	   receptors	   have	   been	  
identified	   of	   which	   α1β1	   and	   α2β1	   integrins	   have	   been	   most	   intensively	   studied.	   These	  
integrins	  are	  expressed	  on	  cardiac,	  dermal,	  and	  lung	  fibroblasts	  (Gullberg	  et	  al.,	  1992;	  Caniggia	  
et	  al.,	  1995;	  Eckes	  et	  al.,	  2006;	  McCall-­‐Culbreath	  and	  Zutter,	  2008).	  Furthermore	  studies	  have	  
shown	   that	   during	   collagen	   matrix	   contraction,	   β1	   integrins	   mediate	   lung	   fibroblast	   cell	  
survival	   via	   the	   phosphatidylinositol-­‐3-­‐Kinase/Akt/protein	   kinase	   B	   (PI3K/Akt/PKB)	   signalling	  
pathway	   (Tian	   et	   al.,	   2002).	   As	   well	   as	   direct	   interaction	   with	   ECM	   protein,	   integrins	   also	  
interact	  with	  profibrotic	  cytokines	  (i.e.	  transforming	  growth	  factor	  beta,	  TGFβ)	  resulting	  in	  the	  
activation	  of	  downstream	  signalling	  pathways	  which	  in	  turn	  lead	  to	  further	  production	  of	  ECM	  
proteins	   and	  ECM	   remodelling.	   The	   importance	  of	   abnormal	   integrin	   signalling	   and	  elevated	  




TGFβ	  levels	  has	  been	  implicated	  in	  several	  pathological	  conditions	  including	  fibrosis,	  which	  will	  
be	  discussed	  in	  greater	  detail	  in	  later	  sections. 
As	  well	  as	  integrins,	  studies	  have	  demonstrated	  three	  other	  receptors	  which	  directly	  associate	  
with	  collagen	  molecules.	  These	  are	  discoidin	  domain	  receptors	  (DDRs),	  glycoprotein	  VI	  (GPVI;	  
an	  activating	  receptor	  on	  platelets),	  and	   leukocyte-­‐associated	   immunoglobulin-­‐like	  receptor	   I	  
(LAIR-­‐1;	   an	   inhibitory	   receptor	   located	   on	   immune	   cells).	   DDRs	   are	   a	   unique	   subfamily	   of	  
receptor	   tyrosine	   kinases	   (RTKs).	   Unlike	   most	   RTKs,	   DDRs	   are	   activated	   by	  mature	   collagen	  
containing	   a	   specific	   DDR	   binding	   site	   (GVMGFO motif) (Carafoli and Hohenester, 2013).	  	  
Extracellular	  domains	  of	  DDRs	  mediate	  binding	  of	  this	  receptor	  to	  the	  GVMGFO	  motif.	  These	  
domains	   include	   an	   N-­‐terminal	   discoidin	   (DS)	   domain,	   a	   DS-­‐like	   domain	   and	   a	   short	  
juxtamembrane	  (JM)	  region	  (Leitinger,	  2003;	   Ichikawa	  et	  al.,	  2007;	  Carafoli	  et	  al.,	  2009).	  Two	  
DDRs	   have	   been	   identified:	   DDR1	   and	  DDR2.	  DDR1	   is	   primarily	   located	   on	   epithelial	   cells	   of	  
most	   tissues	   (including	   lungs,	   kidneys,	   gastrointestinal	   tract,	   and	   mammary	   glands)	   and	  
activated	   by	   collagen	   types	   I,	   VI,	   and	   VIII.	   On	   the	   other	   hand	   DDR2	   is	   expressed	   in	  
mesenchymal	   cells	   (such	   as	   smooth	   muscle	   cells	   and	   fibroblasts)	   and	   activated	   by	   collagen	  
types	  I	  and	  III	  (Shrivastava	  et	  al.,	  1997;	  Vogel	  et	  al.,	  1997;	  Ruiz	  and	  Jarai,	  2011).	  	  Nevertheless,	  
recent	   studies	   have	   demonstrated	   that	   the	   expression	   of	   DDR1	   increases	   on	   the	   surface	   of	  
human	   lung	   fibroblasts	   following	   collagen	   I-­‐induced	   DDR2	   activation	   via	   a	   JAK/ERK1/2-­‐
mediated	   mechanism	   As	   well	   as	   increasing	   receptor	   expression,	   DDRs	   are	   able	   to	   activate	  
several	   downstream	   signalling	   molecules	   including	   Shp-­‐2,	   Src,	   MAPK,	   and	   NF-­‐kB	  
pathways	  (Leitinger,	   2011;	   Ruiz	   and	   Jarai,	   2011)	   in	   order	   to	   regulate	  matrix	   remodelling	   (via	  
matrix	   metalloproteinases;	   MMPs),	   cell	   adhesion,	   migration,	   and	   proliferation	   (Vogel	   et	   al.,	  
1997).	  
ECM	  degradation	  –	  role	  of	  matrix	  metalloproteinases	  
Degradation	   of	   pulmonary	   ECM	  proteins	   is	   primarily	  mediated	   by	  matrix	  metalloproteinases	  
(MMPs)	   with	   some	   contributions	   from	   serine	   proteinases	   including	   tissue	   plasminogen	  
activator	   (tPA),	   urokinase	   plasminogen	   activator	   (uPA),	   and	   plasmin	   (Mutsaers	   et	   al.,	   1997).	  
MMPs	   are	   a	   family	   of	   24	   secreted	   and	  membrane-­‐bound	   proteinases	   in	   humans	   which	   are	  
synthesised	  by	   several	   cells	   in	   the	   lungs	   including	   fibroblasts,	  myofibroblasts,	  epithelial	   cells,	  
and	  macrophages.	  	  They	  are	  zinc-­‐dependent	  endopeptidases	  which	  are	  secreted	  as	  zymogens	  
(inactive	  enzyme	  precursors)	  and	  require	  cleavage	  in	  order	  to	  become	  activated	  (Greenlee	  et	  
al.,	   2007).	   The	   activity	   of	   these	   degrading	   proteins	   is	   dependent	   on	   numerous	   mediators	  
including	   cytokines,	   proteases,	   growth	   factors,	   mechanical	   forces,	   and	   lipid	   mediators.	  




Furthermore,	  MMP	  activity	  is	  also	  regulated	  by	  tissue	  inhibitors	  of	  metalloproteinases	  (TIMPs).	  
Thus,	  the	  balance	  between	  MMPs	  and	  TIMPs	  play	  a	  critical	  role	  in	  ECM	  remodelling.	  As	  well	  as	  
degrading	  ECM	  components,	  MMPs	  have	  also	  been	  recognised	  to	  alter	  cell-­‐cell	  and	  cell-­‐matrix	  
interactions	  ultimately	  making	   cell	   receptors	   available	   to	   growth	   factors	  bound	   to	   ECM	   (e.g.	  
TGFβ).	   The	  balance	  between	  collagen	  production	  and	  degradation	   in	  pathological	   conditions	  
(i.e.	  idiopathic	  pulmonary	  fibrosis)	  will	  be	  discussed	  below.	  
	  
1.2.	   Pulmonary	  Fibrosis	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
Wound	   healing	   is	   an	   absolutely	   critical	   biological	   process	   involved	   in	   direct	   replacement	   of	  
damaged	  or	  dead	  cells	  with	  connective	  tissue,	  following	  injury.	  The	  end	  result	  of	  this	  process	  
involves	  the	  formation	  of	  a	  scar.	  Scars	  have	  many	  useful	  purposes	  including	  the	  reinforcement	  
of	   the	   initial	   clot	   formation	   to	   prevent	   blood	   loss	   at	   the	   site	   of	   injury,	   creating	   a	   barrier	   to	  
prevent	   pathogen	   invasion,	   and	   providing	   a	   provisional	   matrix	   for	   subsequent	  
reepithelialisation	   (Hecker	   and	   Thannickal,	   2011).	   However,	   abnormalities	   in	   the	   wound	  
healing	  process	  can	  lead	  to	  fibrosis	  affecting	  the	  overall	  function	  of	  the	  organ.	  Fibrosis	  typically	  
results	   from	   conditions	   persisting	   for	   several	   weeks,	   months,	   or	   years	   in	   which	   tissue	  
destruction	   and	   repair	   occur	   simultaneously	   leading	   to	   excessive	   connective	   tissue	   deposits.	  
Fibrosis	  can	  occur	  in	  virtually	  any	  tissue	  or	  organ	  in	  the	  body	  including	  lungs,	  liver,	  kidney,	  and	  
skin.	  
Pulmonary	  fibrosis	  (PF)	  is	  the	  end	  stage	  of	  a	  heterogeneous	  group	  of	  lung	  disorders,	  known	  as	  
interstitial	   lung	   diseases	   (ILDs)	   which	   are	   characterised	   by	   fibroblast	   proliferation	   and	  
excessive	  deposition	  of	  extracellular	  matrix	  (ECM)	  proteins	  within	  the	  pulmonary	  interstitium.	  
There	   are	   around	   200	   lung	   diseases	  within	   this	   group,	   all	   of	  which	   share	   features	   of	   clinical	  
presentation,	   however	   the	   pathological	   features	   and	   aetiology	   of	   each	   disease	   are	   different	  
making	  them	  independent	  from	  one	  another	  (Sureshbabu	  et	  al.,	  2011).	  	  
Several	   ILDs	   have	   causes	   which	   have	   been	   well	   characterised,	   including	   environmental	  
exposures	   (e.g.	   asbestosis),	   drug	   toxicity,	   radiation,	   and	   systemic	   fibrotic	   conditions	   (e.g.	  
systemic	   sclerosis,	   rheumatoid	   arthritis,	   and	   collagen	   vascular	   disease).	   Despite	   this,	   the	  
aetiology	  of	  the	  most	  common	  form	  of	  ILDs,	  known	  as	  idiopathic	  interstitial	  pneumonias	  (IIPs)	  
are	  still	  unknown.	  Many	  IIPs	  exhibit	  similar	  clinical,	  pathological,	  and	  radiological	  features.	  This	  




Table	  1.2:	  Categorisation	  of	  major	  idiopathic	  interstitial	  pneumonias	  
	   Clinical-­‐Radiological-­‐Pathological	  
Diagnoses	  





Idiopathic	  pulmonary	  fibrosis	   Usual	  interstitial	  pneumonia	  















Cryptogenic	  organising	  pneumonia	   Organising	  pneumonia	  
Acute	  interstitial	  pneumonia	   Diffuse	  alveolar	  damage	  
	  
*	  Desquamative	  interstitial	  pneumonia	  can	  occasionally	  occur	  in	  non-­‐smokers.	  	  
Reproduced	   and	   adapted	   from	   (Travis	   et	   al.,	   2013)	   with	   permission	   of	   the	   American	   Thoracic	  
Society	  (ATS).	  	  
makes	  diagnosis,	  prognosis,	  and	  treatment	  of	  IIPs	  extremely	  challenging.	  However,	  in	  2002	  the	  
American	  Thoracic	   Society	   (ATS)	   and	  European	  Respiratory	   Society	   (ERS),	  which	  has	   recently	  
been	   updated	   in	   2013	   and	   is	   illustrated	   in	   Table	   1.2,	   introduced	   a	   criterion	   for	   the	  





























1.2.1.	   Idiopathic	  Pulmonary	  Fibrosis	  
Idiopathic	   pulmonary	   fibrosis	   (IPF)	   is	   the	   most	   common	   and	   lethal	   form	   of	   IIP	   affecting	  
approximately	   5	   million	   people	   worldwide	   (Meltzer	   and	   Noble,	   2008).	   It	   is	   an	   irreversible,	  
chronic,	  and	  progressive	  parenchymal	   lung	  disorder	  which	   leads	   to	  respiratory	   failure	  due	  to	  
destruction	  of	  functional	  alveolar	  units	  (Figure	  1.4)	  (Selman	  et	  al.,	  2011).	  	  
Statistics	   show	   that	   the	   survival	   rate	   of	   patients	   diagnosed	   with	   IPF	   is	   much	   worse	   in	  
comparison	   to	  several	  cancers	   (Figure	  1.5)	  with	  over	  5000	  deaths	   recorded	  each	  year	  within	  
the	  UK	  (Hodgson	  et	  al.,	  2002;	  Gribbin	  et	  al.,	  2006;	  Raghu	  et	  al.,	  2006,	  2011).	  The	  prevalence	  of	  




	  	  	  	  	  	  	   	  
Figure	  1.	  4:	  Alveolar	  architecture	  of	  control	  (or	  non-­‐IPF)	  and	  IPF	  lung.	  	  
Martius	   Scarlet	   Blue	   (MSB)	   staining	   illustrating	   collagen	   deposition	   in	   lung	   sections	  
from	  A)	  non-­‐IPF	  patient	  and	  B)	  IPF	  patient.	  Original	  magnification,	  5x	  
IPF	  is	  rising	  and	  currently	  it	  is	  estimated	  to	  be	  7.4	  per	  100,000	  people/year	  in	  the	  UK,	  6.8-­‐16.3	  
per	  100,000	  people/year	  in	  the	  US,	  and	  11.5	  per	  100,000	  people/year	  in	  the	  European	  Union	  
(EU;	  Table	  1.3)	  (Rafii	  et	  al.,	  2013).	  Furthermore,	  no	  distinct	  pattern	  of	  social,	  geographical,	  or	  

























IPF	  is	  commonly	  diagnosed	  in	  patients	  aged	  between	  40	  to	  70	  years,	  with	  prevalence	  higher	  in	  
men	   in	   comparison	   to	  women	   (ratio	   of	   approximately	   1.7:1)	   (Raghu	   et	   al.,	   2006;	  Han	   et	   al.,	  
2008).	  The	  incidence	  rises	  with	  age	  and	  approximately	  two-­‐thirds	  of	  IPF	  patients	  are	  older	  than	  
60,	  giving	  a	  mean	  diagnosis	  age	  of	  66	  years	  (Navaratnam	  et	  al.,	  2011).	  Additionally,	  the	  risk	  of	  
mortality	  as	  a	  result	  of	   IPF	  also	  rises	  with	  age	  (Erbes	  et	  al.,	  1997)	  suggesting	  that	  age-­‐related	  
changes	  affecting	  normal	  cellular	  activity	  are	  most	   likely	  to	  be	  important	   in	  the	  development	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Figure	   1.	   5:	   Comparison	   of	   death	   rate	   and	   five	   year	   survival	   rate	   for	   idiopathic	  
pulmonary	  fibrosis	  (IPF)	  and	  different	  forms	  of	  cancer.	  	  
Statistics	  are	  from	  the	  US	  National	  Cancer	  Institute.	  	  	  
Reproduced	   and	   adapted	   from	   (Vancheri	   et	   al.,	   2010)	   with	   permission	   of	   the	   European	  
Respiratory	  Society	  (ERS)	  	  
Table	  1.3:	  Incidence	  of	  idiopathic	  pulmonary	  fibrosis	  




US	  (healthcare	  claims	  database)	   6.8-­‐16.3	   (Raghu	  et	  al.,	  2006)	  
UK	  (primary	  care	  database	  including	  
diagnostics	  and	  prescribing	  data)	  
7.44	   (Navaratnam	  et	  al.,	  2011)	  
Greece	  (survey	  of	  pneumonology	  
departments)	  
3.38	   (Kadler	  et	  al.,	  2007)	  
Finland	  (hospital	  diagnostic	  coding	  
databases)	  
16-­‐18	   (Hodgson	  et	  al.,	  2002)	  
EU	  (review	  of	  medical	  literature)	   11.5	  
(Orphanet	  Report	  Series,	  
2013)	  
	  




















	   	   	  
	  




























Figure	  1.	  6:	  Progression	  of	  idiopathic	  pulmonary	  fibrosis	  
Majority	   of	   patients	   experience	   a	   slow	   progression	   of	   the	   disease	   (yellow)	   whilst	   a	  
minority	  of	  patients	  have	  a	  rapid	  progression	  (dotted	  purple	   line)	  following	  diagnosis.	  
A	   subpopulation	   of	   patients	   experience	   a	   slow	   progression	   with	   episodes	   of	   rapid	  
deterioration,	  known	  as	  acute	  exacerbations	  (dotted	  blue	  line).	  	  
	  
Reproduced	  from	  (Xaubet	  et	  al.,	  2013)	  with	  permission	  of	  Elsevier.	  
	  
Once	  diagnosed,	  the	  progression	  of	  the	  disorder	  is	  variable	  and	  unpredictable	  from	  patient	  to	  
patient.	   Some	   remain	  asymptomatic	   for	  2-­‐3	   years,	  whilst	   in	  others	   the	  disease	   is	   short	   lived	  
with	  rapid	  deterioration	  (accelerated	  form)	  (Selman	  et	  al.,	  2007).	  However,	  the	  majority	  of	  IPF	  
patients	   experience	   a	   slow	   progression	   with	   clinical	   and	   functional	   deterioration	   which	  
ultimately	   leads	   to	   chronic	   respiratory	   failure.	  Nevertheless,	   a	   subpopulation	   of	   IPF	   patients	  
may	   experience	   a	   steady	   progression	   with	   episodes	   of	   rapid	   deterioration,	   known	   as	   acute	  
exacerbations	  leading	  to	  an	  increase	  in	  morbidity	  as	  well	  as	  mortality	  (Figure	  1.6)	  (Raghu	  et	  al.,	  
2011).	  Such	  patients	  develop	  severe	  dyspnoea	  resulting	  in	  hypoxia	  within	  30	  days	  and	  require	  
hospitalisation	  for	  mechanical	  ventilation.	  Acute	  exacerbations	  may	  result	  from	  known	  factors	  
such	  as	  heart	   failure,	   infection,	  or	  pulmonary	  embolism,	  however	   in	  some	  cases	   the	  cause	   is	  
unknown.	  In	  general,	  the	  median	  survival	  is	  2-­‐3	  years	  following	  diagnosis	  (the	  worst	  prognosis	  

















1.2.2.	   Diagnosis	  of	  IPF	  
Patients	   are	   diagnosed	   with	   this	   disorder	   based	   on	   the	   clinical,	   histopathological	   and	  
radiographical	   evaluations.	   Clinical	   presentations	   include	   chronic	   and	   progressive	   dyspnoea	  
(shortness	  of	  breath)	  induced	  by	  6-­‐minute-­‐walk	  (6mw)	  test,	  dry	  cough,	  impaired	  gas	  exchange	  




(measured	   by	   diffusing	   capacity	   of	   the	   lung	   for	   carbon	   monoxide,	   DLCO),	   and	   reduced	   lung	  
volume	  (i.e.	  forced	  vital	  capacity,	  FVC;	  and	  total	  lung	  capacity,	  TLC).	  Furthermore,	  fever,	  weight	  
loss,	  finger	  clubbing,	  fatigue,	  and	  malaise	  have	  also	  been	  reported	  (ATS	  and	  ERS,	  2002).	  	  
Lung	   biopsies	   from	   IPF	   patients	   show	   the	   histological	   appearance	   of	   usual	   interstitial	  
pneumonia	   (UIP).	   These	   are	   heterogeneous	   appearances	   of	   fibrosis	   and	   honeycombing	  
(bronchial	   epithelium	   lining	   fibrotic	   airspaces,	   which	   are	   often	   filled	   by	   numerous	  
inflammatory	  cells	  as	  well	  as	  mucin),	  alternating	  with	  areas	  of	  less	  affected	  or	  unaffected	  lung	  
parenchyma.	   The	   areas	  which	   are	  more	   severely	   affected	   are	   the	   subpleural	   and	  paraseptal	  
parenchyma.	   In	   addition,	   high-­‐resolution	   computerised	   tomography	   (HRCT)	   scans	   also	   show	  
the	  presence	  of	  UIP	  which	   are	   characterised	   by	   reticular	   opacities	   (Figure	   1.7).	   This	   is	   often	  
associated	   with	   abnormal	   airway	   dilation	   (traction	   bronchiectasis).	   In	   addition,	   the	   lungs	   of	  
some	  patients	  also	  show	  mild	  inflammation	  consisting	  of	  patchy	  lymphoplasmacytic	  interstitial	  
infiltrate.	  The	  analysis	  of	  these	  features	  is	  necessary	  to	  make	  a	  definite	  diagnosis	  (ATS	  and	  ERS,	  





















Figure	  1.	  7:	  High	  resolution	  CT	  scan	  illustrating	  usual	  interstitial	  pneumonia	  
Subpleural	  reticular	  opacities	  and	  areas	  of	  honeycombing.	  
Reproduced	  from	  (Cottin	  et	  al.,	  2014)	  with	  permission	  of	  the	  European	  Respiratory	  Society	  (ERS).	  





Figure	  1.	  8:	  Fibrotic	  focus	  –	  a	  histological	  hallmark	  of	  idiopathic	  pulmonary	  fibrosis	  
A)	   Histological	   analysis	   (Martius	   Scarlet	   Blue	   staining)	   of	   a	   human	   IPF	   lung	   tissue	  
illustrating	  dense	  collagen	  deposition	  (blue)	  within	  the	  pulmonary	   interstitium	  (original	  
magnification	  x10).	  B)	  Fibrotic	  focus,	  highly	  synthetic	  for	  collagen.	  C)	  These	  are	  clusters	  
of	   myofibroblasts	   (positive	   for	  αSMA,	   immunohistochemistry)	   underlying	   hyperplastic	  
epithelial	  cells	  (original	  magnification	  x20).	  	  
	  
Reproduced	  from	  (Datta	  et	  al.,	  2011)	  with	  permissions	  of	  John	  Wiley	  and	  Sons.	  	  
Furthermore,	   small	   regions	   of	   active	   fibrosis	   (fibrotic	   foci)	   are	   present	   in	   the	   lungs	   of	   IPF	  
patients.	   These	   are	   clusters	   of	   activated	   myofibroblasts	   that	   underlie	   hyperplastic	   alveolar	  
epithelial	   cells	   (Figure	   1.8),	   located	   in	   areas	   with	   collagen	   deposition.	   These	   histological	  
hallmarks	   were	   considered	   to	   be	   discrete	   sites	   of	   lung	   injury.	   However,	   Cool	   et	   al.	   (2006)	  
demonstrated	  that	  these	  are	  in	  fact	  an	  extremely	  complex	  and	  interconnected,	  non-­‐malignant	  
continuous	   reticulum,	  which	   extend	   from	   the	   pleura	   into	   the	   lung	   parenchyma	   (Cool	   et	   al.,	  
2006).	  
	  	  
A	   few	   studies	   have	   explored	   the	   relationship	   between	   the	   number	   of	   fibrotic	   foci	   and	   the	  
severity	  of	  the	  disorder.	  For	  instance,	  King	  et	  al.	  (2001)	  used	  surgical	  biopsy	  specimens	  from	  87	  
patients	   with	   UIP	   to	   investigate	   which	   histopathological	   feature	   of	   UIP	   affects	   survival.	   The	  
results	  demonstrated	   that	  patients	  with	  more	   fibrotic	   foci	  had	  a	  poorer	  outcome	   (King	   Jr.	  et	  
al.,	   2001).	   In	   addition	   Nicholson	   et	   al.	   (2002)	   also	   confirmed	   the	   prognostic	   significance	   of	  
fibrotic	   foci	   by	   retrospective	   analysis	   of	   53	   patients	   with	   UIP	   (Nicholson	   et	   al.,	   2002).	  
Furthermore,	   in	   2003	   Flaherty	   et	   al.	   (2006)	   discovered	   that	   patients	   with	   collagen	   vascular	  
disease	   have	   fewer	   fibrotic	   foci	   in	   comparison	   to	   IPF	   patients,	   with	   better	   survival	   of	   the	  
former	  (Flaherty	  et	  al.,	  2003).	  This	  was	  also	  demonstrated	  by	  Enomoto	  et	  al.	  (2006).	  Thus,	  the	  




number	  of	  fibrotic	  foci	  present	  within	  the	  lungs	  of	  the	  patients	  correlates	  with	  the	  progression	  
of	   the	   disorder	   (Enomoto	   et	   al.,	   2006).	   As	   the	   disease	   progresses,	   there	   is	   a	   loss	   of	   lung	  
elasticity	   and	   alveolar	   surface	   area,	   which	   results	   in	   the	   impairment	   of	   gas	   exchange	   and	  
pulmonary	  function,	  leading	  to	  respiratory	  failure	  (ATS	  and	  ERS,	  2002;	  Chambers,	  2008).	  
1.2.3.	  	   Pathogenesis	  of	  IPF	  
Despite	   having	   an	   unknown	   aetiology,	   a	   number	   of	   risk	   factors	   have	   been	   implicated	   in	   IPF	  
development.	   These	   include	   cigarette	   smoking	   (Baumgartner	   et	   al.,	   1997),	   viral	   infections	  
(Tang	  et	  al.,	  2003),	  drug	  toxicity,	  and	  prolonged	  environmental	  exposure	  (e.g.	  wood	  or	  metal	  
dust;	   	   (Raghu	   et	   al.,	   2011).	   Furthermore,	   genetic	   predispositions	   to	   PF	   have	   also	   been	  
proposed	   based	   on	   several	   studies	   of	   PF	   patients	   with	   the	   familial	   form.	   Such	   include	  
mutations	   in	   genes	   encoding	   surfactant	   protein	   A2	   (SFTA2)	   (Thomas	   et	   al.,	   2002),	  mucin	   5B	  
(MUC5B)	  (Seibold	  et	  al.,	  2011),	  and	  telomerase	  (TERT	  and	  TERC)	  (Armanios	  et	  al.,	  2007;	  Tsakiri	  
et	  al.,	  2007).	  Moreover	  polymorphisms	  in	  tumour	  necrosis	  factor	  (TNF)-­‐α	  and	  TGFβ1	  have	  also	  
been	  identified	  (Whyte	  et	  al.,	  2000;	  Xaubet	  et	  al.,	  2003).	  However,	  the	  precise	  genetic	  factor(s)	  
that	  determine	  the	  clinical	  manifestations	  as	  well	  as	  the	  phenotypic	  expression	  of	  sporadic	  IPF	  
remain	  unknown	  and	  are	  also	  extremely	  challenging	  to	  determine	  due	  to	  the	  late	  onset	  of	  the	  
disease	  presentation.	  Nevertheless,	  genetic	  predisposition	  appears	  to	  be	  responsible	  for	  ~5	  %	  
of	  IPF	  cases	  suggesting	  the	  aetiology	  of	  IPF	  is	  likely	  to	  be	  multifactorial	  (Noble	  et	  al.,	  2012).	  
Additionally,	   several	   other	   hypotheses	   have	   been	   postulated	   to	   explain	   the	   possible	  
pathogenesis	  of	  this	  fatal	  disease.	  Originally	  it	  was	  thought	  that	  IPF	  is	  a	  chronic	  inflammatory	  
disease	   initiated	   following	   alveolar	   injury	   (alveolitis)	   resulting	   in	   the	   recruitment	   of	  
inflammatory	   cells	   and	   the	   release	   of	   inflammatory	   and	   profibrotic	   mediators	   leading	   to	  
fibrogenesis.	   However,	   lack	   of	   clinical	   benefit	   in	   response	   to	   anti-­‐inflammatory	   drugs	   and	  
immunosuppressive	  reagents	  suggests	  that	  the	  progression	  of	  IPF	  is	  not	  dependent	  on	  typical	  
inflammation	  (Gross	  and	  Hunninghake,	  2001;	  Thannickal	  et	  al.,	  2004).	  	  
Many	   studies	   now	   focus	   on	   a	   more	   recent	   concept	   suggesting	   that	   IPF	   is	   an	   ‘epithelial-­‐
fibroblastic	  disorder’	  whereby	  continuous	  micro-­‐repetitive	   injury	  to	  the	  epithelial	  cells	  within	  
the	   lung	   causes	   abnormal	   wound	   healing	   responses	   including	   aberrant	   proliferation	   and	  
differentiation	   of	   fibroblasts,	   formation	   of	   fibrotic	   foci,	   and	   excessive	   deposition	   of	   ECM	  
components.	   	  Furthermore,	   in	   this	  hypothesis,	   inflammation	   is	  considered	  to	  be	  a	  secondary	  
event	   (Chakraborty	   et	   al.,	   2014).	   Several	   in	   vitro	   and	   in	   vivo	   studies	   of	   PF	   support	   this	  




hypothesis,	  with	   the	  most	   common	   in	   vivo	  model	   involving	   the	   administration	   of	   bleomycin	  
(discussed	   in	  detail	   in	  Section	  1.3)	   (Gross	   and	  Hunninghake,	   2001;	   Selman	  and	  Pardo,	   2002;	  
Selman	   et	   al.,	   2011).	   However,	   the	   underlying	  mechanisms	   involved	   in	   the	   development	   of	  
fibrotic	  foci	  are	  still	  unclear.	  
1.2.4.	  	   Alveolar	  epithelial	  cells	  
In	  normal	  lungs,	  over	  90%	  of	  the	  alveolar	  surface	  consists	  of	  alveolar	  epithelial	  cells	  (AEC)	  type	  
I	  (AT1)	  which	  interface	  with	  the	  pulmonary	  capillaries	  resulting	  in	  an	  intact	  thin	  surface	  readily	  
permeable	  to	  gases.	  On	  the	  other	  hand,	  approximately	  5%	  of	  the	  alveolar	  surface	  is	  composed	  
of	   AEC	   type	   II	   (AT2).	  Morphologically	   these	   cells	   appear	   as	   large	   rounded	   cells	  which	   are	   in	  
close	  proximity	  to	  mesenchymal	  cells,	  and	  play	  a	  vital	  role	   in	  synthesising	  surfactant	  (Sirianni	  
et	  al.,	  2003;	  Selman	  and	  Pardo,	  2006).	  In	  addition,	  ATII	  cells	  also	  act	  as	  limited	  progenitor	  cells	  
which	  are	  able	  to	  regenerate	  AT1	  during	  injury,	  and	  synthesise	  some	  of	  the	  vital	  components	  
of	   the	   basement	   membrane	   (including	   collagen	   IV,	   fibronectin,	   and	   laminin)	   in	   order	   to	  
maintain	  the	  integrity	  of	  the	  alveolar	  epithelium	  (Chakraborty	  et	  al.,	  2014).	  Furthermore,	  ATII	  
cells	  minimise	  alveolar	   fluid	  by	  aiding	   the	   transport	  of	   sodium	  from	  apical	   to	  basolateral	   cell	  
surfaces	  (Shannon	  and	  Hyatt,	  2004;	  Selman	  and	  Pardo,	  2006).	  	  
Under	  normal	  wound	  healing	  conditions,	  fibroblasts	  (discussed	  in	  more	  detail	  in	  Section	  1.2.5)	  
are	   activated	   to	  myofibroblasts,	   recruited	   to	   the	   injury	   site,	   and	   initiate	   the	   formation	   of	   a	  
provisional	  matrix	  (which	  acts	  as	  a	  scaffold	  for	  normal	  tissue	  repair),	  and	  contract	  to	  promote	  
wound	   closure.	   Following	   this,	   the	   cells	   undergo	   apoptosis	   and	   are	   cleared	   from	   the	  wound	  
area.	  Subsequently,	  ATII	  cells	  proliferate	  and	  differentiate	  for	  the	  regeneration	  of	  the	  denuded	  
epithelium.	   Thus,	   under	   normal	   conditions,	   epithelial	   cells	   and	   fibroblasts	  maintain	   the	   lung	  
homeostasis	   and	   initiate	   repair	   mechanisms	   in	   response	   to	   injury	   without	   affecting	   its	  
structure	   and	   function.	   However,	   as	   mentioned	   above,	   in	   IPF	   patients	   AECs	   undergo	  
phenotypic	  changes	  as	  a	  result	  of	  repetitive	  injury	  to	  the	  epithelial	  layer	  (Kasper	  and	  Haroske,	  
1996;	  Chilosi	  et	  al.,	  2002).	  Abnormalities	  in	  AECs	  have	  been	  illustrated	  in	  lung	  biopsies	  from	  IPF	  
patients	  (Uhal	  et	  al.,	  1998;	  Barbas-­‐Filho	  et	  al.,	  2001;	  Maeyama	  et	  al.,	  2001;	  Plataki	  et	  al.,	  2005)	  
including	  the	  presence	  of	  hyperplastic	  AT2	  	  (Corrin	  et	  al.,	  1985),	  bronchiolar-­‐like	  epithelial	  cells	  
(bronchiolarisation)	   AECs	   (Kawanami	   et	   al.,	   1982;	   Sutinen	   et	   al.,	   1980)	   (Sutinen	   et	   al.,	   1980;	  
Kawanami	   et	   al.,	   1982),	   and	   squamous	   metaplasia	   lining	   regions	   of	   honeycomb	   fibrosis.	  
Furthermore,	   several	   studies	  have	  demonstrated	   that	  AECs	  are	  not	  only	  more	  susceptible	   to	  
apoptosis	  (Kasper	  and	  Haroske,	  1996)	  but	  also	  continue	  to	  undergo	  cell	  death	  in	  the	  absence	  




of	  the	  initial	   injury	  stimulus	  (King	  Jr.	  et	  al.,	  2011).	  The	  key	  question	  here	  is	  does	  AEC	  damage	  
occur	  at	  the	  early	  stage	  of	  the	  disease	  (the	  triggering	  event)	  or	  as	  part	  of	  the	  evolution	  of	  IPF	  (a	  
secondary	  process).	  It	  has	  been	  hypothesised	  that	  AEC	  cell	  death	  is	  involved	  in	  the	  initial	  event	  
in	  the	  pathogenesis	  of	  IPF	  as	  studies	  have	  demonstrated	  AEC	  death	  in	  normal	  areas	  of	  the	  lung	  
parenchyma.	  Furthermore,	   in	  vivo	  models	  of	  fibrosis	  have	   illustrated	  that	  mice	  are	  protected	  
from	   bleomycin-­‐induced	   fibrosis	   when	   epithelial	   cell	   apoptosis	   is	   inhibited	   (Kuwano	   et	   al.,	  
1999a),	  suggesting	  a	  possible	  therapeutic	  target	  for	  IPF	  patients.	  	  
Several	  mediators	  also	  play	  a	  key	  role	   in	  AEC	  apoptosis	   including	  TGFβ	  (Lee	  et	  al.,	  2004),	  Fas	  
ligand	  (FasL)	  (Maeyama	  et	  al.,	  2001),	  reactive	  oxygen	  species	  (ROS)	  (Waghray	  et	  al.,	  2005),	  and	  
angiotensin	  II	  (ANGII).	  More	  recently,	  studies	  have	  illustrated	  that	  IPF	  AECs	  express	  markers	  of	  
ER	  stress	  and	  the	  unfolded	  protein	  response	  (UPR)	  which	  may	  result	   in	  altered	  processing	  of	  
surfactant	  protein	  (Korfei	  et	  al.,	  2008;	  Lawson	  et	  al.,	  2008).	  Moreover,	  defects	  in	  the	  regulation	  
of	   developmental/embryological	   pathways	   may	   explain	   the	   irregular	   behaviour	   of	   AECs	  
(Konigshoff	  and	  Eickelberg,	  2010).	  For	  instance,	  several	  studies	  have	  shown	  that	  epithelial	  cells	  
from	   IPF	   patients	   overexpress	   β-­‐catenin	   suggesting	   that	   the	   Wnt	   pathway	   is	   switched	   on	  
within	   these	  cells	   (Konigshoff	  et	  al.,	  2008).	  Despite	   the	  progression	   in	   the	  number	  of	   in	  vitro	  
and	   in	   vivo	   studies	   performed	   to	   understand	   the	   cause	   of	   AEC	   death,	   currently	   the	   precise	  
cellular	  mediators	   that	  culminate	   in	   the	   initial	  AEC	  dysfunction	  and	  death	  remain	  completely	  
unknown	  and	  require	  intense	  investigation.	  
1.2.5.	   Fibroblasts	  and	  Myofibroblasts:	  matrix	  producing	  cells	  	  
As	   already	   mentioned,	   mesenchymal	   cells	   (i.e.	   fibroblasts	   and	   myofibroblasts)	   have	   a	  
fundamental	  role	   in	  the	  pathogenesis	  of	   IPF	  and	  over	  the	  past	  30	  years	   it	  has	  been	  generally	  
accepted	  that	  these	  cells	  play	  an	  essential	  role	  in	  the	  establishment	  of	  tension	  during	  wound	  
healing	   and	   pathological	   conditions	   (Hinz,	   2007;	   Hinz	   et	   al.,	   2007).	   In	   normal	   lung	   tissue,	  
fibroblasts	  are	  predominately	  located	  in	  the	  parenchymal	  interstitium	  (accounting	  for	  30-­‐50%	  
of	  total	  interstitial	  cells)	  and	  in	  the	  subepithelial	  layer	  of	  the	  conducting	  airways,	  which	  places	  
them	  in	  a	  prime	  location	  to	  interact	  with	  endothelial	  and	  epithelial	  cells	  (Tomasek	  et	  al.,	  2002).	  
However,	  in	  IPF	  lungs	  the	  fibroblast	  cell	  number	  is	  far	  greater	  (Jordana	  et	  al.,	  1994),	  localised	  
to	  sites	  of	  active	  fibrosis	  as	  well	  as	  fibrotic	  foci.	  In	  addition,	  during	  a	  wound	  healing	  process	  or	  
a	   pathological	   environment	   these	   cells	   are	   known	   to	   differentiate	   into	   a	   more	   contractile	  
phenotype	  (myofibroblasts)	  which	  are	  considered	  as	  the	  principal	  effector	  cells	  responsible	  for	  
the	  deposition	  of	  ECM	  proteins	  (including	  collagen).	  Myofibroblasts	  are	  elongated	  spindle-­‐like	  




shaped	  contractile	  cells	  which	  share	  features	  of	  both	  fibroblasts	  and	  smooth	  muscle	  cells,	  and	  
are	  characterised	  by	  the	  presence	  of	  stress	  fibres	  and	  the	  expression	  of	  alpha-­‐smooth	  muscle	  
actin	  (αSMA)	  as	  well	  as	  several	  other	  markers	  (Figure	  1.10).	  	  
Fibroblasts	  express	  several	  receptors	  for	  major	  profibrotic	  mediators	  including	  platelet	  derived	  
growth	  factor	  (PDGF),	  connective	  tissue	  growth	  factor	  (CTGF),	  TGFβ	   (Farkas	  et	  al.,	  2010),	  and	  
protease	  activated	  receptor	  (PAR)1	  (Scotton	  and	  Chambers,	  2007;	  Chakraborty	  et	  al.,	  2014).	  In	  
addition,	   these	   cells	   also	   express	   receptors	   for	   proinflammatory/antifibrotic	   mediators,	  
including	  tumour	  necrosis	  factor	  (TNF)-­‐α.	  It	  is	  believed	  that	  AEC	  injury	  results	  in	  the	  release	  of	  
profibrotic	  mediators,	  which	  promote	  the	  migration,	  proliferation,	  and	  activation	  of	  fibroblasts	  
to	  myofibroblasts.	   Furthermore,	  matrix	  metalloproteinases	   (MMPs),	   such	   as	  MMP2,	  MMP3,	  
and	   MMP9,	   are	   also	   released	   by	   both	   epithelial	   cells	   and	   fibroblasts,	   which	   affect	   ECM	  
remodelling	   and	   disrupt	   the	   basement	   membrane	   in	   lungs	   of	   IPF	   patients	   (discussed	   later)	  
(Lovgren	  et	  al.,	  2011).	  	  
Origin	  of	  myofibroblasts	  
Three	   possible	   origins	   for	   myofibroblasts	   have	   been	   proposed	   (Figure	   1.9).	   Initially	   it	   was	  
thought	  that	  myofibroblasts	  originate	  from	  resident	  fibroblasts	  which	  are	  able	  to	  differentiate	  
in	   the	   presence	   of	   profibrotic	   mediators	   (as	   mentioned	   above).	   However,	   prior	   to	   the	  
formation	  of	  myofibroblasts,	   it	  has	  been	  proposed	  that	   resident	   fibroblasts	  differentiate	   into	  
proto-­‐myofibroblasts.	   These	   are	   cells	  which,	   unlike	  myofibroblasts,	   contain	   stress	   fibres	   that	  
do	   not	   express	   αSMA	   (Table	   1.4).	   Several	   in	   vivo	   studies	   support	   the	   existence	   of	   proto-­‐
myofibroblasts	  –	  for	  example,	  these	  cells	  have	  been	  detected	  in	  lung	  alveolar	  septa	  (Kapanci	  et	  
al.,	  1992)	  as	  well	  as	  the	  early	  phases	  of	  granulation-­‐tissue	  formation	  (Hinz	  et	  al.,	  2001b).	  The	  
distinction	   between	   fibroblasts	   and	   proto-­‐myofibroblasts	   is	   clearly	   visible	   in	   vivo	   and	   it	   has	  
been	   proposed	   that	   these	   cells	   may	   function	   as	   an	   independent	   cell	   type	   (Tomasek	   et	   al.,	  
2002).	   This	   proposal	   is	   based	   on	   the	   fact	   that	   proto-­‐myofibroblasts	   (in	   normal	   tissues)	   are	  
always	   present	   in	   areas	   where	   there	   is	   a	   need	   to	   create	   mechanical	   tension	   (Serini	   and	  
Gabbiani,	   1999).	   However,	   nearly	   all	   fibroblasts	   acquire	   proto-­‐myofibroblastic	   features	   once	  
the	  cells	  are	  grown	   in	   culture	   (in	   the	  presence	  of	   foetal	  bovine	   serum,	  FBS)	  on	  plastic	   (Hinz,	  
2006).	  Thus,	  as	  well	  as	  cell	  signalling	  molecules	  and	  cytokine	  (e.g.	  PDGF),	  mechanical	  tension	  
may	  also	  promote	  the	  formation	  of	  proto-­‐myofibroblasts	  (Hinz	  et	  al.,	  2004;	  Desmouliere	  et	  al.,	  
2005).	  	  





















Figure	  1.	  9:	  Proposed	  origin	  of	  myofibroblasts	  in	  the	  pathogenesis	  of	  IPF	  
Myofibroblasts	   may	   originate	   from	   three	   proposed	   sources:	   resident	   lung	   fibroblasts	  
which	   differentiate	   under	   the	   influence	   of	   pro-­‐fibrotic	   mediators;	   epithelial	   cells	   in	  
response	   to	   injury	   via	   epithelial-­‐mesenchymal	   transition;	   mesenchymal	   cells	   derived	  
from	   circulating	   fibrocytes	   or	   from	   bone-­‐marrow-­‐derived	   progenitor	   cells	   which	  
differentiate	   in	   the	   presence	   of	   pro-­‐fibrotic	   mediators.	   During	   normal	   tissue	   repair,	  
myofibroblasts	   undergo	   apoptosis,	   however	   in	   IPF	   patients,	  myofibroblasts	   proliferate	  
excessively	  with	  excess	  ECM	  deposition	  leading	  to	  remodelling	  of	  the	  lung	  architecture.	  
	  










Table	  1.4:	  Fibroblast-­‐myofibroblast	  features	  in	  different	  situations	  
	   In	  vivo	   Closest	  In	  vitro	  model	  
Fibroblast	   Normal	  connective	  tissue	  
Low	  stiffness	  substrates	  ±	  TGFβ 
Free-­‐floating	  collagen	  gels	  ±TGF-­‐β	  
Proto-­‐
myofibroblast	  




Specialised	  normal	  connective	  
tissue	  (e.g.	  alveolar	  septum),	  
early	  granulation	  tissue	  (e.g.	  
open	  wound)	  
Medium	  stiffness	  substrates	  
Differentiated	  
myofibroblast	  
(stress	  fibres	  that	  
express	  α-­‐SMA)	  
Specialised	  normal	  connective	  
tissue	  (e.g.	  bone	  marrow	  
stroma,	  liver	  capsule);	  	  
Late	  contracting	  granulation	  
tissue	  (e.g.	  open	  wound);	  	  
Fibrocontractive	  diseases	  
Medium	  stiffness	  substrates	  
±TGFβ 
High	  stiffness	  substrates	  ±	  TGFβ 
Attached	  collagen	  gels	  ±	  TGFβ	  
	  
































In	   vivo,	   proto-­‐myofibroblasts	   proceed	   to	   differentiate	   into	   myofibroblasts	   which	   are	  
characterised	  by	  de	  novo	  expression	  of	  αSMA.	  Under	   the	   influence	  of	  high	   tension,	  αSMA	   is	  
recruited	   to	   the	   stress	   fibres	   (Goffin	   et	   al.,	   2006).	   Studies	   have	   illustrated	   that	   the	   level	   of	  
αSMA	   expressed	   in	  myofibroblasts	   correlates	  with	   the	   contractility	   of	   the	   cell	   (Zhang	   et	   al.,	  
1996;	   Hinz	   et	   al.,	   2001a),	   however	   the	   precise	   mechanism	   involved	   in	   this	   correlation	   is	  
currently	  unknown.	  	  
As	   well	   as	   resident	   fibroblasts,	   myofibroblasts	   have	   also	   been	   suggested	   to	   originate	   from	  
AECs.	  It	  has	  been	  proposed	  that	  in	  response	  to	  injury	  AECs	  are	  able	  to	  transdifferentiate	  into	  
mesenchymal	   cells	   (Kim	   et	   al.,	   2006),	   a	   process	   known	   as	   epithelial-­‐mesenchymal	   transition	  
(EMT;	  Figure	  1.10).	  This	  cell	  plasticity	  has	  been	  observed	  in	  distinct	  cellular	  processes	  including	  
embryonic	  development	  and	  metastasis.	  Furthermore,	  EMT	  has	  also	  been	  described	  to	  occur	  
in	   in	   vivo	   and	   in	   vitro	   models	   of	   fibrosis,	   whereby	   in	   the	   presence	   of	   TGFβ	   epithelial	   cells	  
acquire	  migratory	  capacity	  and	  invasive	  properties	  (Kasai	  et	  al.,	  2005;	  Wu	  et	  al.,	  2007).	  	  












	  Figure	  1.	  10:	  Epithelial-­‐mesenchymal	  transition.	  
Markers	  used	  by	  researchers	  to	  determine	  cell	  phenotype	  are	  listed.	  In	  the	  presence	  of	  
resident	   fibroblasts	   or	   inflammatory	   cells	   a	   number	   of	   mediators	   are	   released	   (e.g.	  
TGFβ,	   Type	   1	   collagen,	   MMP2,	   or	   MCP1),	   which	   results	   in	   the	   loss	   of	   epithelial	   cell	  
markers	   and	   gain	   of	   mesenchymal	   markers	   (e.g.	   αSMA),	   process	   known	   as	   EMT.	  
Epithelial	  cells	  are	  more	  susceptible	  to	  apoptosis	  in	  comparison	  to	  mesenchymal	  cells.	  
	  
Reproduced	   from	   (Kalluri	   and	  Weinberg,	  2009)	  with	  permission	  of	  American	   society	   for	   clinical	  
investigations.	  
	  
Moreover,	   decrease	   in	   expression	   of	   epithelial	   cell	   markers	   has	   also	   been	   described.	   Such	  
markers	   include	   junction	   associated	   proteins	   (such	   as	   E-­‐cadherin,	   zonula	   occludens	   [ZO]-­‐1),	  
and	   cytokeratins).	   In	   addition,	   increase	   in	   expression	   of	   mesenchymal	   markers	   (including	  
αSMA,	   MMP2	   and	   MMP9),	   and	   excess	   collagen	   production	   have	   also	   been	   illustrated	  
(Gharaee-­‐Kermani	   et	   al.,	   2009),	  which	  occurs	   via	   a	   Smad3-­‐dependent	  mechanism	   (Hu	  et	   al.,	  
2003).	   More	   importantly,	   approximately	   80	   %	   of	   the	   hyperplastic	   epithelial	   cells	   overlying	  
fibrotic	   foci	   co-­‐express	   epithelial	   and	   mesenchymal	   markers	   in	   IPF	   lung	   biopsies	   which	  
provides	   strong	   evidence	   of	   EMT	   during	   the	   development	   of	   lung	   fibrosis	   (Willis	   and	   Borok,	  
2007),	  and	  it	  has	  been	  proposed	  that	  following	  injury	  EMT	  may	  result	  as	  an	  attempt	  to	  escape	  
epithelial	   cell	   apoptosis	   (Vega	   et	   al.,	   2004).	   If	   this	   proposal	   is	   correct	   then	   EMT	   may	   be	  
considered	   as	   an	   epithelial	   cell	   injury	   marker	   and	   inhibition	   of	   EMT	   may	   in	   fact	   result	   in	  




adverse	  effects	   in	   IPF	  (Kage	  and	  Borok,	  2012).	  However,	  further	  studies	  are	  necessary	  before	  
making	  any	  firm	  conclusions.	  
Recent	  research	  has	  demonstrated	  that	  TGFβ-­‐induced	  EMT	  may	  be	  reversed	  in	  the	  presence	  of	  
fibroblast	   growth	   factor	   (FGF)-­‐1	   which	   promotes	   ERK	   phosphorylation	   and	   Smad2	  
dephosphorylation	  (Ramos	  and	  Becerril,	  2010).	  This	  implies	  that	  inhibiting	  global	  TGFβ	  activity	  
may	  affect	  the	  tissue	  homeostasis	  and	  suggests	  that	  FGF-­‐1	  may	  have	  a	  therapeutic	  role	  in	  the	  
treatment	  of	  PF.	  The	  regulation	  of	  TGFβ	  will	  be	  discussed	   in	  detail	   in	  the	  next	  section.	  Other	  
signalling	  pathways	  which	  also	  promote	  EMT	  are	  Wnt	  and	  Notch	  signalling.	  
Despite	   having	   numerous	   data	   supporting	   EMT,	   some	   studies	   have	   shown	   contradictory	  
results.	  For	  instance,	  Rock	  et	  al.	  (2011)	  illustrated	  that	  ATII	  cells	  (expressing	  surfactant	  protein	  
C)	  did	  not	   transdifferentiate	   into	  myofibroblasts	   following	  bleomycin	  administration	  as	   there	  
was	   no	   change	   in	   expression	   for	  αSMA	  or	   vimentin.	   In	   addition,	   cells	   expressing	   Scgb1a1	   (a	  
marker	  for	  bronchiolar	  clara	  cells	  and	  possibly	  alveolar	  progenitor	  cells)	  also	  showed	  negative	  
results	  with	  regards	  to	  EMT	  (Rock	  et	  al.,	  2011).	  However,	  since	  this	  was	  demonstrated	  only	  in	  
the	   bleomycin	   model	   of	   fibrosis	   (which	   is	   the	   most	   accepted	   model	   of	   PF),	   it	   has	   been	  
suggested	  that	  other	  fibrogenic	  models	  may	  show	  different	  results	  (Degryse	  et	  al.,	  2010;	  Kage	  
and	  Borok,	  2012),	  therefore	  further	  investigations	  are	  required.	  	  
Circulating	   fibrocytes	   also	   show	   evidence	   for	   being	   the	   source	   for	   myofibroblasts	   in	   IPF	  
patients.	  These	  are	  bone	  marrow-­‐derived	  progenitor	  cells	  characterised	  by	   the	  expression	  of	  
mesenchymal	  markers	  (i.e.	  type	  I	  collagen,	  and	  fibronectin)	  and	  haemopoietic	  cell	  markers	  (i.e.	  
CD34	  and	  CD45)	  (Strieter	  et	  al.,	  2009).	  In	  response	  to	  injury,	  fibrocytes	  are	  thought	  to	  migrate	  
to	  affected	  areas	  within	  the	   lung	  and	  differentiate	   into	  myofibroblasts.	  Chemokine	  receptors	  
(i.e.	  CXCR4)	  are	  expressed	  by	  human	  fibrocytes	  which	  have	  affinity	  for	  the	  chemokine	  CXCL12,	  
suggesting	  a	  crucial	  role	  of	  CXCR4-­‐CXCL12	  axis	  in	  the	  trafficking	  of	  the	  cells	  into	  the	  lungs	  of	  IPF	  
patients.	   In	   addition,	   AECs	   express	   CXCL12	  which	  may	   therefore	   be	   involved	   in	   forming	   the	  
chemotactic	   gradient	   required	   for	   the	   CXCR4+	   fibrocyte	   trafficking	   (Andersson-­‐Sjoland	   et	   al.,	  
2008;	  King	  Jr.	  et	  al.,	  2011).	  	  
More	   recent	   studies	   have	   suggested	   that	   myofibroblasts	   may	   also	   originate	   from	   pericytes	  
(Hung	   et	   al.,	   2013a).	   These	   are	   specialised	   mesenchymal	   cells	   that	   share	   a	   basement	  
membrane	  alongside	  endothelial	  cells	  and	  commonly	  express	  several	  markers	  including	  αSMA,	  
PDGFRβ,	  GFAP,	  CD146,	  P75	  NGFR,	  and	  angiopoietin	  1.	  	  




Myofibroblasts	  in	  IPF	  
As	  stated	  above,	  myofibroblasts	  are	  the	  principal	  cells	  for	  collagen	  production.	  The	  first	  study	  
to	   show	  direct	   evidence	   for	   this	   in	   fibrotic	   lung	  was	   conducted	  by	   Zhang	   et	   al	   (1994)	  which	  
involved	   in	   situ	   hybridisation	   on	   bleomycin-­‐induced	   lung	   tissue	   sections	   illustrating	  
colocalisation	  of	  ACTA2	  and	  COL1A1	  mRNA	  (Zhang	  et	  al.,	  1994).	  This	  has	  also	  been	  confirmed	  
in	  our	   lab	  with	  colocalisation	  of	  αSMA	  and	  collagen-­‐I	  and	  collagen-­‐III	   in	   IPF	   lung	  tissue	  serial	  
sections	   (see	   Section	   3.2).	   However,	   the	   precise	   mechanisms	   which	   lead	   to	   elevated	   ECM	  
synthesis	   by	   myofibroblasts	   are	   not	   completely	   understood.	   One	   hypothesis	   suggests	   that	  
myofibroblasts	  undergo	  phenotypic	  changes	  which	  result	   in	  permanent	  ‘reprograming’	  of	  the	  
cells,	  promoting	  fibrogenesis.	  This	  theory	  is	  supported	  by	  studies	  on	  fibroblasts/myofibroblasts	  
isolated	  from	  IPF	  lung	  tissues	  illustrating	  highly	  synthetic	  capacity	  for	  collagen	  and	  other	  ECM	  
proteins,	  as	  well	  as	  greater	  contractility	  of	  collagen	  matrices	  (Miki	  et	  al.,	  2000)	  in	  the	  presence	  
of	  pro-­‐fibrotic	  mediators,	  compared	  to	  cells	  isolated	  from	  control	  lungs	  (Hetzel	  et	  al.,	  2005).	  	  
In	  addition,	  over	  expression	  of	  molecules	  involved	  in	  developmental	  pathways	  is	  evident	  in	  IPF	  
fibroblasts	   (similar	   to	   AECs,	  mentioned	   above).	   Such	   include	  β-­‐catenin	   in	   the	  Wnt	   signalling	  
pathway	  (Coward	  et	  al.,	  2010)	  and	  components	  of	  the	  Sonic	  hedgehog	  signalling	  pathway	  (i.e.	  
Sonic	   hedgehog,	   SHH;	   glioma-­‐associated	   oncogene	   homolog,	   GLI-­‐1	   and	   GLI-­‐2;	   Smoothened,	  
Smo;	  and	  Patched-­‐1)	   (Bolanos	  et	  al.,	  2012).	  Furthermore,	   IPF	  cells	  also	  produce	   low	   levels	  of	  
anti-­‐fibrotic	   mediators	   such	   as	   prostaglandin	   (discussed	   further	   in	   Section	   1.2.7)	  
(Keerthisingam	  et	   al.,	   2001;	   Kohyama	   et	   al.,	   2001;	   Lama	   et	   al.,	   2002;	   Kolodsick	   et	   al.,	   2003;	  
Moore	  et	  al.,	  2003)	  and	  unlike	  AEC,	  myofibroblasts	  are	  more	  resistant	  to	  apoptosis	  (Xu	  et	  al.,	  
2003;	   Ramos	   and	   Becerril,	   2010).	   In	   fact,	   myofibroblasts	   provoke	   AEC	   apoptosis,	   obstruct	  
epithelial	   cell	   regeneration,	  and	  denude	   the	  basement	  membrane.	  This	  provides	  evidence	  of	  
epithelial-­‐mesenchymal	   crosstalk.	   Several	   mediators	   have	   been	   suggested	   to	   modulate	   this	  
imbalance	   in	   apoptosis	   of	   epithelial	   cells	   and	   fibroblasts,	   some	   of	   which	   have	   already	   been	  
discussed	  above	  including	  TGFβ	   (Zhang	  and	  Phan,	  1999;	  Hagimoto	  et	  al.,	  2002),	  FIZZ1	  (Chung	  
et	  al.,	  2007),	   IL-­‐1β	   (Zhang	  et	  al.,	  1997),	   IL-­‐6	   (Moodley	  et	  al.,	  2003),	  and	  TNF-­‐α	   (Piguet	  et	  al.,	  
1993;	  Frankel	  et	  al.,	  2006).	  However	  the	  precise	  molecular	  pathway(s)	  involved	  in	  this	  aberrant	  
epithelial-­‐mesenchymal	  crosstalk	  is	  currently	  an	  area	  of	  intense	  investigation.	  
IPF	  fibroblasts	  also	  have	  enhanced	  an	  migratory	  and	  proliferative	  phenotype	  in	  comparison	  to	  
control	   cells	   (Suganuma	   et	   al.,	   1995;	   Ramos	   et	   al.,	   2001).	   However,	   some	   studies	   have	  
illustrated	   that	   IPF	   fibroblasts	   proliferate	   at	   a	   lower	   rate	   when	   the	   disease	   is	   at	   a	   more	  




advanced	   stage	   (Raghu	   et	   al.,	   1988;	   Hetzel	   et	   al.,	   2005).	   To	   some	   extent	   this	   has	   also	   been	  
assessed	   in	   our	   lab,	   which	   also	   supports	   a	   slower	   proliferation	   rate	   of	   IPF	   fibroblasts	   in	  
comparison	   to	   controls	   (unpublished	  data)	   in	   vitro.	   These	   contradictory	   data	   suggest	   that	   in	  
vitro	  cell	  isolates	  grown	  on	  tissue	  culture	  treated	  plastic	  may	  not	  provide	  a	  true	  representation	  
of	  the	  disease	  pathology	  as	  seen	  in	  vivo	  as	  the	  cells	  may	  undergo	  phenotypic	  modulation	  due	  
to	  the	  change	  in	  microenvironment.	  	  
Collagen	  turnover	  in	  IPF	  
Collagen	  in	  normal	  lungs	  exists	  in	  a	  dynamic	  equilibrium	  where	  synthesis	  and	  degradation	  are	  
regulated	  by	  carefully	  controlled	  processes	  involving	  the	  activity	  of	  several	  enzymes	  as	  well	  as	  
growth	   factors,	   cytokines,	   proteases,	   lipid	   mediators,	   and	   mechanical	   forces	   (see	   Section	  
1.1.3).	  Early	  studies	  in	  our	  lab	  have	  illustrated	  that	  collagen	  synthesis	  and	  degradation	  occurs	  
rapidly	  in	  normal	  adult	  rat	  tissues	  (McAnulty	  and	  Laurent,	  1987).	  However,	  in	  fibrotic	  lung	  this	  
balance	   is	   disrupted	   with	   excessive	   collagen	   deposits	   resulting	   in	   gross	   thickening	   of	   the	  
alveolar	   interstitium	   leading	   to	   the	   remodelling,	   destruction	   of	   the	   lung	   architecture,	   and	  
progressive	   loss	   of	   alveolar	   function.	   Several	   studies	   (including	   past	   and	   current	   research	   in	  
our	  lab)	  have	  illustrated	  this	  in	  both	  in	  vitro	  and	  in	  vivo	  models	  of	  PF	  by	  measuring	  pro-­‐collagen	  
synthesis,	  which	  reflects	  total	  collagen	  content	  (see	  Section	  1.1.3). 
An	   imbalance	   in	   the	   ratio	   of	   collagen	   type	   I	   and	   III	   has	   been	   reportedly	   observed	   in	   lung	  
biopsies	   of	   patients	  with	   IPF,	   whereby	   collagen	   type	   III	   elevates	   excessively	   in	   early	   fibrosis	  
(Kirk	   et	   al.,	   1984).	  However,	   once	   fibrosis	   has	   been	   established	   the	   collagen	   I	   to	   collagen	   III	  
ratio	  alternates	  with	  higher	  levels	  of	  collagen	  I	  observed.	  Since	  collagen	  I	  and	  III	  are	  insoluble	  
proteins	   and	   cannot	   be	  measured	   directly	   from	   the	   patient	  without	   invasive	   biopsy,	   studies	  
analyse	   their	   production	   by	   determining	   the	   levels	   of	   procollagen	   carboxy-­‐terminal	   pro-­‐
peptides	  (PICP	  and	  PIIICP,	  respectively)	  which	  are	  considered	  as	  surrogate	  markers	  for	  collagen	  
synthesis	  (reviewed	  in	  (Dancer	  et	  al.,	  2011)).	  Both	  PICP	  and	  PIIICP	  are	  elevated	  in	  BALF	  of	  IPF	  
patients.	   In	  addition,	  PICP	   levels	   in	   the	  epithelial	   lining	   fluid	  as	  well	  as	  BALF	  had	  a	  significant	  
negative	  correlation	  with	  DLCO	  (Lammi	  et	  al.,	  1999).	  Collagen	  III	  is	  predominantly	  located	  in	  the	  
thickened	   alveolar	   septa	   and	   interstitium,	   although	   collagen	   type	   I	   appears	   to	   be	   the	  major	  
collagen	   at	   later	   stages	   in	   the	   disease	   course.	   This	   has	   been	   demonstrated	   both	  
immunohistochemically	   and	   by	  in	   situ	  mRNA	   studies	   on	   lung	   tissue	   (Raghu	   et	   al.,	   1985).	  	  
Increased	  levels	  of	  other	  ECM	  constituents,	  including	  collagen	  types	  V,	  VI,	  and	  VII,	  fibronectin,	  
elastin,	  and	  proteoglycans	  are	  also	  present	  at	  high	  levels	  in	  IPF	  (Pardo	  et	  al.,	  2008).	  




As	   well	   as	   synthesising	   collagen	   and	   other	   ECM	   proteins,	   fibroblasts	   host	   the	   synthesis	   of	  
matrix	   degrading	   proteins,	   such	   as	  MMPs	   in	   order	   to	   control	   tissue	   architecture	   and	  matrix	  
turnover	  during	  the	   initiation	  and	  resolution	  phases	  following	   injury.	  MMP	  levels	   in	   IPF	   lungs	  
are	  elevated	  in	  comparison	  to	  control	  lungs.	  Since	  MMPs	  degrade	  collagen,	  increased	  levels	  of	  
MMPs	   would	   suggest	   greater	   degradation	   of	   ECM	   protein.	   However	   this	   does	   not	   seem	   to	  
occur	  in	  fibrotic	  lungs	  as	  the	  concentration	  of	  TIMPs	  (endogenous	  MMP	  inhibitors)	  is	  also	  high	  
(Selman,	  2000).	  This	  has	  been	  demonstrated	  by	  many	  studies	  including	  one	  by	  Montano	  et	  al.	  
(1989)	   illustrating	   high	   collagenase	   inhibitory	   activity	   in	   biopsies	   from	   IPF	   patients	   in	  
comparison	   to	   control	   subjects	   (Montaño	   et	   al.,	   1989).	   Additionally,	   Fukuda	   et	   al.	   (1998)	  
showed	   co-­‐localisation	   of	   MMP1,	   MMP2,	   and	   MMP9	   with	   TIMP-­‐2	   at	   the	   epithelium	  
surrounding	  the	  fibrotic	  lesions	  in	  IPF	  lungs.	  High	  levels	  of	  TIMP-­‐2	  suggest	  that	  the	  activity	  of	  
MMP-­‐1,	   -­‐2,	   and	   -­‐9	   are	   inhibited,	   thus	   the	   matrix	   is	   not	   degraded	   (Fukuda	   et	   al.,	   1998).	  
Furthermore,	   immunohistochemical	   analysis	   of	   IPF	   tissue	   has	   demonstrated	   high	   expression	  
levels	  of	  TIMP-­‐1,	  TIMP-­‐3,	  and	  TIMP-­‐4	  in	   interstitial	  macrophages,	  vessels,	  and	  epithelial	  cells,	  
respectively	  (Selman,	  2000).	  
Therefore,	   the	   dysregulated	   balance	   between	   MMPs	   and	   TIMPs	   are	   considered	   to	   aid	  
persistent	  matrix	  deposition	   in	   IPF	   lungs.	  Later	  studies	  have	  also	  reported	  a	  role	  of	  MMP3	  in	  
fibrotic	  diseases.	  Overexpression	  of	  MMP3	  has	  been	  detected	  in	  IPF	  BALF	  (Richter	  et	  al.,	  2009)	  
as	  well	  as	  the	  lungs	  of	   in	  vivo	  model	  of	  PF	  whereby	  mice	  lacking	  MMP3	  were	  protected	  from	  
PF	   in	  comparison	  to	  wild	  type	  (Yamashita	  et	  al.,	  2011).	  Other	  MMPs	  shown	  to	  be	  elevated	  in	  
BALF	  of	   IPF	  patients	   include	  MMP7	   (Fujishima	  et	   al.,	   2010),	  MMP8	   (Henry	  et	   al.,	   2002),	   and	  
MMP12	  (Lanone	  et	  al.,	  2002)	  (Table	  1.5).	  In	  addition,	  membrane-­‐type	  MMPs	  (MT-­‐MMPs)	  are	  
also	   elevated	   in	   IPF	   patients.	   MT-­‐MMPs	   participate	   in	   the	   activation	   of	   pro-­‐MMP2	   to	   form	  
MMP2.	   MT1-­‐MMP	   and	   MT2-­‐MMP	   are	   expressed	   in	   AECs,	   MT3-­‐MMP	   in	   fibroblasts	   from	  
fibroblastic	   foci	   and	   AECs,	   and	   MT5-­‐MMP	   is	   expressed	   in	   basal	   bronchiolar	   epithelial	   cells.	  
Furthermore,	  TGFβ1	  upregulates	  MT3-­‐MMP	  levels	  (both	  mRNA	  and	  protein)	  in	  lung	  fibroblasts	  




	   	  




Table	  1.	  5:	  Elevated	  MMPs	  shown	  in	  IPF	  patients	  
	   Substrate	  
Studied	  in	  IPF	  
patients	  
Cellular	  source	   References	  
MMP1	  










(Nkyimbeng	  et	  al.,	  
2013)	  







(Nkyimbeng	  et	  al.,	  
2013)	  
MMP3	  
Collagen	  II,	  IV,	  IX,	  
fibronectin,	  proteoglycan,	  
laminin,	  elastin,	  gelatins,	  
MMP1,	  MMP7,	  MMP9	  
BALF	   Epithelial	  cells	  
(Matrisian,	  1990;	  
Murphy	  et	  al.,	  
1992;	  Richter	  et	  
al.,	  2009)	  
MMP7	  
Collagen	  IV,	  laminin,	  
fibronectin,	  gelatine,	  
elastin,	  osteopontin,	  FasL,	  
integrin	  β4,E-­‐caderin,	  pro-­‐










(Rosas	  et	  al.,	  
2008;	  McKeown	  
et	  al.,	  2009;	  
Nkyimbeng	  et	  al.,	  
2013)	  
MMP8	   Collagen	  I	   BALF	  







(Henry	  et	  al.,	  
2002;	  McKeown	  
et	  al.,	  2009)	  









Clara	  cells,	  smooth	  
muscle	  cells	  
(McKeown	  et	  al.,	  
2009;	  Nkyimbeng	  
et	  al.,	  2013)	  	  





(Nkyimbeng	  et	  al.,	  
2013)	  







(Henry	  et	  al.,	  
2002;	  Nkyimbeng	  

















































	   	  




Despite	   several	   studies	   focusing	   on	   the	   roles	   of	   MMPs	   in	   IPF,	   there	   are	   several	   potentially	  
important	  MMPs	  which	  currently	   remain	  poorly	   studied.	   For	   instance,	  microarray	   studies	  on	  
IPF	   tissue	   have	   shown	   upregulated	  MMP-­‐10	   and	  MMP-­‐28	   expression	   however	   their	   cellular	  
sources,	   substrates	   and	   function	   are	   unknown.	   MMP-­‐28	   may	   potentially	   be	   of	   interest	   as	  
studies	   have	   proposed	   that	   this	   may	   play	   a	   role	   in	   EMT	   and	   proteolytic	   cleavage	   of	   TGFβ	  
(Illman	   et	   al.,	   2006).	   Further	   work	   to	   elucidate	   the	   significance	   of	   these	   novel	   MMPs	   is	  
currently	  ongoing.	  
1.2.6.	   Transforming	  growth	  factor-­‐beta	  (TGFβ)	  
TGFβ	   is	   a	  multifactorial	   protein	  belonging	   to	   a	  wider	   TGFβ	   superfamily	   composed	  of	   several	  
other	   factors	   including	   bone	   morphogenetic	   proteins	   (BMPs),	  growth	   and	   differentiation	  
factors	  (GDFs),	  activins,	  inhibins,	  and	  nodal.	  TGFβ	   is	  considered	  to	  be	  a	  potent	  cytokine	  which	  
exerts	   several	   cellular	  effects	   including	  differentiation	  and	  proliferation	  during	  development,	  
immune	  responses,	  wound	  healing,	  and	  tumour-­‐cell	  growth/inhibition.	  The	  importance	  of	  this	  
cytokine	  in	  normal	  embryonic,	  foetal,	  and	  adult	  organ	  development	  has	  been	  well	  described.	  
In	  particular,	  the	  role	  of	  TGFβ	   in	  the	  production,	  organisation,	  and	  degradation	  of	  connective	  
tissue	  for	  organ	  homeostasis	  has	  been	  widely	  appreciated.	  
TGFβ exists	   in	  three	   isoforms	  within	  the	  human	  body:	  TGFβ1,	  -­‐2,	  and	  -­‐3,	  each	  having	  distinct	  
non-­‐overlapping	  roles	   in	  vivo	   (Shi	  and	  Massague,	  2003).	  Many	  different	  cell	   types	  express	  all	  
three	  isoforms	  and	  during	  normal	  lung	  development	  the	  expression	  levels	  of	  all	  three	  types	  are	  
elevated	  (Bartram	  and	  Speer,	  2004).	  	  However,	  TGFβ1	  is	  known	  to	  be	  the	  most	  abundant	  and	  
best	   characterised.	   	   From	   this	   point	   forward	   TGFβ1	  will	   be	   abbreviated	   as	   just	   TGFβ,	   unless	  
otherwise	  stated.	  Most	  cells	  express	  TGFβ receptor	  (TβR)-­‐I	  and	  TβR-­‐II	  (Shi	  et	  al.,	  2011).	  Despite	  
having	  a	  widespread	  expression,	  activation	  of	  the	  receptors	   is	   localised	  within	  regions	  where	  
latent	  TGFβ	  is	  converted	  to	  active	  TGFβ (described	  in	  detail	  later).	  	  
Role	  of	  TGFβ 	  in	  normal	  and	  fibrotic	  lungs	  	  
In	   the	   lung,	   cellular	   sources	   of	   TGFβ	   include	   fibroblasts,	  myofibroblasts	   (Kelley	   et	   al.,	   1991),	  
type	   II	   AECs	   (Xu	   et	   al.,	   2003),	   endothelial	   cells	   (Grotendorst	   et	   al.,	   1989b),	   monocytes,	  
neutrophils,	   and	   macrophages	   (Grotendorst	   et	   al.,	   1989a).	   Once	   synthesised	   and	   activated,	  
TGFβ	   can	   regulate	   several	   effects	   some	   of	   which	   have	   already	   been	   described	   above.	  
Moreover,	  TGFβ	   is	  a	  potent	  chemoattractant	  and	  mitogen	   for	   fibroblasts	  and	  myofibroblasts	  	  




(Postlethwaite	  et	  al.,	  1987)	  stimulating	  a	   fibroproliferative	   response.	  Furthermore,	  TGFβ	  also	  
elicits	   several	   negative	   growth	   responses	   in	   epithelial	   and	   endothelial	   cells.	   For	   instance,	   in	  
vitro	  TGFβ	  prevents	  the	  formation	  of	  active	  cyclin	  E/CDK2	  complex	  in	  mink	  lung	  epithelial	  cells,	  
which	   in	   turn	   results	   in	   the	   induction	   of	   G1	   cell	   cycle	   arrest	   and	   inhibits	   mink	   lung	   cell	  
proliferation	  (Koff	  et	  al.,	  1993).	  And	  as	  stated	  before,	  TGFβ	  has	  also	  promotes	  EMT.	  Since	  TGFβ	  
is	  multifactorial	  and	  often	  elevated	  during	  abnormalities	   in	   tissue	  growth,	   it	   is	   considered	  as	  
one	  of	  the	  most	  important	  molecular	  regulators	  of	  tissue	  homeostasis.	  	  
There	  is	  a	  great	  deal	  of	  evidence	  showing	  the	  profibrogenic	  effects	  of	  this	  cytokine	  in	   in	  vitro	  
models,	   in	   vivo	  models,	   and	   in	   IPF	  patients.	   For	   instance,	   TGFβ	   stimulates	   the	  production	  of	  
various	   collagen	   types	   as	   well	   as	   other	   ECM	   proteins	   (such	   as	   elastin,	   tenascin,	   vitronectin,	  
fibronectin,	   and	   proteoglycans)	   by	  mesenchymal	   cells	   (Saharinen	   et	   al.,	   1999).	   Furthermore,	  
TGFβ	  is	  also	  able	  to	  attenuate	  MMP	  production,	  stimulate	  the	  synthesis	  of	  TIMPs	  (Edwards	  et	  
al.,	   1987),	   increases	   the	   expression	   of	   HSP47	   to	   enhance	   the	   efficacy	   of	   procollagen	  
processing,	  and	  sensitise	  fibroblasts	  to	  its	  own	  effects	  and	  maintain	  them	  in	  an	  activated	  state	  
by	   an	   autocrine	   mechanism	   which	   results	   in	   further	   production	   of	   TGF-­‐β	   (Van	   Obberghen-­‐
Schilling	  et	  al.,	  1988;	  Pannu	  et	  al.,	  2007).	  This	  therefore	  suggests	  that	  excess	  activation	  of	  TGFβ	  
contributes	  to	  the	  formation	  of	  a	  pro-­‐fibrotic	  environment.	   	  
TGFβ 	  synthesis	  and	  activation	  	  
TGFB1	   not	   only	   encodes	   the	   12.5	   kDa	   C-­‐terminal	   TGFβ	   moiety,	   but	   also	   an	   N-­‐terminal	  
prodomain	  called	  latency-­‐associated	  peptide	  (LAP;	  25kDa)	  which	  plays	  a	  key	  role	  in	  facilitating	  
the	   release	   of	   the	   entire	   TGFβ-­‐LAP	  molecule	   from	   the	   cell	   into	   the	   ECM	   (Figure	   1.11).	   	   The	  
TGFβ	   monomers	   dimerise	   by	   a	   single	   disulphide	   bond	   while	   two	   disulphide	   bonds	   form	  
between	  the	  larger	  LAP	  monomers	  (Gentry	  et	  al.,	  1988).	  Once	  the	  homodimeric	  LAP-­‐TGFβ	  pro-­‐
peptide	  complex	  enters	  the	  Golgi	  apparatus,	  furin-­‐type	  endopeptidases	  cleave	  the	  pro-­‐peptide	  
causing	  LAP	  to	  surround	  TGFβ	  and	  remain	  non-­‐covalently	  associated.	  This	  LAP-­‐TGFβ	  complex	  
(also	  known	  as	  the	  small	   latency	  complex,	  SLC)	   is	  released	  into	  the	  ECM.	  However	  most	  cells	  
secrete	  latent	  TGFβ	  as	  a	  large-­‐latency	  complex	  (LLC)	  which	  is	  comprised	  of	  the	  LAP-­‐TGFβ	  dimer	  
covalently	   associated	   to	   a	   120-­‐240kDa	   glycoprotein	   known	   as	   latent	   TGFβ	   binding	   protein	  
(LTBP)	  (Gleizes	  et	  al.,	  1997;	  Worthington	  et	  al.,	  2011).	  Studies	  have	  shown	  that	  abnormalities	  
in	  LTBP	   lead	   to	  misfolding	  of	   the	  SLC	  within	   the	  Golgi	  apparatus.	  Thus,	  LTBP	   is	  necessary	   for	  
direct	   processing	   and	   secretion	   of	   TGFβ	   from	   most	   cells	   (Miyazono	   and	   Heldin,	   1991;	  
Miyazono	  et	  al.,	  1991).	  Once	  the	  LLC	  is	  secreted	  from	  the	  cell,	  the	  LTBP	  plays	  a	  crucial	  role	  in	  










targeting	   the	   latent-­‐TGFβ	   complex	   to	   the	   ECM	   (Taipale	   et	   al.,	   1994;	   Koli	   et	   al.,	   2001).	   The	  
amino	   terminus	   of	   LTBP	   is	   covalently	   cross-­‐linked	   to	   components	   of	   the	   ECM	   via	   tissue	  
transglutaminase	  (Nunes	  et	  al.,	  1997).	  In	  the	  LLC,	  TGFβ	  is	  in	  its	  inactive	  state	  and	  is	  unable	  to	  
associate	  with	  its	  receptor.	  
	  
Figure	  1.	  11:	  TGF-­‐beta	  synthesis	  
TGFβ	   is	   transcribed	  as	  a	  propeptide	   consisting	  of	   a	  C-­‐terminal	   TGFβ	  moiety	  and	  an	  N-­‐
terminal	  RGD	  sequence	  containing	  latency	  associated	  peptide	  (LAP).	  This	  RGD	  sequence	  
is	   only	   present	   in	   TGFβ1	   and	   TGFβ3	   isoforms	   (not	   TGFβ2).	   (i)	   The	   propeptide	   forms	   a	  
homodimer.	   (ii)	   In	   the	   Golgi,	   furin	   enzyme	   cleaves	   the	   propeptide.	   (iii)	   TGFβ	   and	   LAP	  
remain	   non-­‐covalently	   associated	   with	   each	   other	   and	   form	   a	   small-­‐latency	   complex	  
(SLC).	  (iv)	  SLC	  associates	  with	  latent	  TGFβ binding	  protein	  (LTBP)	  via	  a	  disulphide	  bridge	  
and	  forms	  a	  large	  latency	  complex.	  
Reproduced	  from	  (Worthington	  et	  al.,	  2011)	  with	  permissions	  of	  Elsevier	  Ltd.	  	  
	  
The	  majority	  of	  cultured	  cells	  are	  unable	  to	  secrete	  significant	  levels	  of	  latent	  TGFβ	  or	  activate	  
TGFβ	   in	   the	   absence	   of	   an	   exogenous	   stimulus.	   Nevertheless,	   numerous	   physiological	  
conditions	   are	   able	   to	   promote	   TGFβ	   activation	   in	   vitro.	   Such	   conditions	   include	   heat,	   pH,	  
radiation,	   enzymatic	   processing,	   detergents,	   urea,	   and	   shear	   stress	   (Brown	   et	   al.,	   1990).	  




Furthermore,	  several	  exogenous	  stimuli	  also	  promote	  TGFβ	  activation.	  These	  include	  reactive	  
oxygen	   species	   (ROS),	   MMPs,	   thrombospondin-­‐1	   (TSP-­‐1),	   and	   integrins.	   TSP-­‐1	   and	   integrin	  
mediated	  TGFβ	  activation	  will	  be	  discussed	  in	  a	  little	  more	  detail	  in	  this	  section.	  
TSP-­‐1	  is	  a	  large,	  disulphide-­‐linked	  homotrimeric	  protein	  which	  is	  elevated	  during	  development	  
and	   in	   response	   to	   injury.	   It	   is	   considered	   to	   be	   a	  major	   activator	   for	   both	   small	   and	   large	  
forms	  of	  latent	  TGFβ (Raugi	  et	  al.,	  1987;	  O’Shea	  et	  al.,	  1990;	  Reed	  et	  al.,	  1995;	  Yehualaeshet	  et	  
al.,	   1999)	   in	   many	   fibrotic	   diseases	   including	   systemic	   sclerosis	   (SSc),	   kidney	   fibrosis,	   liver	  
fibrosis,	   and	   lung	   fibrosis	   (reviewed	   in	   (Nakerakanti,	   2012)).	   Binding	   of	   TSP-­‐1	   to	   LAP-­‐TGFβ	  
latent	   complex	   is	  mediated	  by	   two	  sequences:	  WxxW	  which	  directly	  associates	   to	   the	  active	  
TGFβ	  dimer,	  and	  KRFK	  motif	  which	  binds	  to	  the	  LSKL	  sequence	  located	  on	  the	  amino	  terminal	  
of	   LAP.	   Studies	   have	   suggested	   that	   the	   association	   of	   TSP-­‐1	   KRFK	   motif	   with	   the	   LSKL	  
sequence	  of	  LAP	  results	  in	  a	  conformation	  change	  in	  the	  TGFβ	  latency	  complex	  leading	  to	  the	  
release	   of	   active	   TGFβ	   dimer.	   However,	   a	   mimetic	   LSKL	   peptide	   is	   able	   to	   inhibit	   TSP-­‐1	  
mediated	  TGFβ	  activation	  in	  vitro	  by	  competitively	  associating	  to	  the	  KRFK	  sequence	  of	  TSP-­‐1,	  
preventing	  it	  from	  associating	  to	  the	  LAP	  LSKL	  motif	  (Xie	  et	  al.,	  2010).	  
Over	   the	  past	  decade	   integrin-­‐mediated	  TGFβ	   activation	  has	  been	  studied	  by	  many	   research	  
groups.	  Integrins	  are	  heterodimeric	  type-­‐1	  transmembrane	  cell	  adhesion	  receptors	  composed	  
of	  non-­‐covalently	  associated	  α	  and	  β	  subunits.	  They	  have	  a	  key	  role	  in	  mediating	  interactions	  
between	  the	  ECM	  and	  the	  cytoskeleton.	  24	  integrins	  have	  been	  identified	  in	  mammals,	  and	  in	  
vitro	   studies	  have	   illustrated	   that	  6	   integrins	   (αvβ1,	  αvβ3,	  αvβ5,	  αvβ6,	  αvβ8	  and	  α8β1)	  are	  
able	  to	  recognise	  and	  interact	  with	  a	  tri-­‐peptide	  RGD	  motif	  located	  in	  LAP	  (only	  on	  the	  latent	  
form	   of	   TGFβ1	   and	   TGFβ3,	   not	   TGFβ2).	   However,	   the	   activation	   of	   TGFβ	   has	   only	   been	  
demonstrated	  in	  vivo	  by	  integrins	  αvβ3,	  αvβ5, αvβ6,	  and	  αvβ8.	  The	  physiological	  relevance	  of	  
the	  latent	  TGFβ	  interaction	  with	  integrins	  αvβ1	  and	  α8β1	  is	  not	  known	  (Jenkins	  et	  al.,	  2006).	  	  
Integrins	  αvβ3	  and	  αvβ5	  are	  expressed	   in	  many	  cells	   including	  fibroblasts.	  Both	   integrins	  are	  
able	  to	  activate	  TGFβ,	  and	  it	  is	  believed	  that	  αvβ5	  causes	  the	  transformation	  of	  fibroblasts	  to	  
myofibroblasts	  via	  TGFβ	  activation	  (Zhou	  et	  al.,	  2010).	   In	  addition,	   immunohistochemistry	  on	  
IPF	  tissue	  has	  demonstrated	  that	  αvβ5	  localises	  with	  αSMA	  within	  the	  fibrotic	  foci	  suggesting	  
that	  αvβ5	  may	  have	  an	  important	  role	  in	  the	  development	  of	  IPF	  possibly	  by	  activating	  TGFβ	  
within	  the	  fibrotic	  foci	  (Scotton	  et	  al.,	  2009).	  However,	  recent	  studies	  involving	  the	  bleomycin	  
model	   have	   demonstrated	   that	   mice	   lacking	   both	   αvβ3	   and	   αvβ5	   are	   not	   protected	   from	  
bleomycin-­‐induced	   PF	   (Atabai	   et	   al.,	   2009;	   Worthington	   et	   al.,	   2011).	   Nevertheless,	   it	   is	  




important	   to	   note	   that	   in	   the	   bleomycin	   model	   of	   PF,	   mice	   do	   not	   develop	   fibrotic	   foci.	  
Therefore,	   more	   studies	   are	   required	   to	   investigate	   the	   precise	   role	   of	   these	   integrins	   in	  
fibrosis.	   Unlike	  αvβ3	   and	  αvβ5,	   the	   expression	   of	  αvβ6	   is	   limited	   to	   epithelial	   cells.	   Studies	  
have	  shown	  that	  upon	  tissue	  injury,	  the	  expression	  of	  this	  integrin	  is	  upregulated.	  In	  addition,	  	  	  
Itgb6-­‐/-­‐	  mice	  have	   reduced	  activation	  of	   TGFβ	   and	  are	  protected	   from	  bleomycin-­‐induced	  PF	  
(Munger	   et	   al.,	   1999).	   Integrin	   αvβ6	   may	   also	   have	   a	   vital	   role	   in	   the	   development	   and	  
progression	  of	  PF.	  	  
It	  had	  been	  assumed	  that	  the	  mechanism	  by	  which	  integrins	  activate	  TGFβ	  involves	  cleavage	  of	  
TGFβ.	   However,	   cell	   culture	   models	   have	   demonstrated	   that	   in	   the	   presence	   of	   protease	  
inhibitors,	  αvβ5	  and	  αvβ6-­‐mediated	  latent	  TGFβ	  activation	  is	  not	  inhibited,	  suggesting	  that	  the	  
activation	  is	  independent	  of	  cleavage.	  It	  is	  now	  presumed	  that	  binding	  of	  integrins	  to	  the	  RGD	  
motif	  induces	  a	  conformational	  change	  to	  the	  latent	  TGFβ	  structure,	  allowing	  the	  active	  TGFβ	  
to	  interact	  with	  its	  receptor	  on	  neighbouring	  cells	  (Munger	  et	  al.,	  1999;	  Wipff	  et	  al.,	  2007;	  Hinz	  
and	  Gabbiani,	  2010).	  
Cell	  contraction	  plays	  a	  vital	   role	   in	  αvβ5-­‐	  and	  αvβ6-­‐mediated	  TGFβ	  activation.	   In	  vitro	  work	  
has	  demonstrated	  that	  TGFβ	  activation	  is	  dependent	  on	  an	  intact	  actin	  cytoskeleton.	  Treating	  
cells	  with	  an	  actin	  polymerisation	  inhibitor	  (i.e.	  cytochalasin	  D)	  causes	  a	  decrease	  in	   integrin-­‐
mediated	   TGFβ	   activation.	   Furthermore,	   treatment	   of	   myofibroblasts	   with	   inhibitors	   of	   cell	  
contraction	   (i.e.	   blebbistatin)	   also	   reduces	   TGFβ	   activation	   via	   αvβ5.	   Moreover,	   treating	  
myofibroblasts	   with	   agents	   that	   promote	   cell	   contraction	   enhances	   αvβ5-­‐mediated	   TGFβ	  
activation.	  Such	  agents	  include	  endothelin-­‐1,	  thrombin,	  and	  angiotensin-­‐II.	  In	  addition,	  seeding	  
myofibroblasts	   on	   to	   substrates	   that	   facilitate	   cell	   contraction	   (i.e.	   stiff	   silicone	   substrates)	  
promotes	   the	   activation	   of	   TGFβ	   in	   the	   presence	   of	  αvβ5	   in	   comparison	   to	   myofibroblasts	  
seeded	  on	  to	  more	  flexible	  substrates	  (that	  do	  not	  support	  contraction	  of	  the	  cells).	  All	  these	  in	  
vitro	   studies	  support	   that	  cell	  contraction	   is	   important	   in	  TGFβ	  activation	   (Wipff	  et	  al.,	  2007;	  
Worthington	  et	  al.,	  2011).	  In	  addition,	  over	  the	  past	  few	  years	  the	  role	  of	  proteinase-­‐activated	  
receptor	   (PAR)-­‐1	   in	   promoting	   integrin-­‐mediated	   activation	   has	   also	   been	   studied	   whereby	  
αvβ6	  and	  αvβ5	  are	  activated	  downstream	  of	  PAR1	   signalling	   (Figure	  1.12)	   (Chambers	  et	   al.,	  
2000;	  Jenkins	  et	  al.,	  2006;	  Scotton	  et	  al.,	  2009).	  	  
	  





Figure	  1.	  12:	  Integrin-­‐mediated	  TGF-­‐
beta	  activation	  via	  proteinase	  
activated	  receptor	  (PAR)-­‐1.	  
(A)	   Structure	   of	   the	   latent	   TGFβ	  
complex	   (B)	   Thrombin	  mediated	   PAR1	  
activation	   triggers	   the	   Rho-­‐ROCK	  
pathway,	   which	   in	   turn	   activates	  
myofibroblast-­‐expressed	   integrin	  αvβ3	  
or	  αvβ5,	   or	   epithelial-­‐expressed	   avβ6.	  
These	   integrins	   recognise	   the	   RGD	  
sequence	   on	   the	   latency	   associated	  
peptide	   (LAP),	   resulting	   in	   a	  
conformational	   change	   to	   the	   latent	  
complex,	   releasing	   the	   active	   TGFβ.	  
Active	   TGFβ	   bind	   to	   its	   receptor	   on	  
neighbouring	   cells,	   triggering	   Smad-­‐
dependent	   and	   Smad-­‐independent	  
intracellular	  pathways.	  
Reproduced	   from	   (Worthington	   et	   al.,	  
2011),	  with	  permission	  of	  Elsevier	  Ltd.	  
	  
TGFβ 	  signalling	  pathways	  
Following	   TGFβ	   activation,	   various	   proteoglycans	   enhance	   the	   delivery	   of	   active	   TGFβ	   to	   its	  
receptor.	   The	   best	   characterised	   are	   glypcians.	   These	   are	   small	   proteoglycans	   composed	   of	  
heparin	   sulphate	   glycosaminoglycan	   (GAG)	   side	   chains	   associated	   to	   the	   extracytoplasmic	  
surface	  of	  the	  cell	  membrane	  by	  glycosylphosphatidyl	   intositol	  anchors	  (Cheifetz	  et	  al.,	  1988;	  
Kayed	   et	   al.,	   2006).	   Glypcians	   behaves	   as	   a	   co-­‐receptor	   for	   not	   only	   active	   TGFβ,	   but	   also	  
several	  other	  growth	  factors	  including	  PDGF	  (Higashiyama	  et	  al.,	  1993),	  VEGF	  (Dougher	  et	  al.,	  
1997),	  BMPs	  (Paine-­‐Saunders	  et	  al.,	  2000),	  activins	  (Nakamura	  et	  al.,	  1991),	  and	  Wnt	  family	  of	  
secreted	  glycoproteins	  (Reichsman	  et	  al.,	  1996;	  Kayed	  et	  al.,	  2006).	  
Once	  TGFβ	  associates	  with	   its	   receptor,	  several	   intracellular	  signalling	  processes	  are	   initiated	  
including	  the	  canonical	  pathway	  which	  involves	  the	  activation	  of	  Smad	  protein.	  In	  brief,	  active	  
TGFβ	  associates	  with	  the	  homodimeric	  serine	  threonine	  transmembrane	  kinase	  receptor	  (i.e.	  
Tβ-­‐RII).	  This	  promotes	  the	  recruitment	  of	  homodimer	  Tβ-­‐RI	  (activin-­‐like	  kinase-­‐5,	  ALK-­‐5)	  which	  
interacts	  with	  the	  Tβ-­‐RII	  dimer	  resulting	  in	  the	  formation	  of	  a	  tetrameric	  cell	  surface	  complex.	  
This	   promotes	   the	   Tβ-­‐RII	   kinase	   to	   phosphorylate	   the	   serine	   and	   threonine	   residues	   in	   the	  
short	   juxtamembrane	   glycine/serine	   rich	   (GS)	   domains	   of	   the	   Tβ-­‐RI	   (Souchelnytskyi	   et	   al.,	  




1996).	   This	   results	   in	   a	   conformational	   change	   in	   Tβ-­‐RI	   (Huse	   et	   al.,	   2001)	   causing	   the	  
activation	   of	   its	   kinase	   activity.	   Activation	   of	   ALK-­‐5	   kinase	   activity	   results	   in	   the	   recruitment	  
and	  phosphorylation	  of	  R-­‐Smad	  (Smad	  2/3)	  which	  occurs	  with	  the	  help	  of	  SARA	  (Smad	  anchor	  
for	  receptor	  activation).	  Phosphorylated	  Smad	  2/3	  then	  form	  a	  heteromeric	  complex	  with	  co-­‐
Smad	   (Smad	  4)	   in	   the	   cell	   cytoplasm.	   This	   Smad	   complex	   then	   translocates	   into	   the	  nucleus	  
and	  binds	  to	  specific	  DNA-­‐binding	  sites	  on	  the	  promoter	  regions	  of	  target	  genes	  with	  the	  help	  
of	   intranuclear	   transcriptional	   partners.	   Such	   genes	   including	   those	   encoding	  CTGF,	   collagen	  
type	   I,	   and	   integrin	  β6.	   Thus,	   activation	   of	   TGFβ	   via	  αvβ6	   creates	   a	   positive	   feedback	   loop	  	  
(Margadant	  and	  Sonnenberg,	  2010).	  This	  creates	  a	  profibrotic	  environment,	  which	  exists	  in	  IPF	  
patients	  and	  it	  has	  been	  suggested	  that	  this	  may	  be	  involved	  in	  driving	  the	  progression	  of	  the	  
disease.	  	  
In	  addition,	  the	  Smad-­‐dependent	  TGFβ	  signalling	  pathway	  may	  also	  promote	  the	  synthesis	  of	  
plasminogen	   activator	   inhibitor	   1	   (PAI-­‐1).	   This	   protein	   is	   the	   principle	   inhibitor	   for	   serine	  
proteinases	  tissue-­‐	  and	  urokinase-­‐plasminogen	  activator	  (tPA	  and	  uPA).	  Both	  tPA	  and	  uPA	  are	  
involved	   in	   the	   conversion	  of	  plasminogen	   to	  plasmin	  which	  promotes	   fibrin	  degradation.	   In	  
addition,	   studies	   have	   demonstrated	   that	   plasmin	   also	   plays	   a	   key	   role	   in	   MMP	   activation	  
(including	   MMP2,	   MMP3,	   MMP9,	   MMP12,	   and	   MMP13	   (reviewed	   in	   (Liu,	   2008)).	   Thus,	  
inhibition	   of	   tPA	   and	   uPA	   activity	   via	   PAI-­‐1	   not	   only	   inhibits	   fibrinolysis,	   but	   also	   reduces	  
collagen	  degradation.	  In	  BALF	  of	  IPF	  patients,	  PAI-­‐1	  expression	  is	  elevated.	  This	  has	  also	  been	  
demonstrated	  in	  murine	  models	  of	  PF.	  	  
Activation	  of	  ALK-­‐1	  also	   contributes	   to	   the	   fibrotic	   response	  by	  promoting	   the	  expression	  of	  
target	   genes.	   This	   occurs	   as	   a	   result	   of	   phosphorylation	   and	   activation	   of	   the	   non-­‐receptor	  
tyrosine	   kinase,	   c-­‐Abl	   (cellular	   Abelson	   non-­‐receptor	   kinase)	   (Wilkes	   and	   Leof,	   2006;	   Rahimi	  
and	   Leof,	   2007),	  which	  activates	   several	   downstream	  molecules	   including	  protein	   kinase	  C-­‐δ	  
(PKC-­‐δ),	   and	   EGR	   transcription	   leading	   to	   Smad2/3-­‐independent	   collagen	   synthesis	  
(Bhattacharyya	  et	  al.,	  2009).	  In	  addition,	  TGFβ	  also	  modulates	  the	  activity	  of	  several	  other	  non-­‐
canonical	   (or	  Smad-­‐independent)	  pathways	   including	  phosphatidylinositol-­‐3-­‐kinase(PI3K)/AKT	  
pathway,	   Rho-­‐like	   GTPase	   signalling	   pathway,	   and	  mitogen	   activated	   protein	   kinase	   (MAPK)	  
pathway	  (Moustakas	  and	  Heldin,	  2005;	  Zhang,	  2009;	  Mu	  et	  al.,	  2012).	  
As	   well	   as	   promoting	   gene	   transcription,	   studies	   have	   shown	   that	   activated	   TGFβ	   receptor	  
complexes	  may	  be	  internalised	  via	  lipid	  rafts	  and	  caveolin-­‐1	  where	  they	  are	  poly-­‐ubiquitinated	  
by	   E3	   ubiquitin	   ligase	   (recruited	   by	   Smad	   7	   and	   Smurf	   2)	   and	   destined	   for	   degradation	   (Di	  




Guglielmo	  et	  al.,	  2003;	  Razani	  et	  al.,	  2001).	  Thus,	  TGFβ	  activation	  and	  degradation	  is	  a	  carefully	  
controlled	  process	  and	  alterations	  in	  these	  mechanisms	  play	  a	  role	  in	  the	  pathogenesis	  of	  IPF	  
(Kardassis	  et	  al.,	  2009;	  Heldin	  and	  Moustakas,	  2012;	  Choi	  et	  al.,	  2014). 
Inhibiting	   the	   activity	   of	   active	   TGFβ	   signalling	   has	   been	   studied	   in	   various	   diseases,	   which	  
have	   mainly	   focused	   on	   developing	   TGFβ	   receptor	   inhibitors,	   such	   as	   SB-­‐525334A	  
(GlaxoSmithKline,	   UK)	   and	   SD-­‐208	   (Scios	   Inc.,	   USA).	   Such	   inhibitors	   attenuate	   bleomycin-­‐
induced	  PF	  (Higashiyama	  et	  al.,	  2007).	  In	  addition,	  studies	  also	  aim	  to	  develop	  agents	  that	  may	  
target	   the	  activation	  of	  TGFβ, such	  as αvβ5	  and	  αvβ6	   inhibitors	  which	  could	  possibly	   reduce	  
fibrotic	  responses.	  	  
1.2.7.	   Prostanoids	  	  
Alterations	  in	  the	  levels	  of	  antifibrotic	  mediators	  within	  the	  lung	  may	  result	  in	  PF,	  and	  studies	  
have	  investigated	  the	  potential	  role	  of	  prostanoids	  in	  the	  pathogenesis	  of	  IPF.	  Prostanoids	  are	  
a	   subclass	   of	   eicosanoids	   composed	   of	   prostaglandins	   (PG)	   and	   thromboxanes	   which	   are	  
synthesised	  via	  the	  metabolism	  of	  arachidonic	  acid	  (AA).	  The	  major	  prostanoid	  within	  the	  lung	  
is	   prostaglandin	   E2	   (PGE2)	   which	   is	   produced	   by	   several	   cells	   including	   epithelial	   cells,	  
fibroblasts,	   and	   alveolar	   macrophages	   (Churchill	   et	   al.,	   1989;	   Hempel	   et	   al.,	   1994a,	   1994b;	  
Jordana	   et	   al.,	   1994;	   Kolodsick	   et	   al.,	   2003).	   This	   section	   summarizes	   our	   current	  
understanding	   regarding	   the	   role	   of	   PGE2	   in	   modulating	   lung	   fibrosis.	   In	   addition,	   other	  
prostanoids	  such	  as	  PGI2	  and	  PGF2α	  will	  also	  be	  briefly	  discussed.	  
PGE2	  biosynthesis,	  regulation	  and	  receptor	  signalling	  
Figure	  1.13	  summarises	  the	  prostanoid	  synthesis	  pathway.	  AA	  is	  a	  polyunsaturated	  fatty	  acid	  
located	  in	  phospholipids	  of	  cell	  membranes.	  Free	  AA	  is	   liberated	  from	  the	  membrane	  via	  the	  
activity	   of	   phospholipase	   A2	   (PLA2)	   in	   response	   to	   various	   pathological	   and	   physiological	  
stimuli.	  Following	   this,	   the	   free	  AA	   is	  metabolised	  via	   the	  5-­‐lipoxygenase	   (5-­‐LOX)	  pathway	  or	  
the	   cyclooxygenase	   (COX)	   pathway.	   The	   former	   pathway	   occurs	   primarily	   in	   leukocytes	   and	  
macrophages,	  giving	  rise	  to	  leukotrienes	  (Ford-­‐Hutchinson	  et	  al.,	  1994).	  However,	  it	  has	  been	  
shown	  that	  AECs	  may	  also	  produce	  cycterinyl	  leukotrienes	  at	  low	  concentrations	  (Vannella	  et	  
al.,	  2010).	  On	  the	  other,	   the	  COX	  pathway	  yields	  prostanoid	  products.	  The	   initial	   step	  of	   this	  
pathway	  involves	  the	  bis-­‐dioxygenation	  and	  subsequent	  reduction	  of	  AA	  via	  the	  activity	  of	  COX	  




enzymes	   (the	  rate-­‐limiting	  enzymes),	   resulting	   in	   the	  production	  of	  PGH2.	  Currently	   two	  COX	  
enzymes	  have	  been	  studied	  extensively,	  COX1	  and	  COX2.	  	  
	  
	  
COX1	  is	  expressed	  constitutively	  whereas	  COX2	  expression	  is	  transient	  and	  induced	  via	  several	  
























Figure	  1.	  13:	  Prostaglandin	  biosynthetic	  pathway.	  	  
Arachidonic	  acid	  is	  released	  from	  cell	  membranes	  via	  the	  activity	  of	  phospholipase	  A2	  
(PLA2).	  Cyclooxygenase	  (COX)-­‐1	  and	  COX-­‐2	  catalyse	  the	  production	  of	  prostaglandin	  H2	  
from	   the	   arachidonic	   acid.	   Specific	   prostaglandin	   synthases	   then	   promote	   the	  
formation	  of	   PGE2,	   PGD2,	   PGF2α,	   PGI2,	   or	   thromboxane	  A2.	   Each	  of	   these	  prostanoids	  
have	   specific	   G-­‐protein	   coupled	   receptors	   to	   which	   they	   associate	   to	   and	   activate	  
downstream	  signalling	  pathways.	  
Reproduced	  from	  (Rahnama’i	  et	  al.,	  2012)	  with	  permission	  of	  Nature	  publishing	  group.	  




cells	   which	   express	   COX2	   constitutively)	   (Walenga	   et	   al.,	   1996;	   Ermert	   et	   al.,	   1998;	   Simon,	  
1999).	   Stimuli	   include	   TGFβ,	   IL-­‐1β,	   hepatocyte	   growth	   factor	   (HGF),	   lipopolysaccharide,	   and	  
plasmin	   (Brock	   et	   al.,	   2003;	   Coward	   et	   al.,	   2010).	   These	   mediators	   not	   only	   promote	   the	  
binding	   of	   transcription	   factors	   to	   the	   COX2	   promoter	   regions	   (i.e.	   NFkB,	   AP-­‐1,	   and	   cAMP	  
response	  elements	  or	  CREs)	   (Appleby	  et	  al.,	  1994),	  but	  also	   regulate	  histone	  acetylation	  and	  
chromosome	   accessibility	   (Coward	   et	   al.,	   2009).	   In	   contrast,	   transcriptional	   silencing	   of	   the	  
COX-­‐2	  gene	  can	  result	  from	  epigenetic	  changes	  including	  hypermethylation	  of	  the	  CpG	  islands	  
in	   the	   5ʹ′UTR	   (Song	   et	   al.,	   2001).	   Other	   regulatory	   mechanisms	   affecting	   COX-­‐2	   expression	  
include	   proteosomal	   protein	   degradation	   pathways,	   miRNA	   inhibition	   of	   translation,	  
differential	  utilization	  of	  polyadenylation	  sites,	  and	  suicide	  inactivation	  of	  COX	  catalytic	  activity	  
(Harper	  and	  Tyson-­‐Capper,	  2008;	  Mbonye	  and	  Song,	  2009).	  	  
Following	  PGH2	  production,	  specific	  prostanoid	  end-­‐products	  are	  synthesised	  via	  the	  activity	  of	  
cell-­‐specific	   distal	   prostaglandin	   synthase	   enzymes	   (Hara	   et	   al.,	   2010),	   and	   are	   then	   able	   to	  
associate	   to	   their	   receptors	   to	   promote	   the	   activation	   of	   several	   signalling	   pathways.	   Three	  
isoforms	   of	   PGE2	   synthase	   (PGES)	   have	   been	   identified	   in	   murine	   and	   mammalian	   tissues:	  
microsomal	   PGES	   (mPGES)-­‐1,	  mPGES-­‐2,	   and	   cytosolic	   PGES	   (cPGES).	  As	   stated	   in	   the	  names,	  
mPGES-­‐1	   and	   mPGES-­‐2	   are	   located	   in	   the	   microsomes	   whereas	   cPGES	   is	   situated	   in	   the	  
cytosol.	   In	   general,	   cPGES	   and	   mPGES-­‐2	   are	   constitutively	   expressed	   whereas	   mPGES-­‐1	  
expression	  is	  induced.	  Studies	  have	  illustrated	  cPGES	  is	  capable	  of	  catalysing	  the	  conversion	  of	  
COX1-­‐derived	  PGH2	   to	   PGE2.	  However,	   cPGES	   is	   unable	   to	   convert	   PGH2	  derived	   from	  COX2	  
activity.	  On	   the	  other	  hand,	  mPGES-­‐1	  converts	  COX2-­‐derived	  PGH2	   (not	  COX1).	   Interestingly,	  
mPGES-­‐2	  may	   couple	  with	   either	   COX1-­‐	   or	   COX2-­‐derived	   PGH2,	   although	   it	   is	   slightly	  more	  
partial	  towards	  COX1	  (Samuelsson	  et	  al.,	  2007;	  Hara	  et	  al.,	  2010).	  
Knockout	   mice	   for	   the	   genes	   encoding	   all	   three	   isotypes	   have	   been	   developed.	   mPGES-­‐2	  
deficient	  mice	  showed	  no	  effect	  on	  physiological	  and	  pathophysiological	  conditions;	  mPGES-­‐1-­‐
deficient	   mice	   showed	   reduced	   response	   to	   inflammatory	   stimuli,	   suggesting	   that	   mPGES-­‐1	  
regulate	   inflammation-­‐induced	  PGE2	  synthesis;	  and	  cPGES	  deficiency	   is	  perinatally	   lethal	  with	  
the	   mice	   displaying	   poor	   lung	   development,	   retarded	   growth,	   and	   delayed	   skin	   maturation	  	  
(Nakatani	   et	   al.,	   2007).	   Similarly	   to	   the	  COX	  enzymes,	   it	   is	   generally	   accepted	   that	  mPGES-­‐2	  
catalyses	   the	   production	   PGE2	   for	   housekeeping	   functions,	   while	   mPGES-­‐1	   forms	   PGE2	   in	  
response	  to	  stimuli	  (Samuelsson	  et	  al.,	  2007).	  




Four	   receptors	   for	   PGE2	   have	   been	   identified:	   EP1,	   EP2,	   EP3,	   and	   EP4,	   all	   of	   which	   are	   G-­‐
protein	  coupled	  receptors	  composed	  of	  7-­‐transmembrane-­‐spanning	  domains	  (Narumiya	  et	  al.,	  
1999).	  The	   intracellular	  signalling	  pathways	  activated	   in	   response	  to	   the	  EP	  receptors	  dictate	  
their	  cellular	  functions.	  For	  instance,	  EP2	  and	  EP4	  receptors	  stimulate	  the	  activity	  of	  adenylate	  
cyclase	   which	   in	   turn	   increases	   intracellular	   concentrations	   of	   the	   second	   messenger	   cyclic	  
adenosine	  monophosphate	  (cAMP),	  triggering	  the	  relaxation	  of	  smooth	  muscle	  cells.	  Although	  
EP2	   and	   EP4	   receptors	   activate	   the	   same	  downstream	   signalling	   pathway,	   structurally	   these	  
receptors	  are	  different.	  Of	  the	  six	  loops	  between	  the	  transmembrane	  domains	  only	  the	  second	  
cytoplasmic	  loop	  appears	  to	  be	  the	  same	  in	  both	  receptors	  which	  suggests	  that	  this	  part	  of	  the	  
receptor	   is	  crucial	   for	   the	  common	   intracellular	   signalling	   (Brock,	  2014).	   	  On	   the	  other	  hand,	  
activation	  of	  EP1	  and	  EP3	  receptors	  causes	  an	  increase	  in	  intracellular	  Ca2+	  concentration	  and	  
decreases	  cAMP	  levels,	  respectively,	  thus	  promoting	  smooth	  muscle	  cell	  contraction	  (reviewed	  
in	  (Bozyk	  and	  Moore,	  2011)).	  	  
The	  role	  of	  prostanoids	  in	  normal	  lung	  homeostasis	  	  
In	  a	  healthy	  lung	  microenvironment,	  homeostasis	  is	  considered	  to	  be	  dependent	  on	  epithelial-­‐
mesenchymal	   crosstalk	   (Selman	   et	   al.,	   2001;	   Selman	   and	   Pardo,	   2002).	   The	   homeostatic	  
signalling	  of	  PGE2	  in	  AECs	  and	  fibroblasts	  is	  illustrated	  in	  Figure	  1.14.	  Several	  pieces	  of	  evidence	  
support	  this	  concept	  including	  in	  vitro	  studies	  whereby	  AECs	  from	  control	  animals	  were	  able	  to	  
inhibit	   fibroblast	   proliferation.	   In	   addition,	   AECs	   extend	   through	   the	   basement	   membrane	  
making	  contact	  with	  fibroblasts	  in	  normal	  lung	  sections.	  Inhibition	  of	  fibroblast	  proliferation	  by	  
AECs	  is	  dependent	  on	  the	  ability	  of	  the	  AECs	  to	  synthesise	  PGE2	  (Lama	  et	  al.,	  2002;	  Moore	  et	  
al.,	  2005a;	  Huang	  et	  al.,	  2007,	  2008a)	  and	  studies	  have	  demonstrated	  that	  in	  the	  presence	  of	  
PGE2	  Epac-­‐1	  (exchange	  protein	  activated	  by	  cAMP-­‐1)	  is	  activated	  downstream	  of	  EP2	  receptor	  
signalling	  which	  exclusively	  inhibits	  fibroblast	  proliferation	  (Huang	  et	  al.,	  2008a).	  As	  well	  as	  the	  
inhibition	   of	   fibroblast	   proliferation,	   PGE2	   plays	   an	   essential	   role	   in	   regulating	   apoptosis.	   In	  
normal	  human	  lung	  fibroblasts,	  PGE2	  potentiates	  FasL	  induced	  apoptosis	  via	  EP2/EP4	  receptor	  
signalling	  with	  reduced	  activity	  of	  the	  prosurvival	  molecule	  protein	  kinase	  B	  (Akt)	  (Huang	  et	  al.,	  
2009).	  	  
Activation	   of	   EP2	   receptor	   signalling	   via	   PGE2	   also	   inhibits	   TGFβ-­‐induced	   fibroblast	  
differentiation	  as	  well	  as	  attenuating	  collagen	  synthesis	   (Kolodsick	  et	  al.,	  2003)	  which	  occurs	  
independently	   of	   Smad-­‐signalling.	   Instead,	   PGE2	   is	   able	   to	   alter	   the	   architecture	   of	   the	  
cytoskeleton	  leading	  to	  the	  disruption	  of	  focal	  adhesion	  formation.	  These	  cytoskeletal	  changes	  




were	   detected	   by	   analysing	   the	   expression	   of	   adhesion	   dependent	   signalling	  molecules	   (i.e.	  
FAK,	   paxillin,	   STAT-­‐3,	   and	   Akt)	   (Thomas	   et	   al.,	   2007).	   In	   addition,	   EP2	   receptor	   signalling	  
activates	  PTEN,	  and	  as	  a	   result	   fibroblast	  proliferation	   is	   inhibited	   (White	  et	  al.,	  2005,	  2006).	  
Therefore,	   PTEN	   activation	   via	   PGE2	   is	   another	   mechanism	   by	   which	   prostanoids	   inhibit	  
myofibroblast	  differentiation.	  Furthermore,	  amplification	  of	  cAMP	  generated	  by	  PGE2	  reduces	  
collagen	   synthesis	   (Huang	   et	   al.,	   2007,	   2008a),	   promotes	   collagen	   degradation	   (Baum	  et	   al.,	  
1980),	   inhibits	   fibroblast	   chemotaxis,	   and	   reduces	   the	  expression	  of	   growth	   factor	   receptors	  	  
(Boyle	  et	  al.,	  1999).	  This	  can	  be	  achieved	  by	  using	  phosphodiesterase	  4	  (PDE4)	  inhibitors	  which	  
inhibit	  cAMP	  breakdown	  (Kohyama	  et	  al.,	  2002b;	  Dunkern	  et	  al.,	  2007;	  Togo	  et	  al.,	  2009).	  
 
	  
Figure	  1.	  14:	  PGE2	  signalling	  in	  AECs	  and	  fibroblasts	  in	  monolayer	  cultures.	  	  
Studies	  hypothesise	  that	  in	  monolayer	  cultures,	  PGE2	  protects	  AECs	  from	  apoptosis	  and	  
limits	   fibroblast	  proliferation,	  collagen	  production,	  and	  differentiation	  via	  EP2	  receptor	  
signaling.	  
Reproduced	  from	  (Bozyk	  and	  Moore,	  2011)	  with	  permission	  of	  American	  Thoracic	  Society	  	  
	  
	  
PGE2	  levels	  in	  IPF	  
Imbalance	  of	  eicosanoid	  synthesis	  has	  been	  shown	  in	  human	  and	  animal	  lung	  fibrosis	  studies,	  
whereby	  reduced	  PGE2	  levels	  and	  increased	  leukotriene	  levels	  in	  BALF	  and	  lung	  homogenates	  
of	   IPF	  patients	  have	  been	  detected	   in	  comparison	   to	  healthy	  controls	   (Wardlaw	  et	  al.,	  1989;	  



















1	  and	  COX-­‐2	  expression	  in	  IPF	  patients	  (Petkova	  et	  al.,	  2003;	  Coward	  et	  al.,	  2009;	  Maher	  et	  al.,	  
2010).	   In	   addition,	   studies	   have	   illustrated	   that	   IPF	   fibroblasts	   are	   unable	   to	   upregulate	   the	  
expression	   of	   COX-­‐2	   in	   response	   to	   an	   exogenous	   stimulus.	   The	   reduced	   COX-­‐2	   expression	  
correlates	  with	  increased	  fibroblast	  proliferation	  and	  promotes	  collagen	  production	  following	  
TGFβ	   stimulation	   (Wilborn	   et	   al.,	   1995;	   Keerthisingam	   et	   al.,	   2001;	   Maher	   et	   al.,	   2010).	   In	  
addition,	  COX-­‐2	  deficiency	  promotes	  bleomycin-­‐induced	  PF	  in	  mice	  (Keerthisingam	  et	  al.,	  2001;	  
Hodges	   et	   al.,	   2004).	   	   A	   more	   recent	   study	   has	   illustrated	   that	   the	   role	   of	   mPGES-­‐1	   in	   PF	  
whereby	   mPGES-­‐1	   knockout	   mice	   exhibited	   more	   severe	   fibrotic	   lesions,	   reduced	   PGE2	  
concentrations,	   and	   decreased	   expression	   levels	   for	   EP2	   and	   EP4	   receptors	   following	   the	  
administration	  of	  bleomycin,	   in	  comparison	   to	  wild	   type	  mice	   (Wei	  et	  al.,	  2014).	   In	  addition,	  
diminished	  PGE2	  contributes	  to	  the	  apoptosis	  paradox	  seen	  in	  IPF	  patients	  (i.e.	  increased	  AEC	  
apoptosis	  and	  diminished	  apoptosis	   in	   fibroblasts).	  However,	   fibrotic	   fibroblasts	  are	  resistant	  
to	  the	  pro-­‐apoptotic	  effects	  of	  PGE2.	  Reduced	  COX-­‐2	  expression	  in	  IPF	  fibroblasts	  is	  one	  factor	  
which	  is	  considered	  to	  promote	  fibroblast	  survival	  (Maher	  et	  al.,	  2010).	  
Recent	  studies	  on	  animal	  models	  as	  well	  as	  human	  tissues	  have	  increased	  our	  understanding	  	  	  
of	  the	  role	  and	  regulation	  of	  PGs	  in	  fibrotic	  lung	  diseases	  including	  the	  identification	  of	  many	  
soluble	   mediators	   and	   epigenetic	   changes	   which	   may	   possibly	   explain	   the	   decline	   in	   PG	  
synthesis	   (Coward	   et	   al.,	   2009;	   Huang	   et	   al.,	   2010).	   For	   instance,	   AEC	   injury	   results	   in	   the	  
release	  of	  chemokines	   such	  as	  CCL2	   (Moore	  et	  al.,	  2001)	  and	  studies	  have	   illustrated	   that	   in	  
the	  presence	  of	  CCL2,	  PGE2	  production	  via	  AECs	  is	  diminished	  and	  fibroproliferation	  is	  elevated	  	  
(Moore	   et	   al.,	   2003).	   This	   is	   one	   mechanism	   which	   explains	   the	   reason	   why	   CCR2	   (CCL2	  
receptor)	   knockout	   mice	   are	   protected	   from	   fibrotic	   injury	   (Moore	   et	   al.,	   2001;	   Gharaee-­‐
Kermani	  et	  al.,	  2003).	  
Fibrotic	   lung	   injury	  also	  promotes	  plasma	   leakage	  and	  activation	  of	   the	  coagulation	  cascade.	  
However,	  the	  extravascular	  fibrin	  is	  not	  effectively	  cleared	  in	  fibrotic	  lungs	  due	  to	  the	  increase	  
in	  expression	  of	  PAI-­‐1	  (Chapman	  et	  al.,	  1986;	  Idell	  et	  al.,	  1989;	  Bertozzi	  et	  al.,	  1990).	  As	  already	  
mentioned	  before,	  PAI-­‐1	  prevents	  plasmin	  production	  by	  inhibiting	  the	  activity	  of	  uPA	  and	  tPA	  
and	  thus	  inhibits	  fibrinolysis.	  Studies	  have	  shown	  that	  under	  normal	  wound	  healing	  responses	  
plasmin	   is	   able	   to	   upregulate	   COX2	   expression	   and	   stimulate	   PGE2	   synthesis	   in	   AECs,	  
fibroblasts,	  and	  fibrocytes	  (in	  mice	  and	  human	  lungs)	  via	  hepatocyte	  growth	  factor	  (HGF;	  plays	  
a	  key	  role	  in	  mediating	  lung	  epithelial	  cell	  growth)	  (Hojo	  et	  al.,	  1997).	  This	  supports	  the	  notion	  
that	  increased	  levels	  of	  PAI-­‐1	  diminish	  PGE2	  synthesis.	  In	  addition,	  studies	  have	  also	  illustrated	  
that	  PGE2	   is	  able	  to	  mediate	  HGF	  activation	   in	  a	  positive	  antifibrotic	  feedback	   loop	  in	  normal	  




lung.	  Thus,	  it’s	  likely	  that	  this	  feedback	  loop	  is	  missing	  in	  lungs	  of	  IPF	  patients	  (Marchand-­‐Adam	  
et	  al.,	  2003).	  
More	   recently,	   studies	   have	   been	   focusing	   on	   possible	   epigenetic	   changes	   which	   may	  
contribute	   to	   diminished	   COX2	   expression.	   For	   instance,	   Coward	   et	   al.	   (2009)	   illustrated	  
reduced	  COX2	  mRNA	  levels	   in	  fibrotic	  fibroblasts	  however	  the	  mRNA	  degradation	  rates	  were	  
the	  same	  in	  comparison	  to	  control	  fibroblasts,	  which	  suggested	  that	  reduced	  COX2	  expression	  
may	   be	   a	   result	   of	   defects	   during	   transcription.	   To	   further	   investigate	   this	   the	   same	   study.	  
showed	  that	  despite	  having	  appropriate	  levels	  of	  transcription	  factors	  involved	  in	  driving	  COX2	  
expression	   (i.e.	   CREB1,	   CEBPb,	  NFκB,	   and	   p65),	   these	   factors	  were	   unable	   to	   associate	  with	  
their	   binding	   sites	   on	   the	   COX2	   promoter.	   This	   correlated	   with	   reduced	   levels	   of	   histone	  
acetyltransferase	  (HAT)	  and	  increased	  recruitment	  of	  histone	  deacetylase	  (HDAC)	  leading	  to	  a	  
decrease	   in	   levels	   of	   H3	   and	   H4	   acetylation	   (both	   of	   which	   are	   required	   for	   normal	   COX2	  
transcription	  process).	  However,	  when	  the	   IPF	  fibroblasts	  were	  treated	  with	  HATs	  along	  with	  
HDAC	   inhibitors,	   the	   level	   of	   histone	  H3	   and	  H4	   acetylation	   increased	   and	   cytokine-­‐induced	  
COX2	   expression	   was	   restored.	   These	   results	   support	   the	   concept	   that	   diminished	   COX2	  
expression	   is	   IPF	   is	   due	   to	   epigenetic	   abnormalities	   in	   the	   form	   of	   histone	   hypoacetylation	  
(Coward	  et	  al.,	  2009).	  
Furthermore,	   epigenetic	   changes	   in	   EP	   receptors	   (in	   particular	   EP2)	   leading	   to	   decreased	  
receptor	  expression	  have	  been	  described	  in	  fibrotic	  fibroblasts	  (Moore	  et	  al.,	  2005a;	  Huang	  et	  
al.,	  2008b;	  Sagana	  et	  al.,	  2009).	  Such	  changes	  include	  DNA	  hypermethylation	  at	  CpG	  islands	  in	  
the	  promoter	   region	  of	   prostaglandin	   EP2	   receptor	   gene	   (PTGER2).	  This	   hypermethylation	   is	  
greater	   in	   comparison	   to	   control	   fibroblasts	   and	   results	   from	   increased	   Akt	   signaling	   and	  
decreased	   PTEN	   activity.	   However,	   treating	   IPF	   fibroblasts	  with	   a	   DNA	  methylation	   inhibitor	  
(i.e.	   5-­‐aza-­‐2’-­‐deoxycytidine)	   reduces	   PTGER2	   methylation,	   elevates	   PTGER2	   mRNA	   levels	   as	  
well	   as	   EP2	   protein	   expression,	   and	   restores	   PGE2	   response	   in	   the	   fibrotic	   fibroblasts	   (i.e.	  
reduces	   fibroblast	   proliferation	   and	   collagen	   synthesis).	   DNA	   methyltransferase	   (DNMT)-­‐
specific	   siRNA	   also	   has	   similar	   results	   (Huang	   et	   al.,	   2010).	   These	   results	   suggest	   that	   the	  
expression	   of	   EP2	   receptors	   is	   tightly	   controlled.	   Taken	   together,	   these	   epigenetic	   changes	  
demonstrated	   in	   IPF	   fibroblasts	   prevent	   COX-­‐2	   gene	   transcription	   in	   IPF	   and	   contribute	   to	  
diminished	   production	   of	   PGE2.	   Thus,	   these	   could	   be	   potential	   therapeutic	   target	   for	   the	  
treatment	  of	  IPF.	  	  
	  




Other	  prostanoids	  in	  IPF	  
As	   well	   as	   PGE2	   other	   prostanoids	   have	   also	   been	   reported	   to	   play	   a	   role	   in	   PF,	   and	   have	  
recently	  become	  of	  great	  interest.	  These	  are	  PGI2	  (prostacyclin)	  and	  PGF2α.	  Similar	  to	  PGE2,	  PGI2	  
also	  mediates	   antifibrotic	   effects	   (i.e.	   inhibit	   fibroblast	   proliferation,	  migration,	   and	   collagen	  
synthesis)	   by	   increasing	   intracellular	   cAMP	   levels	   via	   the	   activation	   of	   its	   G-­‐protein	   coupled	  
receptor	  (IP)	  (Stratton	  et	  al.,	  2001;	  Kohyama	  et	  al.,	  2002a;	  Soberman	  	  Peter,	  2006).	  PGI2	  levels	  
in	  IPF	  fibroblasts	  are	  low	  in	  comparison	  to	  control	  cells	   in	  vitro.	   In	  addition,	  IP	  knockout	  mice	  
are	  more	  susceptible	  to	  developing	  severe	  PF	   in	  response	  to	  bleomycin	   in	  comparison	  to	  the	  
wild	   type	   (Lovgren	   et	   al.,	   2006).	   Furthermore,	   a	   synthetic	   prostacyclin	   agonist	   (iloprost)	  
attenuates	   bleomycin-­‐induced	   lung	   fibrosis	   in	   mice	   (Murakami	   et	   al.,	   2006).	   Such	   results	  
support	  that	  as	  well	  as	  PGE2,	  PGI2	  may	  also	  potentially	  be	  a	  therapeutic	  target	  of	   interest	  for	  
the	  treatment	  of	  IPF.	  
Unlike	  PGE2	  and	  PGI2,	   PGF2α	   is	   a	  profibrotic	  mediator,	   as	   in	   the	  bleomycin	   induced	  PF	  model	  
PGF2α	  facilitates	  PF	  via	  PGF	  receptors	  (FP).	  In	  addition,	  the	  levels	  of	  PGF2α	  are	  elevated	  in	  BALF	  
of	  IPF	  patients	  and	  studies	  have	  illustrated	  that	  PGF2α	   is	  able	  to	  stimulate	  collagen	  production	  
by	   lung	   fibroblasts.	   Such	   results	   support	   that	   this	   prostaglandin	   may	   contribute	   to	   disease	  
progression	  (Aihara	  et	  al.,	  2013).	  
1.2.8.	   Therapeutic	  interventions	  of	  IPF	  
As	  already	  mentioned,	  in	  spite	  of	  extensive	  studies	  into	  understanding	  the	  pathogenesis	  of	  IPF,	  
the	  mechanism	   is	   still	  not	  completely	  understood.	  Nevertheless,	   several	   studies	  have	  helped	  
enhance	   our	   understanding	   in	   the	   complexity	   of	   this	   deadly	   disorder	   which	   has	   led	   to	   the	  
identification	  of	  putative	  targets	  for	  the	  treatment	  of	  IPF.	  Over	  the	  past	  ten	  years	  the	  number	  
of	   high-­‐quality	   clinical	   trials	   has	   slowly	   increased.	   However,	   none	   of	   the	   trials	   have	   shown	  
worthwhile	   treatment	  effects	  on	  patients	  with	   the	   severe	   form	  of	   IPF	  which	  emphasises	   the	  
desperate	  need	  in	  determining	  the	  precise	  mechanism	  involved	  in	  the	  progression	  of	  this	  fatal	  
disease.	  Compounds	  which	  have	   failed	   clinical	   trials	   include	   corticosteroid	  monotherapy	   (i.e.	  
prednisone),	   anticoagulant	   therapy	   (i.e.	   warfarin),	   Azathioprine	   (immunosuppressant),	  
cyclophosphamide	   (chemotherapeutic	   agent),	   Everolimus	   (rapamycin	   derivative	   with	  
immunosuppressive	   and	   anti-­‐fibroproliferative	   properties),	   Bosentan	   (endothelin	   receptor	  
antagonist),	  sildenafil	  (PDE5	  inhibitor),	  interferon	  gamma	  (IFNγ),	  Etanercept	  (TNFα	  antagonist),	  




and	   Imatinib	   (an	   anti-­‐proliferation	   protein	   tyrosine	   kinase	   inhibitor	   of	   PDGFR)	   (reviewed	   in	  	  
(Ahluwalia	  et	  al.,	  2014))	  . 	  
Furthermore,	   a	   three-­‐drug	   regimen	   involving	   an	   immunosuppressive	   drug,	   a	   glucocorticoid,	  
and	  an	  antioxidant	  (i.e.	  azathioprine;	  prednisone;	  and	  N-­‐acetylcysteine,	  NAC)	  was	  tested	  in	  the	  
PANTHER	   clinical	   trial	   which	   was	   randomised,	   double-­‐blinded,	   and	   with	   placebo	   controls.	  
Unfortunately	   however,	   due	   to	   increased	   mortality	   and	   hospitalisation	   with	   the	   three-­‐drug	  
regimen,	   the	   trial	   was	   stopped	   at	   interim	   analysis.	   Nevertheless,	   the	   NAC	   only	   part	   of	   this	  
study	  continued.	  	  Previous	  studies	  have	  demonstrated	  that	  oxidative	  stress	  may	  contribute	  to	  
the	  aberrant	  AEC	  injury	  seen	  in	  IPF.	  Since	  the	  lungs	  of	  IPF	  patients	  exhibit	  an	  elevated	  oxidant	  
burden	   (with	   increased	   reactive	   oxygen	   species,	   ROS,	   and	   reduced	   levels	   of	   the	   antioxidant	  
glutathione)	   it	  was	   hypothesised	   that	   treating	   IPF	   patients	  with	   the	   anti-­‐oxidant	  NAC	  would	  
reduce	   this	   oxidant	   burden.	   However	   the	   results	   from	   the	   trial	   published	   earlier	   this	   year	  
illustrated	   that	  NAC	  alone	  also	  had	  no	  significant	  benefit	  with	   respect	   to	   the	  preservation	  of	  
FVC	   in	   IPF	   patients	   (with	   mild-­‐to-­‐moderate	   impairment	   in	   lung	   function)	   (The	   Idiopathic	  
Pulmonary	  Fibrosis	  Clinical	  Research	  Network,	  2014).	  
Despite	   several	   failed	   trials,	   recently	   a	   few	   compounds	   have	   shown	   some	  positive	   results	   in	  
clinical	  trials.	  For	  example	  Pirfenidone	  (5-­‐methyl-­‐1-­‐phenyl-­‐2-­‐[1H]-­‐pyridone),	  which	   is	  the	  only	  
drug	  which	  has	  been	  approved	  for	   IPF	  patients	  with	  mild-­‐to-­‐moderate	  form	  of	  the	  disease	   in	  
Europe,	  Canada,	   India,	  Japan.,	  and	  USA.	  This	  compound	  has	  shown	  anti-­‐fibrotic,	  anti-­‐oxidant,	  
and	  anti-­‐inflammatory	  actions	   in	  vitro	  and	   in	  several	  animal	  models	  of	   fibrosis	   in	   lungs,	   liver,	  
and	  kidney	  (Gurujeyalakshmi	  et	  al.,	  1999;	  Iyer	  et	  al.,	  1999;	  García	  et	  al.,	  2002;	  Oku	  et	  al.,	  2002;	  
Cho	  et	  al.,	  2007).	  For	   instance,	   in	   retinal	  pigment	  epithelial	   cells	  Pirfenidone	   is	  able	   to	  block	  
nuclear	  translocation	  of	  Smad	  proteins	  (Choi	  et	  al.,	  2012)	  and	  inhibit	  TGFβ	  induced	  HSP47	  and	  
collagen	   I	   over	   expression	   in	   A549	   cells	   (Hisatomi	   et	   al.,	   2012)	   as	   well	   as	   human	   lung	  
fibroblasts	   in	  vitro	   (Nakayama	  et	  al.,	  2008).	  Thus,	  Pirfenidone	   is	  able	   to	   inhibit	  TGFβ-­‐induced	  
fibrogenesis.	   In	   addition,	   using	   the	   bleomycin	   hamster	   model	   of	   lung	   fibrosis	   Pirfenidone	  
attenuates	   pro-­‐collagen	   I	   and	   III	   mRNA	   accumulation,	   hydroxyproline	   content,	   prolyl	  
hydroxylase	  activity,	  lipid	  peroxidation	  (a	  marker	  for	  inflammation	  index),	  and	  TGFβ	  mRNA	  and	  
protein	  levels	  (Iyer	  et	  al.,	  1999).	  Moreover,	  Pirfenidone	  inhibits	  the	  synthesis	  of	  PDGF	  in	  lung	  
macrophages	   (Gurujeyalakshmi	  et	  al.,	  1999);	   reduces	  the	   influx	  of	  macrophages,	  neutrophils,	  
and	   lymphocytes	   in	   BALF	   at	   early	   time	   points	   (Corbel	   et	   al.,	   2001);	   reduces	   hydroxyproline	  
content,	  inflammatory	  edema,	  interleukin	  (IL)-­‐1β,	  IL-­‐6,	  IL-­‐12,	  and	  interferon	  (IFN)-­‐γ	  (Oku	  et	  al.,	  




2008);	  and	  attenuates	  the	  elevation	  of	  lung	  FGF,	  lung	  stromal	  cell	  derived	  factor-­‐1α,	  and	  IL-­‐18	  	  
(Iyer	  et	  al.,	  1999;	  Oku	  et	  al.,	  2008).	  	  	  
The	  effect	  of	  Pirfenidone	  on	  IPF	  patients	  has	  been	  evaluated	  in	  three	  phase	  3	  clinical	  trials,	  one	  
of	   which	  was	   performed	   in	   Japan	  with	   275	   participants	   and	   the	   other	   two	   trials	   (known	   as	  
CAPACITY	  studies	  004	  and	  006)	  were	  conducted	   in	   the	  North	  America,	  Europe,	  and	  Australia	  
involving	   a	   total	   of	   435	   and	   344	   patients,	   respectively.	   The	   CAPACITY	   004	   trial	   involved	  
assigning	  patients	   into	   three	  groups:	  placebo,	  high	  dose	  Pirfenidone	   (2403	  mg/day),	  and	   low	  
dose	   Pirfenidone	   (1197	   mg/day)	   which	   were	   administered	   orally.	   CAPACITY	   006	   trial	   only	  
involved	   two	   groups:	   placebo	   and	   high	   dose	   Pirfenidone	   (Noble	   et	   al.,	   2011).	   Both	   the	  
Japanese	  trial	  and	  CAPACITY	  004	  showed	  positive	  results	  with	  reduced	  decline	   in	  forced	  vital	  
capacity	  (FVC)	  at	  52	  and	  72	  weeks	  in	  patients	  treated	  with	  Pirfenidone,	  respectively.	  However,	  
no	   such	   results	   were	   shown	   in	   CAPACITY	   006,	   encouraging	   US	   regulations	   to	   generate	   an	  
additional	   trial	  with	  more	  patients	  recruited	   in	  order	   to	  support	   the	  approval	  of	  Pirfenidone.	  
This	   trial	   was	   known	   as	   the	   ASCEND	   (a	   randomised,	   double	   blinded,	   placebo	   control	   trial),	  
which	  not	  only	  looked	  at	  the	  FVC	  but	  also	  investigated	  the	  effects	  of	  the	  drug	  (high	  dose;	  2403	  
mg/day)	   on	   mortality	   rate	   at	   52	   weeks,	   6MW	   distance,	   dyspnoea,	   and	   progression-­‐free	  
survival.	   In	   addition,	   this	   trial	   differed	   from	   the	   CAPACITY	   trials	   as	   it	   modified	   the	   selected	  
eligibility	  criteria	  in	  order	  to	  only	  enrol	  patients	  that	  are	  at	  a	  higher	  risk	  of	  disease	  progression.	  
The	  results	  from	  this	  trial	   illustrated	  that	  Pirfenidone	  was	  able	  to	  reduce	  disease	  progression	  
(reflected	  by	  exercise	  tolerance,	  lung	  function,	  and	  progression-­‐free	  survival)	  and	  cause	  fewer	  
deaths	   in	  patients	  with	   IPF	   in	  comparison	  to	  placebo	  controls	   (King	  et	  al.,	  2014).	  These	  trials	  
support	  that	  Pirfenidone	  may	  be	  a	  useful	  means	  of	  therapy	  for	  the	  treatment	  of	  IPF.	  However,	  
one	  of	  the	   limitations	  of	  these	  studies	   is	  that	   in	  all	   four	  trials	  the	  patients	  showed	  no	  sign	  of	  
improvement	   in	  respiratory	  symptoms	  and/or	  quality	  of	   life	  (Poletti	  et	  al.,	  2014).	   In	  addition,	  
the	  recruited	  patients	  in	  all	  trials	  had	  mild-­‐to-­‐moderate	  forms	  of	  the	  disease.	  Thus,	  the	  effect	  
of	  this	  drug	  on	  patients	  with	  the	  severe	  form	  is	  currently	  unknown	  and	  needs	  investigation.	  
Another	  compound	  that	  has	  shown	  clinical	  benefits	   is	  Nintedanib	  (also	  known	  as	  BIBF	  1120).	  
This	   compound	   is	   an	   inhibitor	   of	   tyrosine	   kinase	   receptors	   including	   PDGFR	   and	   FGFR,	   and	  
VEGFR	   (Hilberg	   et	   al.,	   2008;	   Wollin	   et	   al.,	   2014),	   all	   of	   which	   have	   been	   implicated	   in	   the	  
pathogenesis	  of	  IPF	  (Kaner	  et	  al.,	  2000;	  Allen	  JT,	  2002).	  Two	  multinational	  replicated	  Phase	  III	  
studies	  of	  Nintedanib	  (INPULSIS-­‐1	  and	  -­‐2),	  which	  involved	  the	  administration	  of	  this	  drug	  at	  a	  
concentration	  of	  150mg	  twice	  daily,	  have	  recently	  been	  completed	  (Richeldi	  et	  al.,	  2014).	  The	  
dose	   of	   the	   compound	  was	   used	   based	   on	   a	   previous	   phase	   II	   trial	   (TOMORROW;	   random,	  




double-­‐blinded,	  placebo	  controlled	  trial)	  illustrating	  that	  at	  150mg	  Nintedanib	  reduced	  the	  FVC	  
decline	   and	   reduced	   the	   frequency	   of	   acute	   exacerbations	   (Richeldi	   et	   al.,	   2011).	   However	  
since	  the	  TOMORROW	  trial	  consisted	  of	  a	  small	  number	  of	  patients,	  the	  study	  was	  repeated	  in	  
two	   trials	   with	   a	   larger	   group	   of	   patients	   at	   205	   different	   sites	   in	   24	   different	   countries	   to	  
evaluate	  the	  efficacy	  and	  safety	  of	  the	  compound.	  The	  primary	  end	  point	  was	  the	  annual	  rate	  
of	   decline	   in	   FVC.	   Both	   trials	   illustrated	   positive	   results	   with	   a	   significantly	   reduced	   rate	   of	  
decline	  in	  FVC,	  thus	  Nintedanib	  may	  also	  be	  used	  to	  reduce	  the	  progression	  of	  IPF.	  However,	  
the	  rate	  of	  acute	  exacerbations	  in	  patients	  treated	  with	  this	  compound	  was	  inconsistent.	  This	  
was	  partly	  due	  to	  the	  fact	  that	  exacerbations	  are	  particularly	  rare	   in	   IPF	  patients	  recruited	   in	  
clinical	   trials,	   thus	   this	   area	   is	   difficult	   to	   assess	   and	   characterise	   (Richeldi	   et	   al.,	   2014).	  
Furthermore,	   patients	   in	   these	   trials	   did	   experience	   some	   adverse	   side	   effects	   including	  
diaorrhea	  and	  myocardial	  infarction.	  	  	  
Many	  other	  clinical	  trials	  are	  currently	  still	  running	  which	  involve	  compounds	  targeting	  various	  
pathways	  that	  have	  been	  implicated	  in	  fibrosis.	  One	  example	  is	  STX-­‐100,	  currently	  running	  in	  
Phase	   II	   trials;	   this	   is	  a	  monoclonal	  antibody	  against	  αvβ6.	  As	  already	   stated	  αvβ6	   is	  able	   to	  
activate	   latent	  TGFβ	  which	   is	   a	  potent	  pro-­‐fibrotic	   cytokine.	   Since	  TGFβ	   is	   also	  an	   important	  
mediator	   for	   homeostatic	   functions	   including	   the	   regulation	   of	   inflammation	   and	   the	  
suppression	   of	   tumourigenesis,	   global	   inhibition	   of	   TGFβ	  may	   lead	   to	   adverse	   effects.	   Thus,	  
studies	   have	   generated	   a	   monoclonal	   antibody	   for	   one	   of	   the	   mediators	   involved	   in	   the	  
activation	  of	   TGFβ	   (i.e.	  αvβ6)	  which	   is	   specifically	  upregulated	  at	   sites	  of	   injury	  and	  has	   low	  
expression	  in	  lungs	  of	  normal	  donors.	  Thus	  it	  is	  suggested	  that	  targeting	  avb6	  will	  block	  TGFβ	  
activation	   specifically	   in	   the	   lungs	   of	   IPF	   patients	   and	   not	   affect	   the	   activity	   of	   global	   TGFβ.	  
Other	   compounds	   currently	   being	   evaluated	   in	   Phase	   II	   trials	   include	   FG-­‐3019	   (CTGF-­‐
neutralising	  antibody),	  BMS-­‐986020	  (LPA1	  receptor	  antagonist),	  and	  simtuzumab	  (monoclonal	  
antibody	  directed	  against	  LOXL2.	  
Despite	   having	   a	   slight	   increase	   in	   the	   number	   of	   high	   quality	   clinical	   trials	   over	   the	   past	  
decade	  only	  a	  few	  have	  reached	  Phase	  II/III	  with	  a	  few	  positive	  effects	  shown	  only	  in	  mild-­‐to-­‐
moderate	  forms	  of	  IPF.	  The	  failures	  in	  the	  majority	  of	  clinical	  trials	  suggest	  that	  in	  vivo	  and	  in	  
vitro	  models	   of	   PF	   only	   partially	   recapitulate	   the	   complex	   pathogenesis	   of	   IPF;	   hence	   these	  
models	  may	  be	  imperfect	  for	  determining	  potential	  therapies	  (Moore	  et	  al.,	  2013;	  Spagnolo	  et	  
al.,	  2014).	  The	  current	  types	  of	   in	  vivo	  and	   in	  vitro	  models	  of	   fibrosis	  will	  be	  discussed	   in	  the	  
next	  two	  sections.	  




1.3.	   Current	  models	  of	  PF	  
1.3.1.	   In	  vivo	  models	  of	  fibrosis	  
Several	   animal	   models	   are	   used	   in	   research	   to	   understand	   fibrotic	   responses	   and	   to	   study	  
pulmonary	  fibrosis	  in	  greater	  detail.	  This	  has	  allowed	  researchers	  to	  identify	  key	  cells	  that	  may	  
be	  involved	  in	  the	  disease	  (described	  above).	  However	  there	  are	  a	  number	  of	  disadvantages	  of	  
using	  such	  models,	  which	  are	  summarised	   in	  Table	  1.6.	  The	  most	  common	   in	  vivo	  model	   for	  
fibrosis	  involves	  the	  use	  of	  bleomycin.	  This	  is	  an	  antibiotic,	  which	  was	  originally	  isolated	  from	  
Streptomyces	  verticillatus	  in	  1966.	  It	  works	  by	  binding	  to	  guanosine-­‐cytosine-­‐rich	  areas	  within	  
the	  DNA	   strands	  and	   inducing	  DNA	   strand	  breaks.	   The	  DNA	  cleavage	   is	  dependent	  on	  metal	  
ions	  (primarily	   iron)	  and	  oxygen.	   It	  has	  been	  suggested	  that	  bleomycin	  is	  able	  to	  chelate	  iron	  
resulting	   in	   the	  production	  of	  a	  pseudoenzyme	  which	   is	   then	  able	   to	   react	  with	  oxygen.	  This	  
reaction	  leads	  to	  the	  production	  of	  superoxide	  and	  hydroxide	  free	  radicals,	  which	  in	  turn	  result	  
in	  DNA	  single-­‐strand	  breaks	  at	  3’-­‐4’	  bonds	  in	  deoxyribose	  (Dorr,	  1992;	  Hecht,	  2000).	  
Bleomycin	  is	  a	  useful	  anti-­‐neoplastic	  agent	  and	  it	  was	  initially	  discovered	  to	  work	  against	  skin	  
tumours	  and	  squamous	  cell	   carcinomas.	  However,	   increasing	   the	  dose	  of	   this	  drug	   results	   in	  
pulmonary	   toxicity,	  which	   in	   turn	  can	   lead	   to	   fibrosis	   (Moore	  and	  Hogaboam,	  2008).	   Several	  
experimental	  animals	  develop	   fibrosis	  when	   treated	  with	   this	  drug	   including	  mice,	  hamsters,	  
rats,	  guinea	  pigs,	  rabbits,	  dogs,	  and	  primates.	  When	  this	  drug	  is	  administered	  via	  intravenous	  
(i.v.),	   intraperitoneal	   (i.p.),	   or	   subcutaneous	   delivery	   it	   is	   assumed	   that	   initial	   lesions	   to	   the	  
pulmonary	   endothelium	   allows	   the	   compound	   to	   enter	   the	   lung	   interstitium	   resulting	   in	  
subsequent	   type	   I	   epithelial	   cell	   damage.	   However,	   intranasal	   (i.n.)	   and	   intratracheal	   (i.t.)	  
administration	   results	   in	   direct	   epithelial	   cell	   damage.	   In	   addition,	   metaplasia	   in	   type	   II	  
epithelial	   cells	   is	   also	   induced	   and	   some	   inflammatory	   cells	   (neutrophils	   and	   macrophages)	  
infiltrate	   into	   the	   affected	   area.	   Another	   route	   of	   administration	   of	   bleomycin	   is	   via	  
oropharyngeal	   instillation.	  This	   is	   currently	  used	   in	  our	   laboratory	  as	   it	   is	   considered	   to	  be	  a	  
more	  representative	  model	  of	  human	  disease	  since	  it	  causes	  more	  homogenous	  injury	  in	  mice	  
with	  presence	  of	  peripheral	  and	   subpleural	   fibrosis	   (Egger	  et	  al.,	   2013;	  Scotton	  et	  al.,	   2013).	  
Fibrotic	   lesions	  develop	  within	   two	  weeks	   following	   administration	  of	   bleomycin	   (Scotton	  et	  
al.,	   2009).	   In	   addition,	  histological	   analyses	   show	  damaged	  basement	  membrane,	   clusters	  of	  
mesenchymal	   cells,	   intra-­‐alveolar	   buds,	   collagen	   deposition,	   and	   obliteration	   of	   the	   alveolar	  
space	   all	   of	   which	   are	   also	   present	   within	   the	   lungs	   of	   IPF	   patients	   (Moeller	   et	   al.,	   2008;	  




Mouratis	  and	  Aidinis,	  2011).	  These	  observations	  illustrate	  that	  bleomycin	  is	  able	  to	  reproduce	  
many	  typical	  features	  of	  the	  human	  disease	  (Moeller	  et	  al.,	  2008).	  Furthermore,	  the	  use	  of	  this	  
model	   has	   contributed	   tremendously	   to	   elucidate	   the	   roles	   of	   several	   cytokines,	   growth	  
factors,	  as	  well	  as	  some	  signalling	  pathways	  that	  may	  be	  involved	  in	  PF.	  
Despite	   this	   there	   are	   many	   disadvantages,	   one	   of	   which	   includes	   the	   lack	   of	   some	   of	   the	  
pathological	   features	   (e.g.	   fibrotic	   foci,	   and	   the	   progressive	   and	   irreversible	   nature	   of	   the	  
fibrotic	   condition)	   shown	   in	   lungs	  of	   IPF	  patients.	   Furthermore,	   studies	   suggest	   that	  most	  of	  
the	  inflammatory	  responses	  shown	  upon	  the	  administration	  of	  bleomycin	  are	  similar	  to	  that	  of	  
acute	   lung	   injury	   (a	   condition	   characterised	   by	   damage	   to	   the	   alveolar	   epithelial	   cells,	  
infiltration	   of	   inflammatory	   cells,	   oedema,	   and	   formation	   of	   hyaline	   membranes)	   in	  
comparison	   to	   fibrosis.	   This	   limitation	   makes	   it	   problematic	   to	   use	   this	   model	   for	   drug	  
development,	   as	   it	  would	   be	   difficult	   to	   interpret	   the	   drug	   benefits	   against	   the	   normal	   lung	  
repair	  mechanism.	  Another	  weakness	  of	  this	  model	  is	  that	  it	  is	  limited	  to	  specific	  mice	  strains.	  
This	   is	   due	   to	   the	   fact	   that	   the	   lungs	   of	   other	   mice	   strains	   are	   able	   to	   produce	   bleomycin	  
hydroxylase	  which	   inactivates	  bleomycin	   (Moeller	  et	  al.,	  2008).	  Despite	   these	  disadvantages,	  
the	  bleomycin	  model	  (intratracheal	  administration)	  remains	  a	  vital	  tool	  for	  future	  use,	  as	  it	  has	  
shown	  some	  critical	  aspects	  of	  PF	  and	  may	  be	  used	  to	  assess	   the	  efficacy	  of	   the	  compounds	  
(with	   a	  potential	   to	  be	  used	   clinically)	   in	   general	   as	  proof	  of	  principle	   (Degryse	  and	   Lawson,	  
2011).	   However,	   new	   models	   should	   be	   developed	   that	   not	   only	   show	   the	   pathological	  
features	  seen	  in	  IPF	  patients,	  but	  also	  be	  a	  useful	  tool	  to	  analyse	  new	  therapeutic	  compounds.	  	  
	   	  



























Reproduced	   and	   adapted	   from	   (Degryse	   and	   Lawson,	   2011;	   Henry	   et	   al.,	   2002)	   with	  
permissions	  of	  Wolters	  Kluwer	  Health.	  	  
	  
Table	  1.	  6:	  Summary	  of	  common	  murine	  models	  of	  pulmonary	  fibrosis	  




- Clinic	  ally	  relevant	  
- Ease	  of	  delivery	  
- Low	  cost	  
- Quick	  development	  of	  
fibrosis	  
- Widely	  used	  and	  accepted	  
in	  literature	  
- Lack	  of	  some	  UIP	  features	  
- Mouse	  strain	  dependent	  
	  
Silica	  
- Persistent	  fibrosis	  
- Clinically	  relevant	  as	  a	  
model	  for	  the	  human	  
disease	  silicosis	  	  
- Lack	  of	  some	  UIP	  features	  
- Prolonged	  time	  to	  develop	  
fibrosis	  
- Expensive	  	  
- Requires	  specialised	  
equipment	  





allows	  for	  identification	  of	  
deposition	  
- Quick	  development	  of	  
fibrosis	  
- Persistent	  fibrosis	  
- Not	  mouse	  strain	  
development	  
- Lack	  of	  some	  UIP	  features	  
- Reports	  of	  variability	  in	  FITC	  
response	  
Radiation	  
- Clinically	  relevant	  as	  a	  
model	  for	  radiation	  
pneumonitis	  and	  fibrosis	  
- Prolonged	  time	  to	  develop	  
fibrosis	  




- Allows	  targeted	  study	  of	  
specific	  fibrosis-­‐related	  
genes	  
- Mouse	  immune	  system	  
identifies	  viral	  vectors	  
rendering	  subsequent	  
exposures	  less	  potent	  
- Transgenes	  are	  typically	  




- Allows	  targets	  study	  of	  
specific	  fibrosis-­‐related	  
genes	  
- Costly	  and	  difficult	  to	  engineer	  
mouse	  
- Transgenes	  are	  typically	  
expressed	  at	  greater	  than	  
physiological	  levels	  
	  




1.3.2.	   In	  vitro	  models	  of	  fibrosis	  
Using	   animal	   models	   and	   humans	   in	   research	   for	   drug	   screening	   is	   often	   restricted	   by	  
feasibility	   of	   testing	   procedures,	   availability	   of	   test	   subjects,	   and	   ethical	   concerns.	   Many	  
studies	  also	  use	  cadaveric	   tissues,	  however	   the	  disadvantages	  of	  using	   tissues	   to	  understand	  
disease	  pathology	  are	  the	   limited	  availability	  of	  donors	  and	  the	  complications	  that	  may	  arise	  
whilst	  maintaining	   the	  viability	  of	   the	   tissue.	   In	  addition,	  other	   factors	  of	   the	  donor	   (such	  as	  
genetic	   variations)	   may	   go	   undetected	   which	   could	   affect	   the	   experimental	   result.	   These	  
limitations	   have	   encouraged	  many	   researchers	   to	   develop	   in	   vitro	  models	   in	   order	   to	   study	  
mechanisms	  of	  diseases	  and	  hopefully	  become	  a	  useful	   tool	   for	  drug	  screening.	  Such	   in	  vitro	  
models	   have	   many	   advantages	   including	   repetitive	   and	   quantitative	   investigations	   on	   cell	  
physiology	  in	  drug	  discovery.	  In	  addition,	  in	  vitro	  models	  are	  less	  expensive	  in	  comparison	  to	  in	  
vivo	  models.	  The	  different	  types	  of	  in	  vitro	  models	  used	  to	  study	  PF	  will	  be	  discussed	  below.	  
2D	  monolayer	  cultures	  
Two-­‐dimensional	   (2D)	   in	   vitro	   models	   of	   mammalian	   cells	   have	   been	   used	   extensively	   in	  
research.	  This	  involves	  seeding	  cells	  suspended	  in	  media	  (composed	  of	  growth	  factors)	  onto	  a	  
tissue	   culture	   treated	   plastic	   or	   glass	   substrate	   to	   determine	   cellular	   characteristics	   (e.g.	  
proliferation,	  apoptosis,	  mRNA	  and	  protein	  expression	  of	  a	   target	  molecule	  of	   interest,	  etc.).	  
The	   simplicity	  of	  a	  2D	  culture	  has	  aided	   in	  understanding	   individual	   cellular	  phenomena	  and	  
has	   led	   to	   the	   identification	   of	   several	   fibrotic	  mediators	   some	   of	  which	   have	   already	   been	  
described.	  However,	  there	  are	  many	  disadvantages	  of	  using	  monolayer	  cultures.	  For	  example,	  
in	   a	   normal	   physiological	   environment	   cells	   are	   surrounded	   by	   a	   complex	   and	   ‘crowded’	  
environment	  composed	  of	  various	  cell	  secreted	  factors	  and	  a	  mixed	  population	  of	  cells	  which	  
interact	   heterotypically,	   influencing	   their	   respective	   function.	   However,	   in	   a	   2D	   monolayer	  
culture	   this	   does	   not	   occur	   (Baker	   and	   Chen,	   2012)	   and	   the	   cells	   are	   unable	   to	   recapitulate	  
some	  of	  the	  characteristic	  features	  seen	  in	  lung	  of	  patients	  diagnosed	  with	  IPF	  (i.e.	  fibrotic	  foci,	  
a	  key	  histological	  feature	  which	  correlate	  with	  the	  progression	  of	  IPF).	  	  
Another	   disadvantage	   of	   2D	   in	   vitro	   systems	   is	   that	   fibroblasts	   are	   unable	   to	   lay	   down	  
significant	  amounts	  of	  collagen,	  even	  in	  the	  presence	  of	  ascorbic	  acid	  (co-­‐enzyme	  essential	  for	  
rendering	  collagen	  triple	  helix)	  (Murad	  et	  al.,	  1983;	  Chen	  and	  Raghunath,	  2009).	  The	  reason	  for	  
this	   lies	   in	   the	   delayed	   procollagen	   C-­‐proteinase	   (PCP)	   activity	   under	   the	   aqueous	   culture	  
conditions	   which	   leads	   to	   the	   accumulation	   of	   unprocessed	   procollagen	   in	   the	   cell	   culture	  




medium	  and	  following	  every	  media	  change	  this	  unprocessed	  pro-­‐collagen	   is	  discarded	  (Lareu	  
et	   al.,	   2007a,	   2007b).	   To	   address	   this	   issue,	   a	   hyperconfluent	   cell	   culture	   fibroplasia	  model	  
(involving	  exogenous	  treatment	  with	  TGFβ)	  has	  been	  developed	  which	  stimulates	  proliferation	  
and	   collagen	   synthesis	   (Clark	   et	   al.,	   1997). However,	   collagen	   cross-­‐linking	   is	   still	   difficult	   to	  
detect	  in	  this	  model.	  
Another	   disadvantage	   of	   2D	   in	   vitro	   system	   is	   the	   use	   of	   a	   stiff	   substrate.	   It	   is	   becoming	  
increasingly	  accepted	  that	  as	  well	  as	  chemical	  compositions,	  mechanical	  cues	  inherent	  to	  stiff	  
substrates	  are	  just	  as	  essential	  in	  affecting	  cellular	  behaviour	  (such	  as	  growth,	  differentiation,	  
protein	  and	  DNA	  synthesis,	  and	  apoptosis)	  (Hinz	  et	  al.,	  2001b;	  Tomasek	  et	  al.,	  2002;	  Hinz	  and	  
Gabbiani,	  2003a,	  2003b;	  Georges	  and	  Janmey,	  2005;	  Engler	  et	  al.,	  2006;	   Janmey	  et	  al.,	  2009;	  
John	  et	  al.,	  2010).	  Studies	  have	  shown	  that	  in	  most	  normal	  tissues	  the	  elastic	  modulus	  ranges	  
from	  0.5-­‐15	  kPa	  whereas	  in	  a	  fibrotic	  tissue	  the	  stiffness	  can	  be	  10-­‐100	  times	  greater	  (Discher	  
et	  al.,	  2005;	  Georges	  and	  Janmey,	  2005;	  Wells,	  2008;	  Janmey	  et	  al.,	  2009;	  Hinz,	  2010;	  Balestrini	  
et	  al.,	  2012).	  However,	   the	  elasticity	   for	  a	  stiff	  surface	  such	  as	  polystyrene	  plastic	   is	  ~106	  kPa	  	  
which	   is	  100,000	   times	   stiffer	   than	  a	   fibrotic	   tissue	   (Gilbert	  et	   al.,	   2010).	   Therefore,	   growing	  
cells	  on	  a	  stiff	  surface	  (i.e.	  tissue	  culture	  treated	  plastic	  or	  glass)	  has	  been	  described	  as	  highly	  
nonphysiological.	   Several	   studies	   on	   fibroblasts	   isolated	   from	   various	   tissues	   across	   many	  
species	  support	   that	   fibroblasts	   show	  distinct	   functional	  behaviours	  which	  are	  dependant	  on	  
substrate	   stiffness.	   For	   instance,	   Jesudason	   et	   al.	   (2010)	   illustrated	   that	   mechanical	   forces	  
regulate	   elastase	   (protein	   involved	   in	   the	   degradation	   elastin)	   activity	   within	   mouse	   lung	  
parenchyma	   (Jesudason	   et	   al.,	   2010).	   In	   addition,	   Goffin	   et	   al.	   (2006)	   identified	  αSMA	   as	   a	  
mechanicosensitive	   protein	   which	   is	   recruited	   to	   stress	   fibres	   under	   significant	   mechanical	  
load	  (Goffin	  et	  al.,	  2006;	  Hinz,	  2006).	  Decreasing	  the	  stiffness	  of	  the	  substrate	  and	  by	  inhibiting	  
myosin	   contraction	  diminishes	   stress	   fibre	   tension	  and	   results	   in	   the	   removal	  of αSMA	   from	  
the	  stress	  fibres	  (Goffin	  et	  al.,	  2006).	  	  Similar	  results	  have	  also	  been	  demonstrated	  by	  Balestrini	  
et	  al	  whereby	  explanting	  fibroblast	  outgrowth	  on	  tissue	  culture	  plastic	  or	  stiff	  collagen-­‐coated	  
silicone	   substrate	   (i.e.	   100	   kPA)	   resulted	   in	   increased	  expression	  of	  αSMA	  and	   increases	   cell	  
proliferation	   in	   comparison	   to	   the	   soft	   substrate	   (i.e.	   5	   kPa)	   (Balestrini	   et	   al.,	   2012).	   One	  
interesting	   finding	   from	   this	   study	  was	   that	   lung	   fibroblasts	   grown	   on	   stiff	  matrix	   for	   three	  
weeks	   sustained	   their	   myofibroblastic	   phenotype	   even	   after	   the	   cells	   were	   returned	   to	   a	  
healthy	  soft	  substrate	  for	  two	  weeks.	  In	  addition,	  culturing	  lung	  fibroblasts	  for	  three	  weeks	  on	  
soft	   substrates	   partially	   protected	   the	   cells	   from	   myofibroblast	   activation	   after	   shifting	   the	  
cells	   to	   stiff	   substrates.	   Thus,	   culturing	   cells	   on	   to	   a	   stiff	   substrate	   may	   have	   a	   permanent	  




impact	  on	  cell	  behaviour	  which	  does	  not	  resemble	  normal	  cellular	  behaviour	  evident	  in	  control	  
tissues	   in	   vivo.	   Nevertheless,	   despite	   having	  many	   disadvantages	   2D	  monolayer	   cultures	   are	  
still	  used	  in	  labs	  to	  determine	  behaviour	  of	  normal	  and	  pathological	  cells.	  
Scar-­‐in-­‐a-­‐jar	  (SIAJ)	  assay	  
The	   SIAJ	   in	   vitro	   assay	   has	   become	   increasingly	   popular	   in	   many	   labs	   in	   particular	   at	   GSK	  
(Stevenage,	  UK)	   for	   screening	   compounds.	   This	   assay	   is	   similar	   to	  a	  2D	  culture	  as	   it	   involves	  
seeding	  a	  monolayer	  of	  fibroblasts	  into	  a	  tissue	  culture	  treated	  plastic	  substrate.	  However,	  the	  
uniqueness	   of	   this	  model	   is	   that	   it	   involves	   the	   addition	  of	   Ficoll	  which	   is	   a	   non-­‐interacting,	  
neutral	   hydrophilic	   polysaccharide	   capable	   of	   causing	   macromolecular	   crowding	   (a	   feature	  
absent	   in	   the	   classical	   2D	  monolayer	   culture)	   promoting	   collagen	   synthesis	   at	   a	   faster	   rate,	  
thus	   reducing	   incubation	   time.	  Therefore,	   this	  assay	  allows	   in	   situ	   assessment	  of	   the	  area	  of	  
collagen	   type	   I	   deposited	   per	   cell	   and	   it	   is	   also	   possible	   to	   detect	   collagen	   cross-­‐linking.	  	  
Furthermore,	   this	   assay	   is	   considered	   to	  be	  high-­‐throughput	   for	   compound	   screening	   as	   the	  
effect	  of	  compounds	  on	  TGFβ-­‐induced	  collagen	  synthesis,	  αSMA	  expression,	  proliferation,	  and	  
cell	  toxicity	  can	  be	  measured	  simultaneously	  within	  a	  single	  well	  (Chen	  and	  Raghunath,	  2009).	  
Although	  this	  model	  produces	  high	  collagen	  levels	  at	  a	  fast	  rate	  and	  is	  considered	  a	  far	  better	  
system	  to	  identify	  therapeutic	  targets	  compared	  to	  the	  standard	  2D	  monolayer	  in	  vitro	  culture,	  
the	  SIAJ	  model	  also	  has	  several	  disadvantages	  some	  of	  which	  have	  already	  been	  described	  (i.e.	  
the	   assay	   only	   involves	   one	   cell	   type,	   cells	   are	   grown	   on	   a	   stiff	   substrate/plastic,	   the	   cells	  
require	   exogenous	   TGFβ	   to	   promote	   collagen	   synthesis,	   and	   the	   model	   is	   unable	   to	  
recapitulate	  fibrotic	  foci).	  
Precision	  cut	  lung	  slices	  	  
Over	   the	   past	   few	   year,	   the	   development	   of	  more	   complex	   three	   dimensional	   (3D)	   in	   vitro	  
models	  that	  mimic	  microenvironments	  observed	  in	  normal	  tissues	  have	  now	  become	  of	  great	  
interest	  (Elliott	  and	  Yuan,	  2011).	  One	  such	  model	  developed	  is	  known	  as	  the	  precision	  cut	  lung	  
slice.	   This	   model	   involves	   embedding	   donor	   lungs	   into	   low	  melting	   point	   agarose	   (inserted	  
through	   the	   trachea)	   to	   preserve	   the	   opened	   alveoli	   and	   provide	   better	   tissue	   compliance,	  
prior	   to	   slicing.	   	   The	   lung	   slices	   are	   then	   cultured	   at	   air-­‐liquid	   interface	   and	   treated	   with	  
compounds	  to	  investigate	  their	  effects.	  TGFβ1-­‐induced	  fibrosis	  has	  been	  studied	  on	  precision	  
lung	   slices	   for	   up	   to	   7	   days	   of	   culture	   whereby	   increased	   thickness	   of	   alveolar	   septa	   was	  
evident,	  and	  concentration	  dependent	  (Lin	  et	  al.	  1998).	  Furthermore,	  elevated	  collagen	  VI	  and	  
αSMA	  expression	  has	  also	  been	  reported	  (Kasper	  et	  al.	  2004).	  This	  model	  offers	  a	  large	  range	  




of	   applications	   for	   biomechanical,	   physiological,	   toxicological,	   and	   pharmacological	   studies.	  
Furthermore,	  the	  greatest	  advantages	  of	  this	  model	  are	  the	  preservation	  of	  the	  differentiation	  
state	  of	  quiescent	  tissue	  and	  the	  possibility	  to	  analyse	  multiple	  cell	  type	  interactions,	  similar	  to	  
in	  vivo	  lungs.	  In	  addition,	  studies	  have	  illustrated	  that	  the	  precision	  cut	  lungs	  slices	  behave	  in	  a	  
similar	  way	  to	  that	  seen	  in	  vivo.	  However,	  one	  of	  the	  major	  disadvantages	  of	  this	  model	  is	  the	  
lack	  of	  tissue	  availability	  due	  to	  limited	  number	  of	  donors.	  Therefore,	  a	  more	  robust	  3D	  system	  
is	   necessary	   which	   not	   only	  mimics	   some	   of	   the	   key	   features	   seen	   in	   IPF	   lungs,	   but	   is	   also	  
reproducible	   and	   easily	   used	   for	   high-­‐throughput	   screening	   of	   potential	   compounds	   for	   the	  
treatment	  of	  IPF.	  	  
	  	  
1.4.	   Spheroids	  and	  Microfluidic	  devices	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
1.4.1.	  	   Spheroids	  
Spheroids	  are	  defined	  as	  spherical	  aggregates	  of	  cells	  in	  culture	  which	  are	  able	  to	  retain	  a	  3D	  
architecture	   (Takezawa	   et	   al.,	   1993).	   The	   aggregates	   are	   organised	   in	   a	   complex	   network	  
involving	   cell-­‐to-­‐cell	   and	   cell-­‐to-­‐matrix	   interactions	   (Berahim	  et	   al.,	   2011).	   It	   is	   believed	   that	  
cells	  within	   the	   spheroids	   are	   able	   to	   form	   gap	   and	   tight	   junctions,	  which	   contribute	   to	   the	  
formation	  of	  the	  spheroid	  (Takezawa	  et	  al.,	  1993).	  Since	  the	  early	  1970s,	  spheroids	  have	  been	  
utilised	   in	   research	   areas	   of	   tissue	   engineering,	   as	   they	   seem	   to	   mimic	   morphological	   and	  
physiological	   characteristics	   of	   cells	   in	   living	   tissues/organs	   thus	   aid	   in	   understanding	   the	  
pathology	   of	   various	   diseases	   (Corbeil	   et	   al.,	   1977;	   Culo	   et	   al.,	   1980;	   Kunz-­‐Schughart	   et	   al.,	  
1998).	  One	  of	  the	  major	  benefits	  of	  establishing	  spheroids	  is	  that	  certain	  cellular	  mechanisms	  
(i.e.	   cell	   growth,	   proliferation,	   and	   differentiation)	   can	   be	   studied	   in	   a	   reproducible	   format	  
(Kunz-­‐Schughart	  et	  al.,	  1998).	  
Spheroid	  forming	  techniques	  
There	  are	  several	  fabrication	  methods	  which	  have	  been	  developed	  to	  form	  spheroids	  some	  of	  
which	   are	   illustrated	   in	   Figure	   1.15.	   The	   most	   classical	   method	   used	   to	   produce	   spheroids	  
involves	   culturing	   cells	   in	   a	   round-­‐bottom	   96	   well	   plate	   with	   a	   non-­‐adherent	   surface.	   Pre-­‐
coating	  the	  tissue	  culture	  treated	  plate	  with	  agarose	  can	  generate	  this	  non-­‐adherent	  surface	  
(Takezawa	  et	  al.,	  1993).	  This	  approach	  is	  simple	  to	  carry	  out	  and	  forms	  reproducible	  spheroids	  













of	  the	  same	  size.	  The	  static	   liquid	  overlay	  method	  is	  similar	  to	  this	  method	  as	  it	  also	  involves	  
culturing	  cells	  on	  non-­‐adherent	  substrates.	  However,	  in	  this	  method	  the	  cells	  are	  cultured	  on	  a	  
larger	   surface	  which	  eventually	   results	   in	   the	  mass	  production	  of	   spheroids.	  However	  unlike	  







Another	  common	  method	  used	  is	  the	  ‘hanging	  drop’	  approach.	  This	  involves	  placing	  a	  drop	  of	  
cell	   suspension	   on	   to	   an	   inverted	   dish	   which	   is	   then	   placed	   above	   a	   reservoir	   to	   prevent	  
evaporation.	   This	   would	   allow	   the	   cells	   in	   the	   drop	   to	   adhere	   to	   one	   another	   forming	   a	  
spheroid.	   Unlike	   the	   previous	  methods	   described,	   this	   approach	   is	   slightly	  more	   tedious	   (in	  
particular	   when	   collecting	   the	   spheroid	   for	   analysis)	   and	   less	   high-­‐throughput.	   To	   address	  
these	   issues,	   manufacturers	   have	   recently	   developed	   commercially-­‐available	   96-­‐	   and	   384-­‐
microwell	  plate	   formats	  which	  provide	  more	  control	  with	  regards	  to	  the	  size	  of	   the	  spheroid	  
and	  are	  theoretically	  less	  labour	  intensive	  (Tung	  et	  al.,	  2011;	  Hsiao	  et	  al.,	  2012).	  
	  
Current	  literature	  on	  cells	  cultured	  as	  spheroids	  
Spheroid	   culture	   is	   a	   versatile	   and	   powerful	   biomimicry	   tool	   used	   in	   many	   areas	   of	   basic	  
science	  and	  regenerative	  medicine.	  Cancer	  cells,	  embryonic	  cells,	  and	  dermal	  fibroblasts	  have	  
been	  studied	  extensively	  as	  spheroids	  (Culo	  et	  al.,	  1980;	  Takezawa	  et	  al.,	  1993;	  Matsuo	  et	  al.,	  
A)	  	   B)	  	  
C)	  	  
Agarose-­‐coated	  well	  
Figure	  1.	  15:	  Spheroid	  formation	  methods	  
(A)	   Non-­‐adherent	   surface	   technique	   (in	   this	   case	   agarose	   coated	   wells);	   (B)	   Liquid	  
overlay	   technique;	   (C)	   Hanging	   drop	   technique.	   B	   and	   C	   are	   reproduced	   from	  
(Fennema	  et	  al.,	  2013)	  with	  permission	  of	  Elsevier	  Ltd.	  




1997).	  For	  instance,	  Culo	  et	  al.	  (1980)	  used	  four	  mouse	  tumours	  to	  form	  multicellular	  tumour	  
spheroids	   in	  order	  to	   investigate	  tumour	  growth	   in	  normal	  and	   immunised	  mice.	   In	  addition,	  
Kaufman	   et	   al.	   (1981)	   analysed	   the	   physiology	   of	  multicellular	   spheroids	   from	   hamster	   lung	  
fibroblast	   cells,	   where	   they	   demonstrated	   that	   in	   the	   presence	   of	   non-­‐toxic	   indirect	  
radiosensitiser	   agents;	   the	   radioresistance	   of	   these	   cells	   was	   significantly	   modified.	  
Furthermore,	   studies	  on	  periodontal	   fibroblasts	  have	  demonstrated	   the	  growth	  of	   spheroids	  
on	   collagen-­‐based	   and	   synthetic	   membranes.	   In	   addition,	   spheroids	   formed	   from	  
mesenchymal	   stem	   cells	   (MSCs)	   derived	   from	  human	  umbilical	   cord	  blood	   appear	   to	   exhibit	  
increased	  therapeutic	  potential	  for	  myocardial	  infarction	  (Lee	  et	  al.,	  2012)	  supporting	  the	  idea	  
that	  spheroid	  systems	  may	  provide	  a	  great	  promise	  for	  drug	  screening	  (Bichay	  et	  al.,	  1990).	  
Spheroid	   cultures	   have	   also	   been	   pivotal	   in	   the	   analysis	   of	   a	   new	   immune-­‐activation	  
phenomenon,	   known	   as	   nemosis.	   This	   process	   is	   described	   as	   programmed	   cell	   death	   of	  
activated	  cancer-­‐associated	  fibroblast	  spheroids	  in	  the	  absence	  of	  apoptotic	  markers.	  This	  cell	  
death	   results	   from	   the	   production	   of	   COX2,	   MMP1,	   MMP10,	   MT-­‐MMP1,	   proinflammatory	  
cytokines	   (e.g.	   IL-­‐1,	   IL-­‐6,	   IL-­‐8)	   and	   chemokines	   (such	   as	   RANTES)	   (Vaheri	   et	   al.,	   2009).	  
Furthermore,	   studies	  have	   illustrated	   that	   integrin-­‐fibronectin	   association	  plays	   a	   key	   role	   in	  
fibrocyte	   spheroid	   formation	  as	   fibronectin	   knockout	   cells	  or	   antibodies	   against	   integrins	  α5	  
and	  β1	  impair	  spheroid	  formation	  and	  promote	  nemosis	  (Salmenperä	  et	  al.,	  2008;	  Vaheri	  et	  al.,	  
2009).	  
Over	  the	  past	  decade,	  studies	  have	  also	  demonstrated	  the	  feasibility	  of	  co-­‐culturing	  fibroblast	  
spheroids	  with	  other	  cell	   types,	   including	  human	  bladder	  cancer	  cells	   (Schuster	  et	  al.,	  1994),	  
hepatocytes	   (Takezawa	   et	   al.,	   1992),	   cholangiocarcinoma	   cell	   line	   (Kubota	   et	   al.,	   1992),	  
esophageal	   squamous	  carcinoma	  cells	   (Shima	  et	  al.,	   1995),	  human	  keratinocytes	   (Butt	  et	  al.,	  
1996),	   breast	   tumour	   cells	   (Kunz-­‐Schughart	   et	   al.,	   2001;	   Kaur	   et	   al.,	   2011;	   Li	   and	   Lu,	   2011).	  
More	   recently,	   Saleh	   et	   al.	   (2011),	   analysed	   the	   effects	   of	   co-­‐culturing	  human	  bone-­‐marrow	  
MSC	  spheroids	  with	  human	  umbilical	   vein	  endothelial	   cells	   (HUVECs),	   and	  demonstrated	   	   an	  
increase	   in	  proliferation	  and	  differentiation	  of	  MSC,	  as	  well	  as	  enhanced	  Wnt/BMP	  signalling	  
(Saleh	  et	   al.,	   2011).	  However,	   human	   lung	   fibroblasts	   (and	   IPF	   fibroblasts	   in	  particular)	   have	  
never	  been	  reported	  in	  spheroid	  studies.	  





Many	  researchers	  are	  also	  greatly	  interested	  in	  cell-­‐based	  microfluidic	  technologies	  in	  order	  to	  
develop	   culture	   conditions	   and	   methodologies	   in	   various	   scientific	   areas	   ranging	   from	  
fundamental	  biological	  studies	  to	  drug	  discovery	  (Whitesides,	  2006;	  Kang	  et	  al.,	  2008;	  Satoh	  et	  
al.,	   2009).	   There	   are	  many	   advantages	   of	   using	  microfluidic	   systems,	   one	   of	   which	   involves	  
precise	  control	  of	   fluidic	  elements.	  For	   instance,	   in	  order	   to	  understand	  the	  effect	  of	  soluble	  
factors	   on	   cell	   behaviour	   (such	   as	  proliferation,	   differentiation,	   and	  migration),	   gradient	   and	  
focusing	   flow	   generators	   have	   been	   used,	   which	   control	   spatial	   distribution	   of	   the	   soluble	  
factors	   (Jeon	   et	   al.,	   2000).	   In	   addition,	   these	   systems	   may	   be	   customised	   easily	   and	   be	  
attractive	  for	  studies	  that	  require	  analysis	  of	  several	  drugs.	  Furthermore,	  due	  to	  the	  fact	  that	  
the	  microfluidic	  experiments	  run	  on	  micro-­‐scale,	  the	  amount	  of	  reagent	  required	  is	  very	  small;	  
thus	   the	   use	   of	   these	   systems	  may	   be	  more	   economical	   (Elliott	   and	   Yuan,	   2011).	   Single	   cell	  
lines	  have	  been	  studied	  by	  many	  researchers	  using	  microfluidic	  systems.	  However,	  researchers	  
now	  focus	  on	  developing	  systems	  that	  culture	  more	  than	  one	  cell	  type	  on	  a	  range	  of	  different	  
matrices	   (natural	   or	   artificial)	   (Scotton,	   2011)	   .	   For	   instance,	   Hermanns	   et	   al.	   (2004)	  
demonstrated	   the	   feasibility	   of	   culturing	   two	   cell	   types	   (i.e.	   human	   lung	   epithelial	   cells	  with	  
pulmonary	  microvascular	   endothelial	   cells)	   on	   opposite	   sides	   of	   a	   polycarbonate	  membrane	  
filter,	  which	   not	   only	   formed	   a	   functional	   barrier	   between	   the	   cells,	   but	   also	   tight	   junctions	  
(Hermanns	  et	  al.,	  2004).	  	  
In	  addition,	  recently	  Huh	  et	  al.	  (2010)	  created	  an	   in	  vitro	  biomimetic	  microsystem	  (lung-­‐on-­‐a-­‐
chip)	  which	  reconstituted	  the	  functional	  alveolar-­‐capillary	  interface	  of	  the	  human	  lung	  (Figure	  
1.16).	   This	   microdevice	   comprised	   three	   polydimethylsiloxane	   (PDMS)	   layers.	   PDMS	   is	   a	  
silicone-­‐based	  polymer	  which	  is	  the	  most	  commonly	  used	  material	  in	  microfluidic	  systems,	  as	  
it	   is	   biocompatible,	   optically	   transparent	   for	   microscopy	   studies,	   and	   permeable	   to	   oxygen	  
(Elliott	   and	   Yuan,	   2011).	   The	   three	   layers	   were	   sandwiched	   together	   to	   form	   parallel	  
microchannels,	   separated	  by	   a	   10	  µm	   thick	   porous	   PDMS	  membrane,	   pre-­‐coated	  with	   ECM.	  
Endothelial	   (HUVEC)	  and	   immortalised	  epithelial	  cells	   (A549)	  were	  then	  cultured	  on	  opposite	  
sides	   of	   membrane	   (lower	   and	   upper	   surfaces,	   respectively),	   and	   once	   the	   cells	   were	  
confluent,	   the	   medium	   from	   the	   upper	   chamber	   was	   removed	   to	   establish	   a	   more	  
physiological	  system,	  air	  liquid	  interface.	  Moreover,	  in	  order	  to	  mimic	  physiological	  breathing	  
movements,	  computer-­‐controlled	  vacuum	  was	  applied	  to	  side	  chambers	  which	  allowed	  cyclic-­‐
stretching	  of	  the	  membrane	  (Huh	  et	  al.,	  2010).	  	  













This	  lung-­‐on-­‐a-­‐chip	  model	  not	  only	  mimicked	  certain	  physiological	  features,	  but	  also	  provided	  
some	  promising	  results	  which	  suggest	  that	  biomimetic	  microsystems	  may	  be	  the	  way	  forward	  
to	  understand	  diseases	  and	  for	  high-­‐throughput	  drug	  screening.	  However,	  further	  refinement	  
to	  this	  system	  is	  required	  to	  establish	  this	  (such	  as	  using	  primary	  human	  epithelial	  cells	  in	  place	  









Figure	  1.	  16:	  Human	  breathing	  lung-­‐on-­‐a-­‐chip	  micro	  device.	  
(A)	  The	  device	   is	  composed	  of	  3	  PDMS	   layers,	  with	  the	  centre	   layer	  being	  a	  porous	  10	  
mm	   thick	  membrane	   coated	  with	   ECM.	   (B)	   Structure	   of	   the	   chambers	   illustrating	   the	  
epithelial	   and	   endothelial	   cells	   cultured	   of	   opposite	   sides	   of	   the	  membrane.	   Applying	  
vacuum	   to	   the	   side	   chambers	   allows	   the	   membrane	   to	   stretch,	   which	   mimics	   the	  
physiological	  system.	  	  
	  
Reproduced	   from	   (Huh	   et	   al.,	   2010)	   with	   permission	   of	   The	   American	   Association	   for	   the	  
Advancement	  of	  Science	  (AAAS).	  	  
	  
	  
As	  well	  as	  developing	  microfluidic	  systems,	  which	  involve	  co-­‐culturing	  one	  or	  two	  different	  cell	  
types	   as	   monolayers,	   some	   studies	   have	   also	   developed	   devices	   that	   involve	   culturing	  
spheroids.	  For	  instance,	  Hsiao	  et	  al.	  (2009)	  developed	  a	  microfluidic	  device	  which	  was	  able	  to	  
culture	  3D	  multi-­‐cell	   type	  spheroids	  composed	  of	  prostate	  cancer	  cells,	  endothelial	  cells,	  and	  
osteoblasts.	   The	   device	   consisted	   of	   two	  PDMS	   layered	  microchannels	   separated	   by	   a	   semi-­‐
permeable	   polycarbonate	   membrane	   (10	   µm	   thickness	   with	   5	   µm	   pore).	   The	   upper	  
microchannel	  composed	  of	  28	  dead-­‐end	  side-­‐chambers,	  which	  were	  200	  x	  200	  x	  200	  µm	  (l	  x	  w	  
x	   d).	   The	   lower	   channel	   was	   used	   for	   perfusion	   of	   media.	   The	   membrane	   and	   the	   28-­‐side	  
channels	  were	   first	  coated	  with	  a	   low-­‐cellular	  attachment,	   followed	  by	  seeding	  cells	   into	   the	  
device,	   which	   resulted	   in	   the	   formation	   of	   equally	   sized	   spheroids	   within	   24	   hours	   (Figure	  
1.17).	  	  	  
A)	  	   B)	  	  















Figure	  1.	  17:	  Spheroid	  formation	  using	  microfluidic	  device.	  
(A)	  &	   (B)	   The	  device	   consists	   of	   2	  PDMS	   layers.	  Upper	   layer	   consisted	  of	   28	  dead-­‐end	  
side	   chambers	   and	   the	   lower	   layer	   was	   used	   for	   media	   perfusion.	   Both	   layers	   were	  
separated	   by	   a	   semi-­‐porous	   polycarbonate	   membrane.	   The	   channels	   and	   membrane	  
were	   coated	  with	   a	   low-­‐cellular	   attachment	   surface.	   (C)	   Cells	  were	   then	   cultured	   into	  
the	  device,	  and	  equally	  sized	  spheroids	  formed	  in	  each	  chamber	  within	  24	  hours.	  	  
Reproduced	  from	  (Hsiao	  et	  al.,	  2009)	  with	  permission	  of	  Biological	  Engineering	  Society.	  
	  
	  
Despite	   great	   success	   in	   co-­‐culturing	   two	   cell	   lines	   in	   microfluidic	   devices	   and	   forming	  
spheroids	  of	  different	  cell	  types,	  to	  date	  there	  is	  no	  evidence	  of	  whether	  it	  is	  feasible	  to	  form	  
spheroids	   from	   lung	   fibroblasts	  and	  co-­‐culture	   them	  with	   lung	  epithelial	  cell.	  Forming	  such	  a	  
model	  could	  answer	  many	  unanswered	  questions	   regarding	  crosstalk	  between	  epithelial	  and	  
mesenchymal	  cells	  in	  particular	  during	  fibrosis	  and	  could	  potentially	  lead	  to	  the	  development	  
of	  new	  therapeutic	  targets.	  	   	  




1.5.	   Summary,	  hypothesis,	  and	  aims	  for	  this	  thesis	  
	  
IPF	  is	  a	  fatal	  interstitial	  lung	  disease,	  with	  an	  unknown	  aetiology.	  The	  incidence	  of	  IPF	  in	  the	  UK	  
is	  increasing	  rapidly	  in	  patients	  aged	  between	  55-­‐75	  years	  and	  unfortunately	  there	  is	  no	  truly	  
effective	   treatment	   available	   to	   halt	   disease	   progression.	   A	   number	   of	   animal	  models	   have	  
been	   developed	   to	   understand	   the	   pathology	   of	   the	   disease,	   which	   has	   suggested	   that	   this	  
disorder	   results	   due	   to	   the	   dysregulation	   of	   epithelial-­‐mesenchymal	   crosstalk	   following	  
repetitive	   injury	   to	   the	   AECs.	   However,	   the	   lack	   of	   key	   histopathological	   features	   in	   these	  
murine	  models	  is	  a	  great	  limitation	  for	  developing	  effective	  therapies.	  	  
Based	   on	   our	   current	   understanding	   about	   the	   disease	   and	   possible	   cells	   and	   mediators	  
involved,	   this	   project	   focused	  on	   the	  development	  of	   organotypic	   cell	   culture	   approaches	   in	  
order	  to	  understand	  the	  disease	  progression	  in	  greater	  detail,	  which	  could	  hopefully	  provide	  a	  
useful	  tool	  for	  drug	  screening.	  Hence,	  the	  aim	  of	  this	  project	  was	  to	  develop	  a	  novel	  in	  vitro	  3D	  
model	  which	  mimics	  a	  particular	  characteristic	  feature	  seen	  in	  IPF	  patients	  	  -­‐	  the	  fibrotic	  focus.	  	  
This	  thesis	  therefore	  addressed	  the	  following	  hypothesis:	  
‘3D	  spheroid	  cultures	  of	   fibroblasts	  will	  provide	  a	  more	  representative	   in	  vitro	  model	  system	  
for	  drug	  screening	  in	  IPF’	  
	  The	  following	  aims	  were	  examined:	  
1. Investigate	   the	   morphological	   characteristics	   of	   non-­‐IPF	   primary	   human	   fibroblasts	  
derived	   from	   lung	   explants	   (pHLF-­‐Ex)	   and	   digested	   lungs	   (pHLF-­‐Di)	   and	   explore	   the	  
spheroid-­‐forming	  capacity	  of	  non-­‐IPF	  and	  IPF	  fibroblasts.	  
2. Determine	   some	   of	   the	   key	   fibroblast	   characteristics	   in	   spheroids	   (e.g.	   apoptosis,	  
proliferation,	  collagen	  synthesis,	  TGF-­‐beta	  production).	  
3. Investigate	   transcriptional	   differences	   between	   non-­‐IPF	   and	   IPF	   spheroids	   by	  
performing	  microarray	  data	  analysis	  on	  samples	  from	  multiple	  donors.	  
4. Investigate	   the	   feasibility	   of	   identifying	   specific	   targets	   by	   screening	   known	  
compounds	  using	  a	  GSK	  compound	  library	  
	   	  
	   	  
















	   	  




2.1. General	  plastic	  ware,	  chemicals,	  and	  cell	  culture	  reagents	  
	  
	  
Sterile	   tissue	   culture	   plates	   and	   flasks	   were	   all	   purchased	   from	   Nunc	   (Roskilde,	   Denmark).	  
Sterile	  polypropylene	  centrifuge	  tubes	  and	  pipettes	  were	  purchased	  from	  Falcon	  (New	  Jersey,	  
USA).	  Whatman	  cyclopore	  0.2	  μm	  polyester	  syringe	  filters	  were	  from	  Whatman	  (UK).	  Collagen-­‐
coated	   transwells	   (12	   mm	   polystyrene	   inserts	   with	   0.4μm	   pore	   PTFE	   membrane,	   collagen	  
coated,	  sterile)	  were	  purchased	  from	  VWR	  International	  Ltd	  (UK).	  Other	  disposable	  plasticware	  
was	   purchased	   from	   Sterilin	   (Ashford,	   UK).	   Deionised	  water	   was	   prepared	   using	   a	  Millipore	  
Water	  Purification	  System	  (Millipore	  R010	  followed	  by	  Milli-­‐Q	  Plus;	  Millipore	  Ltd,	  UK)	  for	  the	  
preparation	  of	  dilutions	  and	  buffers.	  
Sterile	   Dulbecco’s	   Modified	   Eagle	   Medium	   (DMEM;	   high	   glucose,	   sodium	   pyruvate,	   no	   L-­‐
glutamine),	   F12K	   culture	   media,	   Dulbecco’s	   Phosphate	   Buffered	   Saline	   (DPBS),	   Hank’s	  
Balanced	  Saline	  Solution	  (HBSS),	  Trypsin	  Neutralising	  Solution	  (TNS),	  penicillin-­‐streptomycin,	  L-­‐
glutamine,	   0.25%	   trypsin-­‐EDTA,	   amphotericin	   B,	   Foetal	   Bovine	   Serum	   (FBS),	   Neonatal	   Calf	  
Serum	  (NCS),	  and	  geneticin	  (G418)	  were	  purchased	  from	  Gibco	  Life	  technologies	  (UK).	  DCCM-­‐1	  
culture	  media	  was	  obtained	  from	  Biological	  Industries	  Ltd.	  (Glasgow,	  UK).	  Bronchial	  epithelial	  
cell	  growth	  medium	  (BEGM),	  Bulletkit	  growth	  factors,	  and	  HEPES	  buffer	  were	  purchased	  from	  
Lonza	  (UK).	  Pronase	  was	  purchased	  from	  Roche	  (UK).	  DMSO	  and	  L-­‐Ascorbic	  acid	  2-­‐phosphate	  
sesquimagnesium	  salt	  hydrate	  were	  purchased	  from	  Sigma	  Aldrich	  (UK).	  
	  
2.2. Cell	  lines	  and	  primary	  cells	  
	  
	  
The	   A549	   cell	   line	  was	   obtained	   from	   the	   American	   Type	   Culture	   Collection	   (ATCC)	   via	   LGC	  
Promochem	  (Middlesex,	  UK).	  Human	  transformed	  mink	  lung	  epithelial	  cells	  (TMLC)	  were	  a	  kind	  
gift	   from	  Dr	  D.	  Rifkin	   (New	  York	  University,	  New	  York,	  USA).	  Human	  bronchial	  epithelial	  cells	  
(HBECs)	  were	  isolated	  and	  cultured	  in	  our	  laboratory	  with	  the	  help	  of	  Dr	  Manuela	  Platè	  (UCL,	  
UK).	   Primary	   human	   lung	   fibroblasts	   (pHLFs)	   from	   six	   donors	   were	   a	   kind	   gift	   from	   GSK	  
(Stevenage,	  UK);	  10	  donors	  were	  a	  kind	  gift	  from	  Dr	  Robin	  McAnulty	  (UCL,	  CITR,	  UK);	  and	  five	  
further	  donors	  were	   isolated	  during	   this	  project.	   	  The	  method	  used	   to	   isolate	   the	   fibroblasts	  
from	   the	   lungs	  was	   the	   same	   for	   each	   donor	   and	   is	   described	   in	  Section	   2.3.	   Lung	   samples	  




were	   obtained	   from	   11	   patients	   with	   IPF	   (6	   male,	   5	   female;	   mean	   age,	   65	   yrs)	   following	  
diagnostic	  surgical	   lung	  biopsy	  or	   lung	  transplant.	  All	  fibrotic	  samples	  used	  in	  this	  study	  were	  
classified	  using	  the	  diagnostic	  criteria	  of	  the	  American	  Thoracic	  Society/European	  Respiratory	  
Society	   (ATS/ERS)	   consensus	   criteria:	   namely,	   a	   pattern	  of	   usual	   interstitial	   pneumonia	   (UIP)	  
(Raghu	  et	  al.,	  2011).	  Control	  lung	  samples	  were	  obtained	  from	  lungs	  of	  10	  patients	  (8	  male,	  2	  
female;	   mean	   age,	   36	   yrs)	   following	   cancer	   resection	   surgery	   (uninvolved	   tissue)	   or	   from	  
patients	  who	   died	   as	   a	   result	   of	   an	   accident	   or	   suicide	  with	   no	   signs	   of	   lung	   disease.	   Three	  
control	  samples	  were	  obtained	  from	  National	  Disease	  Research	  Interchange	  (NDRI).	  Approval	  
for	   the	  use	  of	   all	  material	  was	  obtained	   from	   the	  Royal	  Brompton	  &	  Harefield	  NHLI	  and	   the	  
ethics	   committee	   of	   University	   College	   London	   and	   University	   College	   London	   Hospital.	  
Informed	  consent	  was	  received	  from	  each	  subject.	  	  
	  
2.3. Isolation	  of	  primary	  cells	  
	  
2.3.1.	   Primary	  human	  lung	  fibroblasts	  from	  explants	  (pHLF-­‐Ex)	  	  
Under	   sterile	   conditions,	  peripheral	   lung	   tissue	  was	  cut	   into	   small	  explants	   (less	   than	  1mm3)	  
and	  placed	   into	  petri	  dishes	  with	  2	  ml	  of	  20	  %	  FBS	   in	  DMEM	  (containing	  400	  U/ml	  penicillin	  
streptomycin,	  4	  mM	  L-­‐glutamine	  and	  0.1	  %	  amphotericin	  B).	  The	  petri	  dishes	  were	  incubated	  
at	  37	  oC	  with	  10	  %	  CO2	   for	  24	  hours	  before	  the	  addition	  of	   further	  8	  mL	  of	  media.	  Every	  2-­‐3	  
days	  the	  petri	  dishes	  were	  topped	  up	  with	  200	  µL	  of	  amphotericin	  B	  and	  400	  U/mL	  penicillin	  
streptomycin	  (1:1	  ratio).	  Upon	  reaching	  80-­‐90	  %	  confluence	  (after	  2-­‐4	  weeks)	  the	  medium	  was	  
removed	  and	  washed	  with	  trypsin-­‐EDTA	  once,	  followed	  by	  an	  additional	  treatment	  with	  fresh	  
trypsin-­‐EDTA	  at	  37	   oC.	   The	   cells	  were	   inspected	  after	   approximately	   three	  minutes,	  using	  an	  
Olympus	  TCK-­‐2	   inverted	  phase	  contrast	   light	  microscope	  (Olympus	  Optical	  Ltd,	  UK)	  for	  shape	  
change	  (rounding	  up)	  and	  detachment	  from	  the	  plastic.	  Trypsin	  was	  subsequently	  neutralised	  
with	  DMEM/10	  %	  FBS.	   The	   cells	  were	   then	   centrifuged	  at	   300	  g	   for	   5	  minutes.	   Supernatant	  
was	  discarded	  and	  the	  pellet	  was	  re-­‐suspended	  in	  DMEM/10	  %	  FBS.	  The	  cells	  were	  counted	  on	  
a	  Glasstic®	  microscope	  slide	  (Hycor	  Biomed,	  USA)	  or	  using	  a	  Handheld	  Automated	  Cell	  Counter	  
(Sceptor,	   Millipore,	   UK)	   and	   seeded	   at	   appropriate	   densities.	   Non-­‐IPF	   pHLF-­‐Ex	   were	   used	  
between	  passages	  3-­‐6	  and	  IPF	  pHLF-­‐Ex	  were	  used	  between	  passages	  4-­‐12.	  




2.3.2.	   Primary	  human	  lung	  fibroblasts	  from	  digested	  lung	  (pHLF-­‐Di)	  	  
Peripheral	   lung	   tissue	  was	   first	  washed	  with	  either	   sterile	   saline	   (Baxter,	  Austria)	  or	  HBSS	   to	  
remove	   erythrocytes.	   This	   involved	   injection	   through	   the	   large	   airways	   in	   order	   to	   achieve	  
better	  distribution	  of	   the	  saline	  and	  prevent	  any	   tissue	  damage.	  This	  was	  done	  until	   the	  cell	  
count	  was	  <1x104	  cells/mL	  (excluding	  erythrocytes).	  The	  tissue	  was	  then	  injected	  with	  0.25	  %	  
trypsin	  (from	  bovine	  pancreas,	  Sigma,	  UK)	  in	  HBSS	  through	  the	  large	  airways	  and	  parenchyma	  
and	   incubated	   at	   37	   °C	   with	   5	   %	   CO2	   for	   45	   minutes.	   The	   activity	   of	   trypsin	   was	   then	  
neutralised	  using	  NCS	  containing	  250	  µg/mL	  DNase1.	  The	  tissue	  was	  minced	  into	  small	  pieces,	  
and	  agitated	  for	  5	  minutes.	  Following	  this,	  the	  tissue	  suspension	  was	  filtered	  through	  400	  µm	  
and	  40	  µm	  filters	  (BD)	  to	  remove	  any	  large	  multicellular	  pieces	  of	  tissue	  and	  then	  centrifuged	  
at	   400	  g,	   12	   °C,	   for	   10	  minutes.	   The	   supernatant	  was	   discarded	   and	   the	   cell	   pellet	   was	   re-­‐
suspended	  in	  DCCM-­‐1	  medium,	  supplemented	  with	  50	  µg/mL	  DNase1.	  The	  cell	  suspension	  was	  
then	  seeded	  into	  tissue	  culture	  treated	  flasks,	  followed	  by	  incubation	  at	  37	  °C	  with	  5	  %	  CO2	  for	  
two-­‐three	   hours	   to	   allow	   adherent	   cells	   (i.e.	   fibroblasts	   and	  macrophages)	   to	   adhere	   to	   the	  
flask,	  incubated	  at	  37	  oC	  with	  10	  %	  CO2.	  Confluence	  of	  the	  fibroblasts	  (80-­‐90	  %)	  was	  achieved	  
within	   1	  week,	   and	   the	   cells	  were	   then	   trypsinised	   (as	  mentioned	   in	  Section	   2.3.1).	   pHLF-­‐Di	  
were	  used	  between	  passages	  2-­‐6.	  
Both	   pHLF-­‐Ex	   and	   pHLF-­‐Di	   were	   morphologically	   characterised	   by	   immunocytochemical	  
staining	   (Section	  2.4)	   for	  a	  selection	  of	   smooth	  muscle	  cell	   (i.e.	   smoothelin),	  endothelial	  and	  
fibroblast	  markers	  such	  as	  a-­‐smooth	  muscle	  actin	  (αSMA).	  	  
2.3.3.	   Primary	  human	  bronchial	  or	  bronchiolar	  epithelial	  cells	  (HBECs)	  
Under	  sterile	  conditions,	  bronchi/bronchioles	  were	  removed	  from	  the	  lung	  and	  cut	  into	  small	  
pieces	   (1	   mm3).	   These	   were	   then	   placed	   into	   a	   50	   mL	   falcon	   tube	   with	   0.15	   %	   pronase	   in	  
DMEM	   (containing	   200	   U/mL	   penicillin-­‐streptomycin,	   4	   mM	   L-­‐glutamine,	   and	   0.1	   %	  
amphotericin	  B)	  and	   incubated	  overnight	  at	  4	  oC	  on	  a	  rotary	  mixer.	  Following	  16-­‐18	  hours	  of	  
incubation,	   the	   tissue	   was	   agitated	   to	   dislodge	   the	   bronchiolar	   epithelial	   cells	   from	   the	  
basement	  membrane	  and	  any	   remaining	  pieces	  of	   solid	   tissue	  were	   removed	  and	  discarded.	  
10	  %	  FBS	  was	  added	  to	   the	  medium	  to	   inactivate	   the	  proteolytic	  activity	  of	   the	  pronase	  and	  
the	  mixture	  was	  centrifuged	  for	  5	  minutes	  at	  150	  g.	  The	  supernatant	  was	  discarded	  from	  the	  
cell	   pellet	   followed	   by	   resuspension	   in	   pre-­‐warmed	   (37	   oC)	   BEGM	   (BEBM	  +	   Bulletkit	   growth	  
factors).	  The	  cells	  were	  then	  seeded	   into	  sterile	  flasks	  at	  1x106	  cells	  per	  25	  cm2.	  The	  medium	  




was	  replaced	  the	  following	  day	  to	  remove	  non-­‐adherent	  and	  dead	  cells.	  Cells	  were	  then	  grown	  
to	   80	   %	   confluence,	   with	   the	   medium	   being	   changed	   every	   2-­‐3	   days.	   Purity	   of	   the	   cell	  
population	  was	  examined	  using	  both	  positive	  and	  negative	  immuno-­‐based	  staining.	  	  
Flasks	  were	  passaged	  as	   follows:	  The	  medium	  was	   removed	   from	   flasks	  and	   the	  monolayers	  
were	  washed	  briefly	  with	  HEPES	  buffer.	   Trypsin	  was	   then	   added	  and	   the	   cells	   incubated	   for	  
five	   minutes	   at	   37	   °C	   with	   5	   %	   CO2.	   After	   incubation,	   the	   cells	   were	   examined	   using	   an	  
Olympus	   TCK-­‐2	   inverted	   phase	   contrast	   light	  microscope	   (Olympus	   optical	   Ltd,	  UK)	   to	   verify	  
cellular	  detachment.	  Trypsin	  was	  then	  inactivated	  by	  the	  addition	  of	  an	  equal	  volume	  of	  TNS.	  
The	  suspension	  was	  then	  centrifuged	  at	  150	  g	   for	  5	  minutes.	  The	  supernatant	  was	  discarded	  
and	  the	  cell	  pellet	  was	  resuspended	  with	  fresh	  media.	  	  Cells	  were	  passaged	  1:5	  and	  used	  up	  to	  
passage	  4.	   For	   experiments,	   trypsinised	  HBECs	  were	   resuspended	   into	  DMEM	  and	  10	  %	   FBS	  
and	  seeded	  at	  a	  density	  of	  1x104	  cells	  per	  spheroid	  (see	  Section	  2.5	   for	  spheroid	  formation).	  
The	   cells	   were	   incubated	   for	   24	   hours	   to	   allow	   adherence	   at	   37	   oC	   with	   10	   %	   CO2	   before	  
analysis.	  
	  
2.4. Immunocytochemistry	  	  
	  
	  
Immunocytochemistry	  was	  performed	  to	  characterise	  the	  phenotype	  of	  the	  cell	  isolates,	  using	  
antibodies	  detailed	   in	  Table	  2.1.	  Cells	  were	   seeded	   into	  a	  96	  well	  plate	   (density	  10,000	  cells	  
per	  well)	  or	  a	  glass	  chamber	  slide	  (50,000	  cells	  per	  well)	  for	  24	  hours.	  Cells	  were	  then	  serum	  
starved	  for	  24	  hours	   followed	  by	  TGFβ	   (1	  ng/mL)	  activation	  for	  a	   further	  24	  hours.	  Cell	  were	  
then	  washed	  with	  DPBS	  and	   fixed	  with	  methanol	   for	   two	  minutes.	  These	  were	   then	  blocked	  
with	   5	   %	   serum	   (from	   same	   species	   as	   secondary	   antibody)	   and	   3	   %	   BSA	   in	   DPBS	   for	   30	  
minutes,	   followed	   by	   incubation	   with	   primary	   antibody	   diluted	   in	   DPBS	   with	   3	   %	   BSA,	  
overnight	  at	  4	  oC	  (Table	  2.1).	  	  
The	  cells	  were	  then	  washed	  three	  times	  with	  DPBS,	  followed	  by	  incubation	  with	  fluorescently	  
labeled	  secondary	  antibody	  for	  1	  hour	  at	  room	  temperature.	  Note,	  for	  cell	  in	  the	  96-­‐well	  plate	  
DAPI	   was	   added	   at	   the	   same	   time	   as	   the	   secondary	   antibody	   at	   a	   dilution	   of	   1:10,000.	  
However,	   for	   chamber	   slides	  Prolong-­‐gold	  anti-­‐fade	  with	  DAPI	  was	  used	   to	  mount	   the	   slides	  
after	  incubating	  the	  cells	  in	  the	  secondary	  antibody.	  A	  Zeiss	  Axioskop	  2	  microscope	  and	  Qicam	  
12-­‐bit	  color	  fast	  camera	  was	  used	  to	  visualize	  and	  capture	  images	  of	  cell	  in	  the	  chamber	  slides.	  




ImageXpress	  Micro	  XL	  was	  used	  to	  visualize	  and	  capture	  images	  of	  the	  cells	  seeded	  in	  the	  96	  
well	  plates.	  Quantification	  analysis	  was	  performed	  using	  MetaXpress	  version	  5.3.0.1.	  	  
	  	  
Table	  2.	  1:	  List	  of	  primary	  antibodies	  used	  for	  immunostaining	  
	   Recognises	   Raised	  in	   Supplier	   Dilution	  used	  
Secondary	  
species	  




Human	   Mouse,	  monoclonal	  
Sigma	  
Aldrich,	  UK	   1:200	   Goat	  
Smoothelin	   Human	   Mouse,	  monoclonal	   Abcam,	  UK	   1:40	   Goat	  
Ki-­‐67	   Human	   Rabbit,	  monoclonal	   Abcam,	  UK	   1:100	   Goat	  
Collagen	  I	   Human	   Rabbit,	  polyclonal	   Abcam,	  UK	   1:200	   Goat	  




2.5. 3D	  culture	  	  
	  
2.5.1.	   Spheroid	  formation	  
4	  %	  agarose	   (Sigma	  Aldrich,	  UK)	  was	  prepared	   in	  Milli-­‐Q	  water.	  This	  was	  then	  diluted	  to	  2	  %	  
agarose	  using	  DMEM	  (1:1	  ratio).	  Using	  an	  Eppendorf	  Multipette,	  50	  µL	  of	  this	  mix	  was	  placed	  
into	  each	  well	  of	  a	  flat-­‐bottom	  96	  well	  plate	  to	  form	  a	  thin	  film	  of	  agarose	  as	  a	  non-­‐adhesive	  
surface.	  The	  plates	  were	  left	  at	  room	  temperature	  for	  approximately	  15	  minutes	  to	  allow	  the	  
agarose	   to	   set.	   Following	   trypsinisation	  pHLF	   (non-­‐IPF	  and	   IPF)	  were	   re-­‐suspended	   in	  DMEM	  
(containing	  50	  U/mL	  penicillin	  streptomycin,	  2	  mM	  L-­‐glutamine)	  and	  0.4	  %	  FBS,	  supplemented	  
with	   100	   µM	   L-­‐Ascorbic	   acid	   2-­‐phosphate	   sesquimagnesium	   salt	   hydrate.	   The	   cells	   were	  
counted	   using	   a	   Handheld	   Automated	   Cell	   Counter	   (Sceptor)	   to	   get	   a	   cell	   count	   of	   1x105	  
cell/mL.	   100	  µL	   of	   the	   cell	   suspension	  were	   seeded	   into	   the	   agarose	   coated	   at	   a	   density	   of	  
1x104	  cells	  per	  well.	  The	  plates	  were	  then	  incubated	  at	  37	  oC	  with	  10	  %	  CO2	  to	  allow	  the	  cells	  to	  
aggregate	  and	  form	  spheroids.	  Samples	  were	  collected	  for	  analysis	  following	  24	  to	  96	  hours	  of	  
incubation.	  




2.5.2.	   Compound	  treatment	  
Indomethacin	   was	   purchased	   from	   Sigma	   (UK).	   SC-­‐560,	   CAY10404,	   LSKL	   (thrombospondin-­‐1	  
inhibitor)	   and	   SLLK	   (control	   peptide	   for	   thrombospondin-­‐1	   inhibitor)	   were	   purchased	   from	  
Cambridge	  Bioscience	  (UK).	  NS398	  was	  obtained	  from	  VWR	  (UK).	  All	  other	  compounds	  were	  a	  
kind	   gift	   from	  GSK	   (Stevenage,	   UK).	   All	   compounds	  were	   serially	   diluted	   by	   a	   factor	   of	   3	   in	  
DMSO	  10	   times	   from	  a	   starting	   concentration	  of	  0.01	  M.	  The	  compounds	  were	   then	   further	  
diluted	  1:100	   in	  media	  (DMEM	  supplemented	  with	  2	  mM	  L-­‐glutamine,	  50	  U/mL	  penicillin,	  50	  
µg/mL	  streptomycin	  and	  0.4	  %	  FBS).	  The	  diluted	  compounds	  were	  then	  added	  into	  each	  well	  
before	   spheroid	   formation	   (prophylactic	   treatment,	   time	   zero)	   or	   24	   hours	   after	   spheroid	  
formation	   (therapeutic	   treatment)	   to	   give	   a	   final	   concentration	   range	   of	   300	   pM	   to	   10	  µM.	  
Each	  spheroid	  was	  treated	  with	  the	  compounds	  for	  24	  hours	  before	  analysis.	  
2.5.3.	   IncuCyte	  Zoom	  
To	  monitor	  spheroid	  formation	  and	  the	  effect	  of	  compounds,	  the	  plates	  were	  cultured	  in	  the	  
IncuCyte	   Zoom	   (Essen	  bioscience,	  UK),	   composed	  of	   a	  microscope	  gantry	   that	   resides	   in	   the	  
cell	   incubator	   capable	   of	   taking	   live	   content	   phase	   contrast	   imaging	   of	   the	   cell	  
aggregation/spheroid	  formation	  over	  time.	  Magnification	  of	  the	  IncuCyte	  Zoom	  was	  set	  to	  x4.	  
Phase	  object	  area	   is	  defined	  as	  the	  total	  area	  of	  a	  well	  containing	  cells.	  A	  reduction	   in	  phase	  
contrast	  object	  area	  represented	  the	  aggregation	  of	   the	  cells	   into	  a	  more	  compact	   form	  (i.e.	  
spheroids).	  Each	  treatment	  had	  eight	  replicates	  for	  statistical	  analysis.	  
	  
	  
2.6. Histological	  evaluations	  of	  spheroids	  
	  
2.6.1.	   Spheroid	  fixation	  and	  paraffin	  embedding	  
Spheroids	  were	  collected	  and	  washed	  with	  DPBS	  followed	  by	  fixation	  with	  4	  %	  PFA	  (diluted	  in	  
PBS;	  Sigma	  Aldrich,	  UK)	   for	  20	  minutes.	  They	  were	  then	  dehydrated	  with	  70	  %	  ethanol	   for	  5	  
minutes	  before	  the	  addition	  of	  ultra-­‐low	  melting	  point	  agarose	  in	  order	  to	  form	  small	  agarose	  
plugs.	  These	  plugs	  were	  then	  left	  to	  cool	  at	  room	  temperature	  and	  then	  placed	  in	  processing	  
cassettes	   (Histosette	   II®;	   Simport,	   Quebec,	   Canada)	   and	   dehydrated	   using	   a	   Leica	   TP1050	  
tissue	   processor	   (Leica	   Microsystems,	   Buckinghamshire,	   UK).	   This	   involved	   dehydrating	   the	  




spheroids	  by	   incubating	   them	   in	   increasing	  concentrations	  of	   IMS	   (70	  %,	  2hrs;	  80	  %,	  1	  hr	  30	  
min;	   90	  %	  1	  hr	  30	  min;	   and	  100	  %,	  1	  hr	   15	  min	  4	   times).	   Following	   this	   the	   spheroids	  were	  
incubated	  in	  xylene	  (3X	  1	  hr)	  and	  then	  paraffin	  wax	  (3X	  1	  hr).	  Subsequent	  the	  spheroids	  were	  
embedded	  into	  paraffin	  wax.	  The	  paraffin	  wax	  blocks	  were	  cooled	  to	  4	  oC	  and	  2	  µm	  sections	  
were	   cut	   using	   Shandon	   A5235	   Retraction	  microtome	   (Thermo	   Shandon,	   Cheshire,	   UK)	   and	  
Tissue-­‐Tek®	  AccuEdge®	  blades	  (VWR,	  UK)	  and	  placed	  on	  poly-­‐lysine	  coated	  microscope	  slides	  
(VWR,	  UK).	  
2.6.2.	   H&E	  and	  MSB	  staining	  
The	  architecture	  of	   the	   spheroids	  was	  analysed	  using	   two	  staining	   techniques:	  haemotoxylin	  
and	  eosin	  (H&E,	  Table	  2.2)	  staining	  and	  a	  modified	  trichrome	  stain	  (martius	  scarlet	  blue,	  MSB	  
staining,	   Table	   2.3).	   H&E	   was	   used	   to	   visualise	   the	   cellular	   structure	   of	   the	   tissue	   and	  
spheroids.	   Gill	   II	   haematoxylin	   (Bios.	   Laboratories,	   USA)	   stains	   the	   nucleus	   of	   the	   cells	   blue	  
whereas	  eosin	  Y	  (1%	  aqueous;	  Bios.	  Laboratories,	  USA)	  stains	  the	  cytoplasm	  of	  cells	  pink.	  	  
MSB	   was	   used	   to	   visualise	   the	   architecture	   of	   connective	   tissue.	   Nuclei	   stain	   brown/red,	  
muscles	   stain	   red,	   fibrin	   stains	   light	  pink,	  and	  collagen	   stains	  blue.	   For	   the	  demonstration	  of	  
collagen	   the	  pivotal	   stage	   is	   the	  Chicargo	   sky	  blue	  6GX	  dye.	   This	   is	   the	   largest	  dye	  molecule	  
used	  in	  the	  technique	  and	  the	  stain	  product	   is	  dependent	  upon	  the	  permeability	  of	  collagen.	  
Automated	  staining	  of	  sections	  was	  performed	  using	  a	  Sakura	  Tissue-­‐Tek	  DRS	  2000	  Diversified	  
Stainer	   (Miles	   Diagnostics/Bayer,	   UK).	   All	   chemicals	   used	   to	   prepare	   the	   solutions	   for	   MSB	  
















Table	  2.	  2:	  Solutions	  and	  incubation	  times	  for	  H&E	  staining	  
Step	  No.	   Solution	   Time	  
1	   Xylene	   3	  min	  
2	   Xylene	   3	  min	  
3	   100%	  IMS	   2	  min	  
4	   90%	  IMS	   2	  min	  
5	   70%	  IMS	   2	  min	  
6	   50%	  IMS	   2	  min	  
7	   dH2O	   1	  min	  
8	   Haematoxylin	   5	  min	  
9	   Wash	  in	  H2O	   10	  sec	  
10	   Wash	  in	  H2O	   10	  sec	  
11	   Acid	  alcohol	  1%	  HCl	  in	  70%	  alcohol)	   8	  sec	  
12	   Wash	  in	  H2O	   30	  sec	  
13	   Wash	  in	  H2O	   2	  min	  
14	   Eosin	   6	  min	  
15	   Wash	  in	  H2O	   15	  sec	  
16	   50%	  IMS	   30	  sec	  
17	   70%	  IMS	   45	  sec	  
18	   90%	  IMS	   1	  min	  
19	   100%	  IMS	   1	  min	  
20	   100%	  IMS	   2	  min	  
21	   Xylene	   1	  min	  
22	   Xylene	   2	  min	  
23	   Xylene	   2	  min	  
	   	  






Table	  2.	  3:	  Staining	  sequence	  for	  Martius	  Scarlet	  Blue	  
Step	  No.	   Solution	   Time	  
1	   Xylene	   3	  min	  
2	   Xylene	   3	  min	  
3	   100%	  Industrial	  Methylated	  Spirit	  (IMS)	   2	  min	  
4	   90%	  IMS	   2	  min	  
5	   70%	  IMS	   2	  min	  
6	   Lugol’s	  Iodine	   5	  min	  
7	   3%	  Sodium	  thiosulphate	   3	  min	  
8	   Wash	  in	  H2O	   2	  min	  
9	   Celestine	  blue	   5	  min	  
10	   Wash	  in	  H2O	   1	  min	  
11	   Rinse	  in	  distilled	  H2O	   30	  sec	  
12	   Haemotoxylin	   5	  min	  
13	   Wash	  in	  H2O	   30	  sec	  
14	   Acid	  alcohol	  (1%	  HCl	  in	  70%	  alcohol)	   3	  sec	  
15	   Wash	  in	  H2O	   8	  min	  
17	   90%	  IMS	   30	  sec	  
18	   0.2%	  Orange	  G	  in	  picric	  alcohol	   8	  min	  
19	   Distilled	  H2O	   5	  sec	  
20	   Red	  mixture	  (0.5%	  ponceaux	  de	  xylidine;	  0.5%	  acid	  fushsin	  in	  1%	  
glacia;	  acetic	  acid)	  
7	  min	  
21	   Distilled	  H2O	   5	  sec	  
22	   1%	  Phosphotungstic	  acid	   30	  sec	  
22	   Distilled	  H2O	   20	  sec	  
22	   0.5%	  Chicago	  Sky	  Blue	  6BX	  (Direct	  Blue)	  in	  1%	  glacial	  acetic	  acid	   80	  sec	  
22	   1%	  Acetic	  acid	   20	  sec	  
22	   70%	  IMS	   20	  sec	  
22	   90%	  IMS	   20	  sec	  
22	   100%	  IMS	   1	  min	  
22	   Xylene	   2	  min	  
22	   Xylene	   2	  min	  
23	   Xylene	   2	  min	  




2.6.3.	   Immunohistochemistry	  
Paraffin	  embedded	  spheroid	  sections	  on	  poly-­‐lysine	  coated	  slides	  (Section	  2.6.1)	  were	  first	  de-­‐
waxed	  using	  a	  Sakura	  Tissue-­‐Tek	  DRS	  2000	  Diversified	  Stainer.	  This	  involved	  incubation	  of	  the	  
slides	  for	  3	  minutes	  in	  xylene	  (twice),	  followed	  by	  rehydration	  by	  incubating	  the	  sections	  in	  
decreasing	  concentrations	  of	  IMS	  (100	  %,	  90	  %,	  70	  %,	  50	  %	  in	  distilled	  water).	  Each	  rehydrating	  
step	  involved	  2	  minute	  incubation.	  The	  slides	  were	  then	  placed	  into	  distilled	  water	  for	  one	  
minute	  prior	  to	  immunostaining.	  	  
The	   sections	   were	   then	  washed	   in	   1x	   Tris	   buffered	   saline	   (TBS;	   1:20	   dilution	   using	   20x	   TBS	  
containing	  0.05	  %	  Tris-­‐base	  and	  16	  %	  NaCl	   in	  deionised	  water	  at	  pH	  7.6)	  for	  five	  minutes.	  An	  
Immedge	  pen	  (Vector	  Laboratories,	  USA)	  was	  used	  to	  draw	  around	  each	  section	  on	  the	  slide	  in	  
order	   to	  make	  a	  hydrophobic	  boundary.	  The	  sections	  were	   then	   incubated	   in	  0.05%	  saponin	  
(Sigma	   Aldrich,	   UK)	   for	   30	   minutes	   at	   room	   temperature	   for	   antigen	   retrieval	   followed	   by	  
washing	   in	   TBS	   twice	   for	   five	   minutes.	   Following	   antigen	   retrieval,	   the	   sections	   were	  
immunostained	  using	  either	  the	  avidin-­‐biotinylated	  enzyme	  complex	  kit	  (Vector	  Laboratories,	  
USA)	  or	  ImmPress	  reagent	  kit	  (Vector	  Laboratories,	  USA).	  
Avidin-­‐biotinated	  enzyme	  complex	  kit	  
During	  the	  early	  stage	  of	  this	  project	  the	  avidin	  biotinated	  enzyme	  complex	  kit	  was	  used	  which	  
involved	   firstly	   incubating	   the	   sections	   in	   3	   %	   hydrogen	   peroxide	   (H2O2)	   for	   30	   minutes	   to	  
neutralise	   endogenous	   peroxidase	   followed	   by	   five	   minute	   washes	   in	   TBS,	   twice.	   Following	  
this,	  the	  sections	  were	  incubated	  with	  ~16	  %	  serum	  of	  the	  secondary	  species	  (as	  displayed	  in	  
Table	   2.1)	   and	   avidin	   block	   (4	   drops/mL,	   as	   stated	   in	  manufacturer’s	   instructions)	   diluted	   in	  
TBS,	   for	  20	  minutes	  at	   room	   temperature.	   The	   sections	  were	   then	  drained	  and	   incubated	   in	  
either	   polyclonal	   non-­‐immune	   control	   IgG	   (used	   as	   an	   isotype	   specific	   negative	   control)	   or	  
primary	  antibody	   (Table	  2.4)	  diluted	   in	  1	  %	  BSA,	  1	  %	  serum	  of	  secondary	  species,	  and	  biotin	  
block	  (4	  drops/mL,	  as	  stated	  in	  manufacturer’s	  instructions)	  in	  TBS,	  overnight	  at	  4	  oC.	  After	  the	  
overnight	   incubation,	   the	   slides	   were	   washed	   twice	   in	   TBS	   for	   five	   minutes	   followed	   by	  
incubation	  in	  secondary	  antibody	  (either	  goat	  anti-­‐rabbit	  IgG	  conjugated	  to	  biotin	  or	  goat	  anti-­‐
mouse	  IgG	  conjugated	  to	  biotin	  (1	  μg/mL;	  Dako,	  Denmark)	  in	  1	  %	  BSA	  diluted	  in	  TBS,	  for	  two	  
hours	  at	  room	  temperature.	  The	  sections	  were	  then	  washed	  twice	  in	  TBS	  for	  five	  minutes	  and	  
then	   incubated	  with	  0.5	  %	  streptavidin/HRP	   (Dako)	  diluted	   in	  TBS	  containing	  1	  %	  BSA	   for	  30	  
minutes	   at	   room	   temperature.	   The	   sections	   were	   washed	   again	   three	   times	   in	   TBS	   for	   five	  




minutes	   followed	   by	   10	   minutes	   incubation	   in	   3,3’-­‐diaminobenzdine	   (DAB)	   solution	   (DAB	  
substrate	   kit;	   Vector	   Laboratories,	   USA)	   as	   instructed	   by	   the	   manufacturer’s	   protocol.	   The	  
sections	  were	  then	  submerged	  in	  tap	  water	  prior	  to	  counterstaining	  with	  haemotoxylin	  (using	  
Sakura	   Tissue-­‐Tek	   DRS	   2000	   Diversified	   Stainer).	   The	   slides	   were	   the	   coverslipped	   using	   an	  
automatic	   coverslip	   machine,	   Sakura	   Coveraid	   SCA5600	   (Bayer	   Diagnostics,	   UK)	   and	   HiQA	  
coverslip	  tape	  (CellPath,	  Powys,	  UK).	  
	  
ImmPress	  reagent	  kit	  
During	  half	  way	  through	  my	  project	  we	  decided	  to	  use	  the	  ImmPress	  reagent	  kit.	  This	  staining	  
system	   involves	   novel	   conjugation	   and	   micropolymer	   chemistries	   to	   create	   a	   ready-­‐to-­‐use,	  
one-­‐step,	   biotin-­‐free	  detection	   system	  which	   is	   highly	   sensitive.	   The	  unique	  micropolymer	   is	  
attached	  to	  the	  affinity	  purified	  secondary	  antibodies	  (provided	  with	  the	  kit),	  which	  results	  in	  
low	  background	  in	  comparison	  to	  the	  previous	  kit.	  	  
Following	   antigen	   retrieval,	   the	   sections	   were	   incubated	   in	   3	   %	   H2O2	   for	   30	   min	   (same	   as	  
before)	   followed	   by	   five	  minute	  washes	   in	   TBS.	   The	   sections	  were	   then	   blocked	  with	   2.5	  %	  
normal	  horse	   serum	  block	   from	  30	  min	   (provided	  by	   the	   ImmPress	   reagent	  kit),	   followed	  by	  
incubation	   in	  primary	  antibody	   (diluted	   in	  1	  %	  BSA	   in	  TBS)	  overnight	  at	  4oC.	  The	   slides	  were	  
then	   washed	   in	   TBS	   twice	   for	   five	   minutes	   and	   subsequently	   treated	   with	   the	   secondary	  
antibody	   (provided	   by	   the	   kit)	   for	   30	   min	   at	   room	   temperature.	   The	   sections	   were	   then	  
washed	   again	   for	   five	   minutes	   in	   TBS	   followed	   by	   treatment	   with	   ImmPact	   NovaRed	  
Peroxidase	  Substrate	  (Vector	  laboratories,	  USA)	  for	  2	  min.	  The	  sections	  were	  then	  submerged	  
in	  tap	  water	  prior	  to	  counterstaining	  (as	  stated	  above).	  
	  
2.7. Electron	  microscopy	  (EM)	  
	  
Cells	   were	   seeded	   for	   spheroid	   formation	   as	   stated	   in	   Section	   2.5.1.	   Following	   24	   hours	   of	  
incubation,	  the	  spheroids	  were	  washed	  twice	  in	  PBS	  followed	  by	  24	  hour	  fixation	  at	  4	  oC	  with	  2	  
%	  paraformaldehyde	  (PFA)	  and	  1.5	  %	  glutaraldehyde	  diluted	  in	  0.1M	  sodium	  cacodylate	  buffer,	  
pH	   7.3.	   Samples	   were	   then	   processed	   for	   EM	   which	   was	   kindly	   performed	   by	   Dr.	   Mark	  




Turmaine	  (Department	  of	  Anatomy	  and	  Developmental	  Biology,	  UCL).	  This	  initial	  step	  involved	  
washing	  the	  spheroids	  in	  0.1	  M	  sodium	  cacodylate	  buffer	  (pH	  7.4)	  twice	  for	  30	  minutes.	  
For	   scanning	  electron	  microscopy	   (SEM),	   the	   spheroids	  were	   then	  post-­‐fixed	   in	   1	  %	  osmium	  
tetraoxide	  (OsO4)	  and	  1.5	  %	  potassium	  ferrocyanine	  in	  	  0.1m	  cacodylate	  buffer	  at	  3	  oC	  for	  1	  ½	  
hours	   followed	   by	   washing	   in	   0.1	   M	   sodium	   cacodylate	   buffer	   and	   rinse	   in	   ddH2O.	   The	  
spheroids	  were	  then	  dehydrated	  through	  a	  graded	  ethanol-­‐water	  series	  to	  100	  %	  ethanol.	  The	  
spheroids	  were	   critical	   point-­‐dried	   using	   CO2	   and	  mounted	   on	   aluminium	   stubs	   using	   sticky	  
carbon	   taps.	   The	   mounted	   samples	   where	   then	   coated	   with	   a	   thin	   layer	   of	   gold/palladium	  
(Au/Pd;	   approximately	   2nm	   thick)	   using	   a	   Gatan	   ion	   beam	   coater.	   Imaging	   was	   performed	  
using	  Jeol	  7401	  FEGSEM	  (Jeol,	  UK).	  
For	   transmission	  electron	  microscopy	   (TEM),	   the	  spheroids	  were	  post-­‐fixed	   in	  1	  %	  OsO4	  and	  
0.1	  M	  sodium	  cacodylate	  (pH	  7.3)	  at	  3oC	  for	  1	  ½	  hours	  followed	  by	  washing	  in	  0.1	  M	  sodium	  
cacodylate	  (pH	  7.4).	  	  The	  samples	  were	  then	  Enbloc	  stained	  with	  0.5	  %	  uranyl	  acetate	  dH20	  at	  
3oC	   for30min.	  After	   rinsing	  with	   dH2O,	   the	   spheroids	  were	  dehydrated	   in	   a	   graded	  ethanol-­‐
water	   series	   and	   infiltrated	   with	   Agar	   100	   resin	   to	   hardened.	   A	   representative	   area	   was	  
selected	   and	   ultra	   thin	   sections	  were	   cut	   at	   70-­‐80	   nm	  using	   a	   diamond	   knive	   on	   a	   Reichert	  
ultracut	   S	   microtome.	   Sections	   were	   collected	   on	   200	   mesh	   copper	   and	   stained	   with	   lead	  
citrate.	  The	  sections	  were	  then	  viewed	  with	  a	  Joel	  1010	  transition	  electron	  microscope	  and	  the	  
images	  recorded	  using	  a	  Gatan	  Orius	  CCD	  camera	  (Gatan,	  UK).	  
	  
2.8. TUNEL	  assay	  
	  
2.8.1.	   Principle	  of	  technique	  
TUNEL	   (Terminal	  deoxynucleotidyl	   transferase	  dUTP	  nick	  ended	   labelling)	  assay	   is	  a	  common	  
assay	  used	  to	  assess	  cell	  death	  by	  detecting	  fragmented	  DNA.	  This	  assay	  is	  dependent	  on	  the	  
activity	  of	  terminal	  deoxynucleotidyl	  transferase	  (TdT)	  which	  is	  able	  to	  catalyse	  the	  addition	  of	  
dUTP	  molecules	   (conjugated	   to	   a	   fluorescent	  marker)	   to	   the	   fragmented	  DNA	  which	   can	   be	  
analysed	  using	  a	  fluorescence	  microscope.	  	  




2.8.2.	   Reagents	  
Proteinase	  K	   (26	  µg/mL	   in	  10	  mM	  TRIS	  5	  mM	  EDTA,	  pH7.4);	  TUNEL	   labelling	  mix	  and	  TUNEL	  
enzyme	  (Roche,	  UK);	  DNase	  I	  recombinant,	  grade	  I	  (3000	  U/mL–	  3	  U/	  mL	  in	  50	  mM	  Tris-­‐HCl,	  pH	  
7.5,	  1	  mg/mL	  BSA);	  Prolong	  anti-­‐fade	  gold	  (with	  DAPI;	  Invitrogen,	  UK).	  
2.8.3.	   Procedure	  
The	   procedure	  was	   followed	   as	   stated	   in	   the	  manufacturer’s	   instruction	   leaflet.	   Briefly,	   this	  
involved	  de-­‐waxing	  paraffin	  embedded	  spheroids	  sections	  and	  incubating	  with	  proteinase	  K	  for	  
15	  minutes.	  For	  the	  positive	  control,	  the	  slides	  were	  incubated	  with	  DNase	  I	  recombinant	  for	  
10	  min	  at	  15-­‐25	  °C	  to	  induce	  DNA	  strand	  breaks,	  prior	  to	  the	  labelling	  procedure.	  The	  labelling	  
procedure	   involved	   incubating	   all	   sections	   with	   the	   TUNEL	   reaction	   mixture	   (5	   µL	   TUNEL	  
enzyme	   and	   45	   µL	   TUNEL	   label	   solution	   per	   section)	   for	   1	   hour	   at	   37	   oC	   in	   a	   humidified	  
atmosphere	  in	  the	  dark.	  For	  the	  negative	  control,	  the	  sections	  were	  incubated	  with	  the	  TUNEL	  
label	   solution	   only.	   Each	   section	  was	   then	  mounted	   under	   coverslip	   using	   Prolong	   anti-­‐fade	  
gold	  (with	  DAPI).	  Sections	  were	  analysed	  under	  the	  microscope	  with	  an	  excitation	  wavelength	  
in	  the	  range	  of	  450–500	  nm	  and	  detection	  in	  the	  range	  of	  515–565	  nm	  (green).	  The	  percentage	  
of	  TUNEL	  positive	  cells	  was	  counted	  using	  the	  publically	  available	  NIH	  Image	  J	  software.	  
	  
2.9. Western	  blotting	  
	  
2.9.1.	   Reagents,	  buffers,	  and	  equipment	  
Reagents:	  Bicinchoninic	  acid	  (BCA)	  protein	  assay	  (Pierce,	  USA);	  phosphosafe	  extraction	  buffer	  
(Merck,	  Germany);	  Complete	  Mini	  Protease	   Inhibitor	  Cocktail	   (Roche,	  UK)	  dissolved	   in	  500µL	  
deionized	  water;	  Bovine	  serum	  albumin	  (BSA;	  Millipore,	  UK);	  PageRuler	  Plus	  Prestained	  Protein	  
Ladder,	  250	  kDa	  to	  10	  kDa	  (Fermentas,	  UK);	  1	  %	  Ponceau	  S	  solution	  (Sigma	  Aldrich,	  UK);	  ECL	  
(Amersham,	  USA).	  
Gels	  and	  membranes:	  Pre-­‐cast	  8-­‐16	  %	  Tris-­‐HEPES	  polyacrylamide	  gradient	  gels	   (Nucep,	  USA);	  
Hybond-­‐ECL,	  GE	  Healthcare	  AmershamTM	  0.45	  µm	  nitrocellulose	  membrane	   (VWR,	  UK);	   filter	  
paper	  (Whatman,	  USA);	  Hyperfilm	  ECL	  (Amersham,	  USA).	  




Buffers:	   5X	   Laemmli	  buffer:	   100	  mM	  dithiothreitol	   (DTT),	   1	  M	  Tris	  pH	  6.8,	   10	  %	  w/v	   sodium	  
dodecyl	  sulphate	  (SDS),	  20	  %	  w/v	  glycerol	  and,	  bromphenol	  blue	  to	  color;	  Running	  buffer:	  0.1	  
M	  Tris,	  0.1	  M	  HEPES,	  0.1	  %	  w/v	  SDS;	  TBS-­‐Tween	  (TBST):	  10	  nM	  Tris	  pH	  8,	  150	  nM	  NaCl,	  0.1	  %	  
v/v	  Tween-­‐20;	  Transfer	  buffer:	  25	  mM	  Tris,	  0.2	  M	  glycine,	  1	  %	  w/v	  SDS,	  20	  %	  v/v	  methanol;	  
Blocking	   buffer:	   5	   %	   w/v	   non-­‐fat	   milk	   powder	   in	   TBS-­‐Tween.	   All	   buffers	   were	   made	   using	  
deionised	  water.	  
Equipment:	  Novex	  semi-­‐dry	  blotter	  (Invitrogen,	  UK);	  Titertek	  Multiscan	  MCC/340	  plate	  reader	  
(Labsystems,	  Finland);	  automated	  film	  developer	  (Kodak,	  UK)	  
2.9.2.	   Sample	  preparation	  
Spheroids	  were	  washed	  with	  cold	  PBS	  and	  lysed	  in	  ice	  cold	  phosphosafe	  extraction	  buffer	  with	  
protease	  inhibitors	  (1:20	  dilution	  from	  stock).	  Spheroids	  were	  homogenized	  with	  a	  hand	  held	  
pestle	   (Eppendorf,	   UK)	   to	   ensure	   complete	   lysis	   and	   lysates	   were	   transferred	   to	  
microcentrifuge	  tubes.	  	  All	  samples	  were	  stored	  at	  -­‐20	  °C	  before	  use.	  
BCA	   protein	   assay	   was	   used	   to	   determine	   protein	   concentration	   in	   each	   spheroid	   lysate	  
sample.	  The	  assay	  works	  on	  the	  basis	  of	  biuret	  reaction	  whereby	  proteins	  are	  able	  to	  reduce	  
Cu2+	  (copper	  ion)	  to	  Cu+	  (cuprous	  ion)	  in	  alkaline	  conditions.	  Two	  bicinchoninic	  acid	  molecules	  
are	   able	   to	   chelate	   with	   Cu+	   resulting	   in	   the	   formation	   of	   an	   intense	   purple	   colour	   and	   its	  
absorbance	  can	  me	  read	  be	  at	  562	  nm.	  The	  amount	  of	  BCA-­‐Cu+	  complex	  formed	  within	  each	  
sample	   is	   directly	   proportional	   to	   protein	   concentration.	   This	   assay	   was	   performed	   as	  
instructed	   by	   the	  manufacturer.	   Briefly,	   bovine	   serum	   albumin	   (BSA)	   was	   used	   to	   generate	  
standard	  protein	  controls	  with	  concentration	  ranging	  from	  2	  mg/mL	  to	  0.0039	  mg/mL.	  In	  a	  96	  
well	  plate,	  10	  µL	  of	  the	  standard	  control	  or	  sample	  were	  placed	   into	  each	  well	   in	  duplicates.	  
Each	  well	  was	  then	  treated	  with	  200	  µL	  of	  freshly	  prepared	  BCA	  working	  reagent	  (combination	  
of	   reagent	   A	   and	   reagent	   B,	   at	   a	   50:1	   ratio).	   The	   components	   were	   then	   gently	  mixed	   and	  
incubated	   for	   30	   minutes	   at	   37	   oC.	   The	   absorbance	   was	   then	   read	   using	   a	   plate	   reader.	   A	  
standard	  curve	  was	  generated	  by	  plotting	  the	  BSA	  standard	  concentration	  against	  absorbance	  
values	  which	  was	  used	  to	  determine	  the	  protein	  concentration	  of	  each	  samples	  based	  on	   its	  
absorbance	  value.	  Each	  sample	  was	  then	  diluted	  as	  appropriate	  with	  deionised	  water	  to	  get	  a	  
final	  protein	  concentration	  of	  7	  µg.	  This	  was	  then	  mixed	  with	  5x	  Laemmli	  buffer,	  followed	  by	  
incubation	   at	   100	   oC	   for	   five	  minutes	   in	   order	   to	   reduce	   any	   disulphide	  bonds.	   The	   samples	  




were	   then	   loaded	   onto	   a	   pre-­‐cast	   8-­‐16	  %	   Tris-­‐HEPES	   polyacrylamide	   gradient	   gel,	   alongside	  
with	  a	  protein	  ladder.	  Electrophoresis	  was	  performed	  at	  120	  V	  for	  45	  minutes.	  
2.9.3.	   Protein	  transfer	  
A	  horizontal	  semi-­‐dry	  transfer	  method	  was	  used	  to	  transfer	  the	  electrophoresed	  protein	  form	  
the	  gel	  onto	  a	  0.45	  µm	  nitrocellulose	  membrane.	  Prior	  to	  transfer,	  the	  gel	  was	  equilibrated	  in	  
transfer	  buffer	   for	   20	  minutes	   and	   the	  nitrocellulose	  membrane	  was	   also	   soaked	   in	   transfer	  
buffer.	   Transfer	   sandwiches	   were	   then	   made	   in	   the	   following	   order	   (from	   bottom	   to	   top):	  
electrode,	  filter	  paper,	  nitrocellulose	  membrane,	  gel,	  filter	  paper,	  electrode.	  The	  proteins	  were	  
transferred	  at	  a	  constant	  voltage	  of	  20	  V	  for	  one	  hour.	  Following	  this	  the	  quality	  of	  the	  transfer	  
was	  assessed	  by	  using	  a	   rapid	   stain	   in	  1	  %	  Ponceau	  S	   solution	  which	  stains	  proteins	  without	  
having	   any	   effect	   on	   the	   downstream	   immunoblot.	   The	   membrane	   was	   then	   destained	   by	  
rinsing	  in	  water.	  
2.9.4.	   Chemiluminescence	  	  
Following	  protein	  transfer,	  the	  membrane	  was	  incubated	  in	  blocking	  buffer	  for	  1	  hour	  at	  room	  
temperature	   with	   gentle	   motion	   to	   block	   against	   non-­‐specific	   antibody	   binding.	   The	  
membrane	  was	  then	   incubated	  overnight	  at	  4	   °C	  with	  primary	  antibodies	  against	  proteins	  of	  
interest	  diluted	  in	  blocking	  buffer.	  After	  the	  overnight	  incubation,	  the	  membrane	  was	  washed	  
three	   times	   for	   five	  minutes	   in	   TBST	   and	   then	   incubated	  with	   a	   species	   specific	   horseradish	  
peroxidase	   (HRP)-­‐linked	   secondary	   antibody	   (diluted	   in	  blocking	  buffer).	   The	  membrane	  was	  
then	   washed	   three	   times	   for	   five	   minutes	   in	   TBST	   and	   positive	   bands	   were	   developed	   by	  
enhanced	  chemiluminescence	  (ECL)	  as	  per	  manufacturer’s	  instructions.	  Immunoreactive	  bands	  
were	   visualized	   by	   exposing	  Hyperfilm	   ECL	   to	   the	  membrane	   and	   developing	   the	   film	  on	   an	  
automated	  film	  developer.	  Exposure	  time	  was	  adjusted	  according	  to	  the	  strength	  of	  the	  signal.	  
2.9.5.	   Densitometric	  analysis	  	  
Semi-­‐quantitative	   analysis	   of	   Western	   blots	   was	   performed	   using	   densitometry.	   A	   flatbed	  
scanner	  (Epson,	  UK)	  was	  used	  to	  scan	  the	  blots.	  NIH	  Image	  J	  was	  used	  to	  calculate	  the	  optical	  
density	   of	   each	   band,	   according	   to	   a	   calibration	   curve	   of	   different	   densities	   (Kodak	  
photographic	  step	  tablet,	  Kodak,	  UK).	  The	  optical	  density	  of	  each	  band	  was	  normalized	  to	   its	  
loading	  control	  (extracellular	  regulated	  kinase-­‐2,	  ERK2).	  






2.10.1.	   Reagents	  and	  primers	  
RNaseZap	   (Sigma	   Aldrich,	   UK)	   was	   used	   to	   thoroughly	   clean	   all	   equipment	   and	   filtered	  
nuclease	   free	   pipette	   tips	   (Continental	   Lab	   Products,	   UK)	   were	   used	   to	   minimise	   RNA	  
degradation.	   Trizol	   (Sigma	  Aldrich,	  UK);	  molecular	   biology	   grade	   chloroform	  and	  2-­‐propanol,	  
(Sigma	   Aldrich,	   UK);	   Nuclease	   free	   water	   (Ambien	   UK);	   0.1	   %	   diethyl	   pyrocarbonate	   (DEPC;	  
Sigma,	   UK)	   water	   (prepared	   in	   deionised	   water,	   left	   overnight	   at	   room	   temperature,	   and	  
subsequently	   autoclaved	   to	   deactivate	   DEPC);	   Glycoblue	   coprecipitant	   (15	   mg/mL;	   Ambion,	  
Life	  technologies,	  UK);	  DNase	  free	  kit	  (Primer	  design,	  UK);	  qScript	  cDNA	  SuperMix	  ®	  kit	  (Quanta	  
Biosciences,	   UK);	  MESA	   FAST	   qPCR	  MasterMix	   plus	   for	   SYBR	   green	   assay	   no	   ROX	  w/o	   UNG	  
(Eurogentec,	   UK).	   GeNorm	   kit	   (composed	   of	   12	   housekeeping	   genes	   to	   select	   the	   best	  
reference	  primers	  for	  normalisation	  of	  mRNA	  levels)	  was	  from	  Primer	  design.	  	  
All	   other	   primers	   used	   in	   real-­‐time	   (RT)-­‐PCR	   studies	   were	   designed	   by	   myself	   or	   Dr.	   Chris	  
Scotton	   using	   an	   internet	   based	   software.	   Accession	   numbers	   were	   located	   from	  
www.ncbi.nlm.gov/gene.	   This	   number	   was	   then	   entered	   into	   primer	   BLAST	  
(www.ncbi.nlm.gov/tools/primer-­‐blast).	  The	  parameters	  were	  set	  at:	  product	   size	  80-­‐130	  bp;	  
primer	   size	   18-­‐22	   nucleotides	   long;	   primer	   melting	   temperature	   58	   °C	   to	   62	   °C	   with	   an	  
optimum	  of	  60	  °C	  and	  a	  maximum	  temperature	  difference	  of	  0.5	  °C;	  primer	  GC	  %	  was	  40	  %	  to	  
60	  %	  with	  an	  optimum	  of	  50	  %;	  maximum	  self-­‐complimentary	  was	  set	  at	  6.0	  and	  maximum	  3’	  
self-­‐complementarity	   of	   2.0	   and	   finally,	   the	  maximum	   poly-­‐X	   was	   set	   at	   3	   to	   avoid	   runs	   of	  
nucleotides.	  A	  BLAST	  search	  was	  also	  performed	  to	  check	  that	  the	  forward	  and	  reverse	  primers	  
were	  specific	   for	   the	   intended	  sequence.	  The	  primers	  were	  manufactured	  by	   Invitrogen,	  UK.	  
Primer	  sequences	  are	  listed	  in	  Table	  2.4.	  	  
	   	  





Table	  2.	  4:	  Sequences	  for	  primers	  used	  
Primer	   Forward	  sequence	   Reverse	  sequence	  	  
ACTA2	   5’ATCCTGACTGAGCGTGGCTATT	  3’	   5’GGCCATCTCATTTTCAAAGTCC	  3’	  
COL1A1	   ATGTAGGCCACGCTGTTCTT	   GAGAGCATGACCGATGGATT	  
COL3A1	   CCAGGAGCTAACGGTCTCAG	   CAGGGTTTCCATCTCTTCCA	  
ITGAV	   TCTGTGCCGCGCCTTCAACC	   AACATCCGGGAAGACGCGCTG	  
ITGB5	   AACCGCCAAGGACTGCGTCATG	   TTTCCACACTCTGGCTCCCTGAGG	  
ITGB3	   TGCGAGTGTGACGACTTCTC	   GTCCAGTCGGAGTCACACAG	  
ITGB8	   GGTCCAGAATGTGGATGGTGT	   TCAACTGAGCAGCCTTTGCT	  
PTGS1	   TCAGGGAGTCTCGGGAGATG	   ATTCCTCCAACTCTGCTGCC	  
PTGS2	   ACGCTTTATGCTGAAGCCCT	   CCACAGCATCGATGTCACCA	  
PTGER1	   TGCCCATCTTCTCCATGACG	   CCACGAACAGCAGGAAGGT	  
PTGER2	   CAGTCTCCCTGCTCTTCTGC	   GCACCGAGACAATGAGAAGC	  
PTGER3	   CAGTGTTCCTCAACCTTGATGTG	   CACAATGTGCAGTTGCCCTC	  
PTGER4	   TGCTCTTCTTCAGCCTGTCC	   AGACTGCAAAGAGCGTGAGG	  
LOXL2	   CCAGTGTGGTCTGCAGAGAG	   CCTGTGCACTGGATCTCGTT	  
MMP1	   GGACCAACAATTTCAGAGAGTACAA	   CCACTGAAGGTGTAGCTAGGG	  
MMP2	   AGTTGGCAGTGCAATACCTGA	   GGCAGTCCAAAGAACTTCTGC	  
MMP7	   TGCCAACAGTTTAGAAGCCAA	   TTCTGCAACATCTGGCACTC	  
	  
	  
2.10.2.	   RNA	  isolation,	  purification	  and	  quantification	  
Spheroids	  were	  made	  as	  previously	  described.	  The	  spheroids	  were	  transferred	  into	  Eppendorf	  
tubes	   (10	   spheroids	   per	   tube).	   The	   medium	   was	   removed	   and	   0.5mL	   of	   TRIzol	   was	   added.	  
TRIzol	  is	  a	  solution	  of	  phenol	  and	  guanidine	  isothiocyanate	  which	  disrupts	  cell	  membrane	  and	  
dissolves	  cell	  components	  leaving	  RNA	  integrity	  intact.	  The	  spheroids	  were	  homogenised	  using	  
handheld	   homogeniser	   in	   TRIzol.	   To	   isolate	   RNA	   from	   TRIzol	   the	   samples	   were	   left	   for	   five	  
minutes	   at	   room	   temperature	   and	   then	   200	  µL	   of	   chloroform	  was	   added.	   The	  mixture	  was	  
mixed	   vigorously	   and	   left	   for	   10	  minutes	   at	   room	   temperature	   to	   allow	   separation	  of	  upper	  
aqueous	   and	   a	   lower	   organic	   layer.	   The	   samples	   were	   then	   centrifuged	   for	   15	   minutes	   at	  
12,000	  g	  at	  4°C	  and	  the	  aqueous	  phase	  containing	  RNA	  was	  transferred	  to	  a	  new	  Eppendorf	  
tube	  containing	  200	  µL	  isopropanol	  and	  1.5	  µL	  Glycoblue.	  Glycoblue	  is	  composed	  of	  glycogen	  




which	   is	   covalently	   linked	   to	   a	   blue	   dye	  which	   is	   able	   to	   facilitate	   nucleic	   acid	   precipitation	  
allowing	  the	  pellet	  to	  become	  easily	  visible.	  	  
The	   RNA	   was	   allowed	   to	   precipitate	   for	   10	   minutes	   at	   room	   temperature	   and	   was	   then	  
centrifuged	  at	  12,000	  g	  for	  15	  minutes	  at	  4°C.	  The	  supernatants	  were	  discarded	  and	  the	  RNA	  
pellet	   was	   re-­‐suspended	   in	   80	   %	   ethanol	   in	   DEPC-­‐treated	   deionised	   water	   (BDH	   VWR	  
International,	   UK).	   Following	   further	   15	   minutes	   centrifugation	   at	   12,000	   g	   at	   4	   °C,	   the	  
supernatants	   were	   discarded,	   the	   pellets	   air	   dried	   and	   then	   re-­‐suspended	   in	   12.5	   µL	   of	  
nuclease	  free	  water.	  Contaminating	  genomic	  DNA	  was	  removed	  using	  DNAfree	  kit	  as	  stated	  in	  
manufacturer’s	  instructions.	  	  
Although	   RNA	   is	   thermodynamically	   stable,	   it	   can	   be	   rapidly	   degraded	   into	   shorter	   RNA	  
fragments	   in	   the	   presence	   of	   ubiquitous	   RNase	   which	   can	   potentially	   lead	   to	   misleading	  
results.	  Therefore	   for	  microarray	  analysis	   in	  particular,	   it	  was	  vital	   to	  measure	   the	  degree	  of	  
RNA	  degradation.	  A	  Bioanalyzer	   (Agilent,	  UK)	  was	  used	   to	  determine	   the	  RNA	   integrity.	   This	  
device	  involves	  a	  combination	  of	  microfluidic	  chips,	  gel	  filled	  channels	  for	  voltage-­‐induced	  size	  
separation	   of	   RNA	   fragments,	   RNA	   stained	   with	   an	   intercalating	   dye,	   and	   laser-­‐induced	  
fluorescence	  (LIF)	  detection.	  The	  amount	  of	  fluorescence	  detected	  correlated	  with	  the	  amount	  
of	   RNA	   of	   a	   given	   size	   which	   was	   demonstrated	   on	   an	   electropherogram	   (Figure	   2.1)	  
(Schroeder	   et	   al.,	   2006)	   and	   gel-­‐like	   images.	   This	   was	   used	   to	   generate	   an	   algorithm	   to	  
calculate	  the	  RNA	  integrity	  number	  (RIN)	  which	  was	  independent	  of	  RNA	  concentration.	  A	  RIN	  
value	  of	  between	  7	  and	  10	  indicated	  good	  RNA	  quality.	  	  
The	   concentration	   and	   purity	   of	   the	   RNA	   was	   further	   quantified	   using	   a	   Nanodrop	   8000	  
spectrophotometer.	  The	  ratio	  of	  the	  A260/A280	  was	  used	  as	  a	  measure	  of	  protein	  contamination	  
of	   the	   sample.	   A	   ratio	   of	   2	   was	   considered	   ideal	   with	   a	   range	   from	   1.7	   to	   2	   considered	  
acceptable.	  
	   	  
















Figure	  2.	  1:	  Example	  of	  an	  electropherogram	  trace.	  	  	  
The	  5S	  region	  covers	  the	  5S	  and	  5.8S	  rRNA	  fragments.	  The	  18S	  and	  28S	  peaks	  illustrate	  
the	  level	  of	  18S	  rRNA	  and	  28S	  rRNA,	  respectively.	  5S,	  5.8S,	  and	  28S	  rRNA	  are	  located	  in	  
large	   ribosomal	   subunit,	   whereas	   18S	   rRNA	   is	   found	   in	   the	   small	   ribosomal	   subunit.	  























2.10.3.	   cDNA	  synthesis	  
cDNA	  was	  prepared	  by	   reverse-­‐transcription	   (RT)	  using	  qScript	  cDNA	  SuperMix	  kit.	  Following	  
the	  manufacturer’s	  instructions	  up	  to	  1μg	  of	  RNA	  sample	  was	  made	  up	  to	  volume	  of	  16	  μL	  with	  
nuclease-­‐free	  water.	  4	  µL	  of	  qScript	  cDNA	  SuperMix	  (5x	  reaction	  buffer	  containing	  optimized	  
concentrations	   of	   MgCl2,	   dNTPs	   (dATP,	   dCTP,	   dGTP,	   dTTP),	   recombinant	   RNase	   inhibitor	  
protein,	  qScript	  reverse	  transcriptase	  and	  random	  primers,	  was	  then	  added	  to	  each	  sample,	  to	  
achieve	   a	   final	   volume	   of	   20µL.	   Samples	  were	   then	   incubated	   for	   five	  minutes	   at	   25	   °C,	   30	  
minutes	  at	  42	  °C	  and	  five	  minutes	  at	  85	  °C.	  




2.10.4.	   Real	  time	  qRT-­‐PCR	  
Real	   time	   qRT-­‐PCR	   was	   performed	   with	   0.4	   ng	   of	   cDNA	   using	   SYBR	   green	   I	   and	   primers	  
(forward	   and	   reverse	   each	   at	   a	   final	   concentration	   of	   800	   nM;	   10	   µL	   reaction)	   on	   a	  
Mastercycler	  EP	  Realplex	  (Eppendorf,	  Germany).	  Cycling	  conditions	  were	  as	  follows:	  activation	  
of	   SYBR	  Green	   95	   °C	   for	   10	  minutes;	   cDNA	   amplification	   95	   °C	   for	   10	   seconds,	   62	   °C	   for	   45	  
seconds	  for	  40	  cycles	  followed	  by	  melting	  curve	  analysis.	  The	  efficiency	  of	  each	  primer	  pair	  was	  
assessed	   by	   determining	   the	   relationship	   of	   primer	   threshold	   cycle	   (Ct)	   values	   with	   cDNA	  
concentration	  using	  a	  series	  of	  half-­‐log	  dilutions	  of	  template	  cDNA.	  Ct	  values	  were	  defined	  as	  
the	  earliest	  point	  of	  the	  linear	  region	  of	  the	  logarithmic	  amplification	  plot	  reaching	  a	  threshold	  
level	  of	  detection.	  The	  log	  of	  cDNA	  concentrations	  was	  plotted	  against	  Ct	  values,	  and	  the	  slope	  
of	   the	   plot	   was	   used	   to	   ascertain	   primer	   efficiency.	   Primer	   efficiency	   was	   given	   by	   the	  
equation:	  Efficiency=	  10(-­‐1/slope)	  and	  were	  only	  used	  if	  the	  value	  was	  close	  to	  two	  indicating	  PCR	  
efficiency	   of	   ~100	  %.	   To	   examine	   the	   quantitative	   differences	   in	   target	  mRNA	   expression	   in	  
each	   sample,	   Ct	   values	   were	   determined	   from	   the	   linear	   region	   of	   the	   logarithmic	  
amplification	  plot.	  Each	  sample	  was	  also	  tested	  for	  the	  expression	  of	  the	  housekeeping	  genes	  
which	  were	  selected	  based	  on	  GeNorm	  analysis.	  The	  Ct	  values	  of	  the	  housekeeping	  genes	  were	  
used	  to	  normalise	  between	  samples.	  Statistical	  analysis	  was	  performed	  using	  the	  ΔCt	  values.	  
The	  melting	  curve	  of	  the	  product	  obtained	  from	  the	  PCR	  was	  analysed	  to	  confirm	  its	  specificity.	  
This	  curve	  was	  generated	  based	  on	  the	  temperature	  required	  to	  denature	  half	  of	   the	  dsDNA	  
sequence	  of	  the	  PCR	  product	  (melting	  temperature;	  Tm)	  which	  was	  measured	  as	  a	  decrease	  in	  
fluorescence.	  The	  value	  was	  dependent	  on	  the	  nucleotide	  sequence	  and	  a	  single	  melting	  curve	  
represented	  a	  single	  PCR	  product.	  	  
2.10.5.	   GeNorm	  
This	  kit	  is	  composed	  of	  12	  housekeeping	  genes	  (18S,	  ACTB,	  ATP5B,	  B2M,	  CYC1,	  EIF4A2,	  GAPDH,	  
RPL13A,	  SDHA,	  TOP1,	  UBC,	  and	  YWHAZ).	  RT-­‐qPCR	  was	  performed	  on	  cDNA	  samples	  from	  both	  
non-­‐IPF	   (n=3)	   and	   IPF	   (n=4)	   spheroids	   to	  measure	  mRNA	   levels	   of	   each	   reference	   gene.	   The	  
software	   qBASE+	   (Primer	   design,	   UK)	  was	   used	   to	   analyse	   the	   Ct	   values	   and	   determine	   the	  
average	   expression	   stability	   of	   all	   reference	   targets	   across	   all	   samples.	   GeNorm	  M	   value	   of	  
<0.5	  was	  considered	  as	  a	  stable	  housekeeping	  gene.	  Based	  on	  the	  analysis	  three	  housekeeping	  
genes	  were	   selected	   for	   normalisation	   of	   RT-­‐qPCR	   data	   set	   (EIF4A2,	   TOP1,	   and	  UBC;	   Figure	  
2.2).	   	  




























Figure	  2.	  2.	  Average	  expression	  stability	  of	  reference	  genes	  using	  GeNorm	  and	  qBase+.	  
GeNorm	  M	  <0.5	  indicates	  the	  gene	  expression	  is	  stable	  under	  the	  specific	  experimental	  














2.11. Measurement	  of	  TGFβ 	  activity	  with	  TMLEC	  bioassay	  
	  
2.11.1.	   Principle	  of	  technique	  
To	  determine	  the	   levels	  of	  active	  TGFβ	   in	  cell	  culture	  supernatants	  or	  spheroid	  homogenate,	  
transformed	   mink	   lung	   epithelial	   cell	   (TMLEC)	   bioassay	   was	   performed.	   This	   assay	   was	  
originally	  set	  up	  by	  Abe	  et	  al.	  (1994)	  and	  utilises	  the	  ability	  of	  TGFβ	  to	  specifically	  induce	  PAI-­‐1	  
expression.	  TMLECs	  are	  stably	  transfected	  with	  an	  expression	  construct	  containing	  a	  truncated	  
PAI-­‐1	  promoter	  which	  is	  fused	  to	  the	  firefly	  luciferase	  reporter	  gene.	  Exposure	  of	  these	  cells	  to	  
TGFβ increases	   the	   activity	   of	   luciferase	   in	   a	   dose-­‐dependent	   manner.	   Luciferase	   is	   a	  
monomeric	  61	  kDa	  protein	  which	   is	  able	   to	  catalyse	   the	  oxidation	  of	   luciferin	   to	  oxyluciferin	  
(by	  using	  ATP•Mg2+	  as	  a	  cosubstrate)	  resulting	  in	  the	  emission	  of	  light	  which	  can	  be	  read	  using	  
a	   luminometer.	   Importantly,	   other	   known	  PAI-­‐1	   expression	   inducers	   (such	   as	   PDGF-­‐BB,	   EGF,	  
bFGF	   and	   rIL-­‐1β)	   have	   shown	  minimal	   effect	   on	   this	   promoter	   fragment.	   Thus,	   this	   assay	   is	  
highly	  specific	  for	  TGFβ	  activity	  (Abe	  et	  al.,	  1994).	  
2.11.2.	   Preparation	  of	  samples	  	  
Following	   spheroid	   formation,	   the	   supernatant	   was	   removed,	   diluted	   1:4	   with	   DMEM	  
(supplemented	   with	   2	   mM	   L-­‐glutamine,	   50	   U/mL	   penicillin,	   50	   µg/mL	   streptomycin),	   and	  
stored	   at	   -­‐20	   oC	   until	   needed.	   On	   the	   other	   hand,	   the	   spheroids	   were	   washed	   twice	   with	  
DMEM	  and	   then	  homogenised	   in	  200	  µL	   fresh	  media	   (without	  FBS).	   The	  homogenates	  were	  
also	  stored	  at	  -­‐20	  oC	  until	  needed.	  
2.11.3.	   Culturing	  TMLEC	  and	  measuring	  luciferase	  activity	  
TMLECs	  were	  seeded	  into	  a	  tissue	  culture	  flask	  in	  the	  same	  media	  as	  fibroblasts	  (DMEM	  with	  2	  
mM	  L-­‐glutamine,	  50	  U/mL	  penicillin,	  50	  µg/mL	  streptomycin,	  and	  10	  %	  FBS)	  with	  the	  addition	  
of	   250	   µg/mL	   Geneticin	   (G418;	   Life	   technologies,	   UK),	   incubated	   at	   37	   oC	   with	   10	   %	   CO2	  
atmosphere.	  Once	  confluent,	  the	  cells	  were	  trypsinised	  with	  Trypsin-­‐EDTA	  and	  centrifuged	  (5	  
min	  at	  300g)	  and	  the	  pellet	  was	  re-­‐suspended	  in	  fresh	  media.	  The	  cells	  were	  then	  seeded	  into	  
a	  flat	  bottom	  96	  well	  plate	  at	  a	  density	  of	  1.6x104	  cells/mL.	  The	  cells	  were	  then	  incubated	  at	  
37oC	   with	   10	   %	   CO2	   atmosphere	   for	   three	   hours	   or	   overnight	   to	   allow	   adherence.	   Once	  
adhered,	  the	  media	  was	  aspirated	  and	  the	  cells	  were	  washed	  using	  serum-­‐free	  media.	  100	  μL	  




recombinant	   porcine	   TGFβ1	   standards	   (0.1-­‐1	   ng/mL	   in	   the	   same	   culture	   medium	   as	   the	  
samples)	   or	   samples	   were	   added	   in	   duplicate	   to	   the	   plated	   TMLECs.	   The	   cells	   were	   then	  
incubated	  for	  14	  hours	  at	  37	  oC	  with	  10	  %	  CO2.	  Following	  incubation,	  media	  were	  aspirated	  and	  
cells	  were	  washed	   in	   twice	   PBS.	   Subsequently	   100	  μL	   of	   luciferase	   reporter	   gene	   assay	   lysis	  
buffer	  (Roche,	  UK)	  was	  added	  to	  each	  well.	  The	  plate	  was	  then	  placed	  into	  -­‐80	  oC	  freezer	  for	  a	  
minimum	  of	  30	  minutes.	  The	   lysates	  were	  then	  thawed	  and	  agitated	  for	  25	  minutes	  to	  allow	  
complete	   lysis	  of	   the	  cells.	  20	  μL	  of	  each	   lysate	  was	   then	   transferred	   into	   the	  corresponding	  
well	  of	  a	  96-­‐well	  opaque	  white	  optiplate	   (Nunc,	  UK).	  The	   luciferase	   substrate	   (Promega,	  UK)	  
was	   automatically	   added	   and	   a	   luminescence	   reading	  was	   obtained	   using	   the	   Tropix	   TR717	  
Microplate	  Luminometer	  (Applied	  Biosystems,	  UK).	  	  
	  
2.12. Measurement	  of	  procollagen	  accumulation	  
	  
2.12.1.	   Principle	  of	  technique	  
Hydroxyproline	  accumulation	  in	  spheroids	  was	  used	  as	  a	  measure	  of	  pro-­‐collagen	  production.	  
Hydroxyproline	  represents	  approximately	  13.5	  %	  of	  the	  primary	  sequence	  of	  procollagen	  and	  
is	   essential	   for	   the	   formation	   of	   the	   collagen	   triple	   helix.	   Hydroxproline	   is	   not	   present	   in	  
significant	   levels	   in	   any	   other	   proteins.	   Levels	   of	   hydroxyproline	   in	   cell	   culture	   hydrolysates	  
were	   quantified	   by	   reverse-­‐phase	   high	   performance	   liquid	   chromatography	   (HPLC)	   following	  
derivitisation	   with	   7-­‐chloro-­‐4-­‐nitrobenzo-­‐oxa-­‐1,3-­‐diazole	   (NBD-­‐Cl)	   (Sigma;	   #17239-­‐0050)	   to	  
generate	  a	  chromophore	  detectable	  at	  495	  nm	  wavelength.	  The	  specificity	  of	   the	   reaction	   is	  
further	  ensured	  by	  keeping	  the	  derivation	  time	  to	  20	  minutes	  at	  37	  oC,	  a	  time-­‐point	  that	  has	  
been	   confirmed	  experimentally	   to	  be	  maximal	   for	  hydroxyproline	  derivatisation	  with	  NBD-­‐Cl	  
for	  up	  to	  20	  nmol	  hydroxyproline.	  
2.12.2.	   Sample	  preparation	  
Cultured	   non-­‐IPF	   and	   IPF	   spheroids	   (as	   described	   in	   Section	   2.5)	   were	   used	   to	   study	  
procollagen	  accumulation.	  Following	  treatment	  of	  the	  compound	  for	  24	  hours,	  the	  media	  was	  
removed	  from	  each	  well	  and	  the	  spheroids	  were	  washed	   in	  PBS	  and	  placed	   into	  sterile	  2	  mL	  
polypropylene	  microcentrifuge	  tubes	  (Fisher;	  UK).	  Each	  tube	  contained	  two	  spheroids	  and	  200	  
µL	  of	  6	  M	  HCl.	  These	  were	  then	  hydrolysed	  at	  110	  oC	  for	  16	  hr.	  100	  µL	  of	  the	  hydrolysate	  were	  




transferred	  to	  1.5	  mL	  centrifuge	  tubes	  and	  evaporated	  to	  dryness	  using	  speedvac	  concentrator	  
(Savant	   SPD	   131DDA,	   Thermo	   Electron	   Corporation,	   Cambridge,	   UK).	  Milli-­‐Q	  water	   (100	   µL)	  
was	   added	   to	   the	  dried	   aliquot	  of	   hydrolysate	   and	   left	   to	   rehydrate	   at	   4	   °C	  overnight	   or	   30	  
minutes	  at	  room	  temperature.	  
Standard	   sample	   preparation:	   250	   µM	   of	   Trans-­‐4-­‐hydroxy-­‐L-­‐proline	   (PHPRO;	   Sigma	   Aldrich,	  
UK)	  was	  diluted	  1:100	  using	  Milli-­‐Q	  water	  (Milli-­‐Q	  Plus;	  Millipore	  Ltd.,	  UK).	  The	  final	  amount	  of	  
Hydroxyproline	  (Hyp)	  standard	  loaded	  onto	  the	  column	  was	  50	  pmol.	  	  
2.12.3.	   Derivitising	  samples	  
100	   µL	   of	   each	   sample	   and	   standard	   were	   buffered	   with	   0.4	   M	   potassium	   tetraborate	  
(adjusted	  to	  pH9.5	  with	  HCl)	  and	  then	  reacted	  with	  100	  µL	  NBD-­‐Cl	  (36	  mM	  in	  methanol)	  to	  a	  
final	  concentration	  of	  12	  mM	  NBD-­‐Cl.	  These	  were	  Vortex	  mixed	  thoroughly	  and	   incubated	  at	  
37	   oC	   (in	   the	   dark)	   for	   20	   minutes.	   The	   reaction	   was	   stopped	   by	   adding	   50	   µL	   1.5	   M	   HCl.	  
Following	   this,	   150	   µL	   of	   a	   concentrated	   solution	   (3.33X)	   of	   HPLC	   running	   Buffer	   A	   (5.68	   g	  
sodium	  acetate	  dissolved	   in	  150	  mL	  Milli-­‐Q	  water	  and	  65	  mL	  acetonitrile,	  corrected	  to	  pH6.4	  
with	   orthophosphoric	   acid	   and	  made	   up	   to	   250	  mL)	  was	   added	   and	  mixed	   thoroughly.	   The	  
samples	  were	  then	  filtered	  through	  a	  HPLC	  low	  dead	  volume	  filter	  (pore	  size	  0.22	  µm,	  type	  GV;	  
Millipore	  Ltd,	  UK)	  into	  a	  polypropylene	  insert.	  The	  insert	  was	  placed	  into	  a	  brown	  glass	  Amber	  
Snap	   Seal	   vial	   (Laboratory	   Sales	   Ltd.,	   Rochdale,	   UK).	   These	   vials	   were	   then	   placed	   in	   the	  
automatic	  sampler	  in	  the	  HPLC	  apparatus	  and	  the	  samples	  were	  sequentially	  injected	  onto	  the	  
HPLC	  column	  and	  eluted	  with	  an	  acetonitrile	  gradient	  as	  described	  below.	  
2.12.4.	   Chromatography	  conditions	  
The	   HPLC	   apparatus	   used	   for	   measurements	   was	   Agilent	   series	   1100	   (Agilen	   Technologies,	  
USA)	  with	  a	   reverse-­‐phase	  cartridge	  column	  (LiCrospher	  100	  Rp-­‐18	   (10	  µm),	  LiChroCART	  250	  
mm	   length	   x	   4	  mm	  diameter,	   5	  µm	  particle	   size;	  Merck,	  UK).	   The	   column	  was	   continuously	  
maintained	  at	  40	  oC	  in	  a	  heated	  column	  oven.	  At	  the	  beginning	  of	  each	  batch	  of	  samples,	  the	  
HPLC	   system	   was	   equilibrated	   in	   running	   buffer	   A	   for	   minimum	   of	   40	   minutes.	   NBD-­‐Cl	  
derivatives	  of	   standards	   and	   samples	  were	   individually	   injected	  onto	   the	   column	  and	  eluted	  
with	   an	   acetonitrile	   gradient,	   which	   was	   achieved	   by	   changing	   the	   relative	   proportions	   of	  
running	   buffers	   A	   and	   B	   over	   time.	   Chromatographic	   conditions	   and	   buffers	   used	   in	   this	  
process	  are	  summarised	  in	  Table	  2.5.	  	  





Table	  2.	  5:	  Conditions	  and	  buffers	  for	  the	  separation	  of	  hydroxyproline	  	  
by	  reverse-­‐phase	  HPLC	  
	  
Column	   LiChrospher,	  100	  RP-­‐18,	  250	  x	  4	  mm,	  5	  µm	  
Mobile	  phase	   Buffer	  A	  -­‐	  aqueous	  acetonitrile	  (8	  %	  v/v)	  
50mM	  sodium	  acetate,	  pH	  6.4	  
Buffer	  B	  -­‐	  aqueous	  acetonitrile	  (75	  %	  v/v)	  
Column	  flow	  rate	   1.0	  mL/min	  
Column	  temperature	   40	  °C	  
Detection	  wavelength	   495	  nm	  
Elution	  gradient	   Time	  (min)	   %	  Buffer	  A	   %	  Buffer	  B	  
0	   100	   0	  
5	   95	   5	  
6	   20	   80	  
12	   20	   80	  
12.5	   100	   0	  
25	   100	   0	  
	  
Post-­‐column	  detection	  was	  achieved	  by	  monitoring	  absorbance	  at	  495nm	  using	  a	  flow-­‐through	  
variable	   wavelength	  monitor.	   Hydroxyproline	   elutes	   as	   a	   discreet	   peak	   between	   four	   to	   six	  
minutes	   following	   sample	   injection	   on	   the	   column	   (Figure	   2.3),	   between	   glutamine	   (3.5	  
minutes)	  and	   serine	   (seven	   to	  nine	  minutes).	  The	  column	   running	  and	   regeneration	   time	   for	  
each	  sample	  was	  25	  minutes.	  	  
2.12.5.	   Quantification	  of	  hydroxyproline	  content	  
Quantification	  of	  the	  hydroxyproline	  content	   in	  each	  100	  µL	  sample	  injected	  into	  the	  column	  
was	  determined	  by	  comparing	  peak	  areas	  of	  chromatograms	  obtained	  for	  each	  sample	  to	  the	  
average	  standard	  peak	  areas.	  This	  value	  represents	  the	  hydroxyproline	  levels	  in	  the	  fraction	  of	  
the	   acid	   hydrolysate	   of	   the	   spheroids	   and	  was	   used	   to	   calculate	   the	   total	   spheroid	   collagen	  
based	  on	  the	  hydroxyproline	  content	  of	  the	  collagen	  and	  the	  dilution	  factors	  at	  the	  processing	  
steps.	  Total	  collagen	  was	  expressed	  as	  ng/spheroid,	  assuming	  that	  hydroxyproline	  accounts	  for	  
13.5	  %	  of	  the	  weight	  of	  collagen.	  
	  
	  















Figure	  2.	  3.	  HPLC	  Chromatogram	  of	  a	  hydroxyproline	  reference	  standard.	  
Hydroxyproline	   peak	   is	   shown	   between	   four	   to	   six	  minutes.	   The	   concentration	   of	   the	  
hydroxyproline	  standard	  was	  2.5	  µM.	  The	  area	  under	  the	  hydroxyproline	  peak	  is	  used	  as	  










2.13.1.	   Principle	  of	  technique	  
Zymography	  is	  a	  technique	  used	  to	  analyse	  the	  activity	  of	  matrix	  metalloproteinases	  (MMPs)	  in	  
biological	  samples.	  It	  involves	  protein	  separation	  under	  denaturing	  (sodium	  dodecyl	  sulphate,	  
SDS)	   and	   non-­‐reducing	   conditions	   through	   a	   polyacrylamide	   gel	   containing	   a	   proteolytic	  
substance	  (in	  this	  case,	  gelatin).	  The	  resolved	  proteins	  are	  renatured	  by	  the	  exchange	  of	  SDS	  
(an	   anionic	   detergent)	   with	   Triton	   X-­‐100	   (a	   non-­‐ionic	   detergent).	   Following	   this,	   the	   gel	   is	  
incubated	   in	   a	   low	   salt	   collagenase	   buffer.	   The	   gel	   is	   then	   stained	   with	   Coomassie	   Blue	   to	  
identify	   proteolytic	   activities	   with	   clear	   bands	   against	   a	   blue	   background	   (non-­‐degraded	  
gelatin).	  




2.13.2.	   Sample	  preparation	  	  
Following	   spheroid	   formation,	   the	   supernatant	   was	   removed	   and	   diluted	   1:4	   with	   media	  
(DMEM	  supplemented	  with	  2	  mM	  L-­‐glutamine,	  50	  U/mL	  penicillin,	  50	  µg/mL	  streptomycin	  and	  
0.4	  %	  FBS).	  The	  samples	  were	  then	  further	  diluted	  1:1	  with	  Tris-­‐Glycine	  SDS	  sample	  buffer	  (0.5	  
M	  Tris-­‐HCl	  at	  pH	  6.8	  diluted	  1:1	  with	  100	  %	  glycerol;	  5	  %	  SDS	  w/v	  bromophenol	  blue).	  20	  µL	  of	  
the	  samples	  and	  2	  µL	  of	  MMP2	  standard	  control	  (1	  µU;	  2B	  scientific	  ltd,	  UK)	  were	  then	  loaded	  
into	   the	   wells	   of	   Novex	   10%	   Tris-­‐glycine	   zymogram	   (0.1	   %	   gelatin)	   protein	   gels	   (Life	  
technologies,	   UK).	   The	   running	   buffer	   used	   was	   1x	   Tris-­‐glycine	   SDS	   running	   buffer.	  
Electrophoresis	  was	  performed	  at	  125	  V	  for	  90	  minutes.	  	  
2.13.3.	   Detecting	  MMPs	  
Following	  electrophoresis	  the	  gel	  was	  washed	  with	  2.5	  %	  Triton	  X-­‐100	  for	  one	  hour	  and	  then	  
incubated	  with	  1x	  low	  salt	  collagenase	  buffer	  (0.02	  %	  Brij-­‐35	  detergent	  in	  0.6	  %	  Tris-­‐base,	  1.17	  
%	  NaCl,	  and	  0.055	  %	  CaCl2,	  at	  pH	  7.6	  adjusted	  with	  concentrated	  HCl)	  overnight	  at	  37	  oC.	  The	  
gels	  were	  then	  incubated	  with	  Coomassie	  blue	  (0.025	  %	  Coomassie	  blue	  in	  10	  %	  glacial	  acetic	  
acid	  and	  50	  %	  methanol)	  and	  destain	  solution	  (10	  %	  glacial	  acetic	  acid	  with	  30	  %	  methanol)	  for	  
two	  hours	  at	  room	  temperature.	  The	  gels	  were	  then	  sandwiched	  between	  two	  acetate	  sheets	  
and	   scanned	  using	   transmissive	   greyscale	  300	  dpi	   settings	  on	  a	   flatbed	   scanner	   (Epson,	  UK).	  
The	  optical	   density	  of	   each	  band	  was	   calculated	   similarly	   to	  Western	  blots	   (as	  mentioned	   in	  
Section	  2.9.5).	  The	  optical	  density	  of	  each	  band	  was	  normalized	  to	  the	  standard	  MMP2	  control	  
in	  order	  to	  compare	  between	  samples.	  	  
	  
2.14. PGE2	  ELISA	  
	  
Prostaglandin	   E2	   Biotrak	   enzymeimmunoassay	   system	   (VWR,	   UK)	   was	   used	   to	  measure	   the	  
levels	  of	  PGE2	  in	  the	  spheroid	  supernatants	  (96	  hours	  post	  seeding;	  1:4	  dilution).	  The	  ELISA	  was	  
performed	   as	   instructed	   by	   the	   manufacturer’s	   guidelines.	   Briefly,	   all	   reagents	   were	  
equilibrated	   to	   room	   temperature	   before	   use.	   PGE2	   stock	   solution	   was	   used	   to	   prepare	  
working	  standard	  concentrations	  (range	  from	  2.5-­‐320	  pg/50µL).	  Each	  of	  the	  working	  standard	  
concentrations	  and	  the	  supernatant	  samples	  were	  placed	  into	  the	  appropriate	  wells	  of	  96-­‐well	  




microplate	  provided,	  pre-­‐coated	  with	  sheep	  anti-­‐mouse	  IgG.	  Assay	  buffer	  (provided	  within	  the	  
kit;	  0.1	  M	  phosphate	  buffer	  pH	  7.5	  containing	  0.9	  %	  w/v	  bovine	  serum	  albumin	  and	  0.5	  %	  w/v	  
kathon)	  was	  used	  to	  identify	  any	  non-­‐specific	  binding	  (NSB).	  Each	  well	  was	  then	  treated	  with	  
anti-­‐PGE2	   antibody	   (excluding	   blank	   and	   NSB	   wells)	   and	   PGE2	   conjugate	   (lyophilised	   PGE2	  
conjugated	   to	   horseradish	   peroxidase;	   excluding	   blank	   wells).	   The	   microplate	   was	   then	  
incubated	   at	   room	   temperature	   for	   one	   hour.	   	   Following	   this,	   each	   well	   was	   washed	  
thoroughly	  with	  the	  wash	  buffer	  provided	  (0.01	  M	  Phosphate	  buffer	  pH	  7.5	  containing	  0.05	  %	  
v/v	   Tween	   20)	   and	   immediately	   treated	   with	   an	   enzyme	   substrate,	   3,3’,5,5’	  
Tetramethylbenzidine	  (TMB)/Hydrogen	  Peroxide.	  The	  microplate	  was	  then	  incubated	  at	  room	  
temperature	  on	  a	  microplate	  shaker	  for	  15-­‐30	  minutes.	  The	  reaction	  was	  then	  halted	  with	  the	  
addition	   of	   1	   M	   sulphuric	   acid.	   The	   optical	   density	   (OD)	   was	   read	   at	   450	   nm	   using	   an	  




2.15.1.	   Principle	  of	  technique	  
A	  microarray	  provides	  quantitative	  gene	  expression	  data	  by	  using	  a	  collection	  of	  microscopic	  
features	   (generally	   DNA)	   acting	   as	   probes	   to	   target	  molecules	   (Miller	   and	   Tang,	   2009).	   One	  
common	  microarray	  technology	  used	  is	  in	  situ-­‐synthesised	  oligonucleotide	  microarrays.	  These	  
are	  extremely-­‐high-­‐density	  microarrays	  that	  use	  different	  oligonucleotide	  probes	  (short	  single	  
stranded	   DNA	   or	   RNA	   sequences	   specific	   to	   a	   particular	   gene	   of	   interest;	   25	   base	   pairs	   in	  
length)	  which	  are	  synthesised	  directly	  on	  the	  microarray	  surface	  (e.g.	  glass	  wafer)	  by	  using	  a	  
semiconductor-­‐based	   photochemical	   synthesis	   technology	   (Dalma-­‐Weiszhausz	   et	   al.,	   2006).	  
One	  of	  the	  most	  widely	  used	  chips	  containing	  oligonucleotide	  probes	  is	  Affymetrix	  GeneChips.	  
Each	  GeneChip	   is	   composed	  of	  many	   probe	   cells,	   each	   of	  which	   is	   specific	   to	   one	   gene	   and	  
there	  are	  millions	  of	  oligonucleotide	  probe	  copies	  per	  probe	  cell.	  Each	  gene	  is	  matched	  to	  11	  
probe	  cells	  which	  are	  evenly	  distributed	  throughout	  the	  chip.	  Each	  oligonucleotide	  probe	  pair	  
is	   composed	  of	   a	   perfect	  match	   (PM)	  probe	   and	   a	  mismatch	   (MM)	  probe	   (Figure	  2.4A).	   PM	  
probes	  consist	  of	  a	  sequence	  which	  is	  complimentary	  to	  the	  specific	  gene	  and	  therefore	  is	  used	  
to	  measure	  the	  gene	  expression.	  On	  the	  other	  hand,	  the	  MM	  probe	  differs	  from	  the	  PM	  probe	  
by	   the	   substitution	  of	  a	   single	  base,	   located	   in	   the	  centre	  of	   the	  probe	   sequence.	  This	  helps	  
identify	  non-­‐specific	  hybridisation	  (Miller	  and	  Tang,	  2009).	  	  




Figure	  2.4B	   illustrates	  the	  steps	   involved	  for	  Affymetrix	  microarray.	   In	  brief,	  RNA	  is	  extracted	  
from	  the	  samples	  and	  converted	  to	  cDNA.	  An	  in	  vitro	  transcription	  reaction	  is	  then	  performed	  
to	   convert	   the	   cDNA	   to	   biotin-­‐labelled	   cRNA.	   The	   cRNA	   generated	   is	   then	   fragmented.	   A	  
hybridisation	   cocktail	   is	   then	   prepared	  which	   includes	   the	   probe	   array	   controls,	   fragmented	  
targets,	  herring	  sperm	  DNA	  (commonly	  used	  as	  a	  blocking	  agent	  in	  hybridisation	  experiments),	  
and	  BSA.	  The	  Affymetrix	  GeneChips	  are	  then	  incubated	  with	  this	  hybridisation	  cocktail	   for	  16	  
hours	   then	   washed	   to	   remove	   any	   unbound	   targets	   followed	   by	   staining	   with	   streptavidin	  
phycoerythrin	  conjugate	  which	  is	  able	  to	  detect	  biotin.	  The	  amount	  of	  light	  emitted	  at	  570	  nm	  
is	  proportional	  to	  the	  bound	  target	  at	  each	  location	  on	  the	  probe	  array.	  	  
2.15.2.	   Sample	  preparation	  
Following	   spheroid	   formation	   of	   non-­‐IPF	   (n=10)	   and	   IPF	   (n=10)	   fibroblasts	   (24	   hours	   post	  
seeding),	  ten	  spheroids	  were	  pooled	  together	  and	  washed	  twice	  in	  PBS	  followed	  by	  treatment	  
with	  500	  µL	  RNaqueous	   lysis	  buffer	   (Ambion,	   Life	   technologies,	  UK).	   The	   samples	  were	   then	  
stored	   at	   -­‐80	   oC	   and	   transported	   to	   Epistem	   (UK)	   for	  microarray	   using	   Affymetrix	   GeneChip	  
Human	  Genome	  U133	  Plus	  2.0	  Array.	  	  
The	   cDNA	   generated	   in	   the	   initial	   steps	   involved	   the	   use	   of	   an	   RNA-­‐Amp	   kit	   (Epistem,	   UK)	  
which	   was	   used	   to	   convert	   10	   ng	   RNA	   (quantified	   using	   a	   NanoDrop)	   to	   poly	   A	   cDNA.	   A	  
bioanalyser	  (Section	  2.10)	  was	  used	  to	  investigate	  the	  integrity	  of	  the	  samples	  (i.e.	  RNA,	  cDNA,	  
biotin-­‐labelled	  fragments)	  at	  each	  step	  prior	  to	  hybridisation.	  
Four	  hybridisation	  controls	  (BioB,	  BioC,	  BioD,	  and	  Cre;	  pre-­‐labelled	  molecules	  derived	  from	  E-­‐	  
coli)	  were	  spiked	  into	  the	  samples	  at	  increasing	  concentrations	  (BioB<BioC<BioD<Cre)	  prior	  to	  
hybridisation	   and	   biotin-­‐labelling	   steps,	   respectively.	   The	   data	   obtained	   from	   these	   controls	  
were	  used	   for	  quality	  control	   (QC)	  analysis	   (see	  below).	  All	   samples	  were	   then	  processed	  on	  
the	  GeneChip	  as	  shown	  in	  Figure	  2.4	  and	  as	  described	  by	  the	  manufacturer’s	  instructions.	  
	   	  












































Figure	  2.	  4.	  Affymetrix	  microarray	  
A)	   The	   Human	  Genome	  U133A	  GeneChip	   Array.	   B)	  Microarray	   protocol.	   RNA	   is	   first	  
extracted	   from	   the	   samples,	   followed	   by	   cDNA	   formation.	   An	   in	   vitro	   transcription	  
reaction	   is	  performed	  to	  convert	   the	  cDNA	  to	  cRNA.	  The	  cRNA	  target	   is	   labelled	  with	  
biotin	   and	   fragmented	   into	   short	   sequences.	   An	   Affymetrix	   GeneChip	   containing	  
oligonucleotide	   probes	   is	   incubated	   with	   the	   target	   for	   hybridisation.	   The	   chip	   is	  
washed	  and	  stained	  with	  a	  fluorescent	  statin.	  Hybridised	  targets	  are	  identified	  using	  a	  












2.15.3.	   Data	  analysis	  
The	  data	  (CEL	   image	  files)	  were	  processed	  using	  Robust	  Multi-­‐array	  Average	  (RMA)	   in	  Partek	  
genomic	   suite	   (Partek,	  USA;	   a	   comprehensive	   suite	   for	   visualisation	   and	   analysis	   of	   genomic	  
data).	   RMA	   is	   an	   algorithm	   used	   to	   background	   correct,	   normalise,	   and	   summarise	   the	  
microarray	  data	  set	  (Bolstad	  et	  al.,	  2003).	  The	  raw	  values	  generated	  on	  the	  array	  are	  a	  mixture	  
of	   background	   signal	   (as	   a	   result	   of	   optical	   noise	   and	   non-­‐specific	   binding,	   i.e.	   MM	   probe	  
signal)	  and	  PM	  values.	  Thus,	  to	  determine	  the	  true	  expression	  of	  the	  genes	  per	  samples	  it	  was	  
vital	  to	  background	  correct	  the	  PM	  values	  by	  a	  non-­‐linear	  approach	  which	  was	  done	  on	  a	  per-­‐
chip	   basis.	   The	   data	   were	   normalised	   using	   the	   RMA	   normalisation	   approach	   (i.e.	   quantile	  
normalisation)	  in	  order	  to	  allow	  direct	  comparisons	  of	  multiple	  chips	  together.	  	  
Following	   background	   correction	   and	   normalisation	   of	   the	   PM	   values,	   the	   data	   were	   then	  
summarised	  by	  converting	  the	  probe	  level	  values	  to	  a	  single	  expression	  measure	  per	  probe	  set	  
(i.e.	  log2	  expression).	  RMA	  summarisation	  is	  based	  on	  the	  assumption	  that	  the	  observed	  log2	  
transformed	   PM	   values	   follow	   a	   linear	   additive	   model	   (non-­‐parametric	   regression	   method)	  
composed	  of	  a	  probe	  affinity	  affect	  (which	  is	  assumed	  to	  sum	  to	  zero),	  gene	  specific	  effect	  (i.e.	  
expression	   level,	   which	   is	   estimated	   using	   a	   robust	   model	   fitting	   technique	   called	   median	  
polishing	  that	  is	  able	  to	  protect	  against	  outlier	  probes),	  and	  an	  error	  term.	  	  	  
A	   QC	   procedure	   was	   used	   in	   Partek	   which	   involved	   comparing	   information	   from	   the	  
hybridisation	  controls	  with	  the	  experimental	  probes	  on	  the	  Affymetrix	  chips	  to	  determine	  the	  
quality	  of	  the	  microarray	  data	  and	  to	  detect	  any	  samples	  which	  did	  not	  pass	  the	  QC	  metrics.	  	  
Using	   Partek	   genomic	   suite,	   two	   factors	   were	   considered	   during	   ANOVA	   analysis:	   condition	  
(i.e.	   non-­‐IPF	   and	   IPF)	   and	   gender.	   Other	   factors	   such	   as	   batch	   effect	   and	   date	   of	   the	  
experiment	   were	   removed.	   The	   software	   was	   also	   used	   to	   perform	   principal	   component	  
analysis	   (PCA),	   generate	   dot	   plots,	   form	   heat	   maps,	   and	   perform	   pathway	   analysis.	  
Differentially	  expressed	  genes	  with	  a	  false	  discovery	  rate	  (FDR)	  p<0.05	  (or	  unadjusted	  p<0.01),	  
and	  fold	  change	  (FC)	  >2	  or	  <-­‐2	  were	  considered	  to	  be	  statistically	  significant.	  String	  9.1	  (online	  
based	   software)	   was	   used	   to	   determine	   interactions	   between	   the	   differentially	   expressed	  
genes.	  	  
	  




2.16. Statistical	  analysis	  
	  
Data	   shown	   as	   percentages	   were	   transformed	   to	   arcsine	   (also	   known	   as	   inverse	   sine)	   to	  
approximate	  a	  Gaussian	  rather	  than	  binomial	  distribution.	  	  In	  most	  cases,	  data	  are	  assumed	  to	  
be	  normally	  distributed	  (Gaussian	  distribution).	  	  	  However,	  if	  the	  data	  are	  in	  percentages	  then	  
the	  values	  are	  restricted	  to	  lie	  between	  0	  to	  100	  %	  and	  such	  data	  cannot	  be	  used	  for	  statistical	  
analysis.	   Arcsine	   transformation	   removes	   this	   restriction	   providing	   values	   that	   lie	   within	   a	  
normal	  distribution	  which	  can	  be	  used	  for	  statistical	  analysis.	  
All	   data	   in	   figures	   are	  presented	  as	  mean	   values	   ±	   standard	  error	  of	  mean,	   unless	   indicated	  
otherwise.	   Statistical	   analysis	   was	   performed	   between	   two	   treatment	   groups	   by	   student’s	   t	  
test,	   and	  between	  multiple	   treatment	   groups	   by	   one/two	  way	   analysis	   of	   variance	   (ANOVA)	  
with	  Bonferroni	  post-­‐hoc	  testing,	  using	  GraphPad	  Prism	  5	  and/or	  SigmaPlot	  12.3	  software.	  The	  
mean	  values	  of	   various	  parameters	  were	  considered	   to	  be	   significantly	  different	  when	   the	  p	  
value	   was	   less	   than	   0.05.	   Concentration-­‐response	   curves	   were	   generated	   using	   GraphPad	  
Prism	  (four-­‐parameter,	  unconstrained,	  variable	  slope	  fit).	  
	  
	   	  
	   	  












CHAPTER	  3:	  RESULTS	  
	  




3.1. Fibroblast	  characterisation	  and	  spheroid	  formation	  
	  
3.1.1.	   Introduction	  
Cell	   culture	   systems	   are	   indispensable	   tools	   required	   for	   basic	   research	   and	   for	   many	   pre-­‐
clinical	  in	   vitro	  studies.	   The	   classical	   approach	  used	   for	  many	  years	   in	  numerous	   laboratories	  
involves	   culturing	   cells	   on	   plastic	   (so	   called	   static	   dish	   culture).	   This	   primarily	   produces	  
adherent	  2D	  cell	  monolayers	  which	  do	  not	  reflect	  the	  conditions	  seen	  in	  vivo,	  where	  cells	  grow	  
within	  a	  complex	  3D	  microenvironment	  (Freed	  and	  Vunjak-­‐Novakovic,	  1998;	  Lee	  et	  al.,	  2008).	  
Furthermore,	   cells	   in	   a	   2D	   environment	   require	   regular	   feeding	   by	   replacing	   the	   overlaid	  
culture	   medium	   every	   2-­‐3	   days	   (Smalley	   et	   al.,	   2006).	   In	   addition,	   morphological	   and	  
physiological	   analyses	   of	   cells	   grow	   on	   plastic	   have	   shown	   substantial	   differences	   in	  
comparison	   to	   their	   counterparts	   in	   vivo.	   Thus,	   the	   inconsistency	   in	   growth	   conditions	   in	  
monolayer	  cultures	  and	  the	  difference	  in	  morphology	  as	  well	  as	  physiology	  of	  the	  cells,	  has	  led	  
to	  debates	  regarding	  the	  suitability	  of	  2D	  culture	  systems	  as	  reliable	  tools	  for	  in	  vitro	  studies.	  
Many	  groups	  are	  now	  in	  the	  process	  of	  developing	  3D	  in	  vitro	  cultures	  which	  are	  considered	  to	  
be	  a	  more	  representative	  approach	  for	  mimicking	  in	  vivo	  conditions.	  3D	  cultures	  demonstrate	  
a	  higher	  degree	  of	  structural	  complexity,	  similar	  to	  tissues	  and	  organs.	  Spheroid	  cell	  aggregates	  
and	  scaffold	  culture	  systems	  are	  becoming	  one	  of	  the	  most	  widely	  used	  3D	  models	  for	  creating	  
3D	   complex	   tissues	   to	   understand	   the	   pathology	   of	  many	   diseases	   (in	   particular	   cancer),	   as	  
they	  can	  be	  created	  with	  minimal	  effort	  (Kunz-­‐Schughart	  et	  al.,	  1998;	  Friedrich	  et	  al.,	  2009;	  Fu	  
et	  al.,	  2014;	  Guo	  et	  al.,	  2014a,	  2014b;	  Hsu	  et	  al.,	  2014;	  Rama-­‐Esendagli	  et	  al.,	  2014;	  Saar	  et	  al.,	  
2014;	  Subramanian	  et	  al.,	  2014).	  
	  
For	  biological	  studies,	  the	  significance	  of	  using	  primary	  cells	  instead	  of	  cancer	  cell	  lines	  is	  also	  
becoming	   widely	   recognized.	   Cancer	   cell	   lines	   carry	   mutations	   in	   genes	   involved	   in	   several	  
cellular	  processes	  including	  cell-­‐cycle	  control,	  DNA	  repair,	  and	  apoptosis	  –	  which	  can	  limit	  their	  
applicability	   for	   understanding	   normal	   physiology	   or	   non-­‐malignant	   pathology	   (such	   as	   that	  
seen	  in	  IPF).	  A	  major	  disadvantage	  of	  using	  primary	  cells	   is	  that	  the	  cells	  cannot	  be	  passaged	  
indefinitely	   due	   to	   the	   onset	   of	   replicative	   senescence.	   Hence,	   new	   primary	   cells	   must	   be	  
isolated	   regularly.	   In	   our	   laboratory,	   fibroblasts	   have	   been	   derived	   from	   the	   lung	   using	   two	  
alternate	   isolation	   protocols.	   The	   original	   protocol	   involves	   chopping	   the	   lung	   into	   small	  
explants	   (~1	  mm3),	   which	   are	   then	   cultured	   in	   petri	   dishes	   and	   incubated	   for	   2-­‐4	   weeks	   to	  




allow	  the	  outgrowth	  of	  fibroblasts.	  However,	  this	  protocol	  is	  not	  only	  time-­‐consuming,	  but	  also	  
results	   in	   a	   relatively	   low	   yield	   of	   fibroblasts.	   We	   have	   recently	   investigated	   an	   alternative	  
protocol	  in	  which	  whole	  human	  lung	  is	  trypsinized	  to	  derive	  both	  primary	  type	  II	  AECs	  as	  well	  
as	  fibroblasts.	  The	  fibroblasts	  grow	  within	  1-­‐2	  weeks,	  the	  yield	  is	  far	  greater	  in	  comparison	  to	  
the	  explants,	  and	   less	  selective	   for	  proliferative	  cell	  subtypes.	  To	  date,	   this	  protocol	  has	  only	  
been	  used	   for	   the	   isolation	  of	   non-­‐IPF	   fibroblasts.	   I	   therefore	  wished	   to	   assess	  whether	   this	  
protocol	   might	   be	   suitable	   for	   future	   extraction	   of	   fibrotic	   fibroblasts,	   or	   whether	   it	  
significantly	   alters	   the	   phenotype	   of	   the	   cells.	   In	   addition,	   the	   spheroid	   forming	   capacity	   of	  
dermal	   fibroblasts	   is	   well	   documented	   but	   to	   date	   fibroblasts	   from	   the	   lung	   have	   not	   been	  
used	   to	   form	  spheroids.	  Therefore,	   the	   feasibility	  of	   forming	  spheroids	  using	   lung	   fibroblasts	  
was	  also	  investigated.	  	  
3.1.2.	   Non-­‐IPF	  pHLF-­‐Di	  cells	  are	  myofibroblast-­‐like	  at	  baseline	  
In	  order	  to	  investigate	  any	  morphological	  differences	  between	  primary	  human	  lung	  fibroblasts	  
from	  explant	  cultures	  (pHLF-­‐Ex)	  and	  from	  lung	  digests	  (pHLF-­‐Di),	  10,000	  cells	  were	  cultured	  in	  
96	  well	  plates	  before	  serum	  starvation	   for	  24	  hours,	   followed	  by	  TGFβ	  activation	   (24	  hours).	  
The	   cells	   were	   then	   fixed	   for	   two	   minutes	   with	   100	   %	   methanol	   following	  
immunocytochemistry	  for	  αSMA,	  Ki-­‐67,	  and	  smoothelin.	  Ki-­‐67	  is	  a	  nuclear	  protein	  encoded	  by	  
MK167.	   The	   precise	   role	   of	   this	   protein	   is	   currently	   unknown;	   however	   it	   is	   expressed	   in	   all	  
stages	  of	  the	  cell	  cycle	  (G1,	  S,	  G2,	  and	  mitosis)	  excluding	  G0	  which	  supports	  an	  important	  role	  
for	   Ki-­‐67	   during	   proliferation.	   Therefore	   in	   this	   study,	   an	   anti-­‐Ki-­‐67	   antibody	  was	   used	   as	   a	  
marker	  for	  proliferation.	  
Figure	   3.1	   illustrates	   that	   at	   baseline,	   non-­‐IPF	   pHLF-­‐Di	   have	   a	  myofibroblast-­‐like	   phenotype,	  
since	  they	  show	  an	  increased	  appearance	  of	  stress	  fibres	  and	  αSMA	  expression	  in	  comparison	  
to	  non-­‐IPF	  pHLF-­‐Ex.	  When	  treated	  with	  TGFβ,	  non-­‐IPF	  pHLF-­‐Ex	  cells	  show	  an	  increase	  in	  αSMA	  
expression	   and	   stress	   fibres.	   However,	   there	   was	   little	   observable	   difference	   in	   αSMA	  
expression	  in	  non-­‐IPF	  pHLF-­‐Di	  following	  TGFβ	  treatment.	  In	  addition,	  Figure	  3.2	  demonstrates	  
phenotypical	   analysis	   of	   non-­‐IPF	   and	   IPF	   pHLF-­‐Ex.	   Similar	   to	   non-­‐IPF	   pHLF-­‐Ex,	   IPF	   fibroblasts	  
also	   shown	   an	   increase	   in	   TGFβ-­‐induced	   αSMA	   expression.	   Furthermore,	   the	   results	   also	  
demonstrate	  that	  all	  cells	  lack	  smoothelin	  expression	  (smooth	  muscle	  cell	  marker),	  supporting	  
that	  the	  cells	  derived	  from	  both	  isolation	  methods	  were	  not	  smooth	  muscle	  in	  origin.	  




Quantitative	   analyses	   of	  Figures	   3.1	   and	  Figure	   3.2	   are	   illustrated	   in	  Figure	   3.3A	   confirming	  
that	   non-­‐IPF	   pHLF-­‐Di	   have	   a	   more	   myofibroblast	   phenotype	   in	   comparison	   to	   pHLF-­‐Ex.	   In	  
addition,	  there	   is	  no	  significant	  difference	   in	  αSMA	  expression	  between	  non-­‐IPF	  pHLF-­‐Ex	  and	  
IPF	   pHLF-­‐Ex	   fibroblasts	   at	   baseline	   (as	   measured	   by	   quantitative	   image	   analysis	   of	  
immunocytofluorescence	   staining	   for	   a-­‐SMA),	   and	   both	   exhibit	   a	   comparable	   elevation	   in	  
αSMA	  after	  addition	  of	  exogenous	  TGFβ. Figure	  3.3B	   and	  Figure	  3.3C	  confirm	   that	  expected	  
elevation	  in	  αSMA	  protein	  levels	  in	  the	  presence	  of	  TGFβ	  in	  non-­‐IPF	  pHLF-­‐Ex,	  by	  western	  blot.	  	  
The	  effect	  of	  TGFβ	  on	   fibroblast	  proliferation	  was	  also	  analysed	  amongst	  all	   cells.	  Figure	  3.4	  
illustrates	   the	  percentage	  of	   Ki-­‐67	  positive	   cells	   in	  non-­‐IPF	  pHLF-­‐Ex	   and	  pHLF-­‐Di.	  At	   baseline	  
pHLF-­‐Di	  are	  more	  proliferative	  in	  comparison	  to	  pHLF-­‐Ex	  despite	  the	  fact	  that	  both	  cell	  isolates	  
are	   from	   the	   same	   donor.	   In	   addition,	   exogenous	   TGFβ increased	   the	   percentage	   of	   Ki-­‐67	  
positive	   cells	   in	   both	   pHLF-­‐Ex	   and	   pHLF-­‐Di.	   This	   result	   was	   reproduced	   in	   three	   different	  
donors.	  
Since	   there	   is	  a	  clear	  difference	   in	   terms	  of	  αSMA	  and	  Ki-­‐67	  expression	  at	  baseline	  between	  
explant	  and	  digest-­‐derived	  non-­‐IPF	  cell	  isolates,	  it	  can	  be	  hypothesised	  that	  similar	  results	  may	  
also	   occur	   in	   IPF	   fibroblasts	   from	   trypsin-­‐digested	   fibrotic	   lungs.	   Given	   that	   our	   existing	  
fibroblast	   biobank	   has	   historically	   been	  derived	   from	  explant	   cultures,	   isolation	   by	   digestion	  
(associated	  with	  significant	  effects	  on	  phenotype)	  was	  abandoned	  as	  a	  replacement	  protocol,	  
despite	   the	   greater	   cell	   yield.	   The	   rest	   of	   my	   project	   focused	   on	   fibroblasts	   isolated	   from	  
explants	  only,	  and	  from	  this	  point	  on,	  pHLF-­‐Ex	  will	  be	  referred	  to	  only	  as	  pHLF,	  for	  simplicity.	  
 	  





























































Non-­‐IPF	  pHLF-­‐Ex	   Non-­‐IPF	  pHLF-­‐Di	  
Figure	  3.	  1.	  α -­‐SMA,	  Ki-­‐67,	  and	  smoothelin	  expression	  in	  non-­‐IPF	  pHLF	  derived	  from	  
explants	  and	  lung	  digests.	  	  	  
Fibroblasts	  were	   cultured	   in	   96	  well	   plates,	   serum	   starved	   for	   24	   hrs,	   then	   stimulated	  
with	  1	  ng/ml	  TGF-­‐beta	  for	  24	  hrs.	  Immunocytofluorescence	  staining	  of	  αSMA	  (green),	  Ki-­‐
67	  (pink)	  and	  DAPI	  (blue)	  is	  shown.	  Cells	  were	  negative	  for	  smoothelin	  expression.	  Non-­‐
IPF	  pHLF-­‐Ex,	  n=3;	  pHLF-­‐Di,	  n=3;	  magnification:	  x100.	  	  






































Non-­‐IPF	  pHLF-­‐Ex	   IPF	  pHLF-­‐Ex	  
Figure	  3.	  2.	  α -­‐SMA,	  Ki-­‐67,	  and	  smoothelin	  expression	  in	  non-­‐IPF	  and	  IPF	  pHLF	  derived	  
from	  explant	  cultures	  
Fibroblasts	  were	   cultured	   in	   96	  well	   plates,	   serum	   starved	   for	   24	   hrs,	   then	   stimulated	  
with	  1	  ng/ml	  TGF-­‐beta	  for	  24	  hrs.	  Immunocytofluorescence	  staining	  of	  αSMA	  (green),	  Ki-­‐
67	  (pink)	  and	  DAPI	  (blue)	  is	  shown.	  Cells	  were	  negative	  for	  smoothelin	  expression.	  Non-­‐
IPF,	  n=3;	  IPF,	  n=3;	  magnification:	  x100.	  	  


























































































Figure	  3.	  3.	  Quantitative	  analysis	  of	  α-­‐SMA	  expression	  in	  primary	  human	  lung	  
fibroblasts.	  	  	  
(A)	  Quantitative	  data	  for	   immunocytofluorescence	  staining	  of	  αSMA	  in	  non-­‐IPF	  pHLF-­‐Ex	  
(n=3),	   non-­‐IPF	   pHLF-­‐Di	   (n=3),	   and	   IPF	   pHLF-­‐Ex	   (n=4)	   exogenously	   treated	  with	   1	   ng/ml	  
TGFβ or	  vehicle	  control.	   (B)	  Western	  blot	   illustrating	   increase	   in	  αSMA	  protein	   levels	   in	  
non-­‐IPF	  pHLF-­‐Ex.	  (C)	  Densitometry.	  **	  p<0.01;	  ***	  p<0.001	  
Non-­‐IPF	  pHLF-­‐Ex	  
A)	   B)	  
C)	  
Figure	  3.	  4.	  Quantitative	  analysis	  of	  Ki-­‐67	  positive	  cells	  in	  non-­‐IPF	  primary	  human	  lung	  
fibroblasts.	  	  	  
Quantitative	   data	   for	   immunocytofluorescence	   staining	   of	   Ki-­‐67	   in	   non-­‐IPF	   pHLF-­‐Ex	  
(green)	   and	   non-­‐IPF	   pHLF-­‐Di	   (blue)	   exogenously	   treated	   with	   1	   ng/ml	   TGFβ or	   vehicle	  
control.	  Data	  are	  representative	  of	  three	  donors.	  ***	  p<0.001	  
Non-­‐IPF	  pHLF-­‐Ex	  




3.1.3.	   Non-­‐IPF	  and	  IPF	  fibroblasts	  aggregate	  to	  form	  spheroids	  	  
Non-­‐IPF	  and	  IPF	  pHLF	  were	  cultured	  in	  96-­‐well	  plates	  (10,000	  cells	  per	  well)	  pre-­‐coated	  with	  a	  
non-­‐adhesive	   surface	   (ultra-­‐low	   melting	   point	   agarose).	   These	   were	   then	   incubated	   for	   24	  
hours	   at	   37	   oC	   with	   10	   %	   CO2.	   Figure	   3.5A	   illustrates	   phase	   contrast	  microscopy	   images	   of	  
spheroid	   formation	   which	   were	   obtained	   using	   IncuCyte	   Zoom	   (Essen	   bioscience,	   UK;	   see	  
Section	   2.5.3).	   As	   illustrated	   in	   Figure	   3.5B,	   within	   2	   hours	   of	   seeding,	   the	   cells	   form	  
aggregates	  which	  approximately	  remain	  the	  same	  size	  (~400	  µm)	  over	  a	  24	  hour	  period.	  The	  
data	  are	  representative	  of	  fibroblasts	  isolated	  from	  10	  non-­‐IPF	  and	  10	  IPF	  lung	  donors.	  Figure	  
3.5C	   and	   Figure	   3.5D	   illustrate	   a	   macroscopic	   view	   of	   the	   spheroid	   and	   H&E	   histological	  
staining	  of	  an	  IPF	  spheroid.	  	  
To	   determine	   any	   morphological	   differences	   between	   non-­‐IPF	   and	   IPF	   spheroids,	   scanning	  
electron	  microscopy	   (SEM)	  and	   transmission	  electron	  microscopy	   (TEM)	  were	  performed,	  24	  
hours	  post	  seeding.	  Spheroid	  samples	  were	  processed	  by	  Mark	  Turmaine	  (Electron	  Microscopy	  
Unit,	   UCL).	   Figure	   3.6	   and	   Figure	   3.7	   illustrate	   SEM	   images	   for	   non-­‐IPF	   (n=6)	   and	   IPF	   (n=6)	  
spheroids,	  respectively.	  Two	  out	  of	  the	  six	  non-­‐IPF	  donors	  (donor	  1	  and	  2),	  in	  particular,	  show	  
a	   more	   rough/blebbed	   surface	   in	   comparison	   to	   all	   other	   non-­‐IPF	   donors	   -­‐	   which	   have	   a	  
smoother	  surface	  with	  visibly	  elongated	  fibroblasts.	  IPF	  fibroblast	  spheroids	  appear	  to	  have	  a	  
smoother	   appearance	   in	   general,	   with	   large,	   flatter	   cells.	   Furthermore,	   some	   dead	   cells	   (or	  
apoptotic	  cells)	  are	  also	  present	  on	  the	  surface	  of	  both	  non-­‐IPF	  and	  IPF	  spheroids	  (cells	  with	  a	  
more	  rounded	  structure,	  Figure	  3.8).	  Furthermore,	   IPF	  spheroids	  show	  actin	  retraction	  fibres	  
possibly	   indicating	   cell	   migration	   or	   contraction.	   All	   fibroblast	   spheroids	   appeared	   to	   have	  
multiple	  microvilli	  (Figure	  3.9).	  Moreover,	  fibrillar	  ECM	  was	  evident	  in	  some	  areas	  of	  both	  non-­‐
IPF	  and	  IPF	  spheroids	  (Figure	  3.10).	  Figure	  3.11	  and	  Figure	  3.12	  illustrate	  TEM	  images	  of	  non-­‐
IPF	  and	  IPF	  spheroids,	  respectively.	  Both	  spheroids	  show	  the	  presence	  of	  fibrillar	  ECM	  proteins	  
(arrows;	  most	  probably	  fibrillar	  collagen).	  In	  addition,	  fibroblasts	  in	  IPF	  spheroids	  appear	  to	  be	  
more	   compact	   and	   form	   junctions	   (Figure	   3.13)	   which	   were	   not	   seen	   in	   non-­‐IPF	   spheroids.	  
These	  junctions	  are	  either	  tight	  or	  adherens	  junctions.	  Data	  are	  representative	  of	  two	  non-­‐IPF	  
donors	  and	  three	  IPF	  donors.	  	  
	   	  






































	   	  
A)	  
D)	  C)	  
Figure	  3.	  5.	  Fibroblast	  spheroid	  formation.	  	  
Fibroblasts	   from	   non-­‐IPF	   and	   IPF	   patients	   (n=10	   and	   n=10,	   respectively)	   have	   the	  
tendency	  to	  form	  spheroids.	  (A)	  Time	  lapse	  for	  spheroid	  formation	  (from	  15	  minutes	  to	  
48	  hours,	  post	  seeding).	  (B)	  Phase	  object	  area	  demonstrating	  size	  of	  the	  spheroid	  over	  
time,	   ~400	   µm.	   (C)	   Macroscopic	   view	   of	   a	   spheroid.	   Scale	   bar	   =	   100	   µM.	   (D)	   H&E	  
staining.	  Magnification	  x10.	  Representative	  data	  shown	  for	  one	  IPF	  line.	  	  
A)	  


















































Figure	  3.	  6.	  Scanning	  electron	  microscopy	  (SEM)	  for	  non-­‐IPF	  spheroids.	  
A)	   Each	  spheroid	   represents	  a	  different	  donor	   (i.e.	  n=6).	  Magnification	  =	  x200;	   scale	  
bar	   =	   100	   µm.	   B)	   Spheroid	   structures	   at	   higher	   magnification	   (x1000)	   for	   the	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Figure	  3.	  7.	  Scanning	  electron	  microscopy	  (SEM)	  for	  IPF	  spheroids.	  
A)	   Each	  spheroid	   represents	  a	  different	  donor	   (i.e.	  n=6).	  Magnification	  =	  x200;	   scale	  
bar	   =	   100	   µm.	   B)	   Spheroid	   structures	   at	   higher	   magnification	   (x1000)	   for	   the	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A)	  
B)	  
Figure	   3.	   8.	   Scanning	   electron	   microscopy	   (SEM)	   of	   non-­‐IPF	   spheroids	   illustrating	  
probable	  apoptotic	  cells.	  
Cells	  likely	  to	  be	  undergoing	  apoptosis	  are	  indicated	  by	  red	  arrows	  of	  (A)	  non-­‐IPF	  and	  (B)	  
IPF	   spheroids.	   White	   arrow	   illustrates	   actin	   retraction	   fibres.	   Scale	   bar	   =	   10	   µm.	  
Magnification	  x1000	  






























Figure	   3.	   9.	   Scanning	   electron	  microscopy	   (SEM)	   for	   non-­‐IPF	   spheroids	   illustrating	  
microvilli.	  
Microvilli	   indicated	   by	   red	   arrows	   on	   the	   surface	   of	   both	   (A)	   non-­‐IPF	   and	   (B)	   IPF	  
fibroblast	  spheroids	  Scale	  bar	  =	  5	  µm.	  Magnification	  x2000	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Figure	   3.	   10.	   Scanning	   electron	   microscopy	   (SEM)	   for	   non-­‐IPF	   and	   IPF	   spheroids	  
illustrating	  extracellular	  matrix.	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Figure	  3.	  11.	  Transmission	  electron	  microscopy	  (TEM)	  for	  non-­‐IPF	  spheroids.	  
(A)	  Magnification	  x8000.	  Scale	  bar	  2	  µm.	  (B)	  Greater	  magnification	  of	  black	  box	  shown	  
in	   panel	   A	   (x40000).	   Scale	   bar	   0.5	   µm.	   Fibrillar	   ECM	   (red	   arrows)	   and	   invaginations	  


















































	  	  	  	  Figure	  3.	  12.	  Transmission	  electron	  microscopy	  (TEM)	  for	  IPF	  spheroids.	  
(A)	   Magnification	   x10000.	   Scale	   bar	   2	   µm.	   (B)	   Greater	   magnification	   of	   black	   box	  
shown	   in	   panel	   A	   (x20000).	   Scale	   bar	   1	   µm.	   Fibrillar	   ECM	   (red	   arrows)	   and	  















































Figure	   3.	   13.	   Transmission	   electron	  microscopy	   (TEM)	   for	   IPF	   spheroids	   illustrating	  
the	  presence	  of	  junctions.	  
(A)	  Magnification	  x6000.	  Scale	  bar	  2	  µm.	  (B)	  Greater	  magnification	  of	  black	  box	  shown	  
in	   panel	   A	   (x50000).	   Scale	   bar	   0.2	   µm.	   Junctions	   (red	   arrows)	   and	   invaginations	  




	   	   	  
	  
	   	  















3.1.4.	   Summary	  
The	  results	  described	  in	  this	  section	  aimed	  to	  illustrate	  any	  morphological	  differences	  between	  
cells	   isolated	  using	  two	  different	   isolation	  protocols	  and	  to	  determine	  the	  propensity	  of	   lung	  
fibroblasts	  to	  form	  3D	  spheroid	  structure.	  The	  results	  showed:	  
• Non-­‐IPF	   pHLF	   isolated	   from	   digested	   lungs	   have	   a	   more	   myofibroblastic	   phenotype	  
with	   high	   expression	  of	  αSMA	  and	  Ki-­‐67	   at	   baseline,	   in	   comparison	   to	   non-­‐IPF	   pHLF	  
derived	  from	  explant	  cultures.	  
• In	  the	  presence	  of	  TGFβ, αSMA	  expression	  increased	  in	  both	  non-­‐IPF	  and	  IPF	  pHLF-­‐Ex,	  
however	   TGFβ	   had	   not	   effect	   on	   αSMA	   expression	   of	   pHLF-­‐Di.	   Nevertheless,	   TGFβ	  
accelerated	  the	  rate	  of	  proliferation	  in	  both	  non-­‐IPF	  pHLF-­‐Ex	  and	  pHLF-­‐Di.	  	  
	  
• Both	  non-­‐IPF	  and	  IPF	  pHLF	  were	  able	  to	  form	  spheroids	  within	  24	  hours	  of	  incubation	  
with	  the	  size	  remaining	  relatively	  constant	  over	  the	  subsequent	  96	  hours.	  
• Morphologically,	  IPF	  spheroids	  appeared	  to	  have	  a	  smoother	  surface	  in	  comparison	  to	  
non-­‐IPF	   spheroids.	   However,	   there	  were	   a	   few	   similarities	   including	   the	   presence	   of	  
microvilli	   and	   ECM	   deposits	   on	   the	   surface	   of	   the	   spheroids.	   Furthermore	   probable	  
apoptotic	  cells	  were	  also	  visible	  on	  both	  non-­‐IPF	  and	  IPF	  spheroids.	  
• TEM	  analysis	  demonstrated	  that	  IPF	  fibroblast	  spheroids	  were	  more	  compact	  with	  the	  
presence	   of	   tight/adherens	   junctions	   which	   were	   not	   evident	   in	   non-­‐IPF	   spheroids.	  
Fibrillar	  matrix	   deposits	   were	   evident	   in	   both	   non-­‐IPF	   and	   IPF	   spheroids	  which	  may	  
potentially	  be	  fibrillar	  collagen.	  	  
	  
	   	  




3.2. Spheroid	   characterisation	   part	   1:	   αSMA,	   Collagen	   and	  
TGFβ  expression	  
	  
3.2.1.	   Introduction	  
Some	   of	   the	   key	   characteristics	   shown	   in	   the	   lungs	   of	   IPF	   patients	   include	   increased	  
populations	  of	  αSMA	  positive	  myofibroblasts,	  excessive	  production	  of	  collagen,	  and	  increased	  
synthesis	   of	   the	   potent	   profibrotic	  mediator,	   TGFβ.	   In	   order	   to	   develop	   a	   novel	   3D	   in	   vitro	  
fibrosis	  model	  it	  is	  vital	  to	  investigate	  whether	  these	  features	  are	  also	  evident	  in	  the	  fibroblast	  
spheroids.	  
3.2.2.	   IPF	  spheroids	  have	  a	  myofibroblastic	  phenotype	  
As	   demonstrate	   earlier	   in	   Section	   3.1,	   there	   was	   no	   significant	   difference	   in	   baseline	  
expression	   levels	   of	   αSMA	   in	   non-­‐IPF	   and	   IPF	   fibroblasts	   cultured	   as	   a	   2D	   monolayer.	   To	  
investigate	  whether	  this	  was	  also	  the	  case	  in	  a	  3D	  system,	  cells	  in	  DMEM	  with	  0.4	  %	  serum	  and	  
100µM	  ascorbic	  acid	  were	  seeded	  into	  a	  96-­‐well	  plate	  (pre-­‐coated	  with	  agarose)	  for	  24	  hours	  
for	   spheroid	   formation	   and	   collected	   for	  mRNA,	   protein,	   and	   immunohistochemical	   analysis	  
following	  24	  hours	  and	  96	  hours	  incubation.	  
Figure	  3.14A	   illustrates	   that	   the	  mRNA	   levels	  of	  ACTA2	   in	   IPF	  spheroids	   (n=10;	   red	   triangles)	  
were	   significantly	   greater	   in	   comparison	   to	   non-­‐IPF	   spheroids	   (n=10;	   green	   circles)	   when	  
cultured	  for	  24	  hours	  (1	  day;	  p	  value	  <0.05,	  two-­‐way	  ANOVA).	  However,	  after	  96	  hours	  (4	  days)	  
of	   spheroid	   incubation	   the	   mRNA	   levels	   between	   non-­‐IPF	   and	   IPF	   spheroids	   were	   not	  
significantly	   different.	   Nevertheless,	   αSMA	   protein	   levels	   (Figure	   3.14B	   and	   C)	   were	  
significantly	   elevated	   in	   IPF	   spheroids	   both	   at	   24	   hours	   (6-­‐8	   fold	   increase;	   p<0.01,	   two-­‐way	  
ANOVA)	  and	  96	  hours	  (3-­‐6	  fold	  increase;	  p<0.05,	  two-­‐way	  ANOVA)	  of	  incubation	  in	  comparison	  
to	  non-­‐IPF	  (<2	  fold).	  The	  densitometry	  data	  were	  normalised	  to	  loading	  control	  (i.e.	  ERK2).	  This	  
is	   also	   demonstrated	   immunohistochemically	   (Figure	   3.14D,	   E	   and	   F)	   with	   strong	  
immunoreactivity	   shown	   in	   IPF	   spheroid	   sections	   (brown	   staining).	   In	   addition,	   αSMA	  
expression	   in	   both	   non-­‐IPF	   and	   IPF	   spheroids	   was	   more	   or	   less	   stable	   over	   time	   with	   no	  
significant	  difference	  in	  protein	  levels	  between	  24	  hours	  and	  96	  hours	  of	  spheroid	  incubation	  
(Figure	   3.14C).	   These	   data	   suggests	   that	   IPF	   fibroblasts	   have	   a	   more	   myofibroblastic	  
phenotype	  in	  a	  3D	  system,	  in	  comparison	  to	  non-­‐IPF.	  	  




The	   next	   step	   involved	   investigating	   the	   deposition	   of	   collagen	   within	   these	   spheroids.	   As	  
stated	  earlier,	  both	  non-­‐IPF	  and	  IPF	  spheroids	  seem	  to	  show	  fibrillar	  ECM	  deposits	  which	  may	  
potentially	  be	  collagen	  (Section	  3.1;	  Figures	  3.11,	  3.12,	  and	  3.13).	  To	  investigate	  this,	  modified	  
Martius	  Scarlet	  Blue	  (MSB)	  staining	  was	  performed	  to	  visualise	  the	  architecture	  of	  connective	  
tissue	  on	  non-­‐IPF	   and	   IPF	   spheroids	   (Figure	  3.15).	   The	   results	   illustrate	   clear	  organisation	  of	  
the	  cells	  in	  the	  spheroids	  with	  a	  greater	  intensity	  of	  blue	  staining	  (collagen)	  in	  IPF	  spheroids	  in	  
comparison	   to	  non-­‐IPF.	  To	  quantify	   this	  data,	  HPLC	  was	  performed.	  Figure	  3.16A	   shows	   that	  
both	  non-­‐IPF	  and	  IPF	  fibroblasts	  produce	  collagen,	  with	  slightly	  elevated	  levels	  in	  IPF	  spheroids	  
(24	  hours	  post	  seeding).	  In	  non-­‐IPF	  spheroids,	  the	  collagen	  concentration	  ranged	  between	  14-­‐
88	  ng	  (n=10),	  whereas	  the	  collagen	  concentration	  for	  IPF	  spheroids	  ranged	  between	  32-­‐185	  ng	  
(n=12;	  p<0.05,	  student	  T-­‐test).	  Furthermore,	  over	  time	  (94	  hours)	  the	  levels	  remain	  relatively	  
stable	  across	  the	  majority	  of	  non-­‐IPF	  or	  IPF	  donors	  (Figure	  3.16B	  and	  C,	  respectively).	  	  
Since	  collagen	  types	  I	  and	  III	  are	  predominately	  found	  in	  the	  lung	  (Raghu	  et	  al.,	  1985),	  the	  type	  
of	   collagen	   deposited	   by	   these	   fibroblast	   spheroids	   was	   investigated.	   Prior	   to	   this,	  
immunohistochemical	  staining	  for	  collagen	  I	  and	  collagen	  III	  was	  performed	  on	  sections	  from	  
both	  non-­‐IPF	  (Figure	  3.17)	  and	  IPF	  formaldehyde-­‐fixed	  paraffin-­‐embedded	  lung	  tissue	  (Figure	  
3.18	  and	  Figure	  3.19).	   In	  non-­‐IPF	  lung,	   immunostaining	  for	  both	  collagen	  I	  and	  III	   localised	  to	  
AECs	  and	  smooth	  muscle	  cells	  surrounding	  blood	  vessels	  (positive	  for	  αSMA;	  Figure	  3.17D).	  In	  
IPF	  lung,	  both	  collagen	  types	  I	  and	  III	  were	  present	  throughout	  the	  tissue,	  including	  localisation	  
to	  myofibroblasts	  (αSMA	  positive	  cells)	  of	  fibrotic	  foci.	   Interestingly,	  strong	  immunoreactivity	  
for	   both	   collagen	   types	   was	   also	   evident	   in	   the	   basement	   membrane	   underlying	   bronchial	  
epithelial	  cells	  (Figure	  3.19)	  which	  to	  our	  knowledge	  have	  not	  been	  reported	  before.	  	  
Figure	  3.20	   illustrates	   that	  mRNA	   levels	   for	  COL1A1	   and	  COL3A1	  between	  non-­‐IPF	   (n=7)	  and	  
IPF	  (n=10)	  spheroids	  are	  not	  significantly	  different	  at	  both	  24	  and	  96	  hours	  of	  incubation	  (two-­‐
way	  ANOVA).	  Figure	  3.21	   shows	   that	  both	  non-­‐IPF	  and	   IPF	  spheroids	  express	  collagen	   type	   I	  
and	  collagen	  type	  III	  with	  slightly	  stronger	  immunoreactivity	  shown	  in	  IPF	  spheroids.	  
	  
	   	  












	   	  
B)	  
Figure	  3.	  14. αSMA	  expression	  in	  spheroids.	  	  
(A)	  mRNA	  levels	  of	  ACTA2	  within	  non-­‐IPF	  (n=10	  donors)	  and	  IPF	  spheroids	  (n=10).	  Data,	  
expressed	   as	  ΔCt,	  were	   normalised	   to	   three	  housekeeping	   genes	   (EIF4A2,	  TOP1,	   and	  
UBC).	  (B)	  Western	  blot	  illustrating	  αSMA	  protein	  levels	  with	  ERK2	  as	  a	  loading	  control.	  
(C)	  Representative	  densitometry	  data	  shown	  for	  one	  non-­‐IPF	  and	  one	  IPF	  line.	  *p<0.05,	  
**p<0.01	   (two-­‐way	   ANOVA.	   Post	   hoc	   test:	   bonferroni	   correction).	   (D)	  
Immunohistochemistry	  for	  IgG	  control,	  (E)	  Non-­‐IPF	  αSMA,	  and	  (F)	  IPF	  αSMA,	  24	  hours	  
post	  seeding.	  Magnification	  x200.	  Scale	  bar	  100	  µm.	  Representative	  data	  shown	  for	  4	  


























































































































Figure	  3.	  15.	  MSB	  staining	  for	  non-­‐IPF	  and	  IPF	  spheroid.	  
Paraffin-­‐embedded	   non-­‐IPF	   (left)	   and	   IPF	   (right)	   spheroid	   sections.	   Each	   spheroid	  
represents	   a	   different	   donor.	   Blue	   indicates	   collagen	   deposition.	   Magnification	   x200.	  
Scale	  bar	  =	  100	  µm.	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   IPF	  

















































































	   	  
Figure	  3.	  16.	  Collagen	  production	  in	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
Spheroids	  were	  formed	  and	  hydrolysed	  in	  6	  M	  HCl	  for	  analysis	  of	  hydroxyproline	  levels	  
by	  HPLC.	  (A)	  Collagen	  levels	  per	  spheroid,	  24	  hours	  post	  seeding.	  Non-­‐IPF	  spheroids	  are	  
represented	  as	  green	  circles	   (n=10)	  and	   IPF	  spheroids	  are	   represented	  as	   red	   triangles	  
(n=12).	  Change	  in	  collagen	  levels	  over	  time	  within	  non-­‐IPF	  (B)	  and	  IPF	  spheroids	  (C).	  Each	  
line	  represents	  an	  individual	  patient.	  *	  p<0.05	  (Student	  T-­‐test).	  
	  
A)	  
B)	   C)	  





	  	  	   	  	  	  
	  	  	   	  





A)	   B)	  
C)	   D)	  
E)	   F)	  
Figure	  3.	  17.	   Immunohistochemical	  staining	  of	  paraffin	  embedded	  non-­‐IPF	  lung	  serial	  
sections.	  
(A)	   H&E	   staining;	   (B)	  MSB	   staining,	   blue	   indicates	   collagen	  deposition;	   (C)	   IgG	   isotype	  
control;	  (D)	  αSMA;	  (E)	  collagen	  type	  I;	  (F)	  collagen	  type	  III.	  Magnification	  x100.	  Scale	  bar	  
=	  200	  µm	  





	  	   	  
	  	   	  
	  	   	  
	  
	  
	   	  
A)	   B)	  
C)	   D)	  
Figure	  3.	  18.	  Immunohistochemical	  staining	  of	  a	  fibrotic	  focus	  in	  paraffin	  embedded	  
IPF	  lung	  serial	  sections	  	  
(A)	  H&E	  staining;	  (B)	  MSB	  staining;	  (C)	  IgG	  isotype	  control;	  (D)	  αSMA;	  (E)	  collagen	  type	  
I;	  (F)	  collagen	  type	  III.	  Fibrotic	  focus	   is	   indicated	  by	  arrows.	  Magnification	  x200.	  Scale	  
bar	  =	  100	  µm	  
E)	   F)	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C)	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Figure	   3.	   19.	   Immunohistochemical	   staining	   illustrating	   collagen	   types	   I	   and	   III	  
immunoreactivity	  at	   the	  basement	  membrane	  of	  paraffin	  embedded	  IPF	   lung	  serial	  
sections	  	  
(A)	   MSB	   staining;	   (B)	   IgG	   isotype	   control;	   (C)	   collagen	   type	   I;	   (D)	   collagen	   type	   III.	  
Magnification	  x200.	  Inserts	  highlight	  the	  whole	  tissue	  section.	  Scale	  bar	  =	  300	  µm	  

































































































	   	  
Figure	  3.	  20.	  COL1A1	  and	  COL3A1	  mRNA	  levels	  in	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
The	  mRNA	  levels	  of	  (A)	  COL1A1	  and	  (B)	  COL3A1	  in	  non-­‐IPF	  (n=7;	  green	  circles)	  and	  IPF	  
(n=9;	   red	   triangles)	   spheroids	   were	   measured	   by	   qRT-­‐PCR.	   All	   CT	   values	   were	  
normalised	   to	   three	   housekeeping	   genes	   based	   on	   GeNorm	   analysis	   (EIF4A2,	   TOP1,	  
and	  UBC).	  Each	  point	  represents	  an	  average	  result	  from	  individual	  patients.	  	  
































Non-­‐IPF	   IPF	  
Figure	  3.	  21.	  Immunohistochemical	  staining	  of	  collagen	  types	  I	  and	  III	  in	  non-­‐IPF	  and	  
IPF	  spheroids.	  	  
Paraffin-­‐embedded	  non-­‐IPF	  (left)	  and	  IPF	  (right)	  spheroids	  were	  stained	  with	  either	  IgG	  
isotype	  control	  or	  antibodies	  against	  collagen	  type	  I,	  or	  collagen	  type	  3.	  Magnification	  
x100.	  Scale	  bar	  100	  µm	  




3.2.3.	   Spheroids	  produce	  high	  levels	  of	  active-­‐TGFβ 	  
	  
TGFβ	  is	  widely	  accepted	  as	  a	  key	  cytokine	  involved	  in	  the	  deposition	  of	  collagen	  	  (Pena	   et	   al.,	  
1994;	  Clark	  et	  al.,	  1997;	  Garrett	  et	  al.,	  2004;	  Gu	  et	  al.,	  2007).	  The	  current	  data	   illustrate	  that	  
within	   just	   24	   hours	   of	   spheroid	   formation,	   fibroblasts	   are	   able	   to	   synthesis	   high	   levels	   of	  
collagen	   (both	  collagen	  type	   I	  and	   III).	  The	  next	  step	  was	  to	   investigate	  whether	   treating	  the	  
spheroids	  exogenously	  with	  active	  TGFβ promotes	  a	  further	  increase	  in	  collagen	  synthesis.	  The	  
spheroids	   were	   cultured	   for	   24	   hours	   in	   the	   presence	   of	   1	   ng/ml	   of	   active	   TGFβ,	   prior	   to	  
analysis.	   Figure	   3.22	   illustrates	   that	   exogenous	   TGFβ	   had	   no	   significant	   effect	   on	   baseline	  
collagen	  synthesis	   in	  either	  non-­‐IPF	  or	   IPF	  spheroids.	  Data	  are	   representative	  of	   two	  non-­‐IPF	  












To	  investigate	  whether	  these	  fibroblast	  spheroids	  are	  capable	  of	  synthesising	  their	  own	  active-­‐
TGFβ	  (possibly	  providing	  an	  explanation	  as	  to	  why	  exogenous	  TGFβ	  treatment	  had	  no	  effect	  on	  
collagen	   synthesis),	   a	   mink	   lung	   bioassay	   was	   performed	   to	   analyse	   active	   TGFβ	   levels	   in	  
conditioned	  media	   (after	   24	   hrs	   of	   spheroid	   culture).	   Transformed	  mink	   lung	   epithelial	   cells	  
(TMLECs)	   were	   cultured	   into	   96	   well	   plates	   (1.6	   x	   104	   cells	   per	   well)	   for	   3	   hours	   to	   allow	  









































Figure	  3.	  22.	  Effect	  of	  active	  TGFβ 	  on	  collagen	  synthesis	  in	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
(A)	  Non-­‐IPF	   (n=2)	  and	   (B)	   IPF	   (n=2)	   fibroblasts	  were	   treated	  with	  1	  ng/ml	  TGFβ.	  Cells	  
were	  cultured	  in	  agarose-­‐coated	  96	  well	  plates	  and	  incubated	  for	  24	  hours	  for	  spheroid	  
formation.	   HPLC	   for	   hydroxyproline	   was	   performed	   following	   acid	   hydrolysis	   of	  
spheroids.	  	  
	  
A)	   B)	  Non-­‐IPF	   IPF	  




prepared	  in	  serum	  free	  media.	  TMLECs	  were	  then	  cultured	  with	  either	  TGFβ	  standard	  sample	  
or	   samples	   (i.e.	   conditioned	   media)	   for	   16	   hours.	   The	   cells	   were	   then	   lysed	   and	   firefly	  
luciferase	   activity	   was	   measured	   using	   a	   luminometer.	   Figure	   3.23	   illustrates	   the	   levels	   of	  
active	   TGFβ	   synthesised	   by	   the	   fibroblastic	   spheroids	   and	   secreted	   into	   the	   conditioned	  
medium	  (24	  hours	  post-­‐seeding).	  For	  non-­‐IPF	  spheroids	  (n=7)	  the	  concentration	  of	  active	  TGFβ	  
in	   the	   conditioned	   medium	   was	   <500	   pg/mL	   whilst	   the	   concentration	   for	   IPF	   (n=8)	   ranged	  
between	   200-­‐1200	   pg/mL.	   Statistical	   analysis	   (Student	   T-­‐Test)	   showed	   there	   is	   a	   significant	  













The	  experiment	  was	  repeated	  to	  determine	  whether	  active	  TGFβ	  was	  also	  present	  in	  spheroid	  
homogenates	   and	  whether	   the	   levels	   changed	  over	   time.	   Conditioned	  media	  were	   collected	  
following	   24	   hours	   and	   96	   hours	   of	   spheroid	   formation.	   In	   addition,	   free-­‐floating	   spheroids	  
were	   removed	   from	   the	   culture	   media	   and	   homogenised	   into	   200	   µL	   of	   fresh	   serum	   free	  
media.	  TMLC	  cells	  were	  treated	  as	  described	  above	  with	  TGFβ	  standard	  samples,	  conditioned	  

















Figure	  3.	  23.	  Active	  TGF-­‐β 	  in	  conditioned	  media	  from	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
Transformed	  mink	  lung	  cells	  (TMLEC)	  were	  cultured	  with	  conditioned	  media	  of	  non-­‐IPF	  
(n=7,	  green	  circles)	  and	  IPF	  (n=8,	  red	  triangles)	  spheroids	  (24	  hours	  post-­‐seeding).	  The	  
TMLC	   cells	  were	   lysed	  with	   1x	   luciferase	   reporter	   buffer	   followed	   by	   the	   addition	  of	  
luciferase	   assay	   buffer	   and	   substrate.	   The	   amount	   of	   TGFβ	   produced	   was	   then	  



















active	   TGFβ	   in	   the	   conditioned	   media	   of	   IPF	   spheroids	   (n=4)	   is	   statistically	   greater	   in	  
comparison	   to	   non-­‐IPF	   (n=5).	   In	   addition,	   although	   there	   is	   a	   slight	   elevation	   in	   active	   TGFβ	  
levels	   in	   IPF	   spheroid	   supernatants	   over	   time	   (96	   hours),	   this	   did	   not	   reach	   statistical	  
significance.	   Figure	   3.24B	   demonstrates	   that	   active	   TGFβ	   is	   also	   present	   within	   spheroid	  
homogenates	   in	  both	  non-­‐IPF	  and	  IPF	  spheroids	  with	  elevated	  levels	   in	   IPF	  spheroids	  at	  both	  
24	  hours	   (p<0.001)	  and	  96	  hours	   (p<0.01)	  of	   incubation	   in	  comparison	   to	  non-­‐IPF	  spheroids.	  
Interestingly	  however,	  in	  IPF	  spheroids	  the	  concentration	  declines	  over	  time	  (by	  approximately	  
50	  %).	  No	  significant	  difference	  is	  shown	  in	  non-­‐IPF	  spheroids	  between	  24	  and	  96	  hours.	  Note,	  
the	  TGFβ	  levels	  in	  the	  conditioned	  media	  shown	  Figure	  3.24	  are	  consistent	  with	  those	  shown	  


























































3.2.4.	   TGFβ  activation	  is	  independent	  of	  TSP-­‐1	  	  
Since	   non-­‐IPF	   and	   IPF	   spheroids	   are	   capable	   of	   synthesising	   collagen	   and	   active	   TGFβ	   (with	  
higher	  levels	  in	  IPF	  spheroids),	  the	  next	  step	  was	  to	  investigate	  possible	  upstream	  mediators	  of	  
TGFβ	  activation.	  Previous	  studies	  have	  shown	  TSP-­‐1	  (a	  multifactorial	  ECM	  protein)	  (Armstrong	  
and	  Bornstein,	  2003)	   is	  able	   to	  activate	  TGFβ	  making	   it	   readily	  available	   to	  associate	  with	   its	  
Figure	  3.	  24.	  IPF	  spheroids	  produce	  higher	  levels	  of	  active	  TGFβ .	  	  
Spheroids	  were	  cultured	  for	  24	  hrs	   (1	  day)	  or	  96	  hrs	  (4	  days).	  Transformed	  mink	  lung	  
cells	  (TMLC)	  were	  cultured	  with	  (A)	  conditioned	  media	  or	  (B)	  spheroid	  homogenates	  of	  
non-­‐IPF	   (n=5,	   green	   circles)	   and	   IPF	   (n=4,	   red	   triangles)	   spheroids.	   Luciferase	   activity	  
was	  measured	  by	  luminescence,	  and	  equated	  to	  TGFβ	  concentration	  by	  reference	  to	  a	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receptor	  and	  activate	  downstream	  signalling	  events	  (Crawford	  et	  al.,	  1998;	  Chen	  et	  al.,	  2009).	  
To	  address	  whether	  this	  was	  also	  the	  case	  in	  this	  3D	  system	  the	  spheroids	  were	  treated	  with	  
the	  TSP-­‐1	   inhibitor	  LSKL.	  LSKL	   is	  an	  amino	  acid	  sequence	   located	  near	   the	  amino	  terminal	  of	  
LAP.	  A	  particular	  tetrapeptide	  sequence	  of	  TSP-­‐1	  (KRFK)	  is	  able	  to	  interact	  with	  LSKL	  resulting	  
in	   a	   conformational	   change	   in	   LAP	   leading	   to	   active	   TGFβ	   release.	   Since	   the	   conserved	   LSKL	  
sequence	   in	   LAP	   is	   necessary	   for	   TSP-­‐1	   induced	   TGFβ	   activation,	   the	   addition	   of	   a	   mimetic	  
peptide	  of	  this	  sequence	  can	  inhibit	  the	  interaction	  by	  acting	  as	  a	  competitive	  antagonist	  (Xie	  
et	  al.,	  2010).	  As	  a	  negative	  control,	  a	  scrambled	  peptide	  (SLLK)	  was	  used.	   	  Cells	  were	  seeded	  
for	  spheroid	  formation	   in	  the	  presence	  of	  either	  vehicle	  control	   (1	  %	  DMSO	  in	  0.4	  %	  media),	  
LSKL,	  or	  SLLK	  at	  concentrations	  ranging	  from	  0.0001	  µM	  to	  10	  µM,	  for	  24	  hrs.	  Spheroids	  were	  
analysed	   to	   determine	   the	   collagen	   content	  whilst	   the	   conditioned	  media	  were	   collected	   to	  
determine	   active	   TGFβ	   concentrations	   by	   performing	   the	   mink	   lung	   bioassay.	   As	   shown	   in	  
Figure	   3.25	   LSKL	   had	   no	   effect	   on	   collagen	   synthesis	   in	   either	   non-­‐IPF	   (n=2)	   or	   IPF	   (n=1)	  
spheroids	   and	   Figure	   3.26	   illustrates	   that	   this	   inhibitor	   had	   no	   significant	   effect	   on	   TGFβ	  
activation	  in	  non-­‐IPF	  or	  IPF	  spheroids.	  A	  slight	  decline	  in	  active	  TGFβ	  levels	  in	  IPF	  spheroids	  was	  
shown	   with	   10	   µM	   of	   LSKL	   (based	   on	   the	   curve	   fit),	   however	   statistical	   analysis	   (one-­‐way	  
ANOVA)	   showed	   this	   was	   not	   significant.	   This	   suggests	   that	   TGFβ	   activation	   and	   collagen	  
synthesis	  is	  not	  dependent	  on	  TSP1.	  
	  




















































Figure	  3.	  25.	  Effect	  of	  TSP-­‐1	  inhibition	  (LSKL)	  on	  collagen	  synthesis	  in	  non-­‐IPF	  and	  IPF	  
spheroids.	  	  
Cells	   were	   treated	   with	   either	   vehicle	   control	   (levels	   shown	   as	   dotted	   lines),	   SLLK	  
(black),	  or	  LSKL	  (red)	  and	  then	  cultured	  for	  spheroid	  formation	  for	  24	  hours.	  HPLC	  was	  
performed	   on	   the	   spheroids	   to	   determine	   collagen	   content.	   (A)	   Non-­‐IPF	   spheroids	  
(data	  representative	  of	  two	  donors)	  and	  (B)	  IPF	  spheroids	  (n=1).	  
	  
A)	   B)	  














3.2.5.	   TGFβ  activation	  is	  dependent	  on	  integrins	  with	  no	  effect	  on	  collagen	  
synthesis	  
As	  well	   as	   TSP-­‐1,	   studies	   have	   also	   shown	   that	   integrins	   play	   a	   key	   role	   in	   the	   activation	   of	  
TGFβ.	   LAP	   contains	   an	   RGD	   sequence	   to	   which	   integrins	   can	   associate	   and	   promote	   a	  
conformational	   change	   in	   LAP	   leading	   to	   the	   release	   of	   TGFβ	   from	   the	   latency	   complex.	  
Integrins	   that	  have	  been	   formally	  demonstrated	   to	   liberate	  active	  TGFβ	   include	  αvβ3,	  αvβ5,	  
αvβ6	   (present	   on	   epithelial	   cells),	   and	  αvβ8	   (Munger	   et	   al.,	   1999;	   Mu,	   2002;	   Asano	   et	   al.,	  
2005a,	  2005b).	  	  
The	  mRNA	   levels	   of	   ITGAV,	   ITGB3,	   ITGB5,	   and	   ITGB8	  were	   assessed	   in	   both	  non-­‐IPF	   and	   IPF	  
spheroids	   24	   hours	   and	   96	   hours	   post-­‐seeding.	   All	   ΔCt	   values	   were	   normalised	   to	   the	  
housekeeping	   genes	   EIF4A2,	   TOP1,	   and	   UBC.	   Figure	   3.27	   illustrates	   that	   ITGAV	   and	   ITGB5	  
mRNA	   levels	  were	   statistically	   greater	   in	   IPF	   spheroids	   at	  both	   time	  points	   in	   comparison	   to	  
non-­‐IPF	  (p<0.01	  and	  p<0.05,	  respectively;	  Two-­‐way	  ANOVA),	  however	  ITGB3	  and	  ITGB8	  mRNA	  





































Figure	  3.	  26.	  Effect	  of	  TSP-­‐1	   inhibitor	  (LSKL)	  on	   levels	  of	  active	  TGFβ 	   in	  non-­‐IPF	  and	  IPF	  
spheroids.	  	  
Cells	  were	  treated	  with	  either	  vehicle	  control	  (dotted	   lines),	  LSKL	  (red),	  or	  SLLK	  (negative	  
control;	  black)	  and	  then	  cultured	  for	  spheroid	  formation	  for	  24	  hours.	  Mink	  lung	  bioassay	  
was	  used	  to	  determine	  the	  concentration	  of	  active	  TGFβ within	  the	  supernatants.	  (A)	  Non-­‐
IPF	  spheroids	  (data	  representative	  of	  two	  donors)	  and	  (B)	  IPF	  spheroids	  (n=1).	  
	  
A)	   B)	  
Non-­‐IPF	   IPF	  




levels	  were	  relatively	  similar	  in	  non-­‐IPF	  and	  IPF	  spheroids.	  Each	  point	  represents	  average	  ΔCt	  






























































































































































































To	   determine	   the	   effect	   of	   integrins	   on	   TGFβ	   activation	   and	   collagen	   synthesis,	   three	   small	  
molecule	  integrin	  inhibitors	  were	  assessed,	  all	  of	  which	  were	  a	  kind	  gift	  from	  GSK.	  These	  were:	  	  
dual	   integrin	  β3/β5	   inhibitor,	   integrin	  β8	   inhibitor,	   and	   integrin	  β3	   inhibitor.	   Spheroids	  were	  
Figure	  3.	  27.	  ITGAV,	  ITGB3,	  ITGB5,	  and	  ITGB8	  mRNA	  levels.	  
Spheroids	  were	  collected	  24	  –	  96	  hours	  post	  seeding.	  RNA	  was	  extracted	  from	  the	  spheroids	  
for	  qRT-­‐PCR	   to	   analyse	   the	  mRNA	   levels	  of	   (A)	   ITGAV,	   (B)	   ITGB3,	   (C)	   ITGB5,	   (D)	   ITGB8.	   All	  
data	   points	   were	   normalised	   to	   three	   housekeeping	   genes	   based	   on	   GeNorm	   analysis	  
(EIF4A2,	  TOP1,	   and	  UBC).	   Non-­‐IPF	   and	   IPF	   spheroids	   are	   represented	  as	   green	   circles	   and	  










treated	  with	  the	  compounds	  at	  concentrations	  ranging	  from	  0.0001	  µM	  to	  10	  µM	  for	  24	  hours	  
either	  prophylactically	  (prior	  to	  spheroid	  formation)	  or	  therapeutically	  (24	  hours	  after	  spheroid	  
formation).	  The	  conditioned	  media	  were	  collected	  to	  determine	  the	   levels	  of	  active	  TGFβ	  via	  
mink	   lung	   bioassay,	   whilst	   the	   spheroids	   were	   used	   to	   assess	   collagen	   content.	   β3/β5	  
antagonist)	  and	  β8	  antagonist	  had	  no	  effect	  on	  collagen	  synthesis	  in	  non-­‐IPF	  or	  IPF	  spheroids	  
(Figure	  3.28	  and	  Figure	  3.29;	  dotted	  lines	  represent	  collagen	  levels	  for	  spheroids	  treated	  with	  
vehicle	  control).	  The	  integrin	  β3	  inhibitor	  also	  showed	  no	  effect	  on	  collagen	  production	  in	  non-­‐
IPF	  spheroids.	  However,	  a	  slight	  attenuation	  in	  collagen	  synthesis	  in	  IPF	  spheroids	  was	  evident	  
at	  high	  concentrations	  of	  the	  compound	  (1-­‐10	  µM,	  with	  approximately	  a	  30	  %	  attenuation	  in	  
collagen	  levels	  at	  10	  µM).	  The	  IC50	  for	  this	  compound	  was	  calculated	  as	  2.1	  µM	  (variable	  slope	  
four	  parameter	  curve	  fit;	  R2	  =	  0.178),	  which	  is	  in	  stark	  contrast	  to	  other	  in	  vitro	  assays,	  where	  
this	   compound	   demonstrates	   highly	   potency	   and	   an	   IC50	   in	   the	   nanomolar	   range	   (personal	  
communication	   from	   Richard	   Hatley,	   GSK).	   The	   attenuation	   in	   collagen	   synthesis	   seen	   here	  
with	   >1	  µM	  concentration	  may	   therefore	  be	   the	   result	   of	   toxicity.	  However,	   further	  work	   is	  
required	  to	  confirm	  this.	  	  
	   	  





	  	  	  	  	   	  	  
	  
	  	  	  	   	  
	   	  




























































Figure	  3.	  28.	  	  Integrin	  inhibition	  has	  no	  
effect	  on	  collagen	  synthesis	   in	  non-­‐IPF	  
spheroids.	  	  
	  
Spheroids	   were	   treated	   either	  
prophylactically	   with	   (A)	   non-­‐specific	  
integrin	   β3	   and	   β5	   inhibitor,	   (B)	   β8	  
inhibitor,	   or	   (C)	  β3	   inhibitor.	   Spheroids	  
were	  collected	  24	  hours	  post-­‐treatment	  
and	   hydrolysed	   in	   6M	   HCl	   for	   HPLC.	  
Dotted	  line	  represent	  vehicle	  control	  24	  
hours	  post	  seeding.	  
	  
A)	   B)	  
C)	  
log[β3	  inhibitor],	  M	  
log[β3/β5	  inhibitor],	  M	   lo [β8	  inhibitor],	  M	  





	   	  
	  
	   	  
	  
	  
To	  determine	  the	  effect	  of	  these	  compounds	  on	  the	  activation	  of	  TGFβ,	  a	  mink	  lung	  bioassay	  
was	   performed.	   Figure	   3.30A	   illustrates	   that	   the	   dual	   β3/β5	   antagonist	   attenuated	   TGFβ	  
activation	   with	   an	   IC50	   of	   11.2	   µM	   (R2	   =	   0.3017).	   	   Figure	   3.30B	   shows	   a	   concentration-­‐
dependent	  partial	  attenuation	  of	  TGFβ	  activation	  	  (~30	  %	  decrease)	  in	  the	  presence	  of	  the	  β8	  
antagonist,	  albeit	  with	  an	  IC50	  of	  4.75	  nM	  (R2	  =	  0.3538).	  Figure	  3.30C	  shows	  that	  10	  µM	  of	  the	  
β3	   inhibitor	   decreased	   the	   levels	   of	   active	   TGFβ by	   ~50	  %.	   Based	   on	   the	   IC50s	   for	   the	   dual	  
β3/β5	  antagonist	  and	  β3	  inhibitor	  the	  data	  suggests	  that	  these	  compounds	  have	  low	  potency	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Figure	   3.	   29.	   Effect	   of	   integrin	  
inhibitors	   on	   collagen	   synthesis	   in	  
IPF	  spheroids.	  	  
	  
Spheroids	   were	   treated	   either	  
prophylactically	   with	   (A)	   non-­‐
specific	  integrin	  β3	  and	  β5	  inhibitor,	  
(B)	  β8	   inhibitor,	   or	   (C)	  β3	   inhibitor.	  
Spheroids	   were	   collected	   24	   hours	  
post-­‐treatment	   and	   hydrolysed	   in	  
6M	   HCl	   for	   HPLC.	   Dotted	   lines	  
represent	   vehicle	   control	   24	   hours	  
post	   seeding.	   *p<0.05,	   ***p<0.001	  
(one-­‐way	  ANOVA).	  
	  
A)	   B)	  
C)	  
log[β3	  inhibitor],	  M	  
log[β3/β5	  inhibitor],	  M	   log[β8	  inhibitor],	   	  




did	   show	   a	   partial	   attenuation	   in	   TGFβ	   activation	   with	   a	   low	   IC50	   suggesting	   that	   TGFβ	  
activation	   in	  non-­‐IPF	  spheroids	   is	  at	   least	  partially	  dependent	  on	   the	  β8	   integrin.	  The	  effects	  
seen	  by	  the	  compounds	  targeting	  integrins	  β3	  and	  β5	  may	  potentially	  be	  as	  a	  result	  of	  toxicity	  
however	  further	  experimentation	  of	  cytotoxicity	  is	  required	  to	  draw	  clear	  conclusions.	  	  
	  	  	  	  	  	  	  




























Figure	   3.31	   illustrates	   that	   all	   three	   integrin	   inhibitors	   result	   in	   a	   concentration-­‐dependent	  
attenuation	   in	  active	  TGFβ	   levels	   in	   the	  conditioned	  media	  of	   IPF	   spheroids.	   IC50s	   for	  β3/β5	  
inhibitor,	  β8	  inhibitor,	  and	  β3	  inhibitor	  were	  600	  nM	  (R2	  =	  0.6854),	  83.6	  pM	  (R2	  =	  0.9384),	  and	  
21.7	  nM	  (R2	  =	  0.8809),	  respectively.	  Based	  on	  the	  IC50	  values,	  the	  β8	  integrin	  inhibitor	  is	  more	  
Figure	   3.30.	   	   Integrin	   inhibitors	  
attenuate	   TGFβ 	   activation	   in	   non-­‐IPF	  
spheroids.	  
Spheroids	  were	  treated	  prophylactically	  
with	  (A)	  non-­‐specific	  integrin	  β3	  and	  β5	  
inhibitor,	   (B)	   β8	   inhibitor,	   or	   (C)	   β3	  
inhibitor.	  Supernatants	  of	  the	  spheroids	  
were	  collected	  24	  hours	  post-­‐treatment	  
and	   active	   TGFβ	   levels	   investigated	   via	  
mink	   lung	   bioassay.	   Dotted	   line	  
represents	   vehicle	   control	   24	   hours	  
post	   seeding.	   Data	   are	   expressed	   as	  
relative	   luciferase	   units.	   *p<0.05,	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potent	   in	   comparison	   to	  β3/β5	   inhibitor	   and	  β8	   inhibitor.	   In	   addition,	   the	  efficacy	  of	   the	  β8	  
antagonist	  is	  greater	  in	  IPF	  spheroids	  in	  comparison	  to	  non-­‐IPF	  spheroids.	  	  
Thus,	   the	   current	   data	   suggest	   that	   integrins	  may	   promote	   TGFβ	   activation	   in	   IPF	   spheroids	  
with	   partial	   concentration-­‐dependent	   attenuation	   also	   shown	   in	   non-­‐IPF	   spheroids	   when	  
treated	  with	  the	  β8	  antagonist.	  However,	  collagen	  synthesis	  in	  both	  non-­‐IPF	  and	  IPF	  fibroblast	  
spheroids	  appears	  to	  be	  largely	  independent	  of	  the	  activity	  of	  the	  β3,	  β5	  and	  β8	  integrins.	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Figure	   3.	   31.	   	   Integrin	   inhibitors	  
attenuate	   TGFβ 	   activation	   in	   IPF	  
spheroids.	  
Spheroids	   were	   treated	   either	  
prophylactically	   with	   (A)	   non-­‐specific	  
integrin	   β3	   and	   β5	   inhibitor	   (IC50	   =	  
600nM),	   (B)	   β8	   inhibitor	   (IC50	   =	  
83.6pM),	   or	   (C)	   β3	   inhibitor	   (IC50	   =	  
21.7nM).	  Supernatants	  of	  the	  spheroids	  
were	  collected	  24	  hours	  post-­‐treatment	  
and	   were	   used	   to	   determine	   active	  
TGFβ	   concentrations	   via	   mink	   lung	  
bioassay.	  Dotted	   line	   represent	   vehicle	  
control	  24	  hours	  post	  seeding.	  Data	  are	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3.2.6.	   Effect	  of	  Alk-­‐5	  receptor	  kinase	  inhibition	  on	  collagen	  synthesis	  
The	   above	   data	   suggest	   that	   blocking	   the	   activation	   of	   TGFβ	   (using	   compounds	   at	   relevant	  
concentrations,	   i.e.	   <1	   µM)	   has	   no	   effect	   on	   collagen	   synthesis.	   To	   determine	   whether	  
antagonising	   TGFβ	   signalling	   has	   any	   effect	   on	   collagen	   production,	   spheroids	   were	   treated	  
with	  a	  potent	  and	  selective	  ALK5	   inhibitor	   (SB525334A)	  which	  has	  previously	  been	  shown	  to	  
block	  ALK5	  kinase	  activity	  in	  vitro	  with	  an	  IC50	  of	  14.3	  nM	  (Grygielko	  et	  al.,	  2005).	  
Spheroids	   were	   treated	   with	   this	   compound	   either	   prophylactically	   (prior	   to	   and	   during	  
spheroid	   formation)	  or	   therapeutically	   (24	  hours	  after	   spheroid	   formation)	  at	  concentrations	  
ranging	   from	   0.0001	   µM	   to	   10	   µM.	   Figure	   3.32	   illustrates	   that	   prophylactic	   (red)	   and	  
therapeutic	  (black)	  treatment	  with	  SB525334A	  had	  no	  effect	  on	  collagen	  production	  in	  either	  
non-­‐IPF	   (n=1)	  or	   IPF	   spheroids	   (n=1),	   although	  an	  extremely	  high	   concentration	   (10	  µM)	  did	  
result	   in	   ~50	   %	   attenuation	   in	   IPF	   spheroids	   (p<0.0.5;	   one-­‐way	   ANOVA)	   when	   used	  
prophylactically.	  Again,	  this	  may	  be	  due	  to	  toxicity,	  and	  demonstrates	  that	  SB525334A	  has	  low	  
potency	   and	   efficacy	   when	   fibroblasts	   are	   cultured	   as	   spheroids,	   in	   terms	   of	   regulating	  
collagen	   synthesis.	   Taken	   together,	   these	   data	   therefore	   suggest	   that	   spheroid	   collagen	  
production	  may	  be	  independent	  of	  TGFβ	  signalling.	  	  
	  






Control (L248, p5) Spheroids
log-dose vs response






100 --- Control (24hr post-seeding) 
--- Control (48hr post-seeding) 
Alk5 inhibitor (treated before 
spheroid formation)

















IPF (L240, p8) Spheroids
log-dose vs response







--- Control (24hr post-seeding) 
--- Control (48hr post-seeding)
Alk5 inhibitor (treated after 
spheroid formation)

















Figure	   3.	   32.	   Effect	   of	   ALK-­‐5	   inhibitor	   on	   collagen	   synthesis	   in	   both	   non-­‐IPF	   and	   IPF	  
spheroids.	  	  
(A)	   Non-­‐IPF	   and	   (B)	   IPF	   spheroids	   were	   treated	   either	   prophylactically	   (red)	   or	  
therapeutically	   (black)	  with	  an	  ALK-­‐5	   inhibitor	  (SB525334A).	  Doses	   ranged	  from	  0.3	  nM	  
to	  10	  µM.	  Spheroids	  were	  collected	  24	  hours	  post-­‐treatment	  and	  hydrolysed	  in	  6M	  HCl	  
for	  HPLC.	  Dotted	  line	  equals	  vehicle	  control	  24	  hours	  post	  seeding	  (red)	  or	  48	  hours	  post	  
seeding	  (black).	  *	  p<0.05,	  one-­‐way	  ANOVA.	  
	  
A)	   B)	  




3.2.7.	   Summary	  
This	  section	  focused	  on	  illustrating	  phenotypic	  characteristics	  of	  non-­‐IPF	  and	  IPF	  spheroids	  (i.e.	  
differentiation	  state,	  collagen	  production,	  and	  TGFβ	  activation).	  The	  results	  showed:	  
• Immunohistochemical	   analysis,	   western	   blotting,	   and	   qPCR	   data	   demonstrated	   that	  
αSMA	  expression	  is	  greater	  in	  IPF	  spheroids	  in	  comparison	  to	  non-­‐IPF	  suggesting	  that	  
IPF	  pHLF	  have	  a	  more	  myofibroblastic	  phenotype	  when	  cultured	  as	  spheroids.	  	  
• Collagen	   I	   and	   III	   expression	   in	   IPF	   lung	   tissue	  was	  evident	   in	   several	   areas	   including	  
fibrotic	  foci	  and	  basement	  membrane	  of	  bronchial	  epithelial	  cells.	  	  
• IPF	   spheroids	   were	   able	   to	   synthesis	   higher	   levels	   of	   collagen	   (types	   I	   and	   III)	   and	  
active-­‐	  TGFβ	  in	  comparison	  to	  non-­‐IPF	  spheroids.	  	  
• The	   activation	   of	   TGFβ	   was	   independent	   of	   TSP-­‐1	   activity	   in	   both	   non-­‐IPF	   and	   IPF	  
spheroids.	  
• Integrin	  αvβ5	  mRNA	  levels	  were	  greater	  in	  IPF	  spheroids	  in	  comparison	  to	  non-­‐IPF,	  but	  
there	  was	  no	  significant	  difference	  in	  mRNA	  levels	  for	  ITGB3	  and	  ITGB5	  
• TGFβ	   activation	   in	   IPF	   spheroids	  was	   partially	   dependent	   on	  β3,	  β5,	   and	  β8	   integrin	  
signalling	  whilst	  in	  non-­‐IPF	  spheroids	  the	  activation	  was	  partially	  dependent	  only	  on	  β8	  
integrin	  signalling.	  	  
• Exogenous	  TGFβ	  had	  no	  effect	  on	  collagen	  production	  24	  hours	  post-­‐seeding	  and	  TGFβ	  
activation	   inhibitors	   (i.e.	   TSP-­‐1	   or	   integrin	   inhibitors)	   had	  minimal	   effect	   on	   collagen	  
synthesis	  in	  either	  non-­‐IPF	  or	  IPF	  spheroids.	  	  
• A	  potent	  ALK5	  inhibitor	  (i.e.	  SB525334A)	  also	  had	  no	  effect	  on	  collagen	  synthesis	  when	  
treated	   prophylactically	   or	   therapeutically.	   This	   suggests	   that	   in	   this	   3D	   system	   the	  










	   	  




3.3. Spheroid	  characterisation	  –	  proliferation	  and	  apoptosis	  
	  
3.3.1.	   Introduction	  
During	  a	  normal	  wound	  healing	  response,	  apoptosis	  plays	  an	  important	  role	  as	  it	  is	  involved	  in	  
the	  removal	  of	  myofibroblasts	  from	  the	  wound	  site	  upon	  wound	  closure.	  However,	  analyses	  of	  
cells	  from	  IPF	  patients	  show	  that	  epithelial	  cells	  undergo	  apoptosis	   (Barbas-­‐Filho	  et	  al.,	  2001;	  
Plataki	   et	   al.,	   2005)	  whereas	   fibroblasts	   are	  more	   resistant	   to	   apoptosis.	   These	  observations	  
are	   not	   usually	   perceived	   in	   normal	   human	   lungs	   In	   addition,	   PGE2	   plays	   a	   role	   in	   apoptosis	  
imbalance.	   Previous	   studies	   have	   demonstrated	   that	   increased	   concentrations	   of	   PGE2	  
promote	   fibroblasts	   to	   become	  more	   susceptible	   to	   Fas-­‐ligand	   induced	   apoptosis.	   However,	  
fibroblasts	   from	   IPF	   lungs	   cultured	   as	  monolayers	   have	   shown	   low	   expression	   of	   COX2	   and	  
PGE2,	  making	  these	  cells	  resistant	  to	  Fas-­‐ligand	  induced	  apoptosis	  (Maher	  et	  al.,	  2010).	  
Cell	   death	   has	   previously	   been	   studied	   in	   spheroids	   composed	   of	   dermal	   fibroblasts.	   In	  
contrast	  to	  tumour	  cell	  spheroids	  (which	  continue	  to	  grow),	  dermal	  fibroblast	  spheroids	  do	  not	  
increase	  in	  size.	  A	  few	  days	  after	  spheroid	  formation,	  dermal	  fibroblasts	  begin	  to	  decompose	  
by	  a	  process	  coined	  nemosis	   (Vaheri	  et	  al.,	  2009).	  This	  type	  of	  cell	  death	  has	  been	  described	  
recently	   as	   a	   programmed	   necrotic-­‐like	   cell	   death,	   with	   similar	   morphology	   features	   to	  
necrotic	  cells.	  However,	  within	  the	  spheroids	  the	  cells	  do	  not	  appear	  to	  undergo	  cell	  death	  due	  
to	  hypoxia	  (a	  common	  cause	  of	  necrosis),	  yet	  they	  lack	  certain	  apoptotic	  markers,	  such	  as	  Bcl	  
and	  caspase-­‐3.	   In	   fact,	   the	   cells	  within	   spheroids	  had	  elevated	  COX2	  expression.	  Thus,	  COX2	  
induction	   and	   production	   of	   prostaglandins	   (i.e.	   PGE2,	   6-­‐keto-­‐PGF1α,	   PGF2α,	   and	   PGD2)	   are	  
hallmarks	  of	  nemosis.	  However,	  cell	  death	  in	  spheroid	  structures	  has	  not	  been	  investigated	  in	  
fibroblasts	  from	  non-­‐IPF	  and	  IPF	  lung	  donors.	  Thus,	  in	  this	  study,	  the	  level	  of	  cell	  death	  within	  
spheroids	   was	   investigated,	   which	   involved	   the	   use	   of	   the	   TUNEL	   assay	   (a	   commonly	   used	  
assay	   to	   detect	   DNA	   fragmentation).	   In	   addition,	   the	   proliferation	   of	   fibroblasts	   within	   the	  
spheroids	  was	  also	  examined.	  	  
	  
3.3.2.	   Fibroblasts	  cultured	  as	  spheroids	  are	  non-­‐proliferative	  
Spheroids	  were	   formed,	   fixed	   in	  4	  %	  PFA,	   and	  embedded	   into	  paraffin	  wax	  at	   four	  different	  
time	  points	   (24,	   48,	   72,	   and	   96	  hours).	   2	  µm	   thick	   sections	  were	   cut	   using	   a	  microtome	   for	  
histological	   analysis.	   Ki-­‐67	   antibody	   was	   used	   to	   identify	   proliferating	   cells.	   As	   a	   positive	  




control,	   pHLF	  were	   cultured	   as	   a	  monolayer	   on	   glass	   chamber	   slides	   (50,000	   cells	   per	  well)	  
followed	  by	  fixation	  in	  100	  %	  methanol	  for	  2	  min.	  Immunofluorescent	  staining	  was	  performed	  
on	  both	   spheroid	   sections	   and	  monolayer	   cells	   on	   the	   same	  day.	  Figure	  3.33	   illustrates	   that	  
both	  non-­‐IPF	  (n=10)	  and	  IPF	  (n=10)	  pHLF	   in	  monolayer	  cultures	  proliferate	  (similar	  to	  section	  
3.1.2).	   However,	   Ki-­‐67	   positive	   cells	   were	   not	   detected	   within	   the	   spheroids.	   Figure	   3.33	  
illustrates	   images	   for	   the	  96	  hour	   time	  point	  however	  similar	   results	  were	  evident	  at	  24,	  48,	  
































A) Monolayer B) Spheroid 
Figure	   3.	   33.	   Proliferation	  of	   primary	  human	   lung	   fibroblasts	   in	  monolayer	   culture	  
and	  within	  3D	  spheroid	  structures.	  
Immunofluorescence	  staining	  for	  Ki-­‐67	  (orange)	  with	  nuclei	  counterstained	  using	  DAPI	  
(blue)	  on	  (A)	  chamber	  slides	  of	  monolayer	  cultures	   in	  the	  presence	  of	  0.4	  %	  FBS;	  and	  
(B)	   Formalin-­‐fixed	   paraffin	   embedded	   sections	   of	   fibroblast	   spheroids	   (4	   days	   post	  
spheroid	  formation).	  Magnification	  x200.	  
	  




3.3.3.	   Non-­‐IPF	  pHLF	  are	  more	  apoptotic	  in	  comparison	  to	  IPF	  
The	  next	  step	  was	  to	  investigate	  whether	  pHLF	  within	  spheroids	  undergo	  cell	  death	  over	  time	  
(24-­‐96	  hours).	  	  This	  was	  determined	  by	  quantifying	  the	  number	  of	  TUNEL	  positive	  cells	  in	  serial	  
sections	   of	   paraffin	   embedded	   spheroids.	   For	   statistical	   analysis,	   the	   percentage	   of	   TUNEL	  
positive	   cells	   was	   transformed	   to	   arcsine	   (also	   known	   as	   inverse	   sine)	   to	   approximate	   a	  
Gaussian	  rather	  than	  binomial	  distribution.	  
Figure	  3.34A	  and	  Figure	  3.34B	  illustrate	  that	  the	  number	  of	  TUNEL	  positive	  cells	  within	  non-­‐IPF	  
spheroids	   significantly	   increases	   over	   time	   following	   3-­‐4	   days	   of	   incubation	   (p<0.001).	   In	  
contrast,	   the	   percentage	   of	   TUNEL	   positive	   cells	   in	   the	   IPF	   spheroids	  was	   significantly	   lower	  
(~10	   %	   of	   the	   total	   number	   of	   nuclei)	   in	   comparison	   to	   non-­‐IPF	   four	   days	   post	   spheroid	  
formation	  (p<0.01).	  	  
To	   determine	  whether	   the	   size	   of	   the	   spheroid	   had	   any	   effect	   on	   the	   percentage	   of	   TUNEL	  
positive	   cells,	   spheroids	   were	   also	   formed	  with	   different	   cell	   densities	   (10,000,	   50,000,	   and	  
100,000	  cells),	   incubated	  for	  four	  days	  followed	  by	  4	  %	  PFA	  fixation	  and	  then	  embedded	  into	  
paraffin	  wax.	  Figure	  3.34C	   illustrates	  that	  the	  cell	  density	  had	  no	  effect	  on	  the	  percentage	  of	  
TUNEL	  positive	  cells	  in	  either	  non-­‐IPF	  (n=1)	  or	  IPF	  spheroids	  (n=1). Since	  a	  significant	  difference	  
was	   clearly	   illustrated	   at	   four	   days	   the	   experiment	   was	   repeated	   in	   multiple	   donors	   (cell	  
density	  =	  10,000;	  non-­‐IPF	  n=6;	  IPF	  n=5;	  Figure	  3.34D)	  which	  illustrates	  that	  fibrotic	  fibroblasts	  
are	  less	  apoptotic	  in	  comparison	  to	  non-­‐IPF	  in	  a	  3D	  structure	  (p<0.01).	   
	  
	   	  























































































	   	  













Figure	  3.	  34.	  TUNEL	  positive	  cells	  within	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
	  
(A)	   Spheroids	  were	   collected	   at	   various	   time	  points	   (24-­‐96	   hours)	   and	   apoptotic	   cells	  
were	  identified	  on	  sections	  by	  TUNEL.	  Dead/dying	  cells	  are	  indicated	  in	  green	  and	  DAPI	  
nuclear	   staining	   is	   shown	   in	   blue.	   Images	   for	   negative	   and	   positive	   controls	   (DNase	  
treated)	   are	   shown	   on	   the	   bottom	   left.	   Magnification	   x10.	   (B)	   Percentage	   of	   TUNEL	  
positive	  cells	  were	  quantified	  using	   Image	   J.	  Data	  are	   representative	  data	  of	  one	  non-­‐
IPF	  (green)	  and	  one	  IPF	  donor	  (red).	  Three	  spheroid	  sections	  were	  analysed	  per	  donor.	  
(C)	  Cell	  density	  has	  no	  effect	  on	  the	  percentage	  of	  TUNEL	  positive	  cells	  four	  days	  post-­‐
seeding.	  (D)	  Less	  DNA	  fragmentation	  is	  detected	  in	  IPF	  spheroids	  (n=5,	  green	  circles)	  in	  








3.3.4.	   COX-­‐1	  inhibition	  attenuates	  apoptosis	  of	  non-­‐IPF	  spheroids	  
Since	  the	  current	  data	  show	  that	  non-­‐IPF	  fibroblast	  spheroids	  are	  more	  apoptotic	  over	  time	  in	  
comparison	   to	   IPF,	   the	   next	   step	   was	   to	   investigate	   the	   COX	   status	   of	   these	   spheroids	   by	  
measuring	   the	   levels	   of	   PGE2.	   As	   mentioned	   before,	   COX2	   is	   an	   enzyme	   essential	   for	   the	  
formation	  of	   PGE2	  within	   lungs	   and	  promotes	   fibroblast	   cell	   death	   in	  monolayer	   cultures.	   In	  
addition,	   IPF	   patients	   have	   reduced	   concentrations	   of	   PGE2	   in	   their	   lung.	   Furthermore,	  
previous	  work	  illustrated	  that	  dermal	  fibroblast	  spheroids	  undergo	  nemotic	   like	  death	  due	  to	  
the	  induction	  of	  COX2.	  Thus,	  it	  was	  pertinent	  to	  investigate	  whether	  this	  was	  also	  the	  case	  in	  
lung	  fibroblast	  spheroids.	  	  
Figure	  3.35	  illustrates	  mRNA	  levels	  of	  PTGS1	  (COX1)	  and	  PTGS2	  (COX2)	  in	  non-­‐IPF	  (n=5)	  and	  IPF	  
(n=8)	   spheroids.	   No	   statistical	   difference	   was	   detected	   across	   all	   donors	   for	   both	   genes.	   In	  
order	   to	  determine	   the	  COX	   status,	   spheroids	  were	   cultured	   for	  4	  days	   and	   the	   conditioned	  
media	   were	   collected	   to	   perform	   a	   PGE2	   ELISA.	   Figure	   3.36A	   illustrates	   high	   levels	   of	   PGE2	  
production	   by	   non-­‐IPF	   (n=12)	   spheroids	   in	   comparison	   to	   non-­‐IPF	   (n=8)	   spheroids	   (p<0.05,	  
student	  T-­‐test).	  With	  the	  exception	  of	  one	  IPF	  donor,	  the	  concentration	  of	  PGE2	  production	  by	  
all	   other	   IPF	   donors	  was	   <1	   ng/mL	  whereas	   for	   non-­‐IPF	   spheroids	   the	   concentration	   ranged	  
between	  1-­‐19	  ng/mL.	  	  
To	   investigate	   which	   COX	   isoform	   is	   involved	   in	   PGE2	   synthesis,	   pHLF	   were	   treated	   with	   1	  
µg/mL	  indomethacin	  (non-­‐specific	  inhibitor	  for	  COX)	  or	  5	  µg/mL	  NS398	  (COX2	  inhibitor)	  prior	  
to	   spheroid	   formation.	   These	   concentrations	   were	   chosen	   based	   on	   previous	   experiments	  
performed	  in	  our	  laboratory.	  The	  amount	  of	  PGE2	  in	  the	  conditioned	  medium	  of	  the	  spheroid	  
cultures	  was	  then	  measured	  following	  four	  days	  of	  incubation.	  Figure	  3.36B	   illustrates	  that	  in	  
the	  presence	  of	   indomethacin,	  PGE2	  synthesis	  was	  attenuated	   in	  non-­‐IPF	  spheroids	  by	  100	  %	  
(p<0.001;	   student	   T-­‐test)	   however,	   surprisingly,	   NS398	   had	   no	   effect.	   Figure	   3.36C	   and	   D	  
demonstrate	  the	  effect	  of	  these	  compounds	  on	  the	  percentage	  of	  TUNEL	  positive	  cells	  in	  non-­‐
IPD	  spheroids.	  As	  shown,	  indomethacin	  attenuated	  the	  total	  percentage	  of	  cell	  death	  (by	  two-­‐
fold)	   following	   four	  days	  of	   culture,	  however	  NS398	  again	  had	  no	  effect.	  These	  data	   suggest	  
that	  COX1	  may	  play	  a	  more	  central	  role	  in	  fibroblast	  cell	  death	  in	  this	  3D	  system.	  	  
To	  further	  investigate	  this,	  non-­‐IPF	  pHLF	  were	  treated	  with	  additional	  specific	  COX	  inhibitors:	  
SC560	   (COX1	   specific	   inhibitor)	   and	   CAY10404	   (COX2	   specific	   inhibitor)	   prior	   to	   spheroid	  
formation.	  Figure	  3.37	   illustrates	   the	  effect	  of	   these	  compounds	  as	  well	   as	   indomethacin	  on	  
PGE2	   synthesis	   in	   three	   different	   non-­‐IPF	   donors.	   Both	   indomethacin	   (red)	   and	   SC560	   (blue)	  




attenuated	   PGE2	   synthesis	   at	   day	   four.	   The	   IC50	   for	   indomethacin	   across	   the	   three	   donors	  
ranged	  between	  0.15-­‐3.18	  nM	  and	  the	  IC50	  for	  SC560	  ranged	  from	  0.05-­‐3.82	  nM.	  In	  contrast,	  
CAY10404	  attenuated	  PGE2	  synthesis	  only	  at	  extremely	  high	  concentrations	  (3-­‐10	  µM)	  across	  
the	  three	  donors.	  Based	  on	  previous	  literature,	  CAY10404	  is	  an	  extremely	  potent	  compound	  in	  
vitro	  with,	  usually,	  nanomolar	  potency.	  However,	  in	  this	  3D	  system	  the	  efficacy	  and	  potency	  of	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A)	  
B)	  
Figure	  3.	  35.	  PTGS1	  and	  PTGS2	  mRNA	  levels	  in	  non-­‐IPF	  and	  IPF	  spheroids.	  
Spheroids	   were	   collected	   24	   –	   96	   hours	   post	   seeding.	   RNA	   was	   extracted	   from	   the	  
spheroids	  for	  qRT-­‐PCR	  to	  analyse	  the	  mRNA	  levels	  of	  (A)	  PTGS1	  and	  (B)	  PTGS2.	  All	  data	  
points	   were	   normalised	   to	   three	   housekeeping	   genes	   based	   on	   GeNorm	   analysis	  
(EIF4A2,	   TOP1,	   and	  UBC).	   Non-­‐IPF	   and	   IPF	   spheroids	   are	   represented	   as	   green	   circles	  
and	  red	  triangles,	  respectively.	  	  
	  





















































	  	  	  	  	  























































	   	  
Figure	  3.	  36.	  PGE2	  levels	  in	  non-­‐IPF	  and	  IPF	  spheroids	  and	  the	  effects	  of	  non-­‐specific	  
COX	  inhibitors.	  	  
	  
(A)	  PGE2	  levels	  were	  measured	  in	  the	  supernatant	  of	  both	  control	  (n=12)	  and	  IPF	  (n=8)	  
spheroids	   96	   hours	   post	   seeding.	   (B)	   Non-­‐IPF	   fibroblasts	   (n=2)	   were	   treated	   with	  
either	  vehicle	  control	  (DMSO),	  indomethacin	  (1	  µg/ml),	  or	  NS398	  (5	  µg/ml)	  and	  then	  
seeded	  for	  spheroid	  formation	  and	  left	  to	  incubate	  for	  96	  hours	  before	  analysing	  the	  
PGE2	   levels	  within	  the	  supernatants.	  The	  spheroids	  were	  then	  fixed	  and	  sectioned	  to	  
investigate	   the	   effect	   of	   (C)	   indomethacin	   and	   (D)	   NS398	   on	   the	   percentage	   of	  
apoptotic	   cells	   by	   using	   the	   TUNEL	   assay	   to	   identify	   DNA	   fragmentation.	   Red	  
represents	   the	   effect	   of	   the	   compound	   and	   black	   represents	   vehicle	   control.	   Three	  
spheroid	  sections	  were	  analysed	  per	  donor/condition	  ***	  p<0.001	  (statistical	  test	  was	  
performed	  on	  %	  after	  arcsine	  conversion).	  
	  
A)	   B)	  
C)	   D)	  







Donor	   Indomethacin	   SC560	   CAY10404	  
	   IC50	   R2	   IC50	   R2	   IC50	   R2	  
A	   0.15	  nM	  	   0.8270	   3.82	  nM	  	   0.7835	   1.50	  µM	  	   0.3723	  
B	   3.18	  nM	  	   0.8633	   0.30	  nM	  	   0.901	   7.70	  µM	  	   0.3215	  








To	   investigate	   the	   effect	   of	   these	   COX-­‐specific	   compounds	   on	   apoptosis/nemesis,	   a	   TUNEL	  
assay	  was	  performed.	  Figure	  3.38	  shows	  that	  in	  the	  presence	  of	  indomethacin	  and	  SC560	  non-­‐
IPF	   pHLF	   cell	   death	   is	   attenuated	   (IC50	   =	   96	   pM	   and	   93.6	   pM,	   respectively).	   However,	  
Figure	  3.	  37.	  Effects	  of	  specific	  COX	  inhibitors	  on	  PGE2	  levels	  in	  non-­‐IPF	  spheroids.	  	  
Non-­‐IPF	  fibroblasts	  (n=3)	  were	  treated	  with	  indomethacin	  (red),	  SC560	  (blue)	  or	  CAY10404	  
(green)	  and	  seeded	  into	  an	  agarose	  coated	  96-­‐well	  plate	  for	  spheroid	  formation.	  Spheroids	  
were	   cultured	   for	   96	  hours.	   PGE2	   levels	  within	   the	   conditioned	  media	  were	  analysed	   (A),	  
(B),	   and	   (C)	   represent	   three	   different	   donors.	   Dotted	   lines	   represent	   vehicle	   control	  










CAY10404	  had	  no	  effect,	  supporting	  the	  notion	  that	   fibroblast	  cell	  death	   in	  this	  3D	  system	  is	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3.3.5.	   COX-­‐1	  inhibition	  accelerates	  collagen	  synthesis	  in	  non-­‐IPF	  spheroids	  
To	   determine	   the	   effect	   of	   COX	   inhibitors	   on	   collagen	   synthesis,	   spheroids	   treated	   with	  
indomethacin,	  SC560,	  and	  CAY10404	  were	  hydrolysed	  in	  6M	  HCl	  (four	  days	  post	  treatment)	  to	  
perform	  HPLC.	  Figure	  3.39	  illustrates	  that	  in	  the	  presence	  of	  indomethacin	  the	  collagen	  levels	  
increased	   in	   all	   three	   donors.	   The	   EC50	   for	   donor	   A	   and	   C	   were	   0.1	   nM	   and	   352	   nM,	  
respectively.	  Based	  on	  the	  curve-­‐fit	  used	  (i.e.	  variable	  slope,	  four	  parameter)	  the	  software	  was	  
unable	   to	   calculate	   the	   IC50	   for	   donor	   B.	   Nevertheless,	   indomethacin	   was	   able	   to	   increase	  
collagen	  synthesis	  even	  at	  low	  dose,	  which	  was	  statically	  significant	  following	  one-­‐way	  ANOVA	  
analysis.	  Similar	  to	  indomethacin,	  SC560	  also	  resulted	  in	  an	  increase	  in	  collagen	  synthesis	  in	  all	  
three	  donors	  however	  the	  levels	  increased	  by	  approximately	  two-­‐fold	  (which	  is	  much	  greater	  
in	   comparison	   to	   the	   spheroids	   treated	   with	   indomethacin).	   The	   EC50	   for	   all	   three	   donors	  
ranged	  between	  2.1	  –	  922	  nM.	  	  A	  slight	  elevation	  in	  collagen	  production	  was	  also	  detected	  by	  
CAY10404	   however	   this	   was	   only	   evident	   at	   high	   concentrations	   3	   –	   10	  µM	   in	   two	   donors	  
(p<0.05,	  one-­‐way	  ANOVA).	  Thus,	  COX1	  inhibition	  accelerates	  collagen	  synthesis.	   	  
Figure	  3.	  38.	  Effects	  of	  specific	  COX	  inhibitors	  on	  spheroid	  cell	  death.	  
(A)	   Non-­‐IPF	   fibroblasts	   were	   treated	   with	   indomethacin	   (red),	   SC560	   (blue),	   or	  
CAY10404	  (green)	  and	  then	  seeded	  for	  spheroid	  formation	  and	  left	  to	  incubate	  for	  96	  
hours	   before	   embedding	   into	  paraffin	  wax.	   2µm	   thick	   sections	  were	   cut	   and	   TUNEL	  
assay	   was	   performed.	   Cell	   count	   was	   performed	   by	   using	   Image	   J.	   Dotted	   lines	  
represent	  vehicle	  control	  (DMSO).	  	  *p<0.05,	  **p<0.01,	  ***	  p<0.001	  (one-­‐way	  ANOVA).	  











Donor	   Indomethacin	   SC560	   CAY10404	  
	   IC50	   R2	   IC50	   R2	   IC50	   R2	  
A	   0.1nM	   0.5458	   2.1	  mM	   0.6188	   7.7	  mM	   -­‐	  
B	   -­‐	   -­‐	   428.3	  nM	   0.6370	   -­‐	   -­‐	  
C	   352nM	   0.5281	   922	  nM	   0.7987	   -­‐	   -­‐	  
	  




Figure	  3.	  39.	  Effects	  of	  specific	  COX	  inhibitors	  on	  collagen	  levels	  in	  non-­‐IPF	  spheroids.	  
	  
Non-­‐IPF	  fibroblasts	  (n=2)	  were	  treated	  with	  either	  indomethacin	  (red),	  SC560	  (blue)	  or	  
CAY10404	  (green))	  and	  then	  seeded	  for	  spheroid	  formation	  and	  left	  to	  incubate	  for	  96	  
hours	  before	  analysing	  hydroxyproline	  levels	  within	  the	  spheroid	  by	  HPLC.	  (A),	  (B),	  and	  
(C)	   represent	   three	  different	   donors.	  Dotted	   lines	   represent	   vehicle	   control	   (DMSO).	  	  
*p<0.05	  (D)	  Table	  illustrating	  EC50	  and	  R2	  values.	  
	  




3.3.6.	   PGE2	  attenuates	  collagen	  synthesis	  in	  spheroids	  via	  EP2	  receptors	  
	  To	  determine	  the	  prophylactic	  and	  therapeutic	  effects	  of	  PGE2	  on	  collagen	  synthesis,	  non-­‐IPF	  
and	   IPF	  pHLF	  were	  treated	  with	  PGE2	  prior	   to	  spheroid	   formation	  or	  24	  hours	  after	  spheroid	  
formation.	   The	   cultures	   were	   incubated	   with	   PGE2	   for	   24	   hours	   before	   analysis	   by	   HPLC.	  	  
Figure	  3.40	  illustrates	  that	  PGE2	  is	  able	  to	  attenuate	  collagen	  synthesis	  in	  both	  non-­‐IPF	  and	  IPF	  
spheroids	   in	   a	   concentration-­‐dependent	   manner.	   The	   IC50	   in	   IPF	   spheroids	   (10.26nM)	   is	  
greater	   in	   comparison	   to	   non-­‐IPF	   spheroids	   (2.06nM)	   suggesting	   that	   PGE2	   has	   a	   greater	  
potency	  in	  non-­‐IPF	  spheroids	   in	  comparison	  to	  IPF.	  No	  statistical	  significance	  was	  detected	  in	  
spheroids	  treated	  with	  PGE2	  24	  hrs	  post-­‐spheroid	  formation	  (therapeutic	  treatment;	  black)	  in	  
IPF	   spheroids.	   However,	   in	   non-­‐IPF	   spheroids,	   10	   µM	   PGE2	   did	   show	   a	   statically	   significant	  
attenuation	  in	  collagen	  synthesis	  (p<0.001;	  one-­‐way	  ANOVA).	  
	   	  
Donor	   Prophylactic	   Therapeutic	  
A	  (Non-­‐IPF)	   2.06	  nM	   3	  µM	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Figure	  3.	  40.	  PGE2	  attenuates	  collagen	  synthesis	  in	  both	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
	  
(A)	   Non-­‐IPF	   and	   (B)	   IPF	   spheroids	   were	   treated	   either	   prophylactically	   (red)	   or	  
therapeutically	   (green)	  with	  PGE2.	  Spheroids	  were	  collected	  24	  hours	  post-­‐treatment	  
and	   hydrolysed	   in	   6M	  HCl	   for	   HPLC.	   Dotted	   line	   illustrates	   vehicle	   control	   24	   hours	  
post	   seeding	   (red)	   or	   48	   hours	   post	   seeding	   (black).	   C)	   PGE2	   IC50	   in	   each	   donor	  
*p<0.05,	  **p<0.01,	  ***p<0.001	  
	  
A)	   B)	  
C)	  




There	   are	   four	   PGE2	   receptors:	   EP1,	   EP2,	   EP3,	   and	   EP4.	  Activation	  of	   EP1	   and	   EP3	   results	   in	  
smooth	   muscle	   cell	   contraction,	   whilst	   EP2	   and	   EP4	   mediate	   cell	   relaxation	   and	   promote	  
fibroblast	  apoptosis	   in	  monolayer	  cultures	  via	   the	  activation	  of	  adenylate	  cyclase	   (Bozyk	  and	  
Moore,	   2011;	  Brock,	   2014).	   In	  non-­‐IPF	  and	   IPF	   spheroids,	  mRNA	   levels	   for	   all	   four	   receptors	  
were	  quantified.	  As	  shown	  in	  Figure	  3.41	  there	  were	  no	  significant	  differences	  in	  mRNA	  levels	  
of	  all	  four	  genes	  between	  non-­‐IPF	  and	  IPF	  spheroids	  at	  either	  24	  hours	  or	  96	  hours.	  However,	  
there	  was	  an	  elevation	   in	  PTGER4	  mRNA	   levels	  over	   time	   in	  both	  non-­‐IPF	  and	   IPF	   spheroids	  
(p<0.05,	   two-­‐WAY	   ANOVA).	   It	   is	   important	   to	   note	   that	   the	   mRNA	   levels	   for	   PTGER3	   were	  
undetectable	   in	   3/6	   non-­‐IPF	   donors,	   and	   these	   data	   points	   are	   not	   presented	  on	   the	   graph.	  
Based	  on	  the	  ΔCT	  values,	  the	  mRNA	  levels	  for	  PTGER2	  and	  PTGER4	  are	  statistically	  greater	  in	  












































1 4 1 4 1 4 1 4 1 4 1 4 1 4 1 4











Figure	  3.	  41.	  EP	  receptor	  mRNA	  levels	  in	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
	  
Spheroids	   were	   collected	   24	   –	   96	   hours	   post	   seeding.	   RNA	   was	   extracted	   from	   the	  
spheroids	   for	   qRT-­‐PCR	   to	   analyse	   the	  mRNA	   levels	   of	  PTGER1,	   PTGER2,	   PTGER3,	   and	  
PTGER4.	   All	   data	   points	   were	   normalised	   to	   three	   housekeeping	   genes	   based	   on	  
GeNorm	  analysis	  (EIF4A2,	  TOP1,	  and	  UBC).	  Non-­‐IPF	  and	  IPF	  spheroids	  are	  represented	  
as	   green	   circles	   and	   red	   triangles,	   respectively.	   *p<0.05,	   **p<0.01,	   ***p<0.001,	  
+p<0.05	  (PTGER2	  vs.	  PTGER3),	  +++p<0.001	  (PTGER2	  vs.	  PTGER3),	  #p<0.05	  (PTGER3	  vs.	  
PTGER4),	  ###p<0.001	  (PTGER3	  vs.	  PTGER4).	  
	  




To	   determine	   which	   EP	   receptor	   is	   activated	   by	   PGE2	   to	   attenuate	   collagen	   synthesis	   and	  
promote	   fibroblast	   cell	   death,	   non-­‐IPF	   and	   IPF	   spheroids	   were	   treated	   with	   EP2	   and	   EP4	  
receptor	  agonists	  and	  antagonists	  all	  of	  which	  were	  a	  kind	  gift	   from	  GSK	  (Stevenage).	   	  These	  
included	   dual	   EP2/4	   agonists,	   EP2	   agonist,	   EP2	   antagonist,	   EP4	   agonist,	   and	   EP4	   antagonist.	  
Cells	  were	  treated	  with	  the	  compounds	  prior	  to	  spheroid	  formation	  and	  collagen	  content	  was	  
investigated	  24	  hours	  post-­‐treatment.	  Figure	  3.42	  and	  Figure	  3.43	   illustrate	  a	  concentration-­‐
dependent	   attenuation	   in	   collagen	   synthesis	   when	   treated	  with	   EP2/4	   dual	   agonists	   or	   EP2	  
agonist	  in	  both	  non-­‐IPF	  and	  IPF	  spheroids,	  respectively.	  EP2	  and	  EP4	  antagonists	  had	  no	  effect	  
on	  collagen	  synthesis	   in	  either	  non-­‐IPF	  or	   IPF	  spheroids.	  The	  EP4	  agonist	  attenuated	  collagen	  
production	  only	  after	  using	  high	  concentrations	  of	  the	  compound	  (3	  –	  10	  µM;	  p<0.05,	  one-­‐way	  
ANOVA)	  with	  an	  IC50	  of	  1	  µM.	  Based	  on	  previous	   in	  vitro	  assays,	  the	  EP4	  agonist	   is	  normally	  
highly	   potent	   with	   an	   IC50	   of	   around	   1	   nM	   (personal	   communication	   from	   Richard	   Hatley,	  
GSK).	  However,	  in	  this	  3D	  culture	  the	  IC50	  is	  1000-­‐fold	  greater	  suggesting	  that	  the	  EP4	  agonist	  
has	   a	   low	   potency	   in	   this	   vitro	   assay.	   Thus,	   the	   data	   illustrates	   that	   PGE2	   may	   attenuate	  
collagen	  synthesis	  via	  EP2	  receptor	  signalling	  and	  since	  antagonising	  EP2	  receptor	  showed	  no	  
effect	  on	  collagen	  synthesis	  it	  suggests	  PGE2	  does	  not	  affect	  collagen	  production	  at	  baseline.	  
3.3.7.	   Spheroid	  cell	  death	  is	  dependent	  on	  EP2	  receptor	  signalling	  
To	   determine	   the	   effect	   of	   EP2	   agonist	   on	   apoptosis,	   four	   days	   post	   spheroid	   formation,	   a	  
TUNEL	  assay	  was	  performed	  on	  2µm	  thick	  paraffin	  embedded	  spheroid	  sections.	  	  Figure	  3.44	  
illustrates	   that	   in	   the	   presence	   of	   this	   compound	   the	   percentage	   of	   TUNEL	   positive	   cells	  
increase	  in	  a	  concentration-­‐dependent	  manner	  for	  non-­‐IPF	  spheroids	  with	  an	  EC50	  of	  7.2	  nM.	  
In	  addition,	  10	  µM	  of	  EP2	  agonist	  resulted	  in	  100%	  cell	  death.	  An	  increase	  in	  cell	  death	  in	  IPF	  
spheroids	  was	  also	  evident	  in	  the	  presence	  of	  100	  pM	  EP2	  agonist,	  however	  this	  elevation	  only	  
resulted	   in	   approximately	   20	  %	   cell	   death	   (which	   is	   similar	   to	   baseline	  non-­‐IPF	   spheroid	   cell	  
death).	  A	  rise	  in	  EP2	  agonist	  concentration	  did	  not	  result	  in	  further	  increase	  in	  the	  percentage	  
of	   TUNEL	   positive	   cells.	   This	   suggests	   that	   non-­‐IPF	   spheroid	   cell	   death	   is	   dependent	   on	   EP2	  
receptor	  signalling,	  and	  it	  may	  be	  partially-­‐dependent	  on	  EP2	  signalling	  in	  IPF	  spheroids.	   	  





	   	  	  	   	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	   	  
	  




	   	  

























































































































Compound	   IC50	   R2	  
Dual	  EP2/EP4	  agonist-­‐1	   2.7	  nM	   0.6217§	  
Dual	  EP2/EP4	  agonist-­‐2	   169.3	  nM	   0.6923	  
EP2	  agonist	   97.1	  pM	   0.5615	  
A)	   B)	  
C)	   D)	  
E)	   F)	  
Figure	   3.	   42.	   Effect	   of	   EP2	   and	   EP4	   compounds	   on	   collagen	   synthesis	   in	   non-­‐IPF	  
spheroids.	  	  
Non-­‐IPF	   fibroblasts	   (n=1)	   were	   treated	   with	   (A)	   and	   (B)	   dual	   EP2/4	   agonists	   (C)	   EP2	  
agonist,	   (D)	   EP2	   antagonist,	   (E)	   EP4	   agonist,	   or	   (F)	   EP4	   antagonist.	   Spheroids	   were	  
collected	   24	   hours	   post-­‐treatment	   and	   hydrolysed	   in	   6M	   HCl	   for	   HPLC.	   Dotted	   line	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NK0373 - 0607 (P6)
 EP2 Antagonist







































NK0374  0607 (P6)
 EP4 Antagonist
Compound	   IC50	   R2	  
Dual	  EP2/EP4	  agonist-­‐1	   10	  nM	   0.5086	  
Dual	  EP2/EP4	  agonist-­‐2	   4.6	  nM	   0.9729	  
EP2	  agonist	   9.9	  nM	   0.9411	  
EP4	  agonist	   1	  µM	   0.8147	  
Figure	  3.	  43.	  Effect	  of	  EP2	  and	  EP4	  compounds	  on	  collagen	  synthesis	  in	  IPF	  spheroids.	  	  
IPF	  fibroblasts	  (n=1)	  were	  treated	  with	  (A)	  and	  (B)	  dual	  EP2/4	  agonists	  C)	  EP2	  agonist,	  
(D)	  EP2	  antagonist,	  (E)	  EP4	  agonist,	  or	  (F)	  EP4	  antagonist.	  Spheroids	  were	  collected	  24	  
hours	   post-­‐treatment	   and	   hydrolysed	   in	   6M	   HCl	   for	   HPLC.	   Dotted	   line	   represents	  
vehicle	  control	  24	  hours	  post	  seeding).	  (G)	  Table	  illustrating	  IC50	  and	  R2	  values.	  
A)	   B)	  
C)	   D)	  
E)	   F)	  
G)	  
log[EP2	  agonist],	  M	  
log[EP4	  agonist],	  M	   log[EP4	  antagonist],	  M	  
log[EP2	  antagonist],	  M	  
log[EP2/4	  agonist-­‐1],	  M	   log[EP2/4	  ago ist-­‐2],	  M	  


















	   	  

































































A)	   B)	  
Figure	  3.	  44.	  Effects	  of	  EP2	  agonist	  on	  cell	  viability	  in	  non-­‐IPF	  and	  IPF	  spheroids	  
	  
(A)	  Non-­‐IPF	  fibroblasts	  (EC50	  =	  7.2	  nM)	  and	  (B)	   IPF	  fibroblasts	  (EC50	  =	  0.05	  pM)	  were	  
treated	  with	  EP2	  agonist,	  seeded	  for	  spheroid	  formation,	  and	  then	  left	  to	  incubate	  for	  
96	  hours	  before	  embedding	  into	  paraffin	  wax.	  2	  µm	  thick	  sections	  were	  cut	  and	  TUNEL	  
assay	   was	   performed.	   Cell	   count	   was	   performed	   by	   using	   Image	   J.	   Dotted	   lines	  
represent	   vehicle	   control	   (DMSO).	   	   Three	   spheroid	   sections	   were	   analysed	   per	  
donor/condition.	  
log[EP2	  agonist],	  M	   log[EP2	  agonist],	  M	  




3.3.8.	   Summary	  
In	  this	  section	  the	  following	  has	  been	  demonstrated:	  
• Both	  non-­‐IPF	  and	   IPF	   fibroblast	   spheroids	  are	  non-­‐proliferative	  when	  cultured	   for	  24-­‐96	  
hours.	  
• Non-­‐IPF	   fibroblast	   spheroids	   are	   more	   apoptotic	   and	   produce	   high	   levels	   of	   PGE2	   in	  
comparison	  to	  IPF	  fibroblast	  spheroids,	  following	  four	  days	  of	  incubation.	  
• PTGS1	   and	   PTGS2	   mRNA	   levels	   are	   not	   statistically	   different	   between	   non-­‐IPF	   and	   IPF	  
spheroids.	  
• Non-­‐IPF	   spheroids	   treated	   with	   a	   COX1	   specific	   inhibitor	   (SC560)	   attenuated	   PGE2	  
synthesis	  and	  reduced	  the	  percentage	  of	  TUNEL	  positive	  cells.	  In	  addition,	  COX1	  inhibition	  
increased	   collagen	   production	   in	   non-­‐IPF	   spheroids.	   On	   the	   other	   hand,	   COX2	   specific	  
inhibitors	   (NS398	   and	   CAY10404)	   showed	   only	   moderate	   effects	   at	   extremely	   high	  
concentrations	  (low	  potency).	  
• In	   the	   presence	   of	   PGE2,	   collagen	   production	   was	   attenuated	   in	   both	   non-­‐IPF	   and	   IPF	  
spheroids	   (prophylactic	   treatment,	   24	   hours).	   However,	   following	   therapeutic	   PGE2	  
treatment	  no	  effect	  was	  evident.	  
• Non-­‐IPF	  and	  IPF	  spheroids	  have	  higher	  PTGER2	  and	  PTGER4	  mRNA	  levels	  in	  comparison	  to	  
PTGER1	  and	  PTGER3	  mRNA.	  Levels	  of	  PTGER4	  mRNA	   increase	  over	  time	   in	  both	  non-­‐IPF	  
and	  IPF	  spheroids.	  	  
• Collagen	  synthesis	  and	  cell	  viability	  is	  dependent	  on	  EP2	  receptor	  signalling	  as	  EP2	  agonist	  
attenuated	   collagen	   production	   and	   promoted	   cell	   death	   in	   both	   non-­‐IPF	   and	   IPF	  
spheroids.	  On	  the	  other	  hand	  EP4	  agonist	  had	  minimal	  effect.	  	  
	  
	   	  




3.4.	  Microarray	  analysis	  of	  non-­‐IPF	  and	  IPF	  spheroids	  
	  
3.4.1. Spheroid	  cell	  death	  is	  dependent	  on	  EP2	  receptor	  signalling	  
Microarray	   is	   a	   high-­‐throughput	   gene	   expression	   profiling	   technique	   which	   involves	  
hybridisation	   of	   labelled	   target	   RNA	   or	   DNA	   to	   oligonucleotide	   probes	   attached	   to	   a	   solid	  
surface,	  allowing	  the	  detection	  of	  gene	  expression	  within	  a	  given	  sample.	  This	  technique	  has	  
been	  used	  extensively	  for	  biological	  research	  in	  the	  past	  10	  years	  (Lipshutz	  et	  al.,	  1995;	  Schena	  
et	  al.,	  1995)	  to	  understand	  mechanisms	  for	  several	  diseases	  including	  lung	  cancer	  (Beer	  et	  al.,	  
2002)	   and	   breast	   cancer	   (Sweet-­‐Cordero	   et	   al.,	   2005).	   In	   addition,	   microarray	   has	   been	  
performed	   on	   samples	   from	   IPF	   patients.	   Such	   samples	   include	   peripheral	   blood	   (which	  
identified	  MMP1	  and	  MMP7	  as	  potential	  biomarkers	  for	  IPF)	  and	  lung	  biopsies	  of	  IPF	  patients,	  
categorised	   as	   rapid	   or	   slow	   progressors	   (which	   in	   rapid	   progressors,	   has	   identified	   several	  
genes	   involved	   in	   oxidative	   stress,	   apoptosis,	   cell	   migration/proliferation,	   cancer,	   and	  
fibroblast/smooth	  muscle	   cell	   specific	   genes	   (Selman	   et	   al.,	   2006,	   2007;	   Rosas	   et	   al.,	   2008).	  
Furthermore,	   in	   our	   laboratory,	   microarray	   has	   been	   performed	   on	   monolayer	   fibroblast	  
cultures	  from	  patients	  diagnosed	  with	  IPF	  and	  system	  sclerosis,	  which	  has	  identified	  a	  number	  
of	   differentially	   expressed	   genes	   relevant	   to	   these	   diseases	   (Ian	   Garner,	   UCL;	   personal	  
communication).	  
So	   far	   my	   data	   support	   a	   clear	   phenotypic	   difference	   between	   non-­‐IPF	   and	   IPF	   fibroblasts	  
cultured	   in	   a	   3D	   system,	  whereby	   IPF	   spheroids	   have	   a	  more	  myofibroblast-­‐like	   phenotype,	  
produce	   higher	   levels	   of	   active	   TGFβ,	   synthesise	   higher	   levels	   of	   collagen,	   and	   are	   less	  
apoptotic	   in	  comparison	  to	  non-­‐IPF	  spheroids.	  Although	  several	  studies	   (including	  2D	   in	  vitro	  
cultures)	   have	   supported	   the	   role	   of	   TGFβ	   in	   collagen	   synthesis,	   in	   this	   3D	   system,	   collagen	  
synthesis	   seems	   to	   be	   largely	   independent	   of	   TGFβ	   signalling.	   The	   next	   step	   of	   this	   project	  
involved	  performing	  microarray	  data	  analysis	  to	  identify	  differentially	  expressed	  genes	  within	  
non-­‐IPF	  and	  IPF	  spheroids	  and	  determine	  key	  biological	  pathway(s)	  which	  may	  be	  involved	  in	  
the	  causing	  morphological	  and	  phenotypical	  differences.	  
3.4.2. Quality	  control	  
24	   hours	   post-­‐seeding	   (~16	   hours	   post-­‐spheroid	   formation),	   ten	   spheroids	   from	   each	   donor	  
were	   pooled	   and	   lysed	   using	   500	   µL	   RNaqueous	   lysis	   buffer.	   The	   samples	   were	   then	  




transported	   to	   Epistem	   (UK)	   subjected	   to	   Affymetrix	   GeneChip	   oligonucleotide	   microarray	  
analysis	  (details	  of	  the	  method	  can	  be	  found	  in	  Section	  2.15).	  In	  total	  there	  were	  20	  samples,	  
each	   from	  a	  different	  donor	   (non-­‐IPF,	  n=10;	   IPF,	  n=10).	  Details	  of	  each	   sample	  are	   shown	   in	  
Table	  3.1.	   Following	  RNA	  extraction,	   an	  Agilent	  Bioanalyzer	  was	  used	   to	  determine	   the	  RNA	  
Integrity	   Number	   (RIN)	   –	   a	   measure	   of	   the	   RNA	   quality.	   All	   samples	   had	   a	   RIN	   above	   7,	  
suggesting	   good	   RNA	   integrity	   (see	   Appendix	   1).	   Following	   this	   the	   samples	   were	   further	  
processed	  and	  hybridised	  to	  Affymetrix	  GeneChip®	  Human	  Genome	  U133+2	  arrays.	  	  
The	   quality	   of	   the	   raw	   data	   generated	  was	   assessed	   by	   background	   correcting	   the	   intensity	  
reading	  by	  using	  the	  Robust	  Multi-­‐array	  Average	  (RMA)	  algorithm	  (with	  median	  polishing).	  This	  
removed	  any	  background	  fluorescence	  as	  a	  result	  of	  non-­‐specific	  binding	  of	  labelled	  samples.	  
The	   data	   were	   then	   quantile	   normalised	   (to	   adjust	   the	   data	   for	   technical	   differences	   as	  
opposed	  to	  biological	  variations	  between	  each	  sample),	  and	   log2	  transformed,	  all	  performed	  
using	  Partek	  Genomic	  Suite.	  	  Boxplots	  and	  histograms	  were	  generated	  to	  visualise	  the	  spread	  
of	   the	   data	   as	  well	   as	   compare	   and	   contrast	   the	   probe	   intensity	   between	   the	   arrays	   of	   the	  
dataset.	  As	   illustrated	   in	  Figure	  3.45A	  and	  B	  there	  were	  no	  obvious	  outliers	  suggesting	  there	  
were	   no	   problems	   with	   the	   probe	   intensity	   levels	   within	   the	   array.	   Figure	   3.45C	   and	   D	  
illustrate	  the	  QC	  metrics	  for	  each	  sample,	  which	  involved	  comparing	  the	  experimental	  probes	  
on	  the	  Affymetrix	  chips	  with	  the	  spiked-­‐in	  hybridisation	  controls.	  All	  samples	  passed	  the	  QC	  at	  
this	  stage.	  	  
	  




	   	  
Table	  3.	  1.	  Microarray	  sample	  information	  	  
Sample/	  









1	   Non-­‐IPF	   M	   6	   <50	   GSK	   12/06/2013	   1	  
2	   IPF	   F	   5	   >50	   UCL	   11/06/2013	   1	  
3	   Non-­‐IPF	   F	   6	   <50	   UCL	   22/06/2013	   1	  
4	   IPF	   M	   5	   <50	   GSK	   02/07/2013	   1	  
5	   Non-­‐IPF	   M	   6	   <50	   UCL	   22/06/2013	   1	  
6	   IPF	   M	   6	   <50	   GSK	   02/07/2013	   1	  
7	   IPF	   F	   7	   <50	   UCL	   08/06/2013	   1	  
8	   Non-­‐IPF	   M	   4	   >50	   UCL	   11/06/2013	   1	  
9	   IPF	   M	   6	   <50	   UCL	   04/08/2013	   1	  
10	   Non-­‐IPF	   M	   6	   <50	   UCL	   06/06/2013	   1	  
11	   IPF	   F	   5	   >50	   GSK	   02/07/2013	   2	  
12	   Non-­‐IPF	   M	   5	   >50	   UCL	   07/08/2013	   2	  
13	   Non-­‐IPF	   M	   5	   <50	   UCL	   04/08/2013	   2	  
14	   IPF	   M	   5	   <50	   GSK	   02/07/2013	   2	  
15	   Non-­‐IPF	   M	   6	   <50	   UCL	   08/06/2013	   2	  
16	   IPF	   M	   6	   <50	   GSK	   17/06/2013	   2	  
17	   Non-­‐IPF	   F	   5	   <50	   UCL	   22/06/2013	   2	  
18	   IPF	   F	   7	   >50	   UCL	   11/06/2013	   2	  
19	   Non-­‐IPF	   M	   5	   <50	   UCL	   04/08/2013	   2	  
20	   IPF	   F	   6	   >50	   UCL	   18/06/2013	   2	  
	  
Each	   sample	   is	   composed	   of	   primary	   human	   lung	   fibroblasts	   spheroids	   from	   different	  
donors.	  These	  spheroids	  were	  either	  generated	  at	  GSK	  or	  UCL	   (which	   is	   indicated	   in	   the	  
table	  as	   location	  of	  the	  experiment).	  RNA	  from	  non-­‐IPF	  and	  IPF	  patients	  was	  randomised	  
between	  array	  batches.	  As	  well	  as	  collecting	  spheroid	  samples	  for	  microarray,	  additional	  
samples	   were	   subsequently	   collected	   to	   determine	   the	   collagen	   levels	   by	   measuring	  
hydroxyproline	  content	  using	  HPLC.	  	  














3.4.3.	   Principal	  Component	  Analysis	  (PCA)	  
PCA	  is	  a	  mathematical	  algorithm	  used	  to	  reduce	  the	  microarray	  data	  to	  a	  manageable	  number	  
of	  dimensions	  by	  identifying	  directions	  (or	  principle	  components)	  which	  retain	  as	  much	  of	  the	  
Figure	  3.	  45.	  Microarray	  Quality	  Control	  (QC)	  analysis.	  	  
(A)	   Box	   plots	   of	   log2	   expression	   values	   following	  normalisation	   and	   summarisation.	  
(B)	  Histogram	  after	   normalisation,	   showing	   frequencies	   at	   probe	   intensity.	   (C)	   Log2	  
expression	   of	   hybridisation	   labelling	   controls.	   (D)	   Intensity	   of	   perfect	   match	   and	  
mismatch	  probe	  sets.	  	  
A)	   B)	  
C)	   D)	  




variation	  as	  possible	  in	  the	  data	  (Jolliffe,	  2002).	  Using	  a	  few	  principal	  components	  (ideally	  two	  
or	   three,	  which	   account	   for	   the	   largest	   variations	   in	   the	   data)	   provides	   each	   sample	  with	   a	  
value	  which	  can	  be	  plotted	   to	  visually	  assess	  difference	  and	  similarities	  between	  all	   samples	  
(Price	  et	  al.,	  2006;	  Ringner,	  2008).	  
Based	  on	   the	  QC	   results,	  PCA	  was	  performed	  on	  all	   20	   samples	   (Figure	  3.46).	  However,	  one	  
outlier	  was	   clearly	   identified	   (circled	   in	  Figure	   3.46).	   This	   sample	  was	   from	  non-­‐IPF	   donor	   8	  
(Table	   3.1).	   Figure	   3.47	   illustrates	   the	   same	   PCA,	   re-­‐plotted	   to	   highlight	   any	   distribution	  
according	   to	   cell	   passage	   number;	   donor	   8	   was	   the	   only	   sample	   derived	   at	   passage	   4	   (red,	  
circled)	  whilst	  all	  other	  samples	  ranged	  between	  passages	  5-­‐7.	  Due	  to	  this	  outlier	  result,	  donor	  
8	  was	  excluded	  from	  the	  remainder	  of	  the	  microarray	  data	  analysis.	  
PCA	   was	   then	   performed	   again	   without	   sample	   8	   (19	   out	   of	   20	   samples	   in	   total)	   which	   is	  
illustrated	   in	   Figure	   3.48.	   After	   re-­‐running	   this	   analysis,	   a	   slight	   batch	   affect	   was	   visible.	   A	  
batch	  effect	  may	  result	  due	  to	  minuscule	  differences	  in	  any	  number	  of	  non-­‐biological	  variables	  
(such	   as	   change	   in	   atmospheric	   ozone	   levels,	   different	   technicians	   running	   the	   batches,	   and	  
reagents	   from	  different	   lots)	   (Fare	  et	  al.,	  2003).	  Passage	  number	  and	   location	  of	  experiment	  
were	   also	   assessed	   on	   this	   PCA	   plot	   (Figure	   3.49	   and	   Figure	   3.50,	   respectively).	   Passage	  
number	  showed	  no	  distinctive	  effect.	  Figure	  3.50	  illustrates	  grouping	  of	  five	  samples	  from	  GSK	  
illustrating	  a	  slight	  effect	  depending	  on	  the	  location	  of	  the	  experiment.	  Gender	  of	  the	  samples	  
showed	   no	   significant	   grouping	   (Figure	   3.51).	   Based	   on	   these	   results,	   a	   further	   PCA	   was	  
performed	  following	  the	  removal	  of	  the	  batch	  effect	  and	  the	  location	  bias	  from	  the	  experiment	  
using	  Partek	   (Figure	  3.52),	  which	  demonstrated	  a	  better	   random	  distribution	  of	   the	   samples	  
according	  to	  batch/location.	  	  
After	  this	  removal,	  a	  clear	  separation	  of	  non-­‐IPF	  and	  IPF	  spheroid	  groups	  was	  evident	  (Figure	  
3.53),	  particularly	  in	  principal	  components	  1	  and	  2	  (accounting	  for	  around	  24	  %	  of	  the	  variation	  
between	  datasets).	  This	  suggests	  that	  the	  overall	  gene	  expression	  patterns	  in	  both	  groups	  are	  
separable	   by	   microarray.	   In	   addition,	   a	   slight	   gender	   effect	   was	   also	   evident	   (Figure	   3.54).	  
Following	   PCA,	   hierarchical	   clustering	   was	   then	   performed	   to	   discriminate	   differentially	  
expressed	  genes	  in	  non-­‐IPF	  and	  IPF	  spheroids	  (Section	  3.4.4).	  	  
	   	  
















	   	  
Figure	  3.	  46.	  Principle	  component	  analysis	  (PCA)	  plots	  for	  non-­‐IPF	  and	  IPF	  spheroid	  
microarray	  data.	  	  
(A)	  Three-­‐dimensional	  PCA	  plot.	  Proportion	  of	  variance	  explained:	  PC1,	  16.6	  %	  (x-­‐axis);	  
PC2,	  10.3	  %	  (y-­‐axis);	  PC3,	  7.57	  %	  (z-­‐axis).	  (B-­‐D)	  Two-­‐dimensional	  PCA	  plots	  for	  the	  same	  
data:	   (B)	   PC1	   vs.	   PC2;	   (C)	   PC1	   vs.	   PC3;	   (C)	   PC2	   vs.	   PC3.	   ANOVA	   factors:	   gender	   and	  
condition	   (i.e.	  non-­‐IPF	   and	   IPF).	  Batch	  effect	  was	  not	   removed.	  Red	  =	  Batch	  1;	  blue	  =	  
Batch	  2;	  circle/sphere	  =	  non-­‐IPF	  (n=10);	  triangle/tetrahedron	  =	  IPF	  (n=10).	  From	  the	  20	  
samples	  one	  outlier	  is	  clearly	  visible	  in	  A,	  B,	  and	  D	  (circled	  in	  black).	  This	  sample	  is	  from	  
a	  non-­‐IPF	  donor	  and	  from	  batch	  1	  of	  the	  microarray	  hybridisations.	  
A)	   B)	  
C)	   D)	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Figure	  3.	  47.	  Principle	  component	  analysis	  (PCA)	  plots	  for	  non-­‐IPF	  and	  IPF	  spheroid	  
microarray	  data	  illustrating	  the	  effect	  of	  passage.	  	  
The	   same	   PCA	   analysis	   from	   Figure	   3.46	   was	   re-­‐plotted	   to	   indicate	   cell	   passage	  
number.	  (A)	  Three-­‐dimensional	  PCA	  plot.	  Proportion	  of	  variance	  explained:	  PC1,	  16.6	  
%	  (x-­‐axis);	  PC2,	  10.3	  %	  (y-­‐axis);	  PC3,	  7.57	  %	  (z-­‐axis).	  (B-­‐D)	  Two-­‐dimensional	  PCA	  plots	  
for	  the	  same	  data:	   (B)	  PC1	  vs.	  PC2;	   (C)	  PC1	  vs.	  PC3;	  (C)	  PC2	  vs.	  PC3.	  ANOVA	   factors:	  
gender	   and	   condition	   (i.e.	   non-­‐IPF	   and	   IPF).	   Batch	   effect	   was	   not	   removed.	   Red	   =	  
passage	  4;	  blue	  =	  passage	  5;	  green	   =	   passage	  6;	  purple	   =	   passage	  7.	  Non-­‐IPF,	  n=10;	  
IPF,	  n=10.	  The	  clear	  outlier	  in	  A,	  B,	  and	  D	  (red)	  is	  the	  only	  line	  derived	  at	  passage	  4.	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Figure	  3.	  48.	  Principle	  component	  analysis	  (PCA)	  plots	  for	  non-­‐IPF	  and	  IPF	  spheroid	  
microarray	  data	  (after	  removing	  sample	  8)	  illustrating	  a	  slight	  batch	  effect.	  	  
(A)	  Three-­‐dimensional	  PCA	  plot.	  Proportion	  of	  variance	  explained:	  PC1,	  17.9	  %	  (x-­‐axis);	  
PC2,	  8.68	  %	  (y-­‐axis);	  PC3,	  7.9	  %	  (z-­‐axis).	  (B-­‐D)	  Two-­‐dimensional	  PCA	  plots	  for	  the	  same	  
data:	   (B)	   PC1	   vs.	   PC2;	   (C)	   PC1	   vs.	   PC3;	   (C)	   PC2	   vs.	   PC3.	   ANOVA	   factors:	   gender	   and	  
condition	   (i.e.	  non-­‐IPF	  and	   IPF).	  Batch	  effect	  was	  not	   removed.	  Red	  =	  batch	  1;	  blue	  =	  
batch2;	   circle/sphere	   =	  non-­‐IPF	   (n=9);	   triangle/tetrahedron	   =	   IPF	   (n=10).	  Two	  sample	  
populations,	  as	  a	  result	  of	  a	  batch	  effect,	  are	  slightly	  visible	  in	  B	  and	  C.	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Figure	   3.	   49.	   Cell	   passage	   showed	   no	   obvious	   effect	   on	   the	   principle	   component	  
analysis	  (PCA)	  plots	  for	  non-­‐IPF	  and	  IPF	  spheroid	  microarray	  data.	  
The	   same	   PCA	   analysis	   from	   Figure	   3.48	   was	   re-­‐plotted	   to	   indicate	   cell	   passage	  
number.	  (A)	  Three-­‐dimensional	  PCA	  plot.	  Proportion	  of	  variance	  explained:	  PC1,	  17.9	  
%	  (x-­‐axis);	  PC2,	  8.68	  %	   (y-­‐axis);	  PC3,	  7.9	  %	   (z-­‐axis).	   (B-­‐D)	  Two-­‐dimensional	  PCA	  plots	  
for	  the	  same	  data:	   (B)	  PC1	  vs.	  PC2;	   (C)	  PC1	  vs.	  PC3;	  (C)	  PC2	  vs.	  PC3.	  ANOVA	   factors:	  
gender	   and	   condition	   (i.e.	   non-­‐IPF	   and	   IPF).	   Batch	   effect	  was	   not	   removed.	   Blue	   =	  
passage	  5;	  green	  =	  passage	  6;	  purple	  =	  passage	  7.	  Non-­‐IPF,	  n=9;	  IPF,	  n=10.	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Figure	  3.	  50.	  Location	  of	  experiment	  had	  a	  slightly	  discernible	  effect	  on	  the	  principle	  
component	  analysis	  (PCA)	  plots	  for	  non-­‐IPF	  and	  IPF	  spheroid	  microarray	  data.	  
The	   same	   PCA	   analysis	   from	   Figure	   3.48	  was	   re-­‐plotted	   to	   indicate	   the	   location	   of	  
spheroid	   production.	   (A)	   Three-­‐dimensional	   PCA	   plot.	   Proportion	   of	   variance	  
explained:	   PC1,	   17.9	  %	   (x-­‐axis);	   PC2,	   8.68	  %	   (y-­‐axis);	   PC3,	   7.9	  %	   (z-­‐axis).	   (B-­‐D)	   Two-­‐
dimensional	  PCA	  plots	  for	  the	  same	  data:	  (B)	  PC1	  vs.	  PC2;	  (C)	  PC1	  vs.	  PC3;	  (C)	  PC2	  vs.	  
PC3.	  ANOVA	  factors:	  gender	  and	  condition	  (i.e.	  non-­‐IPF	  and	  IPF).	  Batch	  effect	  was	  not	  
removed.	  Red	  =	  GSK	  (GlaxoSmithKline);	  blue	  =	  UCL	  (University	  College	  London).	  Non-­‐
IPF,	  n=9;	  IPF,	  n=10.	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Figure	  3.	  51.	  Principle	  component	  analysis	  (PCA)	  plots	  illustrating	  the	  effect	  of	  gender	  on	  
gene	  expression	  for	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
The	  same	  PCA	  analysis	  from	  Figure	  3.48	  was	  re-­‐plotted	  to	  indicate	  distribution	  of	  gender	  
amongst	   the	   samples	   on	   the	   PCA	   plot.	   (A)	   Three-­‐dimensional	   PCA	   plot.	   Proportion	   of	  
variance	   explained:	   PC1,	   17.9	  %	   (x-­‐axis);	   PC2,	   8.68	  %	   (y-­‐axis);	   PC3,	   7.9	   %	   (z-­‐axis).	   (B-­‐D)	  
Two-­‐dimensional	  PCA	  plots	  for	  the	  same	  data:	  (B)	  PC1	  vs.	  PC2;	  (C)	  PC1	  vs.	  PC3;	  (C)	  PC2	  vs.	  
PC3.	  ANOVA	  factors:	  gender	  and	  condition	  (i.e.	  non-­‐IPF,	  n=9;	  and	  IPF,	  n=10).	  Batch	  effect	  
was	  not	  removed.	  Pink	  =	  female;	  blue	  =	  male.	  Ellipses	  were	  applied	  using	  Partek	  Genomics	  
Suite	  to	  help	  visualise	  the	  groupings.	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Figure	  3.	  52.	  Principle	  component	  analysis	   (PCA)	  plots	   for	  non-­‐IPF	  and	   IPF	  spheroid	  
microarray	  data	  after	  the	  removal	  of	  batch	  and	  location	  bias.	  
(A)	  Three-­‐dimensional	  PCA	  plot.	  Proportion	  of	  variance	  explained:	  PC1,	  13.2	  %	  (x-­‐axis);	  
PC2,	   11.3	   %	   (y-­‐axis);	   PC3,	   9.85	   %	   (z-­‐axis).	   (B-­‐D)	   Two-­‐dimensional	   PCA	   plots	   for	   the	  
same	  data:	   (B)	  PC1	  vs.	  PC2;	   (C)	  PC1	  vs.	  PC3;	   (C)	  PC2	  vs.	  PC3.	  ANOVA	   factors:	  gender	  
and	  condition	   (i.e.	  non-­‐IPF,	  n=9;	  and	  IPF,	  n=10).	  Batch	  and	  location	  bias	  effects	  were	  
removed.	   Red	   =	   batch	   1;	   blue	   =	   batch2;	   circle/sphere	   =	   GSK	   (GlaxoSmithKline);	  
triangle/tetrahedron	  =	  UCL	  (University	  College	  London).	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Figure	   3.	   53.	   Principle	   component	   analysis	   (PCA)	   plots	   illustrating	   clear	   separation	   of	  
non-­‐IPF	   and	   IPF	   spheroid	   gene	   expression	   after	   the	   removal	   of	   batch	   and	   location	  
effects.	  
The	  same	  PCA	  analysis	  from	  Figure	  3.52	  was	  re-­‐plotted	  to	  indicate	  the	  distribution	  of	  non-­‐
IPF	   and	   IPF	   samples	   on	   the	   PCA	   plot.	   (A)	   Three-­‐dimensional	   PCA	   plot.	   Proportion	   of	  
variance	  explained:	   PC1,	   13.2	  %	   (x-­‐axis);	   PC2,	   11.3	  %	   (y-­‐axis);	   PC3,	   9.85	  %	   (z-­‐axis).	   (B-­‐D)	  
Two-­‐dimensional	  PCA	  plots	  for	  the	  same	  data:	  (B)	  PC1	  vs.	  PC2;	  (C)	  PC1	  vs.	  PC3;	  (C)	  PC2	  vs.	  
PC3.	   ANOVA	   factors	   included	   condition	   effect	   (i.e.	   non-­‐IPF	   and	   IPF).	   Batch	  and	   location	  
effects	  were	   removed.	  Green	  =	   non-­‐IPF	   (n=9);	   red	   =	   IPF	   (n=10).	   Ellipsoids/ellipses	  were	  
applied	  using	  Partek	  Genomics	  Suite	  to	  help	  visualise	  the	  groupings.	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Figure	   3.	   54.	   Principle	   component	   analysis	   (PCA)	   plots	   illustrating	   a	   slight	   gender	   effect	   in	  
gene	  expression	  of	  non-­‐IPF	  and	  IPF	  spheroids	  after	  the	  removal	  of	  batch	  and	  location	  effects.	  
The	   same	  PCA	  analysis	   from	  Figure	  3.52	  was	   re-­‐plotted	   to	   indicate	   the	  distribution	  of	   gender	  
amongst	  the	  samples	  on	  the	  PCA	  plot.	   (A)	  Three-­‐dimensional	  PCA	  plot.	  Proportion	  of	  variance	  
explained:	  PC1,	  13.2	  %	  (x-­‐axis);	  PC2,	  11.3	  %	  (y-­‐axis);	  PC3,	  9.85	  %	  (z-­‐axis).	  (B-­‐D)	  Two-­‐dimensional	  
PCA	  plots	  for	  the	  same	  data:	   (B)	  PC1	  vs.	  PC2;	   (C)	  PC1	  vs.	  PC3;	   (C)	  PC2	  vs.	  PC3.	  ANOVA	  factors	  
included	  condition	  effect	  (i.e.	  non-­‐IPF	  and	  IPF).	  Batch	  and	  location	  effects	  were	  removed.	  Pink	  =	  
female;	   blue	   =	  male.	   Ellipses	  were	   applied	   using	   Partek	   Genomics	   Suite	   to	   help	   visualise	   the	  
groupings.	  




3.4.4.	   Visualisation	  and	  pathway	  analysis	  
Hierarchical	  clustering	  is	  an	  approach	  used	  to	  identify	  groups	  (or	  clusters)	  of	  genes	  with	  similar	  
expression	  profiles	  (in	  response	  to	  the	  same	  environmental	  factors)	  to	  build	  a	  hierarchy.	  Figure	  
3.55	   illustrates	   a	   heat	   map	   with	   hierarchical	   clustering	   for	   the	   138	   differentially	   expressed	  
genes	   in	  non-­‐IPF	  (n=9)	  and	   IPF	  (n=10)	  spheroid	  samples	   identified	  following	  two-­‐way	  ANOVA	  
with	  a	   fold	  change	  of	  >2	  or	  <-­‐2	  and	  a	  p	  value	   (including	   false	  discovery	   rate	   [FDR])	  of	  <0.05.	  
Red	   indicates	   up-­‐regulated	   genes,	   green	   represents	   down-­‐regulated	   genes,	   and	   black	  
illustrates	   genes	   with	   no	   difference	   in	   expression.	   The	   results	   illustrate	   clear	   separation	   of	  
differentially	   expressed	   genes	   clustered	   into	   two	   groups	   (i.e.	   non-­‐IPF	   and	   IPF).	   There	   is	   also	  
evidence	  of	  gender	  clustering	  in	  non-­‐IPF	  and	  IPF	  cohorts	  	  
Out	  of	  the	  138	  genes,	  76	  had	  known	  functions,	  whilst	  66	  genes	  were	  unknown	  (see	  Appendix	  
2,	   Table	   A1).	   The	   top	   three	   differentially	   expressed	   genes	   are	   shown	   in	   Figure	   3.56	   which	  
were:	   PRR14L	   (proline	   rich	   14-­‐like,	   unknown	   function),	   CTSB	   (cathepsin	   B),	   and	   PTGER3	  
(prostaglandin	  E2	  receptor	  3).	  
STRING	  9.1	  (freely	  available	  online	  software	  tool)	  was	  used	  to	  retrieve	  known	  protein-­‐protein	  
interactions	  (encoded	  by	  the	  72	  genes	  with	  known	  function).	  As	  illustrated	  in	  Figure	  3.57,	  very	  
little	   interaction	   between	   the	   differentially	   expressed	   genes	  was	   evident	   (grey	   line	   indicates	  
co-­‐expression;	  blue	  line	  indicates	  protein	  binding;	  black	  line	  indicates	  evidence	  of	  interaction).	  
Partek	  pathway	  analysis	  was	  also	  used	  to	  determine	  groups	  of	  genes	  that	  are	  regulated	  in	  a	  co-­‐
ordinate	   fashion	   within	   a	   particular	   biological	   pathway.	   This	   was	   based	   on	   the	   pathway	  
enrichment	  score	   (the	  negative	   log/base	  10	  of	   the	  average	  enrichment	  p-­‐value	  derived	   from	  
the	  Fisher’s	   Exact	   test).	   	   The	   software	   identified	  27	  pathways	  with	  an	  enrichment	  p<0.05	  by	  
utilising	   the	   Kegg	   databases	   for	   human	   (See	   Appendix	   2,	   Table	   A2).	   The	   database	   is	   a	  
collection	   of	   pathway	   maps	   which	   represent	   our	   knowledge	   on	   molecular	   interaction	   and	  
reaction	  networks	  for	  genetic	   information	  processing,	  metabolism,	  cellular	  processes,	  human	  
diseases,	  environmental	   information	  processing,	  organismal	  systems,	  and	  drug	  development.	  	  
Based	  on	  the	  analysis	  phototransduction	  pathway	  showed	  the	  highest	  enrichment	  score	  of	  7.3,	  
however	  only	  three	  genes	  from	  this	  pathway	  were	  present	  in	  the	  list	  of	  differentially	  expressed	  
genes.	   These	  were	  CALM1,	  CALM2,	   and	  CALM3	  which	  are	   involved	   in	   encoding	   the	   calcium-­‐
modulated	  proteins,	  calmodulin	  1,	  calmodulin	  2,	  and	  calmodulin	  3,	  respectively	  (also	  known	  as	  
phosphorylase	   kinase	  delta).	   Calmodulin	   is	   also	   involved	   in	   several	  other	  pathways	   including	  
metabolism,	   apoptosis,	   inflammation,	   and	   smooth	   muscle	   contraction	   all	   of	   which	   showed	  




high	  enrichment	  scores	  with	  p<0.05.	  Metabolic	  pathways	  showed	  the	  highest	  number	  of	  genes	  
regulated	   which	   were	   CS	   (citrate	   synthase),	   IMPDH2	   (Inosine-­‐5'-­‐monophosphate	  
dehydrogenase	   2),	   MTHFR	   (methylenetetrahydrofolate	   reductase),	   P4HA1	   (prolyl	   4-­‐
hydroxylase	   subunit	   alpha	   1),	   SPTLC2	   (serine	   palmitoyltransferase),	   SYNJ2	   (synaptojanin	   2),	  
and	  XDH	  (xanthine	  dehydrogenase;	  Figure	  3.58).	  
Since	   only	   a	   limited	   number	   of	   genes	   showed	   differential	   expression	   following	   two-­‐way	  
ANOVA	  with	  a	  fold	  change	  of	  >2	  or	  <-­‐2	  and	  a	  p	  value	  with	  false	  discovery	  rate	  (FDR)	  of	  <0.05,	  
the	  analysis	  was	  also	  repeated	  by	  performing	  two-­‐way	  ANOVA	  with	  a	  fold	  change	  of	  >2	  or	  <-­‐2	  
and	  a	  p	  value	  (unadjusted)	  of	  <0.01.	  Based	  on	  these	  less	  stringent	  criteria,	  730	  genes	  showed	  
differential	  expression	  (Figure	  3.59).	  Unlike	  the	  previous	  analysis,	  the	  clustering	  of	  non-­‐IPF	  and	  
IPF	  is	  less	  well	  defined	  and	  the	  gender	  effect	  is	  less	  apparent.	  
	  Figure	   3.61	   illustrates	   interactions	   between	   the	   differentially	   regulated	   genes	   with	   more	  
protein-­‐protein	   interactions	   evident	   in	   comparison	   to	   Figure	   3.57.	   Partek	   pathway	   analysis	  
identified	  31	  pathways	  with	  an	  enrichment	  p<0.05	   (by	  utilising	   the	  KEGG	  database)	  of	  which	  
the	  ‘Influenza	  A’	  pathway	  showed	  the	  highest	  enrichment	  score	  of	  7.2	  (see	  Appendix	  2,	  Table	  
A3).	   Within	   this	   pathway	   12	   genes	   from	   the	   list	   of	   differentially	   expressed	   genes	   were	  
identified.	  These	   included:	  CASP1,	  CCL2,	  DDX58,	   IFIH1,	   IL1A,	   IL33,	  MX1,	  OAS2,	  OAS3,	  PIK3R1,	  
PML,	  and	  PRKCB	  (Figure	  3.61).	  	   	  








































	   	  
Figure	  3.	  55.	  Hierarchical	  clustering	  for	  differentially	  expressed	  genes	  in	  non-­‐IPF	  and	  
IPF	  fibroblast	  spheroids.	  
Clear	  separation	  of	  differentially	  expressed	  genes	  clustered	  into	  two	  group	  (i.e.	  non-­‐IPF	  
and	   IPF).	  There	  is	  also	  evidence	  of	  gender	  clustering	   in	  non-­‐IPF	  and	   IPF	  cohorts	   (M	  =	  
male;	  F	  =	   female).	  Red	   indicates	  upregulated	  genes,	  green	   represents	  downregulated	  
genes,	  and	  black	  indicates	  genes	  with	  no	  difference	  in	  regulation.	  Fold	  change	  >2	  or	  <-­‐
2	  with	  FDR	  and	  p<0.05.	  In	  total	  138	  genes	  were	  identified.	  







































	   	  
Figure	  3.	  57.	  Known	  protein-­‐protein	  interaction	  identified	  using	  STRING	  9.1.	  
Each	   circle	   represents	   an	   individual	   protein	   encoded	   by	   the	   differentially	   expressed	   genes	   in	  
non-­‐IPF	  and	  IPF	  spheroids	  (fold	  change	  >2	  or	  <-­‐2	  with	  FDR	  and	  p<0.05).	  Grey	  lines	  indicate	  co-­‐
expression;	   blue	   lines	   indicate	   protein	   binding;	   black	   line	   indicates	   evidence	   of	   action.	   This	  
selection	  of	  differentially	  expressed	  genes	  appears	  to	  have	  very	  little	  direct	  interaction.	  
	  
PTGER3	  PRR14L	   CTSB	  
Figure	   3.	   56.	   Distribution	   of	   gene	   intensity	   values	   for	   the	   top	   three	   differentially	   expressed	  
genes	  across	  all	  non-­‐IPF	  and	  IPF	  spheroid	  samples	  following	  microarray	  data	  analysis.	  
Non-­‐IPF	  (green;	  n=9)	  vs.	  IPF	  (red;	  n=10),	  FDR	  P<0.05,	  fold	  change	  >2	  or	  <-­‐2.	  	  






	  	  	  	  	   	  	  	  	   	  	  	  	   	  	  	  	  	  	  
	  






	   	  
CS	   IMPDH2	   MTHFR	   P4HA1	  
SPTLC2	   SYNJ2	   XDH	  
Figure	   3.	   58.	   Distribution	   of	   gene	   intensity	   values	   for	   the	   differentially	   expressed	  
genes	   involved	   in	   metabolic	   pathway	   across	   all	   non-­‐IPF	   and	   IPF	   spheroid	   samples	  
following	  microarray	  data	  analysis.	  
	  
Non-­‐IPF	  (green;	  n=9)	  vs.	  IPF	  (red;	  n=10),	  FDR	  p<0.05,	  fold	  change	  >2	  or	  <-­‐2.	  	  






	   	  
Figure	  3.	  59.	  Hierarchical	  clustering	  for	  differentially	  expressed	  genes	  in	  non-­‐IPF	  and	  
IPF	  fibroblast	  spheroids.	  
The	   clustering	   of	   non-­‐IPF	   and	   IPF	   is	   less	   well-­‐defined	   and	   the	   gender	   effect	   is	   less	  
apparent	   when	   using	   the	   following	   threshold:	   fold	   change	   >2	   or	   <-­‐2,	   unadjusted,	  
p<0.01.	   In	   total	   730	   genes	   were	   identified.	   Red	   indicates	   upregulate	   genes,	   green	  
represents	   down	   regulated	   genes,	   and	   black	   indicates	   genes	   with	   no	   difference	   in	  
regulation.	  	  






	   	  
Figure	  3.	  60.	  Known	  protein-­‐protein	  interactions	  identified	  using	  STRING	  9.1.	  
Each	   circle	   represents	   an	   individual	   protein	   encoded	   by	   the	   differentially	   expressed	  
genes	   in	   non-­‐IPF	   and	   IPF	   spheroids	   (fold	   change	   >2	  or	   <-­‐2	  with	   unadjusted	   p<0.01).	  
Grey	   lines	   indicate	   co-­‐expression;	   blue	   lines	   indicates	   protein	   binding;	   black	   line	  
indicates	   evidence	   of	   action;	   pink	   line	   represents	   post-­‐translational	   modifications;	  
green	  indicates	  activation;	  yellow	  represents	  expression	  with	  inhibition.	  
	  







	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	  
CASP1	   CCL2	   DDX58	   IFIH1	  
IL1A	   IL33	   MX1	   OAS2	  
OAS3	   PIK3R1	   PML	   PKRCB	  
Figure	   3.	  61.	   Distribution	  of	  probe	   intensity	   values	   of	  genes	   involved	   in	   Influenza	  A	  across	  all	  
non-­‐IPF	  and	  IPF	  spheroid	  samples	  following	  microarray	  data	  analysis.	  
Non-­‐IPF	  (green;	  n=9)	  vs.	  IPF	  (red;	  n=10),	  unadjusted	  p<0.01,	  fold	  change	  >2	  or	  <-­‐2.	  




3.4.5.	   Summary	  
In	  this	  section	  the	  following	  were	  demonstrated:	  
• All	  RNA	  samples	  were	  technically	  of	  high	  quality,	  however	  only	  19	  out	  of	  20	  samples	  were	  
taken	  forward	  for	  analysis	  as	  one	  sample	  was	  identified	  as	  a	  clear	  outlier	  by	  PCA.	  
• Removal	  of	  batch	  and	  location	  bias	  resulted	  in	  a	  clear	  separation	  between	  non-­‐IPF	  and	  IPF	  
samples	  by	  PCA.	  	  
• 138	  differentially	  expressed	  genes	  were	  identified	  between	  non-­‐IPF	  and	  IPF	  samples	  with	  
FDR	  and	  p<0.05	  and	   fold	   change	  >2	  or	  <-­‐2.	  However,	  only	  72	  had	  known	   functions	  and	  
only	   a	   few	   protein-­‐protein	   interactions	  were	   detected	   using	   STRING	   9.1.	   The	   top	   three	  
differentially	  expressed	  genes	  were	  PRR14L,	  CTSB,	  and	  PTGER3.	  
• Partek	   pathway	   analysis	   illustrated	   the	   phototransduction	   pathway	   with	   the	   highest	  
enrichment	   score	   however,	   genes	   involved	   in	   encoding	   calmodulin	   were	   the	   only	   ones	  
detected	  in	  this	  pathway.	  Metabolic	  pathways	  showed	  the	  most	  number	  of	  differentially	  
expressed	  genes.	  	  
• 730	  genes	  passed	  the	  threshold	  of	  p<0.01	   (unadjusted)	  and	  fold	  change	  of	  >2	  or	  <-­‐2,	  of	  
which	   414	   genes	   encoded	   proteins	   with	   known	   functions.	   More	   protein-­‐protein	  
interactions	  were	   evident	   in	   comparison	   to	   previous	   analysis,	   of	  which	   a	  majority	  were	  
either	  co-­‐expressed	  or	  known	  to	  directly	  interact	  with	  one	  another.	  
• Partek	   pathway	   analysis	   demonstrated	   the	   ‘Influenza	   A’	   pathway	   with	   the	   highest	  
enrichment	   score.	   12	   genes	   (CASP1,	   CCL2,	   DDX58,	   IFIH1,	   IL1A,	   IL33,	   MX1,	   OAS2,	   OAS3,	  
PIK3R1,	   PML,	   and	   PRKCB)	   were	   identified	   in	   the	   list	   of	   differentially	   expressed	   probes	  
belonging	   to	   this	   pathway.	   Future	   work	   will	   involve	   further	   analysis	   of	   these	   genes	  
identified	  by	  performing	  qRT-­‐PCR.	  
	   	  




3.5. Medium-­‐throughput	  compound	  screening	  	  
	  
	  
3.5.1.	   Introduction	  
Effective	   treatment	   for	   halting	   the	   progression	   of	   IPF	   is	   currently	   unavailable	   (although	   two	  
therapies	  are	  now	  available	  which	  have	  some	  impact	  on	  slowing	  progression,	   i.e.	  pirfenidone	  
and	   nintedanib).	   However,	   numerous	   research	   and	   lead	   compounds	   have	   been	   developed	  
based	  on	   several	   in	   vivo	   and	   in	   vitro	   studies	  on	   lung	   fibrosis.	  GSK	  have	  generated	  a	   focused	  
compound	  toolbox	  (known	  as	  the	  ‘fibrosis	  toolbox’)	  composed	  of	  182	  compounds	  that	  target	  
many	   different	   pathways	   which	  may	   potentially	   be	   involved	   in	   the	   initiation/progression	   of	  
this	   lethal	   disorder.	   Such	   pathways	   include	   TGFβ	   signalling,	   prostanoid	   signalling,	   and	  
developmental	   pathways	   (e.g.	   Wnt	   and	   Shh	   signalling	   pathways).	   Screening	   of	   these	  
compounds	   is	   currently	   being	   performed	   at	   GSK	   using	   other	   in	   vitro	   models	   of	   fibrosis	   (i.e.	  
scar-­‐in-­‐a-­‐jar	   and	   lung	   slices).	   To	   investigate	   the	   effect	   of	   these	   compounds	   on	   fibroblast	  
cultured	  as	  spheroids	  a	  medium-­‐throughput	  screening	  was	  performed.	  This	  involved	  culturing	  
non-­‐IPF	  (n=1)	  and	  IPF	  (n=1)	  fibroblasts	  for	  spheroid	  formation	  with	  a	  10	  µM	  concentration	  of	  
each	   of	   the	   182	   compounds,	   in	   a	   96well	   plate	   format.	   The	   primary	   end	   point	   involved	  
determining	   total	   collagen	   content	   by	   performing	   HPLC.	   Compounds	   that	   showed	   50	   %	   or	  
more	  change	  in	  collagen	  synthesis	  from	  baseline,	  were	  considered	  as	  a	  ‘hit’.	  	  In	  this	  section	  the	  
effects	   of	   some	   compounds	   will	   be	   highlighted.	   Due	   to	   confidentiality,	   only	   a	   more	   limited	  
repertoire	  of	  the	  toolbox	  will	  be	  described.	  
	  
3.5.2.	   Targeting	  collagen	  biosynthetic	  pathway	  
Lysyl	  oxidase	   (LOX)	   is	  an	  amine	  oxidase	  which	  catalyses	   the	  covalent	  crosslinking	  of	   collagen	  
fibres.	  Previous	  studies	  have	  illustrated	  that	  mice	  treated	  with	  anti-­‐lysyl	  oxidase-­‐like	  (LOXL)-­‐2	  
reduced	  the	  fibrotic	  burden	  (i.e.	  decline	  in	  disease-­‐associated	  fibroblasts,	  reduced	  synthesis	  of	  
growth	   factors,	   decrease	   in	   cross-­‐linked	   collagenous	   matrix,	   and	   reduced	   TGFβ	   signalling)	  
following	   bleomycin	   administration.	   Thus,	   it	   has	   been	   postulated	   that	   in	   vivo	   LOXL2	   may	  
mediate	   the	   activation	   of	   fibroblasts	   via	   catalysing	   crosslinking	   of	   fibrillar	   collagen	   and	   a	  
corresponding	   increase	   in	   tension	   of	   the	   local	  matrix,	   leading	   to	   the	   release	   of	   active	   TGFβ	  
from	   its	   latent	   form	   (Barry-­‐Hamilton	   et	   al.,	   2010).	   Therefore,	   it	   was	   hypothesised	   that	  
antagonising	  LOX	  activity	  might	  also	  decrease	  collagen	  deposition	  within	  fibroblast	  spheroids.	  
However,	   as	   shown	   in	   Figure	   3.62	   LOX	   and	   LOXL2	   antagonists	   (at	   10µM)	   only	   partially	  




attenuated	  collagen	  production	  (<25	  %	  change	  from	  baseline)	  in	  non-­‐IPF	  spheroids,	  little	  or	  no	  
effect	   seen	   in	   IPF	   spheroids.	   In	   addition,	  Figure	  3.62	   also	   illustrates	   the	  effect	  of	  heat	   shock	  
protein	   47	   (HSP47)	   inhibitor	   on	   collagen	   synthesis.	   HSP47	   is	   a	   collagen-­‐specific	   molecular	  
chaperone	   which	   transiently	   binds	   to	   procollagen	   in	   the	   ER	   and	   dissociates	   in	   the	   Golgi	   to	  
facilitate	   triple	   helix	   formation	   (Ishida	   and	   Nagata,	   2011).	   Previous	   studies	   in	   experimental	  
animal	   fibrosis	   models	   have	   illustrated	   that	   reduced	   expression	   of	   HSP47	   resulted	   in	   an	  
attenuation	  in	  collagen	  synthesis	  (Sunamoto	  et	  al.,	  1998;	  Nishino	  et	  al.,	  2003;	  Hagiwara	  et	  al.,	  
2007a,	  2007b;	  Obata	  et	  al.,	  2012).	  Furthermore, recent	  studies	  have	  illustrated	  elevated	  levels	  
of	  HSP47	   in	   serum	  of	   IPF	  patients	  experiencing	  acute	  exacerbations	   (Kakugawa	  et	  al.,	  2013).	  
Thus,	  it	  was	  hypothesised	  that	  inhibition	  of	  HSP47	  activity	  would	  attenuate	  collagen	  synthesis	  
within	   spheroids.	   Spheroids	   treated	  with	  10	  µM	  GSK-­‐1,	   in	   fact	   reported	   a	   slight	   elevation	   in	  
collagen	   production	   in	   both	   non-­‐IPF	   and	   IPF	   spheroids	   (approximately	   10	   %	   change	   from	  
baseline).	   The	   fibrosis	   toolbox	   also	   consisted	   of	   bone	   morphogenetic	   protein	   (BMP)-­‐1	  
antagonists.	  Unlike	  most	  BMPs,	  BMP1	  does	  not	  belong	  to	  the	  TGFβ	  superfamily.	  In	  fact,	  BMP-­‐1	  
contributes	  to	  matrix	  stiffness	  by	  promoting	  the	  cleavage	  and	  activation	  of	  LOX.	  Furthermore,	  
studies	  have	  demonstrated	  the	  BMP1	  is	  able	  to	  associate	  with	  a	  matricellular	  protein	  known	  as	  
periostin	   which	   localises	   BMP1	   to	   the	   provisional	   ECM	   deposition	   (Maruhashi	   et	   al.,	   2010).	  
Recently	   two	   studies	   have	   demonstrated	   elevated	   levels	   of	   periostan	   in	   the	   circulation	   and	  
lungs	  of	  IPF	  patients	  (Okamoto	  et	  al.,	  2011;	  Naik	  et	  al.,	  2012).	  My	  results	  illustrate	  that	  BMP1	  
inhibitors	   GSK-­‐4	   and	  GSK-­‐5	   reduced	   collagen	   production	   in	   non-­‐IPF	   spheroids.	   Furthermore,	  
GSK-­‐5	  also	  attenuated	  collagen	  synthesis	  in	  IPF	  spheroids	  by	  ~45	  %.	  
	  
	  
	   	  
Figure	  3.	  62.	  Effects	  of	  HSP47,	  LOX,	  and	  BMP-­‐1	  inhibitors	  on	  collagen	  synthesis.	  	  
Non-­‐IPF	   (green;	  n=1)	  and	  IPF	  (red;	  n=1)	   spheroids	  were	  prophylactically	   treated	  with	  
the	   potential	   anti-­‐fibrotic	   compounds	   shown	   (10	   µM).	   Spheroids	   were	   collected	   24	  
hours	  post-­‐treatment	  and	  hydrolysed	   in	  6	  M	  HCl	   for	  HPLC	  analysis	  of	  hydroxyproline	  
levels.	  	  
	  




3.5.3. Targeting	  TGFβ 	  signalling	  pathway	  
As	  stated	  previously,	  TGFβ	  is	  a	  potent	  pro-­‐fibrotic	  cytokine.	  Several	  studies	  have	  supported	  the	  
role	  of	  TGFβ	   in	  collagen	  synthesis.	  However	  the	  current	  data	   illustrated	   in	  this	  thesis	  suggest	  
that	  collagen	  production	  is	  independent	  of	  TGFβ	  signalling	  in	  fibroblasts	  spheroids.	  This	  is	  also	  
supported	   by	   data	   for	   a	   majority	   of	   the	   compounds	   targeting	   the	   TGFβ	   signalling	   pathway	  
within	  the	  fibrosis	  toolbox	  (Figure	  3.63).	  Nevertheless,	  some	  compounds	  did	  show	  over	  50	  %	  
attenuation	  in	  collagen	  synthesis	  including	  a	  pan	  αv	  integrin	  antagonist	  (100	  %	  attenuation	  in	  
non-­‐IPF	   spheroids)	   and	   a	   non-­‐specific	   ALK-­‐4/5/7	   antagonist	   (100	   %	   attenuation	   in	   IPF	  
spheroids).	   Since	   there	   were	   a	   few	   hits	   in	   the	   compounds	   targeting	   the	   TGFβ	   signalling	  
pathway	  further	  investigations	  are	  needed	  to	  investigate	  the	  IC50/EC50	  of	  these	  compounds	  in	  
multiple	  donors.	  This	   is	  because	  during	  the	  compound	  screening,	  the	  spheroids	  were	  treated	  









Figure	  3.	  63.	  Effects	  of	  compounds	  targeting	  TGFβ 	   signalling	  on	  collagen	  synthesis	   in	  
non-­‐IPF	  and	  IPF	  spheroids.	  	  
Non-­‐IPF	   (green;	   n=1)	   and	   IPF	   (red;	   n=1)	   spheroids	  were	   prophylactically	   treated	  with	  
anti-­‐fibrotic	   compounds	   (10	   µM)	   targeting	   the	   TGF-­‐beta	   receptors	   and	   integrins.	  
Spheroids	  were	  collected	  24	  hours	  post-­‐treatment	  and	  hydrolysed	  in	  6	  M	  HCl	  for	  HPLC	  
analysis	  of	  hydroxyproline	  levels.	  
	  




3.5.4. Targeting	  the	  eicosanoid	  pathway	  
The	   eicosanoid	   pathway	   involves	   the	   generation	   of	   prostaglandins,	   thromboxanes,	   and	  
leukotrienes	  which	   are	   synthesised	   following	   the	  metabolism	   of	   arachidonic	   acid.	   Several	   in	  
vitro	  and	   in	  vivo	  studies	  have	  illustrated	  the	  role	  of	  prostaglandins	  (i.e.	  PGE2,	  PGI2,	  and	  PGF2α)	  
and	   leukotrienes	   in	   the	  pathogenesis	  of	   IPF	   (some	  of	  which	  have	  already	  been	  described).	  A	  
number	   of	   the	   compounds	   within	   the	   toolbox	   also	   targeted	   the	   eicosanoid	   pathway.	   As	  
illustrated	   in	  Section	  3.3,	  PGE2	  plays	  a	  key	  role	   in	  spheroid	  apoptosis	  and	  collagen	  synthesis.	  
This	  is	  also	  demonstrated	  in	  Figure	  3.64	  whereby	  the	  addition	  of	  PGE2	  resulted	  in	  80	  %	  and	  100	  
%	  attenuation	  of	  collagen	  synthesis	  in	  non-­‐IPF	  and	  IPF	  spheroids,	  respectively.	  In	  addition,	  dual	  
EP2/EP4	  agonists	  and	  EP2	  specific	  agonists	  also	  resulted	  in	  a	  hit	  (full	  dose	  responses	  for	  GSK-­‐
16,	   GSK-­‐21,	   GSK-­‐23,	   GSK-­‐24,	   GSK-­‐27,	   and	   GSK-­‐32	   compounds	   can	   be	   seen	   in	   Section	   3.3,	  
Figure	  3.42	  and	  Figure	  3.43).	  	  
Moreover,	   the	   PGF2α	   receptor	   (FP)	   antagonist	   showed	   a	   >50	   %	   increased	   production	   in	  
collagen	  synthesis	   in	   IPF	  spheroids.	  Studies	  have	   illustrated	  that	   the	  plasma	  concentration	  of	  
PGF2α	   metabolite	   (15-­‐keto-­‐dihydro	   PGF2α)	   is	   elevated	   in	   IPF	   patients	   (Aihara	   et	   al.,	   2013).	  
Furthermore,	  PGF2α	   can	  potentiate	  PF	  via	   its	   receptor	   (FP)	   in	  bleomycin-­‐induced	   lung	   fibrosis	  
model	   (Oga	   et	   al.,	   2009).	   Thus,	   the	   increased	   collagen	   synthesis	   in	   IPF	   spheroids	   in	   the	  
presence	   of	   FP	   antagonists	   contrasts	   with	   these	   previously	   published	   studies,	   and	   would	  
benefit	  from	  further	  investigation.	  
5-­‐LO	   antagonist	   and	   leukotriene	   D4	   receptor	   antagonist	   also	   showed	   hits	   with	   increased	  
production	   in	   collagen	   synthesis	   in	   comparison	   to	   baseline,	   in	   non-­‐IPF	   spheroids	   only.	  
Leukotrienes	   are	   products	   of	   lipoxygenase	   (i.e.	   5-­‐LO)	   which	   play	   a	   role	   in	   the	   host	   defence	  
system	  against	  infection	  and	  invasion	  of	  foreign	  bodies	  (Yokomizo	  et	  al.,	  2001).	  BALF	  and	  lung	  









	   	  












	   	  
Figure	  3.	  64.	  Effect	  of	  compounds	  targeting	  eicosanoid	  pathway	  on	  collagen	  synthesis	  
in	  spheroids.	  	  
Non-­‐IPF	   (green;	   n=1)	  and	   IPF	   (red;	   n=1)	   spheroids	  were	  prophylactically	   treated	  with	  
anti-­‐fibrotic	   compounds	   (10	   µM)	   targeting	   eicosanoid	   receptors.	   Spheroids	   were	  
collected	   24	   hours	   post-­‐treatment	   and	   hydrolysed	   in	   6	   M	   HCl	   for	   HPLC	   analysis	   of	  
hydroxyproline	  levels.	  
	  




3.5.5. Targeting	  ion	  channels	  
The	   fibrosis	   toolbox	   also	   consisted	  of	   compounds	   targeting	   the	   following	   ion	   channels:	   Ca2+,	  
KCa3.1,	   and	   Na+	   channels.	   Ion	   channels	   have	   become	   an	   attractive	   therapeutic	   target	   in	  
numerous	   chronic	   diseases	   however	   only	   a	   few	   studies	   have	   illustrated	   the	   effect	   of	   ion	  
channels	   in	  models	  of	  PF.	  For	  instance,	  recent	  unpublished	  data	  by	  Rahaman	  et	  al.	  (2014)	  on	  
Ca2+	  channels	  (i.e.	  TRVP4;	  transient	  receptor	  potential	  vanilloid	  4),	  illustrated	  that	  both	  human	  
and	  murine	  fibroblasts	  express	  TRVP4	  and	  knockdown/antagonism	  of	  this	  receptor	  (via	  siRNA	  
or	   use	   of	   antagonist)	   abrogates	   TGFβ-­‐induced	  myofibroblast	   differentiation	   and	   reduces	   the	  
expression	   levels	   of	   collagen	   type	   I	   and	   PAI-­‐1.	   In	   addition,	   TRVP4	   knockout	   mice	   were	  
protected	   from	   bleomycin	   induced	   PF	   suggesting	   a	   potential	   role	   for	   calcium	   channels	   in	  
fibrogenesis	  (	  abstract	  submitted	  for	  conference	  proceedings	  by	  Rahaman	  et	  al.,	  2014).	  
KCa3.1	   channel	   (calcium	   activated	   potassium	   channel)	   plays	   an	   essential	   role	   in	   calcium	  
signalling	  by	  maintaining	  a	  negative	  membrane	  potential	  during	  cell	  activation	   (Fanger	  et	  al.,	  
2001)	   thus	  modulating	   the	  activity	  of	  many	  cells	   including	   smooth	  muscle	  cells	   (Shepherd	  et	  
al.,	  2007),	  mast	  cells	  (Cruse	  et	  al.,	  2006),	  and	  lymphocytes	  (Ghanshani	  et	  al.,	  2000).	  Studies	  on	  
renal	   fibrosis	   have	   illustrated	   that	   pharmacological	   inhibition	   or	   genetic	   deletion	   of	   KCa3.1	  
prevents	  surgically-­‐induced	  renal	  fibrosis	   in	  mice	  by	  targeting	  myofibroblasts,	  resulting	   in	  the	  
decline	   in	   fibroblast	   proliferation	   and	   collagen	   synthesis	   (Grgic	   et	   al.,	   2009).	   In	   addition,	   a	  
recent	  study	  by	  Roach	  et	  al.	  illustrated	  that	  IPF	  patients	  express	  high	  levels	  of	  KCa3.1	  channel,	  
and	   that	   TGFβ	   activated	   myofibroblasts	   had	   elevated	   KCa3.1	   ion	   channel	   currents;	  
pharmacological	   inhibition	   of	   KCa3.1	   resulted	   in	   anti-­‐fibrotic	   effects	   in	   vitro	   (i.e.	   attenuated	  
collagen	  production	  and	  reduced	  fibroblast	  proliferation).	  These	  data	  support	  KCa3.1	  channels	  
as	  a	  potential	  target	  for	  IPF	  (Roach	  et	  al.,	  2013).	  
Figure	  3.65	  illustrates	  that	  the	  Ca2+	  channel	  blockers	  attenuated	  collagen	  synthesis	  by	  >50	  %	  in	  
non-­‐IPF	   spheroids	   however	   in	   IPF	   spheroids	   only	  minimal	   effects	  were	   seen.	   In	   addition	   the	  
Na+	   channel	   blocker	   increased	   collagen	   synthesis	   in	   non-­‐IPF	   spheroids	   by	   50	   %	   and	   again	  
minimal	  effect	  was	   shown	   in	   IPF	   spheroids.	  The	  KCa3.1	  antagonist	   showed	  minimal	  effects	   in	  
either	  non-­‐IPF	  or	  IPF	  spheroids,	  with	  slight	  increase	  in	  collagen	  synthesis.	  
	  










3.5.6. Targeting	  cytokines	  
Several	  chemokines	  and	  cytokines	  have	  been	  implicated	  in	  modulating	  different	  phases	  of	  the	  
pathogenesis	   of	   lung	   fibrosis	   (namely	   fibrogenesis	   and	   inflammation).	   These	   include	   TGFβ	  
(already	   described),	   macrophage	   migration	   inhibitory	   factor	   (MIF),	   monocyte	   chemotactic	  
protein-­‐1	  (MCP-­‐1/CCL2),	  and	  tumour	  necrosis	  factor-­‐α	  (TNF-­‐α).	  	  
MIF	   is	  a	  pleotropic	  proinflammatory	  cytokine	  synthesised	  by	  several	   cells	   including	  epithelial	  
cells,	  macrophages,	  endothelial	  cells,	  neutrophils,	  lymphocytes,	  and	  eosinophils.	  This	  cytokine	  
is	   considered	   as	  multifactorial	   as	   its	   role	   has	   been	   implicated	   in	   the	   inhibition	   of	   apoptosis	  
(Morand,	  2005),	  promotion	  of	  fibroblast	  migration	  and	  proliferation	  (Dewor	  et	  al.,	  2007),	  and	  
induction	  of	  MMPs	  (Yu	  et	  al.,	  2007).	  Furthermore,	  studies	  have	  also	  illustrated	  elevated	  levels	  
of	  MIF	   in	  BALF	  of	   IPF	  patients	   in	  comparison	  to	  control	  subjects.	  Positive	   immunostaining	  for	  
MIF	   has	   been	   illustrated	   in	   areas	   of	   active	   fibrosis	   (i.e.	   fibrotic	   foci)	   and	   diffuse	   cellular	  
infiltrates	  (Bargagli	  et	  al.,	  2009)	  supporting	  MIF	  as	  a	  potential	  therapeutic	  target.	  
CCL2	   belongs	   to	   the	   C-­‐C	   chemokine	   superfamily	   of	   small	   proteins	   produced	   by	   several	   cells	  
including	  fibroblasts,	  monocytes/macrophages,	  and	  epithelial	  cells	  (Suga	  et	  al.,	  1999). CCL2	  is	  
primarily	   considered	   as	   a	   potent	   chemoattractant	   for	  monocytes,	   natural	   killer	   cells,	   and	   T-­‐
cells.	  However,	   it	  also	  plays	  a	  role	  in	  the	  activation	  of	  fibroblasts,	  promoting	  ECM	  production	  
via	   the	   induction	   of	   TGFβ	   (Gharaee-­‐Kermani	   and	   Phan,	   2005)	   and	   contributing	   to	   excessive	  
Figure	   3.	   65.	   Effect	   of	   compounds	   targeting	   ion	   channels	   on	   collagen	   synthesis	   in	  
spheroids.	  	  
Non-­‐IPF	   (green;	   n=1)	   and	   IPF	   (red;	   n=1)	   spheroids	  were	   prophylactically	   treated	  with	  
anti-­‐fibrotic	   compounds	   (10	   µM).	   Spheroids	   were	   collected	   24	   hours	   post-­‐treatment	  
and	  hydrolysed	  in	  6M	  HCl	  for	  HPLC	  analysis	  of	  hydroxyproline	  levels.	  
	  




collagen	  synthesis	  (Moore	  et	  al.,	  2005b).	  In	  IPF	  patients,	  protein	  and	  mRNA	  levels	  of	  CCL2	  are	  
elevated	  (Moore	  et	  al.,	  2001).	  Furthermore,	  CCL2	   levels	  are	  statistically	  greater	   in	  serum	  and	  
BALF	  of	  IPF	  subjects	  in	  comparison	  to	  healthy	  controls	  (Suga	  et	  al.,	  1999).	  In	  vivo	  studies	  have	  
illustrated	  that	  mice	  deficient	   for	  the	  main	  CCL2	  receptor	  (CCR2)	  and	  mice	  treated	  with	  anti-­‐
CCL2	  gene	  therapy	  are	  protected	  from	  bleomycin	  induced	  PF	  (Smith	  et	  al.,	  1995;	  Inoshima	  et	  
al.,	   2004).	   Together,	   these	   findings	   support	   the	   idea	   that	   CCL2	   plays	   a	   vital	   role	   in	   the	  
development	   of	   fibroproliferative	   lung	   disease	   and	   may	   also	   be	   considered	   as	   a	   potential	  
target	  for	  the	  treatment	  of	  IPF. 
TNFα	  has	  both	   inflammatory	  and	   fibrogenic	  properties	  and	  similar	   to	  MIF	  and	  CCL2,	  TNFα	   is	  
also	   highly	   expressed	   in	   the	   lungs	   of	   IPF	   patients.	   Functional	   polymorphisms	   of	   TNFα	   have	  
been	   linked	  to	  an	   increased	  risk	  of	  developing	   IPF	   (Datta	  et	  al.,	  2011).	  Several	   in	  vivo	  studies	  
have	  supported	  that	  TNFα	   is	  a	  potential	  target	  for	   IPF.	  For	   instance,	  bleomycin-­‐induced	  PF	   is	  
diminished	   in	   mice	   injected	   with	   anti-­‐TNFα	   antibodies	   (Piguet	   et	   al.,	   1989).	   Moreover,	  
overexpression	   of	   TNF	   increases	   ECM	   protein	   deposition	   in	   the	   pulmonary	   interstitium	  
(Miyazaki	  et	  al.,	  1995).	  Based	  on	  these	  findings	  a	  randomized,	  placebo-­‐controlled	  phase	  II	  trial	  
was	   performed	   which	   recruited	   65	   IPF	   patients	   to	   assess	   the	   safety	   and	   efficacy	   of	   a	  
recombinant	   human	   TNFα	   receptor	   which	   inactivates	   TNFα	   (Etanercept).	   Unfortunately,	   no	  
significant	   improvement	   was	   detected	   in	   IPF	   patients	   when	   measuring	   the	   change	   in	   FVC,	  









Figure	  3.	  66.	  Effect	  of	  compounds	  targeting	  cytokine	  receptors	  on	  collagen	  synthesis	  
in	  spheroids.	  	  
Non-­‐IPF	   (green;	   n=1)	   and	   IPF	   (red;	   n=1)	   spheroids	  were	   prophylactically	   treated	  with	  
anti-­‐fibrotic	   compounds	   (10	   µM).	   Spheroids	   were	   collected	   24	   hours	   post-­‐treatment	  
and	  hydrolysed	  in	  6M	  HCl	  for	  HPLC	  analysis	  of	  hydroxyproline	  levels.	  
.	  




The	  fibrosis	  toolbox	  consisted	  of	  compounds	  targeting	  receptors	  for	  MIF,	  MCP-­‐1/CCL2,	  CCR2,	  
and	   TNFα.	   Three	   positive	   hits	   were	   detected:	   MIF	   antagonist	   in	   non-­‐IPF	   spheroids	   (100	   %	  
inhibition	  in	  collagen	  synthesis),	  MCP-­‐1	  inhibitor	  in	  IPF	  spheroids	  (100	  %	  inhibition),	  and	  CCR2	  
antagonist	   in	   non-­‐IPF	   spheroids	   (~60	  %	  elevation	   in	   collagen	  production;	  Figure	   3.66).	   TNFα	  
inhibitor	  showed	  minimal	  effects	  in	  non-­‐IPF	  and	  IPF	  spheroids	  supporting	  the	  results	  from	  the	  
phase	  II	  clinical	  trial	  described	  above.	  
	  
3.5.7. Targeting	  developmental	  pathways	  
Many	  studies	  have	  focused	  on	  the	  role	  of	  developmental	  pathways	  in	  the	  pathogenesis	  of	  IPF.	  
Such	   include	  Wnt/β-­‐catenin	  and	  Sonic	  hedgehog	   (Shh)	  pathways,	  both	  of	  which	  are	   strongly	  
activated	  in	  IPF	  lung	  tissues	  (Chilosi	  et	  al.,	  2003;	  Bolanos	  et	  al.,	  2012).	  The	  toolbox	  composed	  
compounds	   targeting	   these	  pathways:	  Tankyrase-­‐1	   inhibitor,	  Wnt	   inhibitor,	  and	  smoothened	  
(Smo)	   antagonist.	   Tankyrase-­‐1	   is	   a	   poly-­‐ADP-­‐ribosyltransferase	   which	   is	   involved	   in	   the	  
activation	  of	  the	  Wnt	  pathway	  by	  mediating	  poly-­‐ADP-­‐ribosylation	  of	  two	  components	  of	  the	  
β-­‐catenin	  destruction	  complex	  (AXIN1	  and	  AXIN2).	  
As	  shown	  in	  Figure	  3.67A,	  the	  tankyrase	  inhibitor	  GSK-­‐50	  attenuated	  collagen	  synthesis	  in	  non-­‐
IPF	   spheroids	  by	  52	  %.	  However	  minimal	  effect	  was	  evident	   in	   IPF	   spheroids.	  10	  µM	  GSK-­‐49	  
also	  had	  little	  effect	  on	  collagen	  synthesis	  in	  either	  non-­‐IPF	  or	  IPF	  spheroids.	  The	  Wnt	  inhibitor	  
(GSK-­‐51)	   attenuated	   collagen	   synthesis	   by	   ~90	   %	   in	   non-­‐IPF	   spheroids.	   A	   full	   concentration	  
response	  of	  this	  compound	  in	  non-­‐IPF	  (n=1)	  and	  IPF	  (n=2)	  spheroids	  is	  shown	  in	  Figure	  3.67B	  
and	  Figure	  3.67C,	  Figure	  3.67D	  respectively	  (for	  Figure	  3.67B	  and	  D	  the	  donors	  were	  the	  same	  
as	   the	   ones	   used	   in	   the	   screening).	   Based	   on	   these	   concentration	   response	   curves,	   the	  
compound	  attenuated	  collagen	  synthesis	  >50	  %	  in	  non-­‐IPF	  spheroids	  and	  in	  IPF	  spheroids	  (one	  
out	  of	   two	  donors),	  but	  only	  at	  high	  doses	   ranging	  between	  3-­‐10	  µM.	  Both	  Smo	  antagonists	  
(GSK-­‐52	   and	   GSK-­‐53)	   completely	   abolished	   collagen	   production	   in	   IPF	   spheroids	   (100	   %	  
attenuation).	  	  A	  slight	  attenuation	  in	  collagen	  production	  was	  also	  evident	  in	  non-­‐IPF	  spheroids	  
(between	  40-­‐50	  %).	  Given	  that	  Smo	  antagonist	  has	  a	  profound	  affect	  on	  collagen	  synthesis	  in	  
IPF	  spheroids	  in	  comparison	  to	  non-­‐IPF,	  further	  validation	  is	  necessary.	  
	   	  













Figure	   3.	   67.	   Effect	   of	   compounds	  
targeting	   developmental	   pathways	  
on	  collagen	  synthesis	  in	  spheroids.	  	  
(A)	   Non-­‐IPF	   (green;	   n=1)	   and	   IPF	  
(red;	   n=1)	   spheroids	   were	  
prophylactically	   treated	   with	   anti-­‐
fibrotic	   compounds	   (10	   µM).	  
Spheroids	   were	   collected	   24	   hours	  
post-­‐treatment	   and	   hydrolysed	   in	  
6M	   HCl	   for	   HPLC	   analysis	   of	  
hydroxyproline	  levels.	  Concentration	  
response	   curves	   for	   GSK-­‐51	   in	   non-­‐
IPF	   (B)	   and	   IPF	   spheroids	   (C	   and	   D;	  




B)	   C)	  
D)	  




3.5.8. Targeting	  PI3K/Akt/mTOR	  pathway	  
PI3K	   is	   a	   lipid	   kinase	   which	   is	   activated	   in	   response	   to	   receptor	   tyrosine	   kinases,	   G	   protein	  
coupled	   receptors/cytokine	   receptors	   and	  Ras.	   PI3K	   has	   been	   classified	   into	   three	   groups	   of	  
which	  class	   I	  has	  been	  the	  most	  extensively	  studied.	  Class	   I	  PI3Ks	  are	  dimeric	  enzymes	  which	  
are	   composed	   of	   catalytic	   and	   regulatory	   subunits.	   There	   are	   four	   isoforms	   for	   the	   catalytic	  
subunit:	   p110α,	   p110β,	   p110δ,	   and	   p110γ	  which	   have	  both	   unique	   and	  overlapping	   roles	   in	  
physiological	  and	  diseased	  states.	  	  Upon	  activation	  PI3K	  generates	  phosphoinositide	  products	  
(i.e.	   phosphatidylinositol	   3,4,5-­‐trisphosphate,	   PIP3)	   from	   phosphatidylinositol	   4,5-­‐
bisphosphate	   (PIP2)	   which	   promotes	   the	   translocation	   of	   Akt	   from	   the	   cytosol	   to	   the	   cell	  
membrane.	  PDK1	  and	  mTOR-­‐rictor	  complex	  (mTORC-­‐2)	  phosphorylate	  the	  translocated	  Akt	  at	  
Thr308	   and	   Ser473,	   respectively.	   Activated	   Akt	   then	   inactivates	   TSC2	   (tuberous	   sclerosis	  
complex	   2,	   also	   known	   as	   tuberin)	   to	   prevent	   the	   inhibition	   of	   mTORC1.	   Active	   mTORC1	  
regulates	   transcriptional,	   translational	   and	   post-­‐translationalactivity	   for	   a	   variety	   of	   cellular	  
processes	   including	  metabolism,	  migration,	  growth,	   survival,	  differentiation,	  and	  cytoskeletal	  
organisation	  (Cantley,	  2002;	  Carracedo	  and	  Pandolfi,	  2008).	  	  
Although	   the	   PI3K/Akt/mTOR	   pathway	   has	   been	   studied	   extensively	   in	   cancer,	   recently	   this	  
pathway	  has	  become	  of	  great	  interest	  to	  understanding	  the	  pathogenesis	  of	  IPF.	  Studies	  have	  
pinpointed	   a	   key	   role	   of	   the	   PI3K	   in	   the	   proliferation	   and	   differentiation	   of	   lung	   fibroblasts	  
treated	  with	   TGFβ	   whereby	   inhibition	   of	   PI3K	   (in	   particular	   PI3K	   p110α	   and	   p110γ)	   activity	  
abrogated	  TGFβ-­‐induced	  proliferation	  of	  αSMA	  positive	  cells	  (Conte	  et	  al.,	  2011).	  Furthermore,	  
studies	  have	  also	  illustrated	  strong	  immunostaining	  of	  downstream	  effectors	  of	  mTOR	  (e.g.	  p-­‐
S6)	  in	  fibroblasts	  of	  the	  fibrotic	  foci	  in	  IPF	  lung	  tissue	  sections	  (Xu	  et	  al.,	  2013).	  More	  recently,	  
research	   has	   shown	   that	   aberrant	   Akt/mTOR	   kinases	   desensitise	   IPF	   fibroblasts	   to	   type-­‐I	  
collagen	   matrix-­‐induced	   cell	   death	   (Nho	   and	   Hergert,	   2014).	   These	   studies	   support	  
PI3K/Akt/mTOR	  pathway	  as	  a	  target	  for	  modulating	  IPF	  progression.	  	  
The	   fibrosis	   toolbox	   also	   comprised	   compounds	   targeting	   this	   pathway.	   As	   shown	   in	   Figure	  
3.67	  two	  compounds	  showed	  a	  hit,	  both	  of	  which	  are	  non-­‐specific	  mTORC	  1/2	  inhibitors:	  GSK-­‐
56	  and	  GSK-­‐57.	  The	  former	  compound	  attenuated	  collagen	  synthesis	   in	  both	  non-­‐IPF	  and	  IPF	  
spheroids	   by	   58	   and	   64	   %,	   respectively.	   However,	   the	   latter	   compound	   abolished	   collagen	  
production	   in	   non-­‐IPF	   spheroids	   with	  minimal	   effects	   shown	   in	   IPF	   spheroids.	   Furthermore,	  
inhibition	   of	   PI3K	   β/δ	   had	   minimal	   effect	   on	   collagen	   production	   in	   either	   non-­‐IPF	   or	   IPF	  
spheroids.	  	  




Effect	  of	  GSK-­‐X	  on	  spheroid	  formation	  
Another	  compound	  used	   to	   investigate	   the	  effect	  of	   the	  PI3K/Akt/mTOR	  pathway	   in	  pHLF	  of	  
non-­‐IPF	  and	  IPF	  subjects	  using	  the	  three-­‐dimensional	  spheroid	  model	  was	  GSK-­‐X	  (note,	  due	  to	  
confidentiality	  the	  exact	  compound	  ID	  has	  been	  altered	  in	  this	  thesis).	  This	   is	  a	  highly	  potent	  
inhibitor	  for	  class	  I	  PI3Ks	  and	  mTOR	  which	  has	  shown	  many	  anti-­‐fibrotic	  effects	  in	  both	  in	  vitro	  
and	  in	  vivo	  models	  of	  fibrosis	  (unpublished	  confidential	  data	  in	  our	  lab	  and	  at	  GSK).	  	  
Timelapse	   spheroid	   images	   were	   taken	   by	   incubating	   fibroblasts	   in	   the	   IncuCyte	   Zoom.	  
Microscopic	   view	   of	   the	   cells	   cultured	   with	   GSK-­‐X	   (Figure	   3.69)	   illustrates	   that	   increasing	  
concentration	  of	  this	  compound	  caused	  an	  increase	   in	  phase	  object	  area,	  which	  represents	  a	  
reduction	  in	  the	  degree	  of	  cellular	  aggregation.	  These	  results	  were	  observed	  for	  both	  non-­‐IPF	  
and	  IPF	  fibroblasts,	  up	  to	  24	  hours	  post-­‐seeding	  (and	  at	  concentrations	  above	  0.3	  µM).	  This	  is	  
also	  demonstrated	  quantitatively	  in	  Figure	  3.70	  (6-­‐24	  hours	  of	  incubation).	  	  
Effect	  of	  GSK-­‐X	  on	  pro-­‐collagen	  synthesis.	  
Pro-­‐collagen	  production	  was	  assessed	  in	  primary	  human	  lung	  fibroblasts	  cultured	  as	  spheroids	  
by	   measuring	   the	   accumulation	   of	   hydroxyproline	   within	   the	   spheroids.	   GSK-­‐X	   significantly	  
reduced	  levels	  of	  pro-­‐collagen	  in	  IPF	  (n=3/5,	  IC50=	  2.2	  nM	  to	  94.3	  nM;	  Figure	  3.71)	  and	  non-­‐
IPF	  (n=3,	  IC50=	  0.71	  nM	  to	  85.7	  nM;	  Figure	  3.72)	  spheroid	  preparations.	  However,	  this	  effect	  
was	  only	  shown	  when	  treated	  prophylactically.	  Two	  IPF	  lines	  were	  treated	  with	  GSK-­‐X	  24	  hours	  
after	   spheroid	   formation	   (Figure	   3.71C	   and	   Figure	   3.71D)	   and	   collected	   for	   analysis	   after	   a	  
further	  24	  hours	  of	  incubation	  with	  the	  compound.	  The	  data	  show	  that	  the	  baseline	  levels	  of	  
pro-­‐collagen	   are	   slightly	   elevated	   48	   hours	   post-­‐seeding	   in	   comparison	   to	   24	   hours	   post-­‐
seeding	  in	  the	  IPF	  spheroids.	  	  
In	   addition,	   the	   data	   illustrate	   that	   this	   compound	   had	   no	   effect	   on	   pro-­‐collagen	   synthesis	  
when	  used	   therapeutically	   at	   low	  concentrations	   (0.1	  nM-­‐0.1	  µM).	  However	  at	  higher	  doses	  
(0.3-­‐10	   µM)	   there	   was	   a	   slight	   attenuation	   in	   collagen	   synthesis	   in	   one	   of	   the	   IPF	   donors	  
(Figure	  3.72C).	  Since	  this	  was	  only	  shown	  in	  one	  donor	  (Figure	  3.71C),	  further	  work	  is	  required	  
to	  conclude	  the	  therapeutic	  effects	  of	  this	  compound	  in	  multiple	  donors.	  	  
	   	  

















	   	  
Figure	  3.	  69.	  Microscopic	  view	  of	  spheroid	  formation	  in	  the	  presence	  of	  GSK-­‐X.	  	  
Increasing	   concentrations	   of	   GSK-­‐X	   inhibited	   fibroblast	   aggregation	   from	   non-­‐IPF	   (n=2)	  
and	  IPF	  (n=3)	  subjects	  up	  to	  24	  hours	  post	  seeding,	  at	  doses	  ranging	  from	  0.03	  µM	  to	  10	  
µM).	  Scale	  bar,	  200	  µm.	  Representative	  data	  shown	  for	  one	  IPF	  line.	  
Figure	   3.	   68.	   Effect	   of	   compounds	   targeting	  PI3K	   pathway	   on	   collagen	   synthesis	   in	  
spheroids.	  	  
Non-­‐IPF	   (green;	   n=1)	   and	   IPF	   (red;	   n=1)	   spheroids	  were	  prophylactically	   treated	  with	  
anti-­‐fibrotic	   compounds	   (10	  µM).	   Spheroids	  were	   collected	   24	   hours	   post-­‐treatment	  
and	  hydrolysed	  in	  6	  M	  HCl	  for	  HPLC	  analysis	  of	  hydroxyproline	  levels.	  




	   	  
Figure	  3.	  70.	  Spheroid	  formation	  in	  the	  presence	  of	  GSK-­‐X.	  	  
Increasing	   concentrations	   of	   GSK-­‐X	   inhibited	   spheroid	   formation	   (illustrated	   as	   an	  
increase	   in	   average	   phase	   object	   area,	   number	   of	   technical	   replicates	   =	   8).	   This	   is	  
demonstrated	  in	  both	  (A)	  non-­‐IPF	  (n=2)	  and	  (B)	  IPF	  (n=3)	  subjects,	  6	  hours	  (green),	  12	  
hours	  (red),	  and	  24	  hours	  (blue)	  post	  seeding	  (concentration	  ranging	  from	  0.03	  µM	  to	  
10	   µM).	   Representative	   data	   shown	   for	   one	   non-­‐IPF	   and	   one	   IPF	   line.	   **p<0.01,	  
***p<0.001	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Figure	   3.	   71.	   	   Effect	   of	   GSK-­‐X	   on	   pro-­‐collagen	  
accumulation	  within	  IPF	  fibroblast	  spheroids.	  	  
Primary	  human	  lung	  fibroblasts	  from	  five	  IPF	  donors	  
(A-­‐E)	  were	  treated	  with	  GSK-­‐X	  (0.3	  nM	  to	  10	  µM)	  at	  
the	   time	   of	   culturing	   in	   96	   well	   plates	   (pre-­‐coated	  
with	   agarose)	   to	   allow	   spheroid	   formation	   (red	  
curves).	   IC50	   values	   were	   (A)	   2.2	   nM,	   (B)	   94.3nM,	  
and	   (C)	   33.8	   nM.	   Black	   curves	   represent	   pro-­‐
collagen	   production	   of	   fibroblast	   spheroids	   which	  
were	   treated	   24	   hours	   post-­‐seeding/following	  
spheroid	   formation	   and	   incubated	   for	   a	   further	   24	  
hours	   post-­‐treatment	   (therapeutic	   treatment;	   IC50	  
for	  donor	  C	  =0.21	  µM).	  Data	  are	  expressed	  as	  mean	  
±	   S.E.M.	   of	   4	   replicates.	   The	   values	   *p<0.05,	  
**p<0.01	   and	   ***p<0.001	   denote	   statistical	  
significance	   of	   the	   indicated	   data	   compared	   to	  
spheroids	  treated	  with	  vehicle	  (DMSO,	  dotted	  line).	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Figure	   3.	   72.	   	   Effect	   of	   GSK-­‐X	   on	   pro-­‐
collagen	   accumulation	   within	   non-­‐IPF	  
fibroblast	  spheroids	  in	  vitro.	  	  
Primary	   human	   lung	   fibroblasts	   from	   three	  
non-­‐IPF	   donors	   (A-­‐C)	   were	   treated	   with	  
GSK-­‐X	   (0.3	   nM	   to	   10	   µM)	   at	   the	   time	   of	  
culturing	   in	  96	  well	  plates	  (pre-­‐coated	  with	  
agarose)	   and	   incubated	   for	   24	   hours	   to	  
allow	  spheroid	  formation.	  IC50	  values	  were	  
(A)	   0.71	   nM,	   (B)	   4.8	   nM,	   and	   (C)	   85.7	   nM.	  
Data	   are	  expressed	  as	  mean	   ±	  S.E.M.	   for	   4	  
replicates.	   The	   values	   *p<0.05,	   **p<0.01	  
and	   ***p<0.001	   denote	   statistical	  
significance	  of	  the	  indicated	  data	  compared	  
to	   spheroids	   treated	   with	   vehicle	   (DMSO,	  
dotted	  line).	  
log[GSK-­‐X],	  M	  
log[GSK-­‐X],	  M	   log[GSK-­‐X],	  M	  





This	   section	   focused	   on	   analysing	   microarray	   data	   derived	   from	   non-­‐IPF	   and	   IPF	   spheroids,	  
which	  illustrated:	  
• Several	   hits	   (>50	   %	   change	   in	   collagen	   synthesis	   from	   baseline)	   were	   identified	   in	  
compounds	   from	   the	   fibrosis	   toolbox	   including	   compounds	   targeting:	   integrin	  αv,	   ALK-­‐
4/5/7,	   PAI-­‐1,	   EP2	   receptor,	   EP4	   receptor,	   F-­‐prostanoid,	   5-­‐LO,	   leukotriene	   D4,	   Ca2+	  
channels,	  Na+	  channels,	  MIF,	  CCL2,	  CCR2,	  tankyrase-­‐1,	  Wnt,	  Smo,	  and	  PI3K/mTOR.	  
• The	  effect	  of	  GSK-­‐X	  on	  spheroid	   formation	  was	  analysed	   for	  both	  non-­‐IPF	   (n=2)	  and	   IPF	  
fibroblasts	  (n=3).	  Increasing	  concentrations	  of	  GSK-­‐X	  inhibited	  fibroblast	  aggregation	  after	  
6,	  12,	  and	  24	  hours	  of	  incubation	  (concentration	  ranging	  from	  0.3	  μM	  to	  10	  μM).	  
• The	  ability	  of	  GSK-­‐X	  to	   inhibit	  pro-­‐collagen	  production	  by	  non-­‐IPF	  and	  IPF	  spheroids	  was	  
assessed	  by	  a	  high-­‐performance	   liquid	  chromatography	  (HPLC)	  assay	   for	  hydroxyproline.	  
Three	  out	  of	  the	  five	  IPF	  donors	  that	  formed	  spheroids	  showed	  a	  significant	  attenuation	  in	  
procollagen	  synthesis	  when	  treated	  with	  GSK-­‐X	  prophylactically	  (IC50	  2.2	  nM	  to	  94.3	  nM).	  
Furthermore,	   non-­‐IPF	   spheroids	   (n=3)	   also	   showed	   an	   attenuation	   in	   procollagen	  
production	   (IC50	   of	   0.71	   nM	   to	   85.7	   nM).	   In	   conclusion,	   GSK-­‐X	   inhibits	   fibroblast	  

















	   	  










CHAPTER	  4:	  DISCUSSION	  
	  




4.1.	  	   Overview	  
	  
Idiopathic	  pulmonary	  fibrosis	  (IPF)	  is	  the	  most	  common	  form	  of	  pulmonary	  fibrosis	  (PF)	  with	  an	  
unknown	   aetiology	   and	   just	   two	   treatment	   options	   (Pirfenidone	   and	  Nintedanib)	  which	   can	  
slow,	  but	  not	  halt,	  progression	  of	  the	  disease	  (King	  et	  al.,	  2014;	  Richeldi	  et	  al.,	  2014).	  Currently	  
the	  literature	  suggests	  that	  dysregulated	  epithelial	  mesenchymal	  crosstalk	  may	  play	  a	  key	  role	  
in	  the	  development	  of	  this	  ultimately	  fatal	  disease.	  Increasing	  evidence	  suggests	  that	  repetitive	  
injury	   to	   the	   lung	   alveolar	   epithelial	   cells	   (AECs)	   and	   destruction	   of	   the	   alveolar-­‐capillary	  
basement	  membrane	   results	   in	   the	  migration,	   proliferation	   and	   activation	  of	   fibroblasts	   and	  
their	  deposition	  of	  extracellular	  matrix	  proteins,	  which	  disrupts	  the	  lung	  architecture.	  Several	  
in	   vivo	   animal	   models	   have	   been	   developed	   in	   order	   to	   understand	   the	   pathology	   of	   this	  
disease.	  The	  most	  common	  murine	  model	  used	  in	  research	  today	  involves	  the	  administration	  
of	  bleomycin	  (Moeller	  et	  al.,	  2008).	   In	  vitro	  monolayer	  cultures	  are	  routinely	  used	  to	  address	  
the	  underlying	  cell	  biology.	  Both	  in	  vivo	  and	  2D	  in	  vitro	  studies	  have	  led	  to	  the	  identification	  of	  
cells	   and	  mediators	   that	  may	   play	   a	   key	   role	   in	   the	   disease,	   including	   transforming	   growth	  
factor	   (TGF)-­‐β	   and	   prostaglandin	   (PG)-­‐E2.	   However,	   there	   are	   a	   number	   of	   disadvantages	   of	  
using	   such	   models.	   For	   instance,	   in	   vivo	   models	   are	   highly	   expensive,	   often	   variable	   and	  
difficult	  to	  manipulate	  (Moraes	  et	  al.,	  2011).	  In	  addition,	  it	  is	  widely	  considered	  that	  they	  have	  
so	  far	  failed	  to	  be	  predictive	  of	  the	  eventual	  clinical	  outcome	  of	  targeted	  therapies,	  although	  
the	   use	   of	   appropriate	   dosing	   strategies	   does	   improve	   the	   clinical	   predictive	   value	   (Scotton	  
and	   Chambers,	   2010)	   .	   Furthermore,	   both	   in	   vivo	   and	   2D	   in	   vitro	   cultures	   are	   unable	   to	  
recapitulate	   some	  of	   the	   characteristic	   features	   seen	   in	   IPF	  patients,	   including	   fibrotic	   foci	   –	  
which	   correlate	   with	   the	   progression	   of	   the	   disorder	   (Enomoto	   et	   al.,	   2006).	   Therefore,	   it	  
would	  be	  highly	  beneficial	  to	  produce	  a	  novel	  in	  vitro	  model	  which	  would	  mimic	  fibrotic	  foci,	  in	  
order	  to	  investigate	  the	  mechanisms	  involved	  in	  the	  progression	  of	  this	  disease,	  and	  with	  the	  
potential	   to	   be	   a	  more	   predictive	   pre-­‐clinical	   tool	   for	   assaying	   lead	   compounds.	   This	   thesis	  
therefore	  examined	  the	  following	  hypothesis:	  
	  ‘3D	  spheroid	  cultures	  of	  fibroblasts	  will	  provide	  a	  more	  representative	  in	  vitro	  model	  system	  
for	  drug	  screening	  in	  IPF’	  
To	   address	   this	   hypothesis	   the	   initial	   experiments	   of	   this	   thesis	   aimed	   to	   investigate	   which	  
particular	   fibroblast	   isolation	  protocol	  was	   convenient	   and	   ideal	   to	   use	   in	   order	   to	   generate	  
the	  3D	  model.	  The	  results	  illustrated	  that	  primary	  human	  lung	  fibroblasts	  (pHLF)	  isolated	  from	  




control	   (or	   non-­‐IPF)	   lung	   explants	   	   (pHLF-­‐Ex)	   and	   from	   trypsin-­‐digested	   lungs	   (pHLF-­‐Di)	  
exhibited	  phenotypic	  differences.	  Despite	   the	  beneficial	  aspects	  of	   increased	  cell	   yields	   from	  
pHLF-­‐Di,	  we	  decided	  to	  continue	  the	  project	  with	  pHLF-­‐Ex	  to	  provide	  better	  comparisons	  with	  
existing	   IPF	   fibroblast	   lines	   and	   data.	   The	   next	   aim	  was	   to	   determine	   the	   potential	   for	   both	  
non-­‐IPF	  and	   IPF	   fibroblasts	   to	  produce	   spheroid	   structures	  when	  cultured	  on	  a	   low-­‐adhesive	  
surface.	   	  The	  results	   indicated	  that	  both	  were	  able	  to	  form	  spheroids	  within	   just	  24	  hours	  of	  
incubation	  with	  a	  few	  morphological	  differences.	  Spheroids	  were	  characterised	  by	  determining	  
the	  αSMA	  expression,	   their	   ability	   to	  produce	  matrix	   and	  active	  TGFβ, and	  also	   their	   rate	  of	  
proliferation/apoptosis.	  As	   indicated	   in	  the	  results,	   IPF	  spheroids	  had	  a	  more	  myofibroblastic	  
phenotype	  which	  expressed	  high	  levels	  of	  αSMA,	  synthesised	  high	  levels	  of	  collagen,	  and	  also	  
produced	   high	   levels	   of	   active	   TGFβ.	   However,	   although	   the	   spheroids	   were	   capable	   of	  
synthesising	   their	  own	  active	  TGFβ,	   for	   the	   first	   time	   the	   results	   in	   this	   thesis	  demonstrated	  
that	  collagen	  synthesis	  was	  not	  wholly	  dependent	  on	  endogenous	  TGFβ	  signalling.	  In	  addition,	  
non-­‐IPF	  spheroids	  were	  prone	  to	  apoptosis	  which	  was	  dependent	  on	  EP2	  receptor	  signalling,	  
activated	   by	   cyclooxygenase	   (COX)-­‐1	   mediated	   PGE2.	   Moreover,	   both	   non-­‐IPF	   and	   IPF	  
spheroids	   were	   non-­‐proliferative.	   Furthermore,	   microarray	   data	   analysis	   and	   the	   medium-­‐
throughput	  screening	  identified	  potential	  targets	  which	  require	  further	  validation.	  In	  summary,	  
IPF	   fibroblast	   spheroids	  may	   represent	  a	  novel	   assay	   system	   for	  pre-­‐clinical	  drug	  evaluation;	  
this	  chapter	  will	  discuss	  these	  findings	  and	  their	  implications	  in	  further	  detail.	  
	   	  




4.2.	  Isolation	  methods	  affect	  the	  characteristics	  of	  fibroblasts	  
	  
Myofibroblasts	  are	  contractile	  and	  highly	  synthetic,	  spindle-­‐shaped	  cells	  characterised	  by	  the	  
de	   novo	  expression	   of	   alpha	   smooth	  muscle	   actin	   (α-­‐SMA)	   positive	   stress	   fibres.	   These	   cells	  
play	   a	   vital	   role	   in	   reconstruction	   of	   connective	   tissue	   following	   injury	   and	   are	   fundamental	  
cells	   involved	  in	  the	  development	  of	  fibrosis	  (Hinz	  et	  al.,	  2001a;	  Gabbiani,	  2003;	  Desmouliere	  
et	   al.,	   2005).	   In	   normal	   physiology,	   injury	   to	   the	   lung	   epithelium	   causes	   inflammation	   and	  
results	  in	  differentiation	  of	  fibroblasts	  to	  myofibroblasts	  as	  part	  of	  the	  normal	  wound	  healing	  
response.	   This	   differentiation	   has	   been	   suggested	   to	   occur	   in	   a	   two	   phases.	   The	   first	   phase	  
involves	  the	  fibroblasts	  acquiring	  a	  migratory	  phenotype	  and	  developing	  focal	  adhesions	  and	  
contractile	  bundles	  in	  response	  to	  cytokines	  (Werner	  and	  Grose,	  2003),	  mechanical	  properties,	  
and	  organisation	  of	  the	  extracellular	  matrix	  (ECM)	  (Hinz	  and	  Gabbiani,	  2003b).	  The	  contractile	  
bundles	   formed	   are	   referred	   to	   as	   stress	   fibres,	   composed	   of	   cytoplasmic	   actins	   which	   are	  
structural	  components	  of	  the	  cytoskeleton	  in	  non-­‐muscle	  cells.	  Researchers	  have	  termed	  such	  
mesenchymal	  cells	  as	  proto-­‐myofibroblasts	   in	  order	   to	  distinguish	   these	  cells	   from	  quiescent	  
fibroblasts	   (Tomasek	   et	   al.,	   2002;	   Baum	   and	   Duffy,	   2011).	   The	   second	   phase	   involves	   the	  
proto-­‐myofibroblasts	   expressing	   αSMA,	   and	   such	   cells	   are	   termed	   differentiated	  
myofibroblasts.	   Studies	   have	   demonstrated	   that	   αSMA	   expression	   is	   controlled	   by	   growth	  
factors	   (e.g.	   TGFβ),	   ECM	   proteins,	   and	   the	   mechanical	   microenvironment	   (Tomasek	   et	   al.,	  
2002).	  This	   increase	   in	  αSMA	  expression	  augments	  the	  contractile	  activity	  of	   the	  cells,	  which	  
has	  an	  important	  role	  in	  the	  remodelling	  of	  connective	  tissue	  (Hinz	  et	  al.,	  2001a).	  Stress	  fibres	  
and	   αSMA	   expression	   are	   common	   characteristic	   features	   used	   to	   distinguish	   between	  
fibroblasts	  and	  myofibroblasts	  (Phan,	  2008).	  Once	  the	  tissue	  is	  repaired	  the	  contractile	  activity	  
of	   myofibroblasts	   is	   terminated,	   αSMA	   expression	   is	   reduced,	   and	   the	   cells	   undergo	   a	  
programmed	   cell	   death,	   termed	   apoptosis	   (Desmouliere	   et	   al.,	   1995).	   Thus,	   cell	   death	   is	   an	  
important	  process	  during	  the	  normal	  wound	  healing	  response.	  	  However,	  in	  patients	  with	  IPF,	  
the	   activity	   of	   myofibroblasts	   persists,	   which	   eventually	   leads	   to	   disruption	   of	   the	   lung	  
architecture.	  
In	  our	  laboratory,	  the	  standard	  protocol	  used	  to	  isolate	  primary	  human	  lung	  fibroblasts	  (a	  non-­‐
clonal	   heterogeneous	   cell	   population)	   involved	   growing	   fibroblasts	   from	   small	   (<1mm3)	  
explants	  over	  a	  period	  of	  2-­‐4	  weeks.	  The	  more	  recent	  protocol	  investigated	  during	  this	  thesis,	  
involved	  using	  trypsin	  to	  digest	   the	   lung	  sample,	  while	   isolating	  both	   fibroblasts	  and	  primary	  




type	  II	  AECs.	  The	  latter	  protocol	  not	  only	  isolates	  cells	  more	  rapidly,	  but	  also	  gave	  a	  far	  greater	  
yield	  in	  comparison	  to	  the	  explant	  protocol.	  My	  results	  illustrate	  that	  fibroblasts	  isolated	  using	  
the	   latter	   protocol	   (i.e.	   pHLF-­‐Di)	   have	   a	   more	   myofibroblast-­‐like	   phenotype	   at	   baseline	   in	  
comparison	  to	  pHLF-­‐Ex,	  as	  these	  cells	  show	  greater	  αSMA	  protein	  expression	  and	  the	  presence	  
of	   stress	   fibres.	   In	   addition,	   pHLF-­‐Di	   cells	   have	   the	   tendency	   to	   grow	   at	   a	   faster	   rate	   in	  
comparison	  to	  pHLF-­‐Ex	  cells	  at	  baseline.	  These	  differences	  between	  the	  two	  cell	   isolates	  may	  
have	  arisen	  directly	  due	  to	  the	  activity	  of	  the	  trypsin-­‐EDTA	  used	  in	  the	  isolation	  protocol.	  While	  
commonly	  used	   in	  tissue	  culture	  for	  cell	  detachment,	  trypsin	   is	  also	  able	  to	  activate	  a	  seven-­‐
transmembrane	  domain	  G-­‐protein	  coupled	  receptor,	  protease	  activated	  receptor	   (PAR)-­‐2,	  on	  
several	  cell	  types	  including	  fibroblasts.	  This	  activation	  is	  mediated	  via	  the	  cleavage	  of	  a	  specific	  
site	   on	   the	   N-­‐terminus	   of	   PAR-­‐2	   (Olejar	   and	   Nouza,	   1999;	   Akers	   et	   al.,	   2000),	   	   exposing	   a	  
tethered	  ligand	  which	  then	  binds	  to	  the	  second	  extracellular	  loop	  of	  the	  receptor	  resulting	  in	  a	  
conformational	   change	   and	   activating	   intracellular	   signalling	   cascades	   (Dery	   et	   al.,	   1998).	   As	  
well	  as	  trypsin,	  other	  trypsin-­‐like	  proteases	  (i.e.	  tryptase)	  can	  also	  activate	  PAR-­‐2	  in	  fibroblasts	  
–	  which	  can	  result	  in	  fibroblast	  differentiation.	  Therefore,	  the	  presence	  of	  stress	  fibres	  in	  pHLF-­‐
Di	   may	   have	   resulted	   due	   to	   lengthy	   exposure	   to	   trypsin,	   resulting	   in	   PAR-­‐2–mediated	  
activation.	  	  
TGFβ	   is	  a	  pleiotropic	  regulatory	  cytokine	  ubiquitously	  expressed	   in	   it’s	   latent	   form	  (bound	  to	  
the	  latency	  associated	  peptide,	  LAP)	  by	  all	  cells/tissues	  sequestered	  in	  the	  matrix	  (linked	  to	  the	  
latent	   TGFβ	   binding	   protein,	   LTBP)	   and	   is	   considered	   as	   the	   primary	   mediator	   involved	   in	  
wound	  healing	  (Lee	  et	  al.,	  2006).	  Furthermore,	  there	  is	  compelling	  evidence	  that	  TGFβ	  plays	  a	  
crucial	   role	   in	   the	  pathogenesis	  of	   IPF,	  as	   it	   is	  known	  as	  a	  potent	  mediator	   for	  myofibroblast	  
differentiation	   and	   proliferation.	   The	   results	   in	   this	   project	   illustrated	   that	   TGFβ	   activation	  
upregulated	  αSMA	   expression	   and	   stress	   fibre	   formation	   in	   pHLF-­‐Ex,	   as	   expected,	   however	  
TGFβ	   had	  no	  effect	  on	  pHLF-­‐Di.	   Previously	   in	  our	   lab	   it	   has	  been	  demonstrated	   that	   control	  
pHLF-­‐Ex	  at	  higher	  passage	  number	  (>10)	  have	  increased	  αSMA	  expression	  and	  reduced	  TGFβ	  
responsiveness.	   Therefore,	   it	   is	   feasible	   that	   frequent	   treatment	  of	   cells	  with	   trypsin	   (during	  
routine	  passage)	  may	  not	  only	  play	  a	  role	  in	  altering	  the	  cell	  phenotype	  but	  also	  some	  of	  the	  
cells’	   responses	   to	   certain	   mediators	   (in	   this	   case	   TGFβ).	   The	   high	   baseline	   level	   of	   αSMA	  
expression,	  and	  lack	  of	  change	  in	  the	  presence	  of	  TGFβ suggests	  that	  the	  vast	  majority	  of	  pHLF-­‐
Di	  cells	  are	  already	  directed	  towards	  a	  myofibroblasts	  phenotype	  during	  the	  isolation	  process.	  
Although	   TGFβ	   had	  no	   effect	   on	  αSMA	  expression	   in	   pHLF-­‐Di,	   the	   cytokine	  did	   increase	   the	  
rate	   of	   proliferation	   (similar	   to	   pHLF-­‐Ex)	   illustrating	   that	   these	   cells	   still	   respond	   to	   this	  




exogenous	  stimulus.	  The	  increase	  in	  proliferation	  rate	  in	  response	  to	  TGFβ	  may	  have	  resulted	  
via	   the	   activation	   of	   a	   Smad-­‐independent	   pathway	   (i.e.	   PI3K/Akt/mTOR	   signalling	   pathway)	  
(Conte	  et	  al.,	  2011;	  Fagone	  et	  al.,	  2011).	  
Since	  αSMA	  is	  a	  marker	  for	  not	  only	  myofibroblasts	  but	  also	  smooth	  muscle	  cells,	  it	  was	  vital	  to	  
investigate	  whether	  the	  population	  of	  cells	   isolated	  from	  both	  protocols	  were	  actually	   in	  fact	  
fibroblasts/myofibroblasts.	   This	   involved	  performing	   immunocytochemistry	   for	   the	  detection	  
of	   smoothelin.	   Despite	   previous	   work	   from	   our	   lab	   reporting	   that	   smoothelin	   may	   be	  
expressed	  in	  myofibroblasts	  (Chambers	  et	  al.,	  2003),	  it	  is	  generally	  accepted	  that	  smoothelin	  is	  
a	  marker	  for	  differentiated	  smooth	  muscle	  cells	  (van	  der	  Loop	  et	  al.,	  1996;	  Krämer	  et	  al.,	  2001;	  
Nam	  et	  al.,	  2012).	  The	  results	  in	  this	  thesis	  also	  support	  this	  idea,	  as	  all	  cells	  (both	  at	  baseline	  
and	  TGFβ	  treated)	  were	  negative	  for	  smoothelin.	  
Despite	   the	   benefits	   of	   the	   trypsin-­‐digestion	   protocol	   (higher	   yield	   of	   fibroblasts,	   faster	  
isolation,	   faster	   proliferation),	   pHLF-­‐Di	  were	   not	   used	   for	   the	   rest	   of	   the	   project	   due	   to	   the	  
deviation	  in	  phenotype	  compared	  with	  the	  traditional	   isolation	  protocol,	  and	  hence	  potential	  
for	   comparison	  with	   the	  existing	  biobank	  of	   fibroblast	   lines.	  Thus,	   for	   the	   rest	  of	   the	  project	  
pHLF-­‐Ex	   from	   non-­‐IPF	   and	   IPF	   lung	   tissues	  were	   used	   to	   produce	   a	   novel	   3D	   in	   vitro	  model	  
system.	  
It	   is	   worth	   noting	   that	   in	   2D	   monolayer	   culture,	   several	   studies	   have	   illustrated	   that	   IPF	  
fibroblasts	  have	  a	  more	  myofibroblasts-­‐like	  phenotype	  with	  increased	  expression	  of	  αSMA	  and	  
stress	   fibres	   at	   baseline,	   in	   comparison	   to	   control	   cells.	   However	   in	   this	   study	   the	   results	  
demonstrated	   no	   statistical	   difference	   in	   αSMA	   expression	   between	   non-­‐IPF	   and	   IPF	  
fibroblasts,	  with	  or	  without	  TGFβ	  when	  cultured	  as	  a	  monolayer.	  A	  possible	  reason	  for	  these	  
contrasting	  results	  may	  be	  related	  to	  the	  passage	  number	  of	  the	  cells.	  As	  already	  mentioned,	  
cells	  at	  a	  high	  passage	  have	  increased	  αSMA	  expression	  and	  reduced	  responsiveness	  to	  TGFβ,	  
which	   may	   result	   from	   mechanical	   tension	   or	   due	   to	   continuous	   treatment	   with	   trypsin.	  
However,	   at	   low	  passage	   the	   cells	   are	   considered	   to	   receive	   less	   culture	   stress	   -­‐	   have	   lower	  
αSMA	  expression	  with	  an	   increased	  response	  to	  TGFβ.	   In	   this	  project,	  all	  cells	   (including	   IPF)	  
were	   cultured	   at	   low	  passages	  which	  may	   explain	  why	   there	  was	   no	   statistical	   difference	   in	  
αSMA	   expression	   between	   non-­‐IPF	   and	   IPF	   fibroblasts.	   Other	   possible	   reasons	   for	   these	  
contradictory	   results	   may	   be	   donor-­‐to-­‐donor	   variation	   (i.e.	   age,	   gender,	   stage	   of	   disease	  
progression)	   and	   the	   lung	   region	   from	   which	   the	   IPF	   fibroblasts	   were	   isolated	   (i.e.	   fibrotic	  
region	  or	  less	  affected/unaffected	  lung	  parenchyma).	  	  




4.3.	  Spheroid	  characterisation	  
	  
4.3.1.	  	   Non-­‐IPF	  and	  IPF	  fibroblast	  spheroids	  are	  morphologically	  different	  
Tissue	  engineering	  has	  become	  an	  area	  of	  great	  interest	  over	  the	  past	  decade	  and	  many	  3D	  in	  
vitro	   models	   have	   been	   developed	   to	   study	   diseases	   including	   cancer.	   Such	   models	   have	  
included	  the	  generation	  of	  spheroids	  or	  the	  use	  of	  more	  high-­‐throughput	  microfluidics	  systems	  
which	  not	  only	  mimic	  certain	  physiological	  features	  but	  also	  have	  the	  great	  advantage	  of	  being	  
used	   for	  high-­‐throughput	  drug	  screening	   (Scotton,	  2011).	  However,	  at	  present	  no	  3D	   in	  vitro	  
model	  has	  been	  developed	  to	  specifically	  study	  IPF.	  Therefore,	  the	  aim	  of	  this	  project	  was	  to	  
develop	  a	  model	  which	  mimics	  one	  of	  the	  hallmark	  pathological	  features	  of	  IPF,	  namely	  fibrotic	  
foci.	  
Videomicroscopy	  and	  electron	  microscopy	  (EM)	  demonstrated	  that	  fibroblasts	  (from	  both	  non-­‐
IPF	   and	   IPF	   patients)	   are	   able	   to	   form	   spheroids	   when	   cultured	   on	   a	   non-­‐adhesive	   surface	  
within	   just	   24	  hours	  of	   incubation.	   In	   addition,	   the	   size	  of	   the	   spheroids	   remained	   relatively	  
constant	  (~400	  µM	  in	  diameter)	  over	  96	  hour	  window	  of	  culture	  investigated.	  Morphologically	  
IPF	  spheroids	  have	  a	  smoother	  surface	  with	  larger	  elongated	  flatter	  cells	  in	  comparison	  to	  non-­‐
IPF,	  which	  appear	  to	  have	  a	  rougher	  surface	  with	  smaller,	  more-­‐rounded	  cells.	  In	  addition,	  IPF	  
fibroblasts	  form	  tight	  junctions	  when	  cultured	  in	  this	  3D	  system	  which	  was	  not	  evident	  in	  the	  
non-­‐IPF	   spheroids	   (as	   demonstrated	   by	   transmission	   electron	   microscopy,	   TEM),	   providing	  
evidence	   of	   cell-­‐cell	   communication	   and	   adhesion	   only	   in	   IPF	   spheroids.	   Furthermore,	   TEM	  
analysis	  also	  illustrated	  fibrillar	  deposits	  which	  are	  likely	  to	  be	  ECM	  proteins.	  	  
4.3.2.	  	   IPF	  spheroids	  have	  a	  myofibroblast	  phenotype	  
Based	  on	  these	  morphological	  differences,	   the	  next	  step	  was	  to	  determine	  the	  expression	  of	  
αSMA.	  The	  data	   illustrate	  that	  αSMA	  expression	   is	  greater	   in	   IPF	  spheroids	   in	  comparison	  to	  
non-­‐IPF.	  These	  data	  are	  in	  support	  of	  previous	  published	  studies	  illustrating	  that	  IPF	  fibroblasts	  
have	   a	   myofibroblast	   phenotype.	   It	   is	   important	   to	   note	   that	   the	   IPF	   cells	   used	   to	   form	  
spheroids	  were	   from	   the	   same	  donors	   and	   grown	  at	   the	   same	  passage	   as	   those	   cultured	   as	  
monolayers	   (see	  Sections	  3.1	  and	  4.2).	  This	   suggests	   that	  although	  the	   results	   show	  that	   IPF	  
fibroblasts	  have	  similar	  αSMA	  levels	  to	  non-­‐IPF	  fibroblasts	  when	  cultured	  on	  plastic,	  in	  this	  3D	  
system,	  the	  same	  IPF	  cells	  acquire	  a	  myofibroblast	  phenotype	  suggesting	  that	  cell-­‐cell	  or	  cell-­‐




matrix	   interaction	   may	   play	   an	   additional	   key	   role	   in	   mediating	   the	   differentiation	   of	   IPF	  
fibroblasts	  (Hinz	  et	  al.,	  2004).	  
4.3.3.	  	   IPF	  spheroids	  produce	  high	  levels	  of	  collagen	  	  
Excessive	  collagen	  deposition	  is	  the	  key	  feature	  shown	  in	  the	  lungs	  of	  IPF	  patients,	  particularly	  
in	   areas	   of	   active	   fibrosis	   (i.e.	   fibrotic	   foci).	   As	   stated	   above,	   EM	   illustrated	   fibrillar	   ECM	  
deposition,	  suggesting	  that	  spheroids	  may	  potentially	  synthesise	  their	  own	  matrix.	  To	  address	  
this	  hydroxyproline	  content	  was	  measured.	  Hydroxyproline	  (in	  particular	  4-­‐hydroxyproline,	  4-­‐
Hyp)	   is	  the	  major	  amino	  acid	  present	   in	  all	  collagen	  types	  and	   its	  measurement	   is	  commonly	  
used	  to	  determine	  the	  total	  concentration	  of	  collagen	  within	  biological	  samples	  (Kliment	  et	  al.,	  
2011).	  The	  results	   illustrated	  that	   in	  the	  absence	  of	  any	  exogenous	  stimuli,	  both	  non-­‐IPF	  and	  
IPF	  spheroids	  were	  capable	  of	  synthesising	  their	  own	  matrix	  (i.e.	  collagen)	  within	  just	  24	  hours	  
of	  culture,	  with	  statistically	  greater	   levels	  seen	  in	   IPF	  spheroids.	  This	   is	  an	   intriguing	  result	  as	  
other	   in	   vitro	   assays	   for	   pulmonary	   fibrosis	   (i.e.	   2D	  monolayer	   cultures	   and	   the	   scar-­‐in-­‐a-­‐jar	  
assay)	   require	   the	   addition	   of	   exogenous	   mediators	   (such	   as	   TGFβ),	   often	   at	   supra-­‐
physiological	  concentrations,	  to	  stimulate	  collagen	  production	  (Chen	  and	  Raghunath,	  2009).	  In	  
addition,	  since	  IPF	  spheroids	  have	  an	  increased	  αSMA	  expression,	  elevated	  collagen	  deposition	  
in	  these	  spheroids	  support	  the	  concept	  that	  αSMA	  positive	  myofibroblasts	  are	  highly	  synthetic	  
for	  collagen	  (Hinz	  et	  al.,	  2001a;	  Hinz	  and	  Gabbiani,	  2003b;	  Scotton	  and	  Chambers,	  2007;	  Hinz,	  
2010).	  
In	  most	  donors,	  the	  spheroid	  collagen	  levels	  remained	  relatively	  stable	  over	  96	  hours,	  however	  
there	  were	  a	  few	  exceptions	  where	  the	  collagen	  levels	  either	  declined	  or	  elevated	  over	  time.	  
These	  results	  highlight	  one	  issue	  of	  donor-­‐to-­‐donor	  variation.	  In	  addition,	  a	  decline	  in	  collagen	  
synthesis	   over	   time	   in	   some	   donors	   (in	   particular	   some	   of	   the	   non-­‐IPF	   donors)	   may	   have	  
resulted	  due	  to	  the	  increase	  cell	  death	  within	  the	  spheroids	  as	  a	  result	  of	  increased	  production	  
of	   PGE2	   (Casini	   et	   al.,	   1984;	   Fine	   et	   al.,	   1989),	   which	   will	   be	   discussed	   in	   greater	   detail	   in	  
Section	   4.3.5.	   Another	   potential	   explanation	   may	   be	   the	   increase	   in	   activity	   of	   matrix	  
metalloproteinases	  (MMPs),	  in	  particular	  MMP2	  (see	  Appendix	  4).	  MMPs	  are	  matrix-­‐degrading	  
enzymes	  which	  are	   synthesised	  by	   fibroblasts	   in	  order	   to	   control	  matrix	   turnover	  during	   the	  
initiation	   and	   resolution	   phases	   following	   injury.	   As	   shown	   in	   Appendix	   4,	   MMP2	   levels	  
increase	   over	   time	   in	   both	   non-­‐IPF	   and	   IPF	   spheroids,	   thus	  may	   degrade	   the	   collagen	   levels	  
over	  the	  96	  hours	  of	  culture.	  Studies	  have	  demonstrated	  that	  IPF	  patients	  have	  elevated	  levels	  
of	  MMPs	   in	   comparison	   to	   control	   subjects	   which	   would	   imply	   greater	  matrix	   degradation,	  




however,	   this	   does	   not	   occur	   in	   the	   lungs	   of	   IPF	   patients	   due	   to	   elevated	   levels	   of	   tissue	  
inhibitor	   of	  metalloproteinases	   (TIMPs)	   (Montaño	   et	   al.,	   1989;	   Fukuda	   et	   al.,	   1998;	   Selman,	  
2000;	   Greenlee	   et	   al.,	   2007;	   Dancer	   et	   al.,	   2011).	   	   The	   results	   in	  Appendix	   4	   illustrate	   that	  
although	   there	   is	   an	   increase	   in	   MMP2	   levels	   over	   time	   there	   is	   no	   statistical	   difference	  
between	  non-­‐IPF	  and	  IPF	  spheroids.	  A	  possible	  reason	  for	  this	  is	  the	  limited	  number	  of	  donors	  
used	   to	   measure	   MMP2	   levels;	   also	   the	   IPF	   fibroblasts	   used	   to	   investigate	   MMP	   levels	  
happened	  to	  be	  those	  donors	  which	  produced	  lower	  collagen	  levels	  (i.e.	  <50	  ng	  per	  spheroid,	  
which	  is	  similar	  to	  the	  mean	  level	  in	  non-­‐IPF	  spheroids).	  Therefore,	  further	  experiments	  should	  
be	  performed	   in	   the	  donors	  which	  produce	  high	   levels	  of	   collagen	   (>50	  ng),	  and	  TIMP	   levels	  
would	  also	  need	  to	  be	  investigated,	  before	  drawing	  clearer	  conclusions.	  
There	  are	  a	  number	  of	  explanations	  why	  some	  fibroblast	  spheroids	  from	  IPF	  patients	  produced	  
high	  collagen	   levels	   (>50	  ng)	  whilst	  others	  produced	   lower	   levels	  (<50	  ng):	  1)	   fibroblasts	  may	  
have	  been	  isolated	  from	  patients	  who	  experienced	  either	  a	  slow	  or	  a	  rapid	  progression	  of	  their	  
disease,	  2)	  the	  cell	  isolates	  may	  have	  been	  taken	  from	  different	  regions	  of	  the	  IPF	  lung	  (i.e.	  less	  
effected	  areas	  or	  fibrotic	  regions),	  3)	  passage	  number	  or	  cell	  population	  doubling	  (defined	  as	  
the	  total	  number	  of	  times	  a	  population	  of	  cells	  have	  doubled	  since	  they	  were	  initially	  isolated	  
in	  vitro).	  	  
There	  are	  28	  types	  of	  collagen	  present	  within	  the	  human	  body,	  of	  which	  collagen	  types	  I	  and	  III	  
are	  considered	  to	  be	  the	  most	  abundant	  in	  the	  lung	  (McAnulty	  and	  Laurent,	  1987;	  Lodish	  et	  al.,	  
2000).	  This	  has	  also	  been	  demonstrated	  in	  this	  thesis	  with	  strong	  immunoreactivity	  of	  collagen	  
I	  and	  III	  in	  both	  control	  and	  fibrotic	  lung	  tissue	  sections,	  particularly	  in	  areas	  with	  evidence	  of	  
αSMA	   expression	   –	   again	   supporting	   the	   concept	   that	   myofibroblasts	   are	   synthetic	   for	  
collagen.	  In	  IPF	  lung	  tissue	  sections	  immunoreactivity	  for	  collagen	  I	  and	  III	  was	  illustrated	  in	  the	  
fibrotic	   foci.	   Interestingly,	   strong	   staining	   was	   also	   shown	   in	   the	   basement	   membrane	  
underlying	   the	   bronchial	   epithelial	   cells,	   which	   to	   our	   knowledge	   has	   not	   been	   reported	  
previously.	  
The	  next	  step	  was	  to	  identify	  which	  collagen	  type	  is	  synthesised	  by	  the	  fibroblasts	  cultured	  in	  
the	   3D	   spheroid	   system.	   The	   results	   showed	   that	   both	   non-­‐IPF	   and	   IPF	   spheroids	   express	  
collagen	  types	  I	  and	  III.	  Although	  on	  the	  transcriptional	  level	  there	  was	  no	  statistical	  difference	  
in	   COL1A1	   and	   COL3A1	   mRNA	   levels,	   IPF	   spheroids	   appeared	   to	   show	   slightly	   stronger	  
immunoreactivity	   in	  comparison	  to	  non-­‐IPF	  spheroid	  sections.	  This	   is	   in	  accord	  with	  previous	  
studies	  illustrating	  that	  at	  a	  translational	  level	  a	  large	  set	  of	  genes	  are	  regulated	  in	  IPF	  samples	  
and	   the	  differential	  expression	  cannot	  be	  appreciated	  at	   the	   transcriptional	   level	   (Larsson	  et	  




al.,	  2008).	  Since	  the	   immunostaining	  was	  not	  quantified,	   further	  experiments	  are	  required	  to	  
provide	  quantitative	  analysis	   illustrating	  the	  difference	  in	  collagen	  I	  and	  III	  expression	  in	  non-­‐
IPF	  and	   IPF	   spheroids.	   This	   could	  be	  done	  by	  determining	   the	   levels	  of	  procollagen	   carboxy-­‐
terminal	   pro-­‐peptides	   (PICP	   and	   PIIICP,	   respectively).	   These	   are	   considered	   as	   surrogate	  
markers	  for	  collagen	  synthesis,	  and	  are	  elevated	  in	  BALF	  of	  IPF	  patients	  (reviewed	  in	  (Dancer	  et	  
al.,	  2011)).	  
A	   number	   of	   endogenous	   paracrine	   and	   autocrine	  mediators	  may	   be	   involved	   in	   promoting	  
collagen	  synthesis	  in	  these	  spheroids	  including	  increased	  production	  of	  TGFβ,	  PDGF,	  IGF1,	  and	  
EGF	  and	  reduced	  synthesis	  of	  anti-­‐fibrotic	  mediators	  such	  as	  PGE2.	  The	  next	  section	  will	  discuss	  
the	  effect	  of	  TGFβ	  signalling	  on	  collagen	  synthesis.	  
4.3.4.	  	   Fibroblast	  spheroids	  produce	  active	  TGFβ 	  	  
As	  stated	  above,	  TGFβ	   is	  well	  recognised	  for	  promoting	  the	  synthesis	  of	  collagen	  both	   in	  vivo	  
and	  in	  vitro,	  thus	  the	  next	  step	  was	  to	  determine	  whether	  treating	  the	  spheroids	  exogenously	  
with	  active	  TGFβ	  would	  accelerate	  collagen	  synthesis.	  Surprisingly	  however,	  exogenous	  TGFβ	  
had	   no	   effect	   on	   collagen	   production	   in	   both	   non-­‐IPF	   and	   IPF	   spheroids.	   This	   lead	   to	   the	  
hypothesis	   that	   fibroblasts	   cultured	   as	   spheroids	   might	   produce	   their	   own	   active	   TGFβ (in	  
contrast	   to	   what	   is	   seen	   in	   monolayer	   culture).	   To	   investigate	   this	   hypothesis,	   active	   TGFβ	  
levels	  were	  measured	  in	  both	  spheroid	  homogenates	  and	  conditioned	  media	  by	  using	  the	  mink	  
lung	   bioassay.	   This	   assay	   involves	   the	   use	   of	   transformed	  mink	   lung	   epithelial	   cell	   (TMLECs)	  
which	  are	  stably	  transfected	  with	  a	  truncated	  plasminogen	  activator	  inhibitor	  (PAI)-­‐1	  promoter	  
fused	  to	  the	  firefly	  luciferase	  reporter	  gene.	  The	  activity	  of	  luciferase	  increases	  when	  exposed	  
to	  TGFβ	  in	  a	  dose-­‐dependent	  manner	  (Abe	  et	  al.,	  1994).	  
The	  results	  showed	  that	  both	  non-­‐IPF	  and	  IPF	  spheroids	  synthesise	  their	  own	  active	  TGFβ	  with	  
higher	   levels	   shown	   in	   IPF	   spheroids	   following	   24	   and	   96	   hours	   of	   culture.	   Over	   time,	   the	  
concentration	   remains	   relatively	   constant	   in	   non-­‐IPF	   spheroids,	   however	   in	   IPF	   spheroid	  
homogenates	  active-­‐TGFβ	   levels	  decline.	  Possible	  explanations	  could	  be	  that	  over	   time	  TGFβ	  
signalling	  is	  initiating	  a	  negative	  feedback	  loop	  resulting	  in	  TGFβ	  internalisation	  for	  degradation	  
(Mitchell	  et	  al.,	  2004;	  Vilar	  et	  al.,	  2006)	  or	  that	  the	  TGFβ	  is	  being	  predominantly	  secreted	  into	  
the	   media	   over	   time.	   A	   slight	   elevation	   of	   active	   TGFβ	   levels	   is	   indeed	   evident	   in	   the	  
conditioned	   media	   from	   IPF	   spheroid	   cultures	   over	   96	   hours	   of	   incubation	   however	   this	  
increase	   does	   not	   reach	   statistical	   significance.	   Another	   possible	   explanation	   could	   be	   that	  




there	   may	   be	   autocrine/paracrine	   signals	   within	   the	   spheroid	   which	   downregulate	   TGFβ	  
expression.	  
4.3.5.	  	   Integrins	  mediate	  TGFβ 	  activation	  in	  spheroids	  
Various	  processes	  have	  been	  proposed	  to	  activate	  latent	  TGFβ,	  including	  heat,	  reactive	  oxygen	  
species,	  acidic	  pH,	  matrix	  metalloproteinases	  (MMPs),	  thrombospondin	  (TSP)-­‐1,	  and	  integrins.	  
In	   this	   project	   the	   involvement	   of	   TSP-­‐1	   and	   integrins	   was	   investigated.	   TSP-­‐1	   is	   a	   large,	  
disulphide-­‐linked	  homotrimeric	  protein	  which	   is	   considered	   to	  be	   a	  major	   activator	   for	  both	  
small	  and	  large	  forms	  of	  latent	  TGFβ	  (Raugi	  et	  al.,	  1987;	  O’Shea	  et	  al.,	  1990;	  Reed	  et	  al.,	  1995;	  
Yehualaeshet	  et	  al.,	  1999;	  Nakerakanti,	  2012).	  The	  association	  of	  the	  TSP-­‐1	  KRFK	  motif	  with	  the	  
LSKL	  sequence	  of	  the	  latency	  associated	  peptide	  (LAP)	  results	  in	  a	  conformation	  change	  in	  the	  
TGFβ	   latency	  complex	  leading	  to	  the	  release	  of	  active	  TGFβ	  dimer.	  Treatment	  with	  a	  mimetic	  
LSKL	  peptide	   inhibits	   TSP-­‐1	  mediated	  TGFβ	   activation	   in	   vitro	   (Xie	   et	   al.,	   2010),	   however	  my	  
results	   demonstrated	   that	   the	   LSKL	   mimetic	   peptide	   had	   no	   effect	   on	   TGFβ	   activation	   or	  
collagen	   synthesis	   in	   either	   non-­‐IPF	   or	   IPF	   spheroids	   suggesting	   that	   another	   mechanism	   is	  
predominant	  in	  promoting	  TGFβ	  activation	  in	  this	  3D	  system.	  
Integrins	  are	  transmembrane	  linker	  cell	  surface	  receptors	  composed	  of	  α and	  β	  subunits	  which	  
regulate	   bi-­‐directional	   signalling.	   Previous	   studies	   have	   illustrated	   six	   out	   of	   24	   integrins	   are	  
able	   to	   associate	  with	   the	   RGD	   sequence	   in	   LAP:	   αvβ1,	   αvβ3,	   αvβ5,	   αvβ6,	   αvβ8,	   and	   α8β1.	  
However,	   αvβ3	  (Asano	   et	   al.,	   2005a),	   αvβ5	  (Asano	   et	   al.,	   2005b),	   αvβ6	  (Munger	   et	   al.,	  
1999)	  and	  αvβ8	  (Mu,	  2002)	  are	  the	  only	   integrins	  which	  have	  been	  formally	  demonstrated	  to	  
release	  active	  TGFβ.	  Integrins	  αvβ3,	  αvβ5,	  and	  αvβ8	  are	  expressed	  in	  fibroblasts	  (supported	  by	  
the	  results	  in	  this	  thesis,	  confirming	  their	  expression	  by	  qRT-­‐PCR).	  Although	  all	  three	  integrins	  
anchor	  to	  the	  RGD	  sequence	  to	  facilitate	  TGFβ	  activation,	  the	  mechanisms	  by	  which	  this	  occurs	  
are	  different.	  For	   instance,	   integrins	  αvβ3	  and	  αvβ5	  result	   in	  a	  conformational	  change	   in	   the	  
latency	   complex	   as	   a	   result	   of	   cell	   traction	   leading	   to	   the	   release	   of	   the	   homodimeric	  
TGFβ (Asano	   et	   al.,	   2005a,	   2005b;	   Wipff	   et	   al.,	   2007).	   Integrin	   αvβ8,	   on	   the	   other	   hand,	  
presents	  the	  latent	  complex	  to	  cell	  surface	  MMPs	  (MT1-­‐MMP	  or	  MMP14)	  which	  degrades	  LAP	  
and	  releases	  active	  TGFβ into	  the	  extracellular	  milieu	  (Mu,	  2002).	  	  
The	   results	   in	   this	   thesis	   demonstrated	   that	   integrin	  αvβ5	  mRNA	   levels	  were	   greater	   in	   IPF	  
spheroids	   in	  comparison	  to	  non-­‐IPF.	  Since	   IPF	  spheroids	  have	  a	  myofibroblast	  phenotype	  the	  
increase	   in	  αvβ5	  mRNA	   levels	  may	   support	   previously	   published	   data	   illustrating	   that	  αvβ5	  




mediates	  fibroblast	  differentiation	  to	  myofibroblasts	  via	  TGFβ	  activation	  (Scotton	  et	  al.,	  2009;	  
Zhou	   et	   al.,	   2010).	   In	   addition,	   αvβ5	   expression	   localises	   to	   areas	   positive	   for	   αSMA	  
expression,	  in	  particular	  fibrotic	  foci,	  suggesting	  that	  αvβ5	  may	  have	  an	  important	  role	  in	  the	  
development	   of	   IPF	   (Scotton	   et	   al.,	   2009).	   The	   elevated	  αvβ5	  mRNA	   levels	   in	   IPF	   spheroids	  
therefore	  reflects	  what	  is	  seen	  in	  fibrotic	  foci.	  
The	   mRNA	   levels	   for	   integrins	  αvβ3	   and	  αvβ8	   were	   also	   assessed	   however	   there	   were	   no	  
statistical	   differences	   between	   non-­‐IPF	   and	   IPF	   spheroids.	   This	   led	   to	   the	   hypothesis	   that	  
collagen	   synthesis	   by	   fibroblast	   spheroids	   is	   dependent	   on	   integrin	   αvβ5-­‐mediated	   TGFβ	  
activation.	  To	   investigate	   this	  hypothesis	   the	  spheroids	  were	   treated	  with	   integrin	   inhibitors.	  
Due	  to	  the	   lack	  of	  availability	  of	  a	  specific	   integrin	  αvβ5	  small	  molecule	   inhibitor,	  a	  selective	  
β3/β5	  dual	   inhibitor	  was	  used.	   In	  addition,	  β3	  and	  β8	   integrin	   inhibitors	  were	  also	  assessed.	  
The	   results	   illustrated	   that	   in	   non-­‐IPF	   spheroids,	   treatment	   with	   αvβ8	   inhibitor	   partially	  
attenuated	   TGFβ	   activation	   (high	   potency	   with	   low	   efficacy).	   Furthermore,	   the	   dual	   β3/β5	  
inhibitor	  and	  β3	  inhibitor	  also	  caused	  a	  decline	  in	  TGFβ	  activation,	  however	  this	  only	  occurred	  
at	   extremely	   high	   concentration	   of	   the	   compounds.	   	   In	   other	   in	   vivo	   and	   in	   vitro	   model	  
systems,	  these	   integrin	   inhibitor	  compounds	  were	  highly	  potent	  with	   IC50s	   in	  the	  nanomolar	  
range	  (personal	  communication	   from	  Richard	  Hatley,	  GSK).	  However,	   in	   this	  system	  the	  non-­‐
specific	   β3/β5	   inhibitor	   and	   β3	   inhibitor	   appeared	   to	   have	   low	   potency	   in	   blocking	   TGFβ	  
activation	  with	  an	  effect	  shown	  only	  at	  micromolar	  concentration.	  This	  affect	  is	  likely	  to	  be	  the	  
result	   of	   toxicity	   of	   the	   compounds,	   however	   further	   investigations	   are	   required	   to	   confirm	  
this.	   Nevertheless,	   since	   β8	   inhibition	   did	   show	   some	   attenuation	   in	   TGFβ	   activation,	   it	  
suggests	  that	  in	  non-­‐IPF	  spheroids	  TGFβ	  activation	  is	  partially	  dependent	  on	  the	  αvβ8	  integrin.	  
However,	   this	   partial	   attenuation	   suggests	   that	   another	   mechanism	   is	   also	   involved	   in	  
activating	  TGFβ,	  which	  could	  include	  the	  β5	  integrin	  (not	  directly	  interrogated	  here)	  or	  MMPs,	  
both	   of	   which	   have	   previously	   shown	   to	   associate	   to	   LAP	   and	   release	   active	   TGFβ.	   Further	  
experiments	  must	   be	   performed	   to	   investigate	   this,	  which	   could	   potentially	   involve	   treating	  
the	  spheroids	  with	  GM6001	  (a	  potent	  pan-­‐MMP	  inhibitor)	  or	  a	  specific	  β5	  antagonist	  (which	  to	  
our	   knowledge	   has	   not	   yet	   been	   developed)	   or	   a	   neutralising	   antibody.	   In	   IPF	   spheroids	  
however,	   both	   integrin	   β3	   and	   β8	   inhibition	   abolished	   TGFβ	   activation	   with	   high	   potency.	  
Integrin	   β3/β5	   inhibitor	   also	   blocked	   the	   activation	   however	   at	   low	   potency.	   This	   suggests	  
TGFβ	  activation	  in	  IPF	  spheroids	  is	  highly	  dependent	  on	  integrins	  β3	  and	  β8.	  




4.3.6.	  	   Collagen	  synthesis	  may	  be	  independent	  of	  TGFβ 	  signalling	  
Despite	  the	  impact	  of	  β3	  and	  β8	  inhibition	  on	  TGFβ	  activation,	  there	  was	  no	  subsequent	  effect	  
on	  collagen	  synthesis,	  suggesting	  that	  in	  this	  system	  collagen	  synthesis	  was	  not	  dependent	  on	  
integrin-­‐mediated	  TGFβ	  activation.	  These	  findings	  are	  in	  support	  with	  previously	  published	   in	  
vivo	   data	   which	   illustrated	   that	   mice	   null	   for	   αvβ3	   and	   αvβ5	   are	   not	   protected	   from	  
bleomycin-­‐induced	  PF	  (reviewed	  in	  (Tatler	  and	  Jenkins,	  2012)).	  
As	  stated	  before,	  active	  TGFβ	  exert	   its	  cellular	  effects	  via	  the	  activation	  of	   its	  receptor	  which	  
can	   induce	   multiple	   pro-­‐fibrotic	   effects.	   Active	   TGFβ	   interacts	   with	   TGFβ	   receptor	   type	   II	  
(TBRII)	  which	  then	  phosphorylates	  and	  dimerises	  with	  TGFβ	  receptor	  I	  (TBR1/ALK5).	  This	  forms	  
an	   active	   ligand-­‐response	   complex	   which	   initiates	   pro-­‐fibrotic	   responses	   in	   fibroblasts	   via	  
canonical	   (Smad-­‐dependent	  pathway)	  and	  non-­‐canonical	   signalling	  pathways	   (i.e.	  MAPK,	  and	  
PI3K/Akt	  pathways;	   reviewed	   in	   (Sakai	  and	  Tager,	  2013)).	  Several	   studies	  support	   the	   role	  of	  
TGFβ	   in	   promoting	   collagen	   synthesis	   via	   the	   activation	   of	   its	   receptor,	   ALK-­‐5.	   For	   instance,	  
bleomycin-­‐induced	  PF	  mice	  show	  a	  significant	  attenuation	  in	  collagen	  synthesis,	  following	  the	  
treatment	  with	  a	  potent	  ALK5	  inhibitor	  (i.e.	  SB525334A)	  (Scotton	  et	  al.,	  2013)	  via	  the	  reduction	  
Smad2/3	   translocation	   into	   the	   nucleus.	   In	   addition,	   reduced	   Smad	   2/3	   signalling	   also	  
decreases	  CTGF	  production	  and	  attenuates	  myofibroblasts	   	   proliferation	   (Higashiyama	  et	   al.,	  
2007).	   Unexpectedly,	   in	   this	   spheroid	   system	   ALK-­‐5	   inhibition	   had	   no	   effect	   on	   collagen	  
synthesis	   (following	   either	   prophylactic	   or	   therapeutic	   treatment).	   These	   data	   suggest	   that	  
although	   TGFβ	   signalling	   is	   postulated	   to	   be	   the	   major	   cytokine	   stimulating	   pro-­‐fibrogenic	  
responses,	  when	  fibroblasts	  are	  cultured	  as	  spheroids	  the	  initial	  impetus	  for	  collagen	  synthesis	  
may	  not	  be	  dependent	  on	  TGFβ	  signalling.	  One	  thing	  to	  note	  is	  that	  this	  experiment	  was	  only	  
performed	  using	  one	  non-­‐IPF	  donor	  and	  one	  IPF	  donor	  which	  were	  the	  same	  donors	  used	  to	  
investigate	  the	  effect	  of	  β3	  and	  β5	  integrin	   inhibitors	  on	  TGFβ	  production	  (described	  above).	  
Due	   to	   donor-­‐donor	   variation	   and	   fibroblast	   heterogeneity,	   it	   is	   vital	   this	   experiment	   is	  
subsequently	  repeated	  in	  multiple	  donors	  to	  further	  support	  this	  observation.	  In	  addition,	  the	  
lack	   of	   effect	   following	   therapeutic	   treatment	   may	   possibly	   suggest	   that	   the	   compound	   is	  
unable	   to	   penetrate	   the	   spheroid	   to	   show	   its	   effects.	   Thus,	   further	   research	   is	   required	   to	  
determine	   whether	   compounds	   are	   capable	   of	   penetrating	   the	   matrix	   rich	   spheroids.	   This	  
could	   involve	   treating	   the	   spheroids	  with	   a	   labelled	   substance	   to	   assess	   its	   penetration	   (see	  
Future	  Directions	  Section	  5.1.8).	  




Although	  my	  data	  suggests	  that	  TGFβ	  may	  not	  be	  essential	  for	  the	  initial	  collagen	  production	  in	  
these	  spheroids	  it	  does	  not	  rule	  out	  the	  fact	  that	  the	  TGFβ	  may	  be	  vital	  in	  mediating	  other	  pro-­‐
fibrotic	   and	   pro-­‐inflammatory	   effects.	   For	   example,	   as	   stated	   before	   IPF	   spheroids	   have	   a	  
myofibroblast	   phenotype.	   Since	   IPF	   spheroids	   produce	   high	   levels	   of	   active	   TGFβ	   in	  
comparison	   to	   non-­‐IPF	   spheroids	   we	   can	   postulate	   that	   TGFβ	   is	   involved	   in	   promoting	  
fibroblast	   differentiation	   which	   would	   support	   several	   published	   data.	   However,	   further	  
investigations	   would	   be	   necessary	   before	   drawing	   conclusions	   which	   could	   involve	  
determining	   the	  effect	  of	  antagonising	  TGFβ	   receptor	   signalling	   (by	  using	  an	  ALK-­‐5	   inhibitor)	  
on	  αSMA	  expression	   in	   the	  spheroids.	   In	  addition,	  previous	  studies	  have	  shown	  that	  TGFβ	   is	  
involved	   in	   upregulating	   the	   expression	   of	   collagen	   crosslinking	   genes	   (such	   as	  
transglutaminase	   2,	   TGM2)	   resulting	   in	   overstabilisation	   of	   ECM	   and	   potentially	   leading	   to	  
stiffer	  matrix	   (George	  et	  al.,	  1990;	  Schittny	  et	  al.,	  1997;	  Ritter	  and	  Davies,	  1998;	  Quan	  et	  al.,	  
2005).	  Thus,	  it	  could	  be	  hypothesised	  that	  in	  this	  3D	  system	  TGFβ	  plays	  a	  role	  in	  maturation	  of	  
ECM.	  Furthermore,	  TGFβ	  activation	  has	  also	  been	  implicated	  in	  fibroblast	  survival	  by	  mediating	  
PI3K/Akt	   signalling	   pathway	   and	   inhibiting	   PGE2-­‐mediated	   cell	   death	   (Nakerakanti,	   2012).	  
However,	  further	  investigations	  will	  be	  necessary	  to	  determine	  the	  precise	  role	  of	  active	  TGFβ	  
in	  this	  3D	  system.	  
4.3.7.	  	   Non-­‐IPF	  spheroids	  are	  prone	  to	  cell	  death	  	  
Following	  a	  normal	  wound	  healing	  response	  and	  after	  the	  tissue	  has	  been	  repaired,	  activated	  
fibroblasts	   are	   cleared	   from	   the	   site	   of	   injury	   by	   undergoing	   apoptosis	   (Desmouliere	   et	   al.,	  
1995).	  Apoptosis	  is	  a	  programmed	  cell	  death	  involving	  the	  activation	  of	  caspases	  which	  cleave	  
key	   cellular	   components	   required	   for	   normal	   cell	   function.	   Such	   components	   include	  
cytoskeletal	  proteins	  (e.g.	  actin	  filaments)	  and	  nuclear	  proteins	  (e.g.	  lamins)	  which	  result	  in	  cell	  
shrinkage,	  bleb	  formation,	  and	  chromatin	  condensation.	  In	  addition,	  activated	  caspase-­‐3	  may	  
also	   initiate	   the	   activity	   of	   DNase	   via	   the	   activity	   of	   caspase-­‐activated	   DNase	   (CAD)	   which	  
results	   in	   DNA	   fragmentation.	   In	   turn,	   apoptotic	   bodies	   form	   which	   are	   phagocytosed	   and	  
degraded.	  	  
Fibroblast	  apoptosis	  is	  considered	  to	  be	  critical	  for	  prevention	  of	  the	  pathological	  scarring	  seen	  
in	  the	  lungs	  of	  IPF	  patients	  (Thannickal	  and	  Horowitz,	  2006).	  When	  activated	  fibroblasts	  persist	  
in	  the	  tissue	  due	  to	  abnormal	  apoptotic	  mechanisms,	  undesirable	  fibrosis	  occurs	  which	  is	  one	  
of	  the	  key	  hallmarks	  of	  fibrotic	  foci	  (Kuhn	  and	  McDonald,	  1991;	  Moodley	  et	  al.,	  2004;	  Bühling	  
et	   al.,	   2005).	   Compelling	   evidence	   reveals	   that	   fibroblasts	   derived	   from	   the	   lungs	   of	   IPF	  




patients	  are	  resistant	  to	  apoptosis,	  in	  particular	  Fas	  ligand	  (FasL)-­‐induced	  apoptosis	  (Tanaka	  et	  
al.,	  2002;	  Moodley	  et	  al.,	  2004;	  Bühling	  et	  al.,	  2005;	  Huang	  et	  al.,	  2009)	  which	  has	  a	  pivotal	  role	  
in	  the	  pathogenesis	  of	  pulmonary	  fibrosis	  (Kuwano	  et	  al.,	  1999b).	  Fibroblast	  resistance	  to	  FasL-­‐
induced	  apoptosis	  can	  result	  from	  limited	  expression	  of	  PGE2	  (Maher	  et	  al.,	  2010).	  In	  addition,	  
studies	   on	   murine	   models	   and	   patients	   with	   pulmonary	   fibrosis	   have	   highlighted	   the	  
importance	  of	  histone	  modifications	   in	  the	  development	  of	  fibroblast	  resistance	  to	  apoptosis	  
suggesting	  novel	  approaches	  to	  therapy	  for	  fibroproliferative	  disorders	  (Huang	  et	  al.,	  2013).	  
To	  investigate	  whether	  fibroblasts	  cultured	  as	  spheroids	  undergo	  apoptosis,	  the	  percentage	  of	  
nuclei	   undergoing	   fragmentation	   was	   measured	   by	   using	   terminal	   deoxynucleotidyl	  
transferase	  dUTP	  nick	  end	   labelling	   (TUNEL)	  assay.	  This	  assay	   is	  dependent	  on	  the	  activity	  of	  
terminal	   deoxynucleotidyl	   transferase	   (TdT)	  which	   catalyses	   the	   addition	   of	   dUTP	  molecules	  
(conjugated	   to	   a	   fluorescent	  marker)	   to	   the	   fragmented	   DNA,	   visualised	   using	   fluorescence	  
microscopy.	   The	   results	   illustrated	   that	   after	   96	   hours	   in	   culture	   there	   was	   a	   significant	  
increase	   in	   the	   percentage	   of	   cells	   with	   fragmented	   DNA	   in	   non-­‐IPF	   spheroids.	   In	   contrast,	  
fibrotic	   spheroids	   were	   less	   prone	   to	   cell	   death	   in	   this	   3D	   system.	   This	   supports	   previous	  
studies	   demonstrating	   that	   IPF	   fibroblasts	   are	   resistant	   to	   apoptosis	   (Maher	   et	   al.,	   2010).	  
However,	  unlike	  2D	  monolayer	  cultures,	  fibroblasts	  in	  spheroid	  do	  not	  require	  the	  addition	  of	  
an	   exogenous	   mediator	   to	   induce	   apoptosis	   (i.e.	   Fas-­‐ligand).	   In	   fact,	   these	   spheroids	   are	  
capable	   of	   synthesising	   their	   own	   anti-­‐fibrotic	   mediators	   to	   mediate	   this	   programmed	   cell	  
death.	  Thus,	  non-­‐IPF	  and	  IPF	  spheroids	  are	  reminiscent	  of	  the	  fibroblast	  aggregates	  seen	  in	  a	  
healing	  wound	   following	   lung	   injury	   in	   control	   and	   fibrotic	  patients,	   respectively.	   This	  would	  
add	  credence	  to	  the	  use	  of	  spheroids	  as	  a	  relevant	  model	  for	  pulmonary	  fibrosis.	  	  
It	  is	  also	  important	  to	  note	  that	  TUNEL	  positive	  cells	  were	  randomly	  distributed	  throughout	  the	  
spheroids	  and	  not	  focused	  in	  the	  centre,	  where	  oxygen	  tension	  would	  be	  lowest.	  In	  addition,	  
the	  size	  of	  the	  spheroids	  did	  not	  have	  a	  significant	  effect	  on	  the	  percentage	  of	  TUNEL	  positive	  
cells.	   These	   findings	   suggest	   that	   hypoxia	   may	   not	   be	   the	   cause	   of	   cell	   death	   within	   the	  
spheroids	   and	   the	   cells	   are	   unlikely	   to	   be	   necrotic	   (non-­‐programmed	   cell	   death).	   However,	  
further	   analysis	   would	   be	   required	   to	   confirm	   this,	   which	   could	   involve	   measuring	   the	  
expression	  of	  hypoxia	  markers	   (such	  as	  hypoxia	   induced	   factor-­‐1α,	  HIF-­‐1α)	   (Carmeliet	  et	  al.,	  
1998;	  Iyer	  et	  al.,	  1998).	  In	  addition,	  to	  further	  confirm	  that	  the	  cells	  are	  undergoing	  apoptosis	  
additional	  studies	  can	  be	  performed	  which	  could	  involve	  measuring	  apoptotic	  markers	  (such	  as	  
FasL	  and	  cleaved	  caspase	  3).	  




There	   are	   a	   number	   of	   possible	   reasons	   which	   could	   explain	   why	   IPF	   spheroids	   are	   less	  
apoptotic	   in	   comparison	   to	   non-­‐IPF.	  One	  possible	   reason	   is	   the	   IPF	   spheroids	   synthesis	   high	  
levels	  of	  active	  TGFβ	  which	  has	  previously	  been	  reported	  to	  promote	  fibroblast	  cell	  survival	  in	  
vitro	   via	   the	   activation	   of	   PI3K/Akt	   pathway	   (reviewed	   in	   (Zhang,	   2009).	   Another	   possible	  
explanation	   is	   that	   IPF	   spheroids	   express	   high	   levels	   of	   CC	   chemokine	   ligand	   2	   (CCL2,	   also	  
known	   as	  monocyte	   chemotactic	   protein-­‐1,	  MCP1)	   transcriptionally	   (see	  Appendix	   6,	   Figure	  
A11	  which	  illustrates	  high	  CCL2	  mRNA	  levels	  in	  IPF	  spheroids	  in	  comparison	  to	  non-­‐IPF)	  which	  
has	   previously	   shown	   to	   mediate	   fibroblast	   survival	   by	   regulating	   interleukin	   (IL)-­‐6/STAT3	  
pathway	  (Liu	  et	  al.,	  2007).	  	  Furthermore,	  reduced	  expression	  of	  anti-­‐fibrotic	  mediators	  (such	  as	  
PGE2)	   may	   also	   play	   a	   key	   role	   in	   protecting	   IPF	   fibroblasts	   from	   apoptosis.	   This	   will	   be	  
discussed	  in	  detail	  in	  the	  next	  section.	  
4.3.8.	  	   EP2	   receptor	   signalling	   via	   COX1-­‐mediated	   PGE2	   synthesis	   promotes	  
fibroblast	  cell	  death	  in	  spheroids	  
PGE2	  is	  an	  antifibrotic	  lipid	  mediator	  derived	  from	  arachidonic	  acid	  metabolism	  via	  the	  activity	  
of	  COX.	  It	  is	  the	  most	  abundant	  prostanoid	  found	  in	  the	  lung,	  where	  it	  is	  synthesised	  by	  many	  
cells	   including	  fibroblasts	   (Wilborn	  et	  al.,	  1995).	  PGE2	   inhibits	   fibroblast	  proliferation	   (Elias	  et	  
al.,	  1985;	  Bitterman	  et	  al.,	  1986),	  differentiation	   (Kolodsick	  et	  al.,	  2003),	  migration	   (White	  et	  
al.,	   2005),	   and	   collagen	  production	   (Fine	   et	   al.,	   1989).	   	   Furthermore,	   in	   epithelial	   cells,	   PGE2	  
acts	   as	   a	   potent	   pro-­‐survival	  mediator	   (Nishihara	   et	   al.,	   2003;	   Tessner	   et	   al.,	   2004).	   Several	  
studies	   have	   illustrated	   that	   patients	   diagnosed	   with	   IPF	   have	   a	   relative	   deficiency	   in	   PGE2	  
synthesis	  (Wilborn	  et	  al.,	  1995;	  Keerthisingam	  et	  al.,	  2001;	  Petkova	  et	  al.,	  2003).	  The	  results	  in	  
this	  thesis	  also	  support	  this,	  as	  non-­‐IPF	  spheroids	  produced	  high	  levels	  of	  PGE2	  four	  days	  post	  
spheroid	   formation,	  whilst	  PGE2	   levels	  were	  deficient	   in	   IPF	  spheroids.	  Previous	  studies	  have	  
illustrated	   that	   TGFβ-­‐induced	   fibroblast	   differentiation	   is	   dependent	   on	   integrin	   signalling	  
involving	   focal	   adhesion	   kinase	   (FAK),	   however	   in	   the	   presence	   of	   PGE2,	   TGFβ-­‐induced	   FAK	  
phosphorylation	   in	   diminished	   which	   in	   turn	   limits	   Akt	   pathway	   and	   prevents	   fibroblast	  
differentiation	   (Kolodsick	   et	   al.,	   2003;	   Thomas	   et	   al.,	   2007).	   These	   findings	   may	   also	   partly	  
explain	  why	  non-­‐IPF	   spheroids	   lack	   a	  myofibroblast	   phenotype,	   as	   the	   increased	  PGE2	   levels	  
may	  diminish	  TGFβ	  induced	  myofibroblast	  differentiation	  in	  this	  3D	  system.	  
Although	  there	  is	  a	  clear	  difference	  in	  PGE2	  synthesis	  between	  control	  and	  fibrotic	  spheroids,	  
transcriptionally	  the	  mRNA	  levels	  for	  COX1	  and	  COX2	  between	  non-­‐IPF	  and	  IPF	  spheroids	  were	  
not	  statistically	  different.	  This	  contradicts	  many	  studies	   illustrating	   reduced	  COX	   levels	   in	   IPF	  




lung	   tissue	   samples	   in	   comparison	   to	   control	   samples	   (Petkova	   et	   al.,	   2003).	   Nevertheless,	  
since	  this	  was	  only	  interrogated	  at	  the	  transcriptional	  level,	  further	  investigations	  are	  required	  
to	  determine	  protein	  levels	  of	  COX1	  and	  COX2	  within	  these	  spheroids.	  	  
The	  next	  step	  was	  to	  identify	  which	  COX	  isoform	  is	  involved	  in	  PGE2	  synthesis	  by	  the	  fibroblast	  
spheroids.	   In	   this	   thesis,	   the	   results	   demonstrated	   that	   non-­‐IPF	   fibroblast	   cell	   death	   is	  
dependent	  on	  the	  activity	  of	  COX1	  rather	  than	  COX2	  when	  cultured	  as	  3D	  spheroid	  structures.	  
This	   data	   contradicts	   previously	   studies	   which	   demonstrated	   the	   role	   of	   COX2	   in	  mediating	  
fibroblast	  apoptosis	  in	  vitro	  (Maher	  et	  al.,	  2010)	  which	  suggests	  that	  fibroblasts	  cultured	  in	  this	  
3D	   system	   behave	   differently	   to	   fibroblasts	   cultured	   as	   a	   monolayer.	   Nevertheless,	   some	  
studies	  have	  supported	  the	  role	  of	  COX2/PGE2	  mediated	  cell	  death	  within	  spheroids	  composed	  
of	   dermal	   fibroblasts	   (Bizik	   et	   al.,	   2004;	   Vaheri	   et	   al.,	   2009).	   A	   possible	   reason	   for	   these	  
contradicting	   results	   is	   the	   type	   of	   compound	   used	   and	   the	   concentration.	   Many	   studies	  
(including	   the	  ones	  described	  above)	  used	  NS398	   to	  determine	   the	  effect	  of	  COX	  activity	  on	  
fibroblast	   apoptosis.	   This	   compound	  has	   been	   classified	   as	   a	   COX2	   specific	   inhibitor	  with	   an	  
IC50	  of	  1.77	  µM	  for	  human	  recombinant	  COX2.	  However,	  based	  on	  manufacturer’s	   literature	  
this	   compound	  may	  also	  have	  off	   target	  effects	  on	  COX1	  activity	   (IC50	  value	  of	  75	  µM).	  The	  
concentration	   of	   the	   compound	   used	   in	   both	   studies	   was	   15	   µM	   (or	   5	   µg/mL)	   which	   is	  
relatively	  high	   in	  comparison	  to	  the	   IC50	  values	  stated.	  Thus,	   it	  could	  be	  speculated	  that	  the	  
results	  shown	  in	  those	  studies	  may	  in	  fact	  be	  due	  to	  the	  activity	  of	  COX1.	  In	  this	  thesis	   I	  also	  
used	  NS398	  and	  my	  results	  illustrated	  that	  NS398	  had	  no	  effect	  on	  apoptosis.	  In	  addition,	  I	  also	  
used	  more	  specific	  COX1	  and	  COX2	  inhibitors.	  These	  were	  SC560	  (700	  fold	  selectivity	  for	  COX1	  
with	  an	   IC50	  of	  9	  nM,	  according	   to	  manufacturer’s	  description)	  and	  CAY10404	   (500,000	   fold	  
selectivity	   for	   COX2	   with	   an	   IC50	   of	   <1	   nM).	   In	   the	   presence	   of	   these	   more	   selective	  
compounds	  my	  data	  supported	  the	  role	  of	  COX1	  mediated	  apoptosis	  of	  fibroblast	  spheroids.	  In	  
order	  fully	  appreciate	  the	  role	  of	  COX1	  in	  pHLF	  apoptosis	  further	  studies	  could	  be	  performed	  
on	  2D	  monolayer	  cultures	  using	  these	  highly	  specific	  compounds.	  	  	  
Four	   receptors	   for	   PGE2	   have	   been	   described	   (EP1,	   EP2,	   EP3,	   and	   EP4)	   all	   of	   which	   are	   G-­‐
protein	   coupled	   receptors	   (GPCR).	   Activation	   of	   EP1	   and	   EP3	   promote	   smooth	   muscle	   cell	  
contraction	   by	   increasing	   in	   intracellular	   Ca2+	   concentration	   and	   decreases	   cAMP	   levels,	  
respectively.	  On	   the	  other	   hand,	   EP2	   and	   EP4	   receptor	   signalling	   elevate	   cAMP	   levels	  which	  
activates	  downstream	  signalling	  molecules	  to	  mediate	  smooth	  muscle	  cell	  relaxation,	  increase	  
apoptosis,	   decrease	   cell	   proliferation,	   and	   attenuate	   collagen	   synthesis	   (reviewed	   in	   (Bozyk	  
and	  Moore,	  2011)).	  My	  data	  demonstrated	  that	  prophylactic	  treatment	  with	  PGE2	  attenuated	  




collagen	  production	  in	  both	  non-­‐IPF	  and	  IPF	  spheroids	  (with	  greater	  potency	  shown	  in	  non-­‐IPF	  
spheroids),	  although	  both	  express	  similar	  levels	  of	  PTGER2	  and	  4	  mRNA,	  as	  well	  as	  lower	  levels	  
of	   PTGER1	   and	   3.	   However,	   only	   treatment	   with	   a	   small	   molecule	   EP2	   receptor	   agonist	  
attenuated	  collagen	  synthesis	  in	  either	  non-­‐IPF	  or	  IPF	  spheroids	  in	  a	  concentration-­‐dependent	  
manner	  (with	  slightly	  higher	  potency	  seen	  in	  non-­‐IPF	  spheroids).	  This	  supports	  published	  data	  
substantiating	   the	   importance	   of	   EP2	   receptor	   signalling	   in	   attenuating	   collagen	   synthesis	  
(Huang	  et	  al.,	  2007).	  Given	  that	   the	   fibroblasts	  also	  showed	  high	   levels	  of	  PTGER4	  mRNA	  we	  
would	   have	   expected	   PGE2	   to	   also	   have	   some	   effect	   via	   this	   receptor.	   However	   the	   results	  
illustrated	  that	  in	  the	  presence	  of	  EP4	  agonist	  or	  antagonist	  collagen	  synthesis	  did	  not	  occur.	  A	  
possible	   explanation	   for	   this	   could	   be	   that	   translational	   levels	   of	   EP4	  may	   be	   low	   thus	   the	  
expression	   of	   this	   protein	   on	   the	   membrane	   surface	   may	   be	   low	   in	   comparison	   to	   EP2	  
receptors.	  
Based	   on	   these	   findings	   it	   was	   also	   assumed	   that	   an	   EP2	   antagonist	   would	   allow	   increased	  
collagen	  deposition	  within	   the	   spheroids	   compared	   to	  baseline	   levels.	  However	   this	  was	  not	  
the	   case,	   suggesting	   that	   although	   PGE2-­‐mediated	   EP2	   receptor	   activation	   may	   decrease	  
collagen	  production	  in	  the	  3D	  system	  after	  exogenous	  PGE2	  treatment,	  the	  excessive	  collagen	  
deposition	  is	  not	  otherwise	  attenuated	  by	  endogenous	  PGE2	  signalling	  at	  baseline.	  A	  possible	  
reason	  for	  this	  could	  be	  that	  at	  early	  stage	  of	  spheroid	  formation	  the	  PGE2	  levels	  are	  too	  low	  
and	  EP2	   receptor	   signalling	   is	  not	  active.	  Therefore,	  antagonising	  an	   inactive	   receptor	  would	  
not	  show	  effect.	  Based	  on	  these	  findings	  it	  can	  be	  proposed	  that,	  the	  non-­‐IPF	  spheroids	  may	  to	  
some	   extent	   represent	   what	   is	   seen	   in	   a	   normal	   wound	   healing	   process	   (i.e.	   promote	   the	  
synthesis	   of	   a	   provisional	   matrix	   following	   cell-­‐to-­‐cell	   contact	   and	   then	   eventually	   undergo	  
apoptosis	  via	  increased	  production	  of	  PGE2).	  
Unsurprisingly,	   a	   small	   molecule	   EP2	   agonist	   reduced	   the	   viability	   of	   non-­‐IPF	   fibroblast	  
spheroids	   in	   a	   dose-­‐dependent	  manner	   akin	   to	   exogenous	   treatment	  with	   PGE2,	   however	   it	  
had	  a	  more	  limited	  impact	  on	  the	  percentage	  of	  TUNEL	  positive	  cells	  in	  IPF	  spheroids.	  Although	  
at	   the	   transcriptional	   level	   there	  was	  no	  statistical	  difference	   in	  PTGER2	  expression	  between	  
non-­‐IPF	  and	  IPF	  spheroids,	  there	  may	  be	  a	  difference	  at	  the	  translational	  level	  (Larsson	  et	  al.,	  
2008),	  and	   it	  could	  be	  hypothesised	  EP2	  receptor	  protein	   levels	  are	   lower	   in	   IPF	  spheroids	   in	  
comparison	  to	  non-­‐IPF,	  although	  this	  would	  require	  further	  validation.	  
Previous	   studies	   have	   illustrated	   that	   PTGER2	   mRNA	   levels	   are	   lower	   in	   IPF	   fibroblasts	   in	  
comparison	   to	   non-­‐IPF	   which	   is	   as	   a	   result	   of	   DNA	   hypermethylation	   (Moore	   et	   al.,	   2005a;	  




Huang	  et	  al.,	  2008b,	  2010).	  However,	  my	  data	  contrast	  these	  studies,	  which	  possibly	  suggest	  
that	   following	   cell-­‐to-­‐cell	   contact	   DNA	  methylation	   of	   the	  PTGER2	   gene	   is	   altered.	   However	  
further	  research	  is	  required	  to	  investigate	  this.	  
4.3.9.	  	   Fibroblast	  spheroids	  are	  non-­‐proliferative	  
In	   monolayer	   culture,	   fibroblasts	   (normal	   and	   fibrotic)	   derived	   from	   human	   lungs	   have	   the	  
ability	   to	   proliferate.	   In	   order	   to	   investigate	   whether	   similar	   results	   are	   shown	   within	   3D	  
spheroids,	   immunocytofluorescence	  labelling	  was	  conducted	  to	  detect	  Ki-­‐67	  positive	  cells.	  Ki-­‐
67	  is	  a	  nuclear	  protein	  with	  an	  unknown	  function,	  however	  it	  has	  shown	  to	  be	  expressed	  in	  all	  
stages	  of	  the	  cell	  cycle	  (G1,	  S,	  G2,	  and	  mitosis)	  excluding	  G0.	  This	  supports	  a	  possible	  role	  for	  
Ki-­‐67	  during	  proliferation	  which	  is	  one	  the	  main	  reason	  why	  it	  is	  considered	  as	  a	  proliferation	  
marker.	   In	   3D	   cultures,	   fibroblasts	   (from	   both	   normal	   and	   fibrotic	   lung)	   did	   not	   proliferate.	  
Such	   observations	   have	   also	   been	   observed	   in	   dermal	   fibroblasts	   which	   also	   form	   non-­‐
proliferating	  spheroids	  (Bizik	  et	  al.,	  2004).	  The	  non-­‐proliferative	  property	  of	  non-­‐IPF	  fibroblast	  
spheroids	  may	  be	  due	  to	  the	  increased	  synthesis	  of	  PGE2	  and	  low	  levels	  of	  active	  TGFβ,	  both	  of	  
which	   have	   previously	   shown	   to	   affect	   fibroblast	   proliferation	   by	   affecting	   the	   PI3K/Akt	  
pathway	  (Keerthisingam	  et	  al.,	  2001;	  Wilkes	  et	  al.,	  2005;	  Takai	  et	  al.,	  2013).	  
However,	   since	   the	   IPF	   spheroids	   also	   showed	   no	   sign	   of	   proliferation	   (despite	   having	   low	  
levels	  of	  PGE2	  and	  high	  levels	  of	  TGFβ)	  it	  could	  be	  postulated	  the	  cells	  do	  not	  proliferate	  as	  a	  
result	   of	   contact	   inhibition.	   Contact	   inhibition	   is	   defined	   as	   the	   termination	   of	   ruffling	   and	  
forward	   movement	   in	   the	   filopodia	   (cytoplasmic	   projections	   extending	   beyond	   the	   leading	  
edge	   lamellipodia)	   following	   cell-­‐to-­‐cell	   contact	   (Abercrombie,	   1979;	   Heckman,	   2009)	   which	  
has	   previously	   been	   described	   in	   human	   fibroblast	   (Wieser	   and	   Oesch,	   1986).	   However	   the	  
precise	   mechanism/signalling	   processes	   involved	   in	   causing	   contact	   inhibition	   is	   currently	  
unknown.	  Nevertheless,	  studies	  have	  postulated	  the	  role	  of	  cell	  adhesion	  molecules	   (such	  as	  
cadherins)	   in	   mediating	   contact	   inhibition	   via	   the	   activation	   of	   the	   Hippo	   pathway.	   This	  
pathway	  is	  involved	  in	  the	  regulation	  of	  cell	  proliferation	  and	  apoptosis.	  This	  pathway	  involves	  
the	   activation	   of	   a	   kinase	   cascade,	   where	   Mst1/2	   kinases	   and	   Sav1	   form	   a	   complex	   to	  
phosphorylate	   and	   activate	   LATS1/2	   kinase.	   This	   in	   turn	   phosphorylates	   and	   inhibits	   the	  
transcription	  co-­‐activators	  YAP	  and	  TAZ	  leading	  to	  an	  inhibition	  of	  cell	  proliferation.	  However,	  
when	  YAP	  and	  TAZ	  are	  dephosphorylated	   they	   can	   translocate	   into	   the	  nucleus	  and	   interact	  
with	   transcription	   factors	   to	   promote	   cell	   proliferation	   and	   inhibit	   apoptosis	   (Yu	   and	   Guan,	  
2013).	   Studies	   have	   illustrated	   that	   components	   of	   tight	   and	   adherens	   junctions	   are	   able	   to	  




associate	   with	   YAP/TAZ	   preventing	   its	   translocation	   into	   the	   nucleus	   thus	   inhibit	   cell	  
proliferation.	   Disruption	   of	   these	   tight	   and	   adherens	   junctions	   result	   in	   the	   induction	   of	  
YAP/TAZ	   nuclear	   localisation,	   promoting	   cell	   proliferation.	   Since	   IPF	   spheroids	   have	   shown	  
tight/adherens	  junctions	  it	  can	  be	  hypothesised	  that	  these	  junctions	  are	  regulating	  the	  Hippo	  
pathway	   in	   the	   fibroblast	   spheroids	   leading	   to	   contact	   inhibition.	   However,	   further	   work	   is	  
required	  to	  investigate	  the	  role	  of	  this	  signalling	  pathway	  in	  the	  pHLF	  cultured	  as	  spheroids.	  	  
	  
	  
4.4.	  Microarray	  data	  analysis	  
	  
4.4.1.	  	   Overview	  
Gene	   expression	  microarray	   technology	   has	   revolutionised	   the	   field	   of	  molecular	   biology	   by	  
allowing	   the	   detection	   of	   expression	   patterns	   and	   interactions	   of	   thousands	   of	   genes	  
simultaneously,	  by	  using	  multiple	  probes	   to	  assay	  each	   transcript.	  Although	  this	   technique	   is	  
increasingly	   robust	   for	   the	   detection	   of	   genes/pathways	   whose	   expression	   changes	   in	  
response	  to	  specific	  perturbations,	  there	  are	  still	  some	  concerns	  with	  regards	  to	  the	  reliability,	  
which	  is	  why	  quantitative	  and	  qualitative	  validation	  are	  often	  necessary	  (Kerr,	  2003).	  
Microarray	   analysis	   has	   been	   used	   extensively	   to	   compare	   transcriptional	   profiles	   of	   lung	  
samples	  from	  control	  subjects	  with	  those	  from	  patients	  diagnosed	  with	  IPF	  (Pardo	  et	  al.,	  2005),	  
nonspecific	   interstitial	   pneumonitis	   (NSIP),	   and	   hypersensitivity	   pneumonitis	   (Selman	   et	   al.,	  
2006)	  –	  all	  of	  which	  focused	  on	  differences	  in	  mRNA	  abundance.	  In	  addition,	  analysis	  has	  also	  
been	   performed	   on	   myofibroblasts	   isolated	   from	   control	   and	   IPF	   lungs	   (Kaminski	   and	  
Friedman,	  2002;	  Renzoni	  et	  al.,	  2004;	  Selman	  et	  al.,	  2007).	  Furthermore,	  ongoing	  work	  in	  our	  
laboratory	  has	  been	  investigating	  transcriptional	  profiles	  of	  monolayer	  fibroblast	  cultures	  from	  
lungs	  of	  IPF	  and	  system	  sclerosis	  patients.	  
Since	   this	   report	   has	   highlighted	   phenotypic	   differences	   between	   non-­‐IPF	   and	   IPF	   fibroblast	  
spheroids	  (i.e.	  cell	  death,	  collagen	  deposition	  and	  TGFβ	  activation),	  we	  decided	  to	  analyse	  the	  
transcriptional	   profiles	   of	   the	   spheroids	   to	   determine	   possible	   pathways	   that	   may	   be	  
dysregulated	   in	   IPF	   spheroids,	   resulting	   in	   the	  phenotypical	   changes	  described.	   Interestingly,	  
while	   performing	   quality	   control	   of	   the	   array	   data,	   Principal	   Component	   Analysis	   (PCA)	  
revealed	  a	  major	  sample	  outlier	  (which	  was	  subsequently	  excluded	  from	  further	  analysis);	  this	  




sample	   comprised	   a	   non-­‐IPF	   fibroblast	   line	   from	   a	   low	   passage	   culture	   (i.e.	   passage	   4,	   in	  
comparison	   to	   the	   remainder	   fibroblast	   spheroids	   cultured	   at	   passage	   5-­‐7).	   As	   stated	  
previously,	   cell	   passage	   can	   affect	   cell	   behaviour,	   differentiation	   state	   and	   senescence,	   and	  
may	  also	  have	  early	  effects	  on	  the	  transcriptome.	  
Another	   quality	   control	   PCA	   plot	   also	   illustrated	   slight	   batch	   and	   location	   effects.	   Minor	  
differences	   in	   non-­‐biological	   variables	   (such	   as	   reagent	   lot,	   operator,	   and	   even	   changes	   in	  
atmospheric	  ozone	  levels)	  can	  affect	  the	  gene	  expression	  microarray	  results	  (Fare	  et	  al.,	  2003;	  
Chen	  et	  al.,	  2011).	  The	  term	  ‘batch’	  refers	  to	  the	  microarrays	  that	  have	  been	  processed	  at	  the	  
same	   time	   at	   one	   site	   using	   the	   same	   array	   platform.	   The	   term	   ‘batch	   effect’	   refers	   to	  
cumulative	  errors	  induced	  by	  these	  time-­‐	  and	  place-­‐dependent	  experimental	  variations.	  Batch	  
effects	   in	  microarray	   studies	   are	   extremely	   common	  and	   almost	   inevitable,	   primarily	   due	   to	  
the	  fact	  that	  the	  majority	  of	  the	  available	  microarray	  platforms	  can	  only	  assay	  <20	  samples	  at	  
one	  time	  (Chen	  et	  al.,	  2011).	  In	  addition,	  the	  location	  at	  which	  the	  spheroid	  experiments	  were	  
initially	   formed	   can	   also	   affect	   the	   array	   also	   due	   to	   place-­‐dependent	   variations	   (e.g.	   lot	  
number	   of	   the	   reagents	   used).	   Since	   the	   spheroid	   samples	  were	   generated	   at	   two	   different	  
locations	  (i.e.	  UCL	  and	  GSK)	  and	  processed	  in	  two	  batches,	  variation	  due	  to	  these	  effects	  was	  
removed	  by	  using	  a	  statistical	  algorithm	  within	  Partek	  Genomics	  Suite.	  	  
After	  applying	  these	  quality	  control	  measures,	  the	  PCA	  plot	  then	  demonstrated	  that	  there	  was	  
a	  clear	  difference	  between	  non-­‐IPF	  and	  IPF	  spheroid	  samples.	  However,	  only	  138	  differentially	  
expressed	  genes	  were	  identified	  (false	  discovery	  rate,	  FDR,	  p<0.05	  and	  fold	  change	  >2	  or	  <-­‐2).	  
From	  this	  list	  76	  genes	  encoded	  proteins	  with	  known	  functions.	  Compared	  to	  other	  microarray	  
published	  data	  the	  number	  of	  differentially	  expressed	  genes	  is	  this	  system	  is	  quite	  low	  (Selman	  
et	  al.,	  2006;	  Lindahl	  et	  al.,	  2013).	  There	  are	  a	  number	  of	  possible	   reasons	   that	  could	  explain	  
why	   only	   a	   few	   genes	   were	   differentially	   expressed.	   The	   most	   obvious	   reason	   is	   that	  
fibroblasts	   spheroid	   is	   a	   completely	   different	   system	   in	   comparison	   to	  monolayer	   fibroblast	  
cultures.	  Thus	  difference	  in	  gene	  expression	  profile	  is	  entirely	  justifiable.	  	  
Another	  possible	  reason	  that	  could	  explain	  why	  a	  low	  number	  of	  differentially	  expressed	  genes	  
were	   detected	   is	   the	   presence	   of	   noise	   within	   the	   samples	   created	   by	   donor-­‐to-­‐donor	  
variations	   (e.g.	   gender,	   age,	  medical	   status,	  medication	   taken	   by	   the	   patients,	   and	   smoking	  
status).	  Due	   to	  patient	  confidentiality	   it	  was	  difficult	   to	  obtain	   the	  complete	  medical	   reports	  
for	   all	   of	   the	  donors,	  which	  was	   one	   reason	  why	   these	   factors	  were	  not	   taken	   into	   account	  
during	  the	  analysis.	  	  




Furthermore,	  my	  data	  illustrated	  that	  within	  just	  24	  hours	  of	  spheroid	  formation,	  both	  non-­‐IF	  
and	   IPF	   spheroids	   are	   capable	   of	   synthesising	   their	   own	   active	   TGFβ	   and	   collagen.	   Thus,	   to	  
some	  extent	  both	  non-­‐IPF	  and	   IPF	  spheroids	  behave	  similarly	   following	  cell-­‐to-­‐cell	  contact	  at	  
the	  early	  stage	  of	  spheroid	  formation	  (irrespective	  with	  the	  fact	  that	  active	  TGFβ	  and	  collagen	  
levels	  were	  greater	  in	  IPF	  spheroids).	  Therefore,	  since	  the	  microarray	  samples	  only	  composed	  
of	   spheroids	  cultured	   for	  24	  hours,	   it	  may	  not	  be	  entirely	   surprising	   to	   see	  a	   low	  number	  of	  
differentially	  expressed	  genes	  at	   that	  particular	   time	  point.	  However,	  after	  96	  hours	  non-­‐IPF	  
spheroids	  undergo	  apoptosis	  whilst	  IPF	  spheroids	  remain	  fairly	  resistant.	  Therefore,	  it	  may	  be	  
of	   great	   interest	   to	   perform	   another	  microarray	   study	   where	   spheroids	   are	   cultured	   for	   96	  
hours	  which	  could	  potentially	  lead	  to	  the	  detection	  of	  more	  differentially	  expressed	  genes	  and	  
could	  help	  identify	  a	  specific	  pathway.	  	  
Moreover,	   previously	   published	   microarray	   data	   studies	   on	   non-­‐IPF	   and	   IPF	   myofibroblasts	  
revealed	   a	   greater	   number	   of	   differentially	   expressed	   genes	   at	   the	   level	   of	   ribosomal	  
recruitment	  than	  at	  the	  level	  of	  transcript	  abundance,	  suggesting	  that	  pathological	  translation	  
control	  is	  a	  major	  characteristic	  of	  IPF	  myofibroblasts	  (Larsson	  et	  al.,	  2008).	  Similar	  may	  also	  be	  
the	   case	   in	   this	   3D	   system	   which	   may	   also	   explain	   the	   low	   levels	   of	   differed	   genes	   at	   the	  
transcriptional	  level.	  	  
4.4.2.	   Differentially	  expressed	  genes	  
The	  top	  three	  differentially	  expressed	  genes	  identified	  were	  PRR14L	  (proline	  rich	  14-­‐like),	  CTSB	  
(cathepsin	  B),	  and	  PTGER3	   (prostaglandin	  E2	  receptor	  3).	  Currently	   the	   function	  of	  PRR14L	   is	  
unknown.	   However	   many	   studies	   have	   illustrated	   the	   importance	   of	   cathepsin	   B	   and	   EP3	  
receptor	  signalling	  in	  pulmonary	  fibrosis	  which	  will	  be	  described	  below.	  	  
Cathepsins	  are	  a	   class	  of	  proteases	  primarily	   involved	   in	   lysosomal	  end	  stage	  degradation	  of	  
endocytosed	  proteins	   (Turk	  et	  al.,	  2012).	   In	  addition,	  cathepsins	  also	  play	  a	  role	   in	  degrading	  
ECM	  proteins	   (Lecaille	   et	   al.,	   2002;	  Novinec	   and	   Lenarčic,	   2013).	   Their	   proteolytic	   activity	   is	  
regulated	  by	   their	   inhibitors	   (i.e.	   steins,	   kininogens,	  and	  cystatins,	  all	  of	  which	  belong	   to	   the	  
cystatins	   superfamily)	   (Abrahamson	   et	   al.,	   2003;	   Turk	   et	   al.,	   2008)	   which	   suggests	   that	   the	  
balance	   between	   cathepsins	   and	   cystatins	   may	   be	   important	   for	   the	   degradation	   of	   ECM	  
components.	  Studies	  have	  demonstrated	  increased	  cathepsin	  production	  in	  many	  chronic	  lung	  
diseases	  including	  asthma	  and	  cystic	  fibrosis	  which	  contribute	  to	  the	  remodelling	  of	  ECM	  and	  
basement	   membrane	   (Lalmanach	   et	   al.,	   2006).	   Furthermore,	   studies	   have	   illustrated	   that	  
deficiency	  in	  cathepsin	  activity	  exacerbated	  lung	  fibrosis	  thus	  overexpression	  of	  cathapsin	  may	  




be	  beneficial	  as	  a	  therapeutic	  strategy	  for	  the	  treatment	  of	  pulmonary	  fibrosis	  which	  could	  aid	  
in	   the	   ECM	   degradation	   (Lalmanach	   et	   al.,	   2006;	   Quinn	   et	   al.,	   2010).	   	   The	   results	   fro	   the	  
microarray	   study	   in	   this	   thesis	   illustrated	   that	   transcriptionally	   CTSB	   levels	   are	   low	   in	   IPF	   in	  
comparison	  to	  non-­‐IPF	  spheroids.	  This	   is	   in	  support	  with	  a	  recent	  study	  published	  which	  also	  
demonstrated	  reduced	  cathepsin	  B	  levels	  in	  differentiated	  lung	  fibroblasts.	  It	  has	  been	  shown	  
that	   intracellular	   cathepsin	   B	   contributes	   in	   the	   TGFβ	   mediated	   differentiation	   of	   lung	  
fibroblasts	  via	   intracellular	  processing	  of	  pro-­‐TGFβ	   to	   its	  mature	   form.	  Following	   release	  and	  
activation	   of	   TGFβ,	   the	   canonical	   Smad	   signalling	   pathway	   initiates	   myofibrogenesis.	  
Furthermore	   the	   same	   study	   demonstrated	   that	   Smad-­‐signalling	   regulates	   the	   expression	   of	  
cystatin	   C	   which	   inhibits	   the	   activity	   of	   extracellular	   cathepsin	   leading	   to	   reduced	   ECM	  
degradation	  (Kasabova	  et	  al.,	  2014).	  This	  provides	  evidence	  of	  a	  negative	  feedback	  look	  for	  the	  
activity	  of	  cathepsin	  B.	   	  Since	  IPF	  spheroids	  spontaneously	  synthesis	  TGFβ	   it	  can	  be	  proposed	  
that	  reduced	  CTSB	  may	  be	  as	  a	  result	  of	  this	  negative	  feedback	  loop,	  contributing	  to	  increased	  
collagen	  levels.	  However,	  further	  validation	  is	  required.	  
As	  stated	  before,	  EP3	  receptors	  which	  mediate	  cellular	  activity	  via	   the	   inhibition	  of	  acetylate	  
cyclase	  resulting	  in	  reduced	  cAMP	  levels.	  My	  current	  qPCR	  data	  has	  illustrated	  that	  there	  is	  no	  
significant	   difference	   in	  PTGER3	  mRNA	   levels	   between	   non-­‐IPF	   and	   IPF	   spheroids.	   However,	  
the	  microarray	   data	   illustrated	   that	   PTGER3	   levels	   are	   elevated	   in	   IPF	   spheroids.	   There	   are	  
several	  possible	   reasons	   for	   these	  contradicting	  data	  which	  will	  be	  discussed	   later	   in	  Section	  
4.4.5.	   However,	   these	   contradicting	   results	   support	   the	   need	   of	   further	   validation	   regarding	  
the	  expression	  of	  this	  gene.	  
4.4.2.	  	   Pathway	  analysis	  
Following	  the	  identification	  of	  the	  differentially	  expressed	  genes,	  Partek	  pathway	  analysis	  was	  
then	  performed	  to	  provide	  an	  enrichment	  score.	  This	   is	  a	   formal	  statistical	  evaluation	  of	   the	  
dataset	  which	   assesses	   the	   overlap	   of	   the	   differentially	   expressed	   genes	  with	   those	   in	   each	  
pathway	   in	   a	  database	  of	  pathways	   (Subramanian	  et	   al.,	   2005).	   In	   this	   case	   the	  Kegg	   (Kyoto	  
encyclopaedia	   of	   genes	   and	   genomes)	   pathway	   database	   was	   used.	   Based	   on	   this	   analysis,	  
several	  pathways	  were	   identified	   including	  some	  that	  are	  highly	  topical	   in	  understanding	  the	  
pathogenesis	   of	   pulmonary	   fibrosis.	   These	   include	   phosphatidylinositol	   signalling,	   calcium	  
signalling,	  vascular	  smooth	  muscle	  contraction,	  cell	  cycle,	  Notch	  signalling,	  vascular	  endothelial	  
growth	   factor	   (VEGF)	   signalling	   pathway,	   chemokine	   signalling	   pathway,	   inositol	   phosphate	  
metabolism,	   metabolic	   pathways,	   cell	   adhesion,	   mitogen-­‐activated	   protein	   kinases	   (MAPK)	  
signalling,	  and	  the	  PI3K-­‐Akt	  signalling	  pathway.	  	  




Although	   these	   pathways	   were	   identified	   following	   the	   enrichment	   analysis,	   in	   many	   cases	  
only	  a	  single	  differentially	  expressed	  gene	  was	  detected	  for	  each	  pathway	  listed	  (Appendix	  2).	  
In	   addition,	   the	   pathway	   with	   the	   highest	   enrichment	   score	   was	   the	   phototransduction	  
pathway	   (involved	   in	   processing	   light	   in	   the	   retina	   of	   the	   eye).	   However,	   the	   three	   genes	  
detected	  in	  this	  pathway	  are	  all	  involved	  in	  encoding	  calmodulin	  (calcium	  modulated	  protein;	  
Figure	  A7,	  K).	  This	  protein	  not	  only	  plays	  a	  role	  in	  the	  phototransduction	  pathway	  but	  also	  in	  
several	   other	   processes	   including	   smooth	  muscle	   contraction	   (Masuda	   et	   al.,	   1984),	   calcium	  
signalling	   pathway,	   cell	  migration	   (Verploegen	   et	   al.,	   2002),	   inflammation	   (Nakashima	   et	   al.,	  
1986),	   phosphatidylinositol	   signalling	   system	   (MacNicol	   et	   al.,	   1990),	   and	   ras	   signalling	  
(Villalonga	  et	  al.,	  2002).	  This	  suggests	  that	  data	  analysis	  based	  solely	  on	  enrichment	  scores	  may	  
sometimes	   be	  misleading	   (particularly	  when	   the	   number	   of	   differentially	   expressed	   genes	   is	  
small)	  or	  unhelpful.	  The	  enrichment	  analysis	  is	  also	  dependent	  on	  the	  accuracy	  of	  the	  pathway	  
databases	  and	  how	  up-­‐to-­‐date	  they	  are.	  	  
4.4.3.	  	   Differentially	  expressed	  genes	  involved	  in	  metabolic	  pathways	  
The	   pathway	   that	   consisted	   of	   the	   most	   differentially	   expressed	   genes	   was	   the	   metabolic	  
pathway.	  Seven	  genes	  belonged	  to	  this	  pathway	  group:	  CS	  (citrate	  synthase),	  IMPDH2	  (Inosine-­‐
5’-­‐monophosphate	  dehydrogenase	  2),	  MTHFR	   (methylenetetrahydrofolate	  reductase),	  P4HA1	  
(prolyl	   4-­‐hydroxylase	   subunit	   alpha	   1),	   SPTLC2	   (serine	   palmitoyltransferase),	   SYNJ2	  
(synaptojanin	   2),	   and	   XDH	   (xanthine	   dehydrogenase).	   Although	   these	   genes	   belong	   to	  
metabolic	   pathways	   none	   of	   them	   form	   any	   direct	   protein-­‐protein	   interactions.	   However,	  
there	  are	  a	   few	   indirect	  protein-­‐protein	  associations	   (Appendix	  2;	  Figure	  A5).	  Each	  of	   theses	  
genes	  will	  be	  discussed	  briefly	  below.	  
CS	   encodes	   for	   citrate	   synthase	   which	   is	   located	   in	   mitochondria	   and	   commonly	   used	   as	   a	  
marker	   for	   the	   presence	   of	   intact	  mitochondria.	   This	   enzyme	   plays	   a	   vital	   role	   in	   the	   Krebs	  
cycle	   by	   catalysing	   the	   conversion	   of	   acetyl-­‐CoA	   and	   oxaloacetate	   into	   citrate.	   It	   has	   been	  
postulated	   that	   factors	   affecting	   the	   Krebs	   cycle	   can	   profoundly	   influence	   the	   cellular	  
energetics	  of	  a	  cell	  and	  may	  therefore	  affect	  fibroblast	  cell	  growth	  and	  proliferation	  (Emblom-­‐
Callahan	  et	  al.,	  2010).	  Based	  on	  the	  microarray	  results	  CS	  regulation	  is	  low	  in	  IPF	  spheroids	  in	  
comparison	  to	  non-­‐IPF	  spheroids	  (Figure	  A5,	  J)	  which	  suggests	  that	  IPF	  fibroblasts	  may	  exhibit	  
defects	  in	  respiratory	  activity	  with	  potentially	  reduced	  ATP	  levels	  (Lin	  et	  al.,	  2012).	  This	  result	  
contradicts	  previously	  published	  data	  illustrating	  elevated	  ATP	  content	  in	  BALF	  of	  IPF	  patients	  
in	   comparison	   to	   control	   subjects.	   Furthermore,	   in	   bleomycin-­‐induced	   PF	   mice	   and	   in	   vitro	  
assays	  (involving	  epithelial	  cells)	  ATP	  has	  been	  postulated	  as	  a	  major	  endogenous	  danger	  signal	  




as	  it	  results	  in	  IL-­‐1β	  maturation	  leading	  to	  lung	  fibrosis	  (Riteau	  et	  al.,	  2010).	  However,	  as	  stated	  
these	  finding	  were	  demonstrated	  in	  epithelial	  cells.	  The	  expression	  of	  CS	  and	  ATP	  and	  the	  role	  
of	  Krebs	  cycle	   in	   fibrotic	  pHLF	  have	  not	  been	  demonstrated.	  Thus,	   further	   investigations	  and	  
validations	  would	  be	  necessary	  to	  investigate	  this.	  	  
IMPDH2	  encodes	  the	  rate	  limiting	  enzyme	  inosine-­‐5’-­‐monophosphate	  (IMP)-­‐dehydrogenase	  2	  
which	   is	   involved	   in	   the	   de	   novo	   guanine	   nucleotide	   biosynthesis.	   The	   encoded	   protein	  
catalyses	   NAD-­‐dependent	   oxidation	   of	   IMP	   into	   xanthine-­‐5’-­‐monophosphate	   (XMP)	  which	   is	  
then	  converted	  into	  guanosine-­‐5’-­‐monophosphate	  (GMP).	  Thus,	  this	  enzyme	  plays	  a	  vital	  role	  
in	   the	   maintenance	   of	   cellular	   guanine	   deoxy-­‐	   and	   ribonucleotide	   pools	   essential	   for	   the	  
synthesis	  of	  genomic	  material	  (i.e.	  of	  DNA	  and	  RNA).	  Microarray	  data	  illustrate	  that	  this	  gene	  is	  
high	  in	  non-­‐IPF	  spheroids	  in	  comparison	  to	  IPF	  (Figure	  A8,	  K).	  This	  could	  suggest	  two	  things	  –	  
either	  there	  is	  a	  potential	  deficit	  in	  generating	  genomic	  material	  in	  IPF	  spheroids	  or	  in	  non-­‐IPF	  
spheroids	  this	  gene	  is	  upregulated	  to	  increase	  to	  pool	  of	  genomic	  material	  as	  a	  consequence	  of	  
cell-­‐to-­‐cell	  contact.	  However,	  further	  validation	  is	  required	  before	  drawing	  any	  conclusions.	  	  
MTHFR	   encodes	   for	  methylenetetrahydrofolate	   reductase,	   an	  enzyme	   involved	   in	  processing	  
amino	  acids,	   particularly	   the	   conversion	  of	  homocysteine	   to	  methionine.	   Similar	   to	   IMPDH2,	  
this	   gene	   is	   also	   low	   in	   IPF	   spheroids	   in	   comparison	   to	   non-­‐IPF	   (Figure	   A8,	   D)	   suggesting	  
defects	  in	  processing	  amino	  acids	  in	  IPF	  spheroids.	  	  
P4HA1	   encodes	   for	   prolyl	   4-­‐hyroxylase	   (P4H),	   an	   enzyme	   involved	   in	   the	   hydroxylation	   of	  
proline	  resulting	  in	  the	  formation	  of	  4-­‐hydroxyproline	  which	  plays	  a	  vital	  role	  in	  proper	  folding	  
of	   newly	   synthesised	   procollagen	   chains.	   This	   gene	   is	   upregulated	   in	   IPF	   spheroids	   in	  
comparison	   to	   non-­‐IPF	   (Figure	  A9,	   C)	  which	   correlates	  with	   previously	   published	   findings	   as	  
well	  as	  the	  results	  in	  this	  thesis	  illustrating	  that	  IPF	  spheroids	  produce	  high	  levels	  of	  collagen	  in	  
comparison	  to	  non-­‐IPF.	  	  
SPTLC2	   encodes	   for	   serine	   palmitoyltransferase,	   a	   key	   enzyme	   for	   sphingolipid	   metabolism	  
(Hanada,	  2003).	  	  This	  gene	  is	  downregulated	  in	  IPF	  spheroids	  in	  comparison	  to	  non-­‐IPF	  (Figure	  
A10,	  L).	  Sphingolipids	  are	  one	  of	  the	  three	  classes	  of	  lipids	  found	  in	  the	  cell	  membrane	  which	  
(along	  with	  cholesterol	  and	  proteins)	  form	  lipid	  rafts	  (Lahiri	  and	  Futerman,	  2007).	  These	  form	  
liquid-­‐ordered	   phases	   in	   the	   lipid	   bilayer	   (Lingwood	   and	   Simons,	   2010).	  Many	   sphingolipids,	  
particularly	  sphingosine	  1-­‐phosphate	  (S1P)	  and	  ceramide,	  are	  recognised	  as	  critical	  mediators	  
of	   various	   basic	   cellular	   processes	   involved	   in	   tissue	   responses	   to	   injury.	   Such	   processes	  
include	   cell	   survival,	   migration,	   proliferation,	   contraction,	   gene	   expression,	   and	   cell-­‐cell	  




interactions	  (Ishii	  et	  al.,	  2004;	  Hannun	  and	  Obeid,	  2008;	  Rivera	  and	  Chun,	  2008).	   In	  addition,	  
recent	   studies	   have	   substantiated	   the	   role	   of	   S1P	   in	   regulating	   the	   development	   of	   tissue	  
fibrosis	   in	   several	   organ	   systems	   including	   lungs.	   For	   instance,	   inhibition	   of	   S1P1	   receptor	  
signalling	  worsened	  bleomycin-­‐induced	  pulmonary	  fibrosis	  indicating	  that	  this	  pathway	  acts	  as	  
an	   endogenous	   inhibitor	   of	   fibrogenesis	   in	   the	   lungs	   (Shea	   et	   al.,	   2010).	   In	   addition	   in	   vitro	  
studies	   have	   shown	   that	   S1P	   attenuates	   fibroblast	   chemotaxis	   (Goparaju	   et	   al.,	   2005)	   and	  
conveys	   autocrine	   and	   paracrine	   protection	   of	   epithelial	   cells	   (i.e.	   A549s)	   (Schnitzer	   et	   al.,	  
2009).	   Further	   evidence	   that	   sphingolipids	   may	   regulate	   the	   development	   of	   lung	   fibrosis	  
comes	   from	   studies	   showing	   increased	   activity	   of	   sphingomyelin-­‐degrading	   enzyme	   acid	  
sphingomyelinase	   (ASM)	   in	   the	   lungs	   of	   mice	   following	   intratracheal	   bleomycin	   challenge.	  
Furthermore,	  mice	  genetically	  deficient	  for	  this	  enzyme	  demonstrated	  an	  attenuation	  of	   lung	  
fibrosis	   in	   this	   model	   (Dhami	   et	   al.,	   2010).	   Thus,	   dysregulation	   in	   the	   S1P	   pathway	   could	  
potentially	  contribute	  to	  decreased	  fibroblast	  apoptosis	  and	  increased	  epithelial	  cell	  apoptosis	  
which	  are	  key	  cellular	  features	  observed	  in	  lung	  fibrosis	  (reviewed	  in	  (Shea,	  2012)).	  As	  well	  as	  
illustrating	   anti-­‐fibrotic	   effects,	   several	   studies	   have	   also	   demonstrated	   contradicting	   data	  
whereby	  S1P	  signalling	  can	  induce	  TGFβ	  –induced	  fibroblast	  differentiation	  (Kono	  et	  al.,	  2007).	  
Since	  the	  microarray	  results	  illustrate	  a	  downregulation	  in	  the	  enzyme	  involved	  in	  sphingolipid	  
metabolism	  it	  could	  potentially	  suggest	  that	  dysregulation	  of	  the	  sphingolipid	  pathway	  may	  be	  
relevant	   for	   some	   of	   the	   phenotypical	   features	   seen	   in	   IPF	   spheroids,	   and	   this	   is	   worthy	   of	  
further	  investigation	  	  	  
SYNJ2	   encodes	   for	   synaptojanin-­‐2	   which	   is	   a	   member	   of	   the	   inositol-­‐polyphosphate	   5-­‐
phosphatase	  which	   is	   involved	   in	  blocking	  clatherin-­‐mediated	  endocytosis.	  To	  date	  the	  effect	  
of	   this	   protein	   on	   fibrosis	   has	   never	   been	   studied	   before.	   However,	   since	   this	   gene	   is	  
downregulated	  in	  IPF	  spheroids	  in	  comparison	  to	  non-­‐IPF	  (Figure	  A6,	  E)	  further	  investigations	  
and	  validations	  could	  be	  performed.	  
4.4.4.	  	   Differentially	  expressed	  genes	  involved	  in	  influenza	  
Since	   only	   a	   small	   number	   of	   differentially	   expressed	   genes	   were	   identified	   overall,	   which	  
resulted	  in	  minimal	  identification	  of	  protein-­‐protein	  interactions	  (based	  on	  String	  9.1	  analysis),	  
it	   was	   decided	   to	   perform	   the	   analysis	   again	   with	   p<0.01	   (a	   more	   stringent	   p-­‐value,	   but	  
unadjusted/without	   FDR)	   and	   a	   fold	   change	  of	   <-­‐2	   or	   >2.	   Based	  on	   these	   criteria	   730	   genes	  
passed	   the	   threshold,	   of	   which	   414	   genes	   encoded	   proteins	   with	   known	   functions.	   More	  
protein-­‐protein	   interactions	   were	   also	   evident	   in	   comparison	   to	   the	   previous	   analysis.	  
Bizarrely,	   Partek	   pathway	   analysis	   demonstrated	   the	   Influenza	   A	   pathway	   with	   the	   highest	  




enrichment	  score.	  12	  genes	  (CASP1,	  CCL2,	  DDX58,	  IFIH1,	  IL1A,	  IL33,	  MX1,	  OAS2,	  OAS3,	  PIK3R1,	  
PML,	  and	  PRKCB)	  were	  identified	  in	  the	  list	  of	  differentially	  expressed	  probes	  belonging	  to	  this	  
pathway.	  	  
Influenza	  A	  virus	   is	  a	  genus	  of	   the	  orthomyxoviridae	   family	  of	  viruses	  which	  causes	  an	  acute	  
respiratory	   illness	   known	   as	   influenza	   (commonly	   referred	   to	   as	   ‘the	   flu’).	   Clinical	  
presentations	   include	   fever,	   cough,	   and	   dyspnoea.	   In	   addition,	   majority	   of	   patients	   have	  
clinically	   apparent	   pneumonia	   (Bay	   et	   al.,	   2007)	  which	  die	   of	   progressive	   respiratory	   failure.	  
There	  are	  several	  subtypes	  of	  this	  virus	  of	  which	  the	  H5N1	  subtype	  has	  previously	  been	  shown	  
to	  result	  in	  pulmonary	  fibrosis	  in	  mice	  infected	  with	  this	  virus	  (Qiao	  et	  al.,	  2009).	  This	  provided	  
evidence	   that	   this	   virus	  may	   possibly	   play	   a	   role	   in	   the	   pathogenesis	   of	   pulmonary	   fibrosis.	  
Since	  this	  pathway	  was	  identified	  with	  the	  highest	  enrichment	  score	  further	  validation	  of	  the	  
microarray	   results	   is	   vital.	   This	   would	   involve	   performing	   qRT-­‐PCR	   of	   the	   differentially	  
expressed	  genes.	   In	  addition	  the	  effect	  of	  this	  pathway	  on	  the	  phenotype	  of	  non-­‐IPF	  and	   IPF	  
spheroids	   (i.e.	   collagen	   synthesis,	   active	   TGFβ	   production,	   and	   apoptosis)	   also	   should	   be	  
investigated.	  	  
One	   thing	   to	   note	   is	   that	   the	   fibroblasts	   were	   not	   exposed	   to	   influenza	   A	   virus	   in	   this	   3D	  
spheroid	  system.	  Therefore,	   the	  detection	  of	   this	  pathway	   following	   the	  enrichment	  analysis	  
was	   unexpected.	   Furthermore,	   although	   the	   12	   genes	   detected	   belong	   to	   the	   Influenza	   A	  
pathway,	  some	  of	  those	  genes	  are	  functionally	   linked	  to	  many	  other	  pathways.	  For	  example,	  
CASP1	  encodes	  caspase	  1	  which	  plays	  a	  key	  role	  in	  the	  activation	  of	  IL-­‐1β (Denes	  et	  al.,	  2012).	  
IL-­‐33	   is	   a	  member	   of	   the	   IL-­‐1	   family	   however	   unlike	   IL-­‐1β,	   IL33	   activity	   is	   not	   dependent	   of	  
caspase	   1.	   Both	   IL1β	   and	   IL33	   are	   pro-­‐inflammatory	   and	   pro-­‐fibrotic	   cytokines.	   In	   addition,	  
CCL2	   is	   also	   a	   chemoattractant	   cytokine	   which	   exerts	   pro-­‐fibrotic	   effects	   on	   fibroblasts	   by	  
stimulating	  ECM	  production	  (discussed	  in	  more	  detail	  in	  Section	  4.5.5).	  
4.4.5.	  	   Microarray	  analysis	  contradict	  some	  qRT-­‐PCR	  results.	  	  
Since	   previous	   qRT-­‐PCR	   analysis	   of	   non-­‐IPF	   and	   IPF	   spheroids	   illustrated	   some	   differences	  
between	   the	   two	   (such	   as	   differential	   mRNA	   levels	   for	   ACTA2,	   ITGAV,	   and	   ITGB5),	   it	   was	  
expected	  that	  these	  genes	  would	  also	  be	  detected	  after	  performing	  microarray	  data	  analysis.	  
However,	   this	   was	   not	   the	   case.	   In	   addition,	   qRT-­‐PCR	   data	   for	   PTGER3	   expression	   (gene	  
involved	   in	   encoding	   PGE2	   receptor	   EP3)	   illustrated	   that	   there	   was	   no	   statistical	   difference	  
between	  non-­‐IPF	  and	  IPF	  spheroids,	  however	  microarray	  data	  analysis	  suggested	  this	  gene	  was	  
differentially	   expressed	   with	   an	   upregulation	   seen	   in	   IPF	   spheroids.	   There	   are	   a	   number	   of	  




possible	  reasons	  which	  could	  explain	  these	  differences.	  For	  instance,	  since	  the	  samples	  in	  the	  
microarray	   included	   only	   one	   replicate	   from	   each	   donor,	   it	   could	   suggest	   that	   some	   of	   the	  
array	  data	  may	  have	  resulted	  due	  to	  chance.	  Another	  possible	  reason	  for	  these	  contradicting	  
results	   is	   the	  method	  used	  to	   isolate	  RNA.	  For	  qRT-­‐PCR	  Trizol	   reagent	  was	  used	  however	   for	  
microarray	   studies	   RNaqueous	   lysis	   buffer	   was	   used	   for	   RNA	   isolation.	   Thus,	   for	   direct	  
comparisons	  between	  qRT-­‐PCR	  and	  microarray	  analysis	  it	  would	  be	  ideal	  to	  use	  the	  same	  RNA	  
isolation	  protocol	  (something	  that	  could	  be	  considered	  in	  the	  future).	  In	  addition,	  studies	  have	  
shown	  that	  qRT-­‐PCR	  is	  actually	  more	  sensitive	  for	  detecting	  small	  changes	  in	  gene	  expression	  
in	   comparison	   to	   microarrays	   which	   could	   also	   explain	   the	   contradicting	   results	   and	   also	  
support	   the	   importance	   of	   thorough	   validation	   of	   the	   microarray	   data	   (Wang	   et	   al.,	   2006;	  
Allanach	  et	  al.,	  2008).	  
	  
4.5.	  Medium-­‐throughput	  compound	  screening	  
	  
4.5.1.	  	   Overview	  
High/medium-­‐throughput	   screening	   is	   the	   process	   of	   testing	   a	   large	   number	   of	   diverse	  
compounds	   against	   disease	   targets	   to	   identify	   ‘hits’	   (Liu	   et	   al.,	   2004).	  GlaxoSmithKline	   (GSK)	  
has	   developed	   a	   library	   composed	   of	   182	   compounds	   which	   target	   several	   pathways	  
potentially	  involved	  in	  the	  initiation	  and/or	  the	  progression	  of	  IPF.	  This	  compound	  library	  was	  
termed	  the	  ‘fibrosis	  toolbox’.	  A	  medium-­‐throughput	  screening	  was	  performed	  which	  involved	  
treating	   the	   non-­‐IPF	   and	   IPF	   spheroids	   prophylactically	   with	   each	   compound	   at	   high	  
concentration	   (10	   µM).	   The	   primary	   endpoint	   involved	   determining	   total	   spheroid	   collagen	  
content	   by	   HPLC.	   Due	   to	   confidentiality,	   only	   a	   selected	   subgroup	   of	   compounds	   were	  
analysed	  and	  presented	  in	  this	  thesis.	  The	  results	  illustrated	  a	  number	  of	  hits	  (or	  >50	  %	  change	  
in	  baseline	  collagen	  synthesis)	  within	  the	  compound	  library	  some	  of	  which	  will	  be	  discussed	  in	  
detail	   below.	   It	   is	   important	   to	   note	   that	   all	   these	   compounds	   require	   further	   validation,	   as	  
there	  is	  the	  potential	  for	  these	  ‘hits’	  to	  have	  arisen	  due	  to	  toxicity.	  
4.5.2.	  	   Targeting	  collagen	  crosslinking	  
BMP-­‐1	  has	  been	  reported	  to	  play	  a	  key	  role	  in	  matrix	  stiffening	  by	  promoting	  the	  cleavage	  and	  
activation	  of	   a	   collagen	   crosslinking	  enzyme	  known	  as	   lysyl	   oxidase	   (LOX).	   LOX	   catalyses	   the	  




oxidation	  of	   lysine	  residues	   in	  elastin	  and	  collagen,	  which	   lead	  to	  the	  formation	  of	   intra-­‐	  and	  
intermolecular	  crosslinks	  vital	  for	  ECM	  stabilisation	  (Grimsby	  et	  al.,	  2010).	  Elevated	  activity	  of	  
LOX	  has	  previously	  been	  reported	  in	  PF	  or	  models	  thereof	  (Almassian	  et	  al.,	  1991;	  Kagan	  and	  
Li,	   2003).	   For	   instance,	   studies	   have	   illustrated	   that	   bleomycin-­‐exposed	   human	   foetal	   lung	  
fibroblasts	   had	   an	  upregulation	   in	   LOX	   levels	   (Chen	  et	   al.,	   2010).	   Furthermore,	   a	   rise	   in	   LOX	  
activity	   elevates	   bleomycin-­‐induced	   total	   lung	   hydroxyproline	   in	   rats	   (Counts	   et	   al.,	   1981).	  
Moreover,	   antagonising	   LOX	   and	   LOXL2	   activity	   has	   previously	   been	   shown	   to	   attenuate	  
bleomycin-­‐induced	  PF	  in	  hamsters	  (Kagan,	  2000),	  reduce	  the	  production	  of	  growth	  factors,	  and	  
attenuate	  TGFβ	  signalling	  due	  to	  reduced	  matrix	  stiffness	  (Barry-­‐Hamilton	  et	  al.,	  2010).	  Thus,	  
these	  findings	  support	  the	  concept	  that	  targeting	  the	  pathway	  involved	  in	  collagen	  crosslinking	  
(i.e.	  BMP-­‐1,	  LOX,	  and	  LOXL2)	  could	  be	  an	  attractive	  therapeutic	  angle	  for	  IPF.	  Based	  on	  these	  
findings,	   an	   allosteric	   inhibitor	   of	   LOXL2	   (GS-­‐6624,	   formerly	   known	   as	   AB0024)	   has	   been	  
developed	  and	  evaluated	  in	  a	  phase	  I	  clinical	  trial	  as	  a	  potential	  compound	  for	  the	  treatment	  
of	  IPF	  (clinicaltrials.gov	  identifier	  NCT01362231)	  and	  a	  phase	  II	  trial	  is	  scheduled.	  
My	  results	  illustrated	  that	  targeting	  BMP-­‐1	  could	  attenuate	  collagen	  synthesis	  with	  a	  profound	  
effect	   seen	   in	   non-­‐IPF	   spheroids.	   On	   the	   other	   hand,	   antagonising	   LOX	   and	   LOXL2	   activity	  
showed	   minimal	   effects.	   This	   is	   clearly	   in	   contrast	   to	   the	   published	   data	   stated	   above.	   A	  
possible	   reason	   for	   this	   could	  be	   that	   the	   fibroblasts	   in	   these	   spheroids	  do	  not	  express	  high	  
levels	  of	   LOX	  and	  LOXL2.	  This	  assumption	   is	  based	  on	   the	   fact	   that	   these	  genes	   showed	   low	  
expression	  by	  microarray	  analysis,	  confirmed	  by	  qRT-­‐PCR	  analysis	  showing	  a	  low	  level	  of	  mRNA	  
levels	   for	   LOXL2	   (see	   Appendix	   5,	   Figure	   A10).	   Another	   possible	   assumption	   could	   be	   that	  
crosslinking	  has	  no	  impact	  on	  the	  amount	  of	  collagen	  synthesised	  in	  this	  system.	  It	  is	  important	  
to	   note	   that	   HPLC	   is	   used	   primarily	   to	   measure	   hydroxyproline	   levels	   which	   correlate	   to	  
collagen	   synthesis,	   it	   does	   not	  measure	   collagen	   cross-­‐linking.	   So	   it	  may	   be	   entirely	   feasible	  
that	  the	  collagen	  within	  the	  spheroids	  is	  not	  cross-­‐linked	  at	  that	  particular	  time	  point	  (24	  hours	  
of	   spheroid	   formation).	   However,	   further	   studies	   are	   required	   to	   determine	   collagen	   cross-­‐
linking	  within	  the	  spheroids.	  	  
4.5.3.	  	   Targeting	  TGFβ 	  signalling	  pathway	  
As	   stated	  previously,	  my	  data	   illustrate	   that	   spheroids	  are	   capable	  of	   synthesising	   their	  own	  
active	   TGFβ,	   however	   collagen	   production	   appeared	   to	   be	   independent	   of	   TGFβ	   signalling.	  
Several	  compounds	  in	  the	  fibrosis	  toolbox	  targeted	  TGFβ activation	  and	  receptor	  signalling	  (i.e.	  
ALK-­‐5	   antagonist,	   TGFβ	   antagonist,	  β3	   antagonist,	   and	  dual	  β3/β5	   antagonist	   dual	   TGFβRI/II	  




antagonist)	  and	  these	  also	  showed	  similar	  results	  with	  little	  or	  no	  effect	  on	  collagen	  synthesis.	  
This	   further	   supports	   the	   notion	   that	   another	   mechanism/mediator	   may	   be	   involved	   in	  
promoting	   collagen	   production	   (see	  Section	   4.3.6),	   at	   least	   at	   this	   early	   timepoint	   following	  
spheroid	  formation.	  
Interestingly	  however,	  a	  pan	  integrin	  αv	  antagonist	  completely	  abolished	  collagen	  synthesis	  in	  
non-­‐IPF	   spheroids	   with	   little	   effect	   seen	   in	   IPF.	   This	   potentially	   suggests	   that	   in	   non-­‐IPF	  
spheroids	  blocking	  all	  αv	   integrins	   in	  fibroblast	  spheroids	  (i.e.	  αvβ3,	  αvβ5,	  and	  αvβ8)	  plays	  a	  
role	   in	   collagen	   production.	   As	   stated	   before,	   my	   data	   illustrates	   that	   β3	   and	   β8	   integrins	  
partially	   affect	   TGFβ	   activation,	   but	   have	   no	   effect	   on	   collagen	   synthesis.	   Thus,	   it	   could	   be	  
postulated	  that	  the	  effects	  seen	  through	  αv	  antagonist	  may	  be	  primarily	  due	  to	  blocking	  αvβ5	  
integrin	  which	  would	   support	   previously	   published	  data	   (Scotton	   et	   al.,	   2009).	   Therefore,	   to	  
investigate	   this	   further	   it	   is	   essential	   to	   determine	   the	   effect	   of	   β5	   integrin	   on	   collagen	  
synthesis	   (potentially	  by	  using	  a	  neutralising	  antibody).	  Another	  possible	  explanation	   for	   this	  
result	  is	  that	  in	  the	  presence	  of	  pan	  αv	  antagonist	  the	  cell-­‐matrix	  interaction	  is	  altered	  which	  
may	   lead	   to	  knock-­‐on	  effects	  on	  cell	  biosynthetic	  pathways.	  However,	   since	   this	   compounds	  
used	  in	  this	  library	  were	  at	  an	  extremely	  high	  concentration	  it	  is	  entirely	  feasible	  that	  the	  result	  
for	  integrin	  αv	  antagonist	  may	  have	  occurred	  due	  to	  toxicity.	  	  
In	   addition,	   although	   antagonising	   ALK-­‐5	   receptor	   had	   no	   effect	   on	   collagen	   production,	   an	  
ALK-­‐4/5/7	  antagonist	  attenuated	  collagen	  synthesis	  in	  IPF	  spheroids	  with	  minimal	  effect	  shown	  
in	   non-­‐IPF.	   ALK-­‐4	   (ACVR-­‐1B)	   and	   ALK-­‐7	   (ACVR-­‐1C)	   are	   also	   transmembrane	   receptor	  
serine/threonine	  kinases	  (similar	  to	  ALK-­‐5)	  which	  are	  activated	  in	  the	  presence	  of	  activin-­‐A.	  In	  
addition,	  nodal	  has	  also	  shown	  to	  be	  a	  ligand	  for	  ALK-­‐4	  and	  ALK7.	  Similar	  to	  TGFβ	  (types	  I,	   II,	  
and	  III),	  activin-­‐A	  and	  nodal	  also	  belong	  to	  the	  TGFβ	  superfamily	  which	  mediate	  the	  activation	  
of	  the	  canonical	  Smad	  pathway.	  	  
Several	   studies	   have	   implicated	   a	   role	   for	   activin	   in	   the	   pathogenesis	   of	   PF.	   For	   instance,	  
bleomycin-­‐induced	  PF	  mice	  show	  enhanced	  expression	  of	  activin	  A,	  particularly	   in	   fibroblasts	  
and	  alveolar	  macrophages	  at	  areas	  of	  fibrotic	  change	  (Matsuse	  et	  al.,	  1995;	  Aoki	  et	  al.,	  2005)	  
These	   results	   were	   subsequently	   confirmed	   in	   humans,	   with	   enhanced	   activin	   A	   expression	  
shown	   in	  patients	  with	   conditions	   associated	  with	   interstitial	   pulmonary	   fibrosis	  (Matsuse	  et	  
al.,	   1996).	   In	   addition,	   activin	   A	   induces	   lung	   fibroblast	   proliferation,	   differentiation,	   and	  
increases	  the	  ability	  of	   fibroblasts	  to	  contract	  collagen	  gels	   in	  vitro	   (Ohga	  et	  al.,	  1996,	  2000).	  
Furthermore,	  studies	  on	  other	  fibrotic	  diseases	  such	  as	  systemic	  sclerosis	  have	  demonstrated	  




an	   increase	  procollagen	  production	  and	  expression	  of	  COL1A1	  mRNA	  following	  the	  activation	  
of	  the	  activin	  A-­‐ALK4-­‐Smad-­‐dependent	  pathway,	  which	  also	  increased	  the	  expression	  of	  CTGF	  
(Takagi	   et	   al.,	   2011).	  Moreover,	   a	   recent	   study	   demonstrated	   an	   attenuation	   in	   bleomycin-­‐
induced	  PF	  (with	  reduced	  collagen	  accumulation,	  tissue	  damage,	  and	  inflammation)	  following	  
the	  administration	  of	  follistatin	  (a	  protein	  involved	  in	  sequestering	  activins	  and	  hindering	  their	  
biological	  activity)	   (Aoki	  et	  al.,	  2005).	  All	   these	  findings	  support	  a	   functional	  role	  of	  activin	   in	  
the	  pathogenesis	  of	  pulmonary	  fibrosis.	  Since	  the	  results	  in	  the	  toolbox	  illustrated	  a	  complete	  
block	  in	  collagen	  synthesis	  for	  IPF	  spheroids	  in	  the	  presence	  of	  an	  ALK-­‐4/5/7	  antagonist	  it	  can	  
be	  hypothesised	   that	   in	   this	  3D	  system	  the	  collagen	  synthesis	   is	  more	  dependent	  on	  activin-­‐
ALK4/7-­‐mediated	   Smad	   signalling	   rather	   than	   ALK5-­‐dependent	   TGFβ signalling.	   It	   also	  
highlights	  the	  potential	  of	  a	  combinatorial	  approach,	  targeting	  all	   three	  receptors	   in	  order	  to	  
attenuate	   collagen	  production	  within	   the	   IPF	   spheroids.	   In	  non-­‐IPF	   spheroids	   this	   antagonist	  
showed	  minimal	   effects	   on	   collagen	  production;	   this	   could	   be	  due	   to	   reduced	   expression	  of	  
these	   receptors,	   or	   suggests	   that	   collagen	   production	   in	   non-­‐IPF	   fibroblast	   spheroids	   is	  
dependent	   on	   a	   different	   mechanism	   (e.g.	   PDGF).	   Thus,	   further	   studies	   are	   required	   to	  
determine	   to	   expression	   of	   these	   receptors	   in	   the	   fibroblast	   spheroids	   and	   produce	  
concentration-­‐response	   curves	   of	   this	   compound	   in	   non-­‐IPF	   and	   IPF	   spheroids,	   since	  
therapeutics	  with	  differential	  effects	  in	  IPF	  vs.	  non-­‐IPF	  could	  be	  highly	  beneficial.	  
4.5.4.	  	   Targeting	  the	  eicosanoid	  pathway	  
My	   results	   have	   demonstrated	   a	   role	   for	   COX1-­‐PGE2-­‐EP2	   signalling	   in	   fibroblast	   spheroid	  
apoptosis	   and	   collagen	   synthesis	   which	   has	   already	   been	   discussed	   in	   Section	   4.3.8.	   In	  
addition,	   the	   toolbox	   also	   identified	   compounds	   which	   support	   the	   role	   of	   EP2	   receptor	  
signalling	   in	   attenuating	   collagen	   production	   in	   both	   non-­‐IPF	   and	   IPF	   spheroids.	   However,	  
there	  were	   a	   few	   contradicting	   results.	   For	   instance,	   in	   the	   toolbox	   screen,	   an	   EP2	   receptor	  
antagonist	   completely	   abolished	   the	   synthesis	   of	   collagen	   in	   non-­‐IPF	   spheroids.	   However,	  
when	   a	   full	   concentration-­‐response	   curve	   was	   subsequently	   developed	   for	   this	   compound	  
using	   fibroblasts	   from	   the	   same	  donor,	   no	   effect	   on	   collagen	  production	  was	   seen.	   This	   is	   a	  
clear	  example	  of	  a	  false	  positive	  result	  (which	  may	  have	  resulted	  due	  to	  technical	  issues	  with	  
HPLC),	   and	   supports	   the	   importance	   of	   further	   validating	   compounds	   showing	   a	   ‘hit’,	   in	  
addition	  to	  repeat	  the	  experiments	  with	  additional	  donors.	  
The	  screening	  also	  identified	  prostaglandin	  F	  receptor	  which,	  following	  inhibition,	  exaggerated	  
collagen	  production	  in	  IPF	  spheroids	  but	  had	  no	  effect	  on	  non-­‐IPF.	  This	  result	  does	  not	  support	  
previously	  published	  data	  as	  PGF2α	  has	  been	  detected	  at	  high	  levels	   in	  IPF	  patients	  (Aihara	  et	  




al.,	   2013)	   and	   FP	   receptor	   signalling	   accelerates	   bleomycin-­‐induced	   pulmonary	   fibrosis	  
(independently	  of	  TGFβ)	  (Oga	  et	  al.,	  2009).	  This	  may	  be	  a	  false	  positive	  result	  but	  does	  require	  
further	  validation.	  However,	  it	  is	  important	  to	  note	  that	  single	  cell-­‐based	  in	  vitro	  assay	  systems	  
are	   likely	   to	   show	   some	   difference	   and	   may	   have	   more	   flaws	   in	   comparison	   to	   the	   more	  
complex	  in	  vivo	  systems	  which	  are	  composed	  of	  multiple	  cells	  types	  which	  affect	  fibroblast	  cell	  
behaviour.	  Thus,	  increased	  PGF2α	  levels	  shown	  in	  IPF	  patients	  and	  bleomycin-­‐induced	  PF	  mice	  
may	  be	  as	  a	  result	  of	  other	  cell	  types	  (e.g.	  epithelial	  cells).	  	  
In	   addition,	   the	   toolbox	   also	   consisted	   of	   compounds	   targeting	   5-­‐lipoxygenase	   (5-­‐LO)	   and	  
leukotriene	  (LT)-­‐D4.	  5-­‐LO	   is	  a	  rate-­‐limiting	  enzyme	  essential	   for	   the	  synthesis	  of	   leukotriene’s	  
which	   promote	   fibroblast	   proliferation,	   chemotaxis,	   and	   collagen	   production	   (Ozaki	   et	   al.,	  
1992;	   Wilborn	   et	   al.,	   1996).	   Leukotriene-­‐deficient	   mice	   show	   protection	   from	   PF	   (Peters-­‐
Golden	  et	  al.,	  2002)	  and	  LTD4	   stimulates	  collagen	  synthesis	   in	  vitro	   following	  TGFβ-­‐mediated	  
fibroblast	   differentiation.	   Thus,	   it	   was	   expected	   that	   antagonising	   the	   leukotriene	   pathway	  
would	  attenuate	  collagen	  synthesis.	  However,	  the	  results	  from	  the	  screening	  did	  not	  support	  
this.	  In	  fact,	  antagonising	  this	  pathway	  exaggerated	  collagen	  production	  in	  non-­‐IPF	  spheroids,	  
although	   no	   effect	   was	   shown	   in	   IPF	   spheroids.	   This	   suggests	   that	   in	   this	   3D	   system,	   the	  
leukotriene	   pathway	   may	   play	   a	   protective	   role	   in	   preventing	   over	   production	   of	   collagen	  
following	  cell-­‐to-­‐cell	  contact.	  However,	  further	  work	  is	  required	  to	  investigate	  this.	  
4.5.5.	   CCL2/MCP-­‐1	  antagonist	  
MCP-­‐1	   (also	   known	  as	  CCL2)	   is	  primarily	   considered	  as	   a	  potent	   chemoattractant	   for	   T-­‐cells,	  
monocytes	  and	  natural	  killer	  cells.	  However,	  several	  studies	  have	  demonstrated	  the	  role	  of	  this	  
chemokine	  in	  direct	  activation	  of	  fibroblasts,	  resulting	  in	  ECM	  production	  via	  the	  induction	  of	  
TGFβ (Gharaee-­‐Kermani	  et	  al.,	  1996;	  Hogaboam	  et	  al.,	  1998;	  Moore	  et	  al.,	  2005b).	  In	  addition,	  
BALF	  of	  IPF	  patients	  has	  elevated	  levels	  of	  CCL2	  (Suga	  et	  al.,	  1999)	  and	  CC-­‐chemokine	  receptor	  
2	   (CCR2;	   the	   major	   receptor	   for	   CCL2)	   knockout	   mice	   are	   protected	   against	   FITC-­‐	   and	  
bleomycin-­‐induced	  pulmonary	  fibrosis	  (Moore	  et	  al.,	  2001;	  Okuma	  et	  al.,	  2004)	  which	  further	  
support	  the	  role	  of	  this	  chemokine	  in	  fibrosis.	  Recently,	  a	  randomised	  double-­‐blinded	  placebo-­‐
controlled	   phase	   II	   trial	   was	   completed,	   to	   evaluate	   the	   safety	   and	   efficacy	   of	   an	   anti-­‐CCL2	  
antibody	   in	   IPF	   patients	   (CNTO	   888;	   clinicaltrials.gov	   identifier	   NCT00786201),	   although	   the	  
results	  have	  not	  yet	  been	  reported.	  
The	   toolbox	   screening	   results	   illustrated	   that	   in	   the	   presence	   of	   a	   CCL2/MCP1	   inhibitor,	  
collagen	  synthesis	   in	   IPF	  spheroids	  was	  completely	  abolished.	  This	  same	  compound	  had	  very	  




little	  effect	  on	  non-­‐IPF	  spheroids.	  A	  possible	  reason	  for	  this	  difference	  may	  relate	  to	  the	  fact	  
that	  IPF	  fibroblasts	  express	  high	  levels	  of	  CCL2	  in	  comparison	  to	  non-­‐IPF,	  at	  least	  at	  the	  levels	  
of	  mRNA	  (see	  qRT-­‐PCR	  data	  in	  Appendix	  6).	  This	  supports	  that	  CCL2/MCP1	  may	  be	  a	  potential	  
therapeutic	  target,	  however	  further	  validation	  is	  necessary.	  
4.5.6.	   Targeting	  Smoothened	  (Smo)	  
The	   Hedgehog	   signalling	   pathway	   plays	   an	   essential	   role	   in	   embryonic	   development,	   tissue	  
patterning,	   and	   organogenesis	   (Riobo	   and	  Manning,	   2007).	   Three	   hedgehog	   homologs	   have	  
been	  identified	  in	  mammals	  of	  which	  Sonic	  Hedgehog	  (Shh)	  is	  the	  most	  broadly	  expressed	  and	  
involved	   in	   patterning	   the	   lung	   (Litingtung	   et	   al.,	   1998;	   Pepicelli	   et	   al.,	   1998).	   In	   brief,	   SHH	  
binding	   to	   its	   receptor	   (PTCH1)	   relieves	   Smo	   repression,	   and	   results	   in	   Smo-­‐dependent	  
downstream	  signalling	  events	  which	  culminate	  in	  activation	  of	  transcription	  factors	  (e.g.	  GLI).	  	  
Studies	  in	  human	  adult	  lungs	  have	  discovered	  overexpression	  of	  Shh	  in	  the	  alveolar	  epithelium	  
of	  patients	  diagnosed	  with	  IPF	  and	  other	  idiopathic	  interstitial	  pneumonias	  (Coon	  et	  al.,	  2006;	  
Fitch	  et	  al.,	  2011;	  Bolanos	  et	  al.,	  2012).	  However,	  the	  Shh	  receptor	  (PTCH1)	  and	  downstream	  
signalling	  molecules	  (i.e.	  GLI1	  and	  Smo)	  are	  expressed	  in	  mesenchymal	  cells	  in	  the	  fibrotic	  foci,	  
which	   supports	   an	   epithelial-­‐mesenchymal	   crosstalk.	   Furthermore,	   Shh	   promotes	   fibroblast	  
migration,	   proliferation	   and	   enhance	   collagen	   synthesis;	   Shh	   signalling	   is	   also	   involved	   in	  
fibroblast	   resistance	   to	   apoptosis.	   These	   findings	   suggest	   that	   targeting	   the	   Sonic	   hedgehog	  
pathway	  may	  be	  a	  promising	  therapeutic	  strategy	  for	  IPF.	  The	  results	  in	  this	  thesis	  also	  support	  
this	   as	   targeting	   Smo	   abolished	   collagen	   synthesis	   in	   IPF	   spheroids	   with	   a	   partial	   inhibition	  
shown	   in	   non-­‐IPF.	   This	   suggests	   that	   Shh	   signalling	   pathway	   is	   active	   in	   IPF	   spheroids.	  
However,	   since	   these	   fibroblast	   spheroids	   are	   not	   in	   contact	  with	   epithelial	   cells	   (which	   are	  
thought	   to	   express	   Shh)	   it	   could	   be	   suggested	   that	   the	   fibroblasts	   in	   this	   system	  may	   also	  
express	  Shh	  which	  result	  in	  an	  autocrine	  and/or	  paracrine	  activation	  of	  the	  pathway.	  However	  
further	   investigations	   for	   the	   expression	   of	   all	   the	   proteins	   involved	   in	   the	   Shh	   signalling	  
pathway	  in	  this	  spheroid	  system	  is	  required.	  
4.5.7.	   Targeting	  the	  PI3K/Akt/mTOR	  pathway	  
The	   PI3K/Akt/mTOR	   pathway	   has	   recently	   become	   of	   great	   interest	   in	   understanding	   the	  
pathogenesis	   of	   IPF.	   PI3K	   plays	   a	   key	   role	   in	   mediating	   TGFβ-­‐treated	   lung	   fibroblast	  
differentiation	  and	  proliferation	  (Conte	  et	  al.,	  2011).	   In	  addition,	  strong	   immunoreactivity	  for	  
downstream	  effectors	  of	  mTOR	   (e.g.	  p-­‐S6)	  have	  been	   illustrated	   in	   fibroblasts	  of	   the	   fibrotic	  
foci	  (Xu	  et	  al.,	  2013).	  More	  recently,	  research	  has	  proposed	  that	  Akt/mTOR	  kinases	  play	  a	  role	  




in	  the	  desensitisation	  of	   IPF	  fibroblasts	  to	  type-­‐I	  collagen	  matrix-­‐induced	  cell	  death	  (Nho	  and	  
Hergert,	  2014).	  These	  studies	  support	  PI3K/Akt/mTOR	  pathway	  as	  a	  target	  for	  modulating	  IPF	  
progression	  and	  currently	  compounds	  targeting	  this	  pathway	  are	  being	  investigated	  for	  clinical	  
application.	  	  
This	  thesis	  also	  investigated	  the	  effect	  of	  a	  similar	  compound	  (GSK-­‐X)	  on	  pHLF	  of	  non-­‐IPF	  and	  
IPF	  subjects	  using	  my	  three-­‐dimensional	  spheroid	  model.	  As	  shown	  in	  the	  results,	  prophylactic	  
treatment	   of	   this	   compound	   attenuated	   both	   spheroid	   formation	   and	   collagen	   synthesis	   of	  
non-­‐IPF	   and	   IPF	   pHLF	   (in	   a	   concentration-­‐dependent	   manner).	   Collagen	   attenuation	   was	  
detected	  at	  very	  low	  concentrations	  of	  the	  compound.	  However,	  at	  high	  concentrations	  (above	  
0.3	  μM),	  the	  fibroblasts	  were	  unable	  form	  cellular	  aggregates.	  This	  may	  have	  possibly	  resulted	  
due	   to	   toxicity.	   In	   addition,	   the	   results	   showed	   that	   the	   IC50	   differed	   from	  donor	   to	   donor,	  
most	  likely	  due	  to	  simple	  donor-­‐to-­‐donor	  variations.	  	  
The	   ability	   of	   this	   compound	   to	   have	   therapeutic	   effects	   in	   this	   spheroid	   model	   was	   also	  
investigated,	  however,	   in	   line	  with	  other	  compounds	   investigated	   (e.g.	  ALK5	   inhibitor)	  GSK-­‐X	  
showed	  no	  effect	  on	  collagen	  synthesis	  when	  given	  therapeutically.	  As	  mentioned	  previously,	  
this	  could	  be	  due	  to	  an	  inability	  of	  the	  compound	  to	  penetrate	  the	  spheroid,	  or	  a	  general	  issue	  
where	   reversal	   of	   the	   established	   collagen	   deposition	   was	   not	   amenable	   to	   modulation.	  
Nevertheless,	  the	  current	  data	  for	  this	  model	  supports	  that	  targeting	  PI3K/Akt/mTOR	  signalling	  
pathway	  may	  be	  a	  potential	  therapeutic	  agent	  to	  prevent	  the	  progression	  of	  the	  disease.	  
Furthermore,	  the	  medium	  throughput	  screening	  identified	  mTORC1/2	  as	  a	  potential	  target	  for	  
attenuating	  collagen	  production.	  However,	  PI3K	  β/δ	   inhibitor	  had	  minimal	  effect	  on	  collagen	  
production	   in	   both	   non-­‐IPF	   and	   IPF	   spheroids.	   This	   suggests	   that	   collagen	   synthesis	  may	   be	  
dependent	  of	  mTORC2-­‐mediated	  Akt	  activation	  (independent	  of	  PI3K	  activity)	  which	  supports	  
that	  mTORC2	  may	  be	  a	  potential	  therapeutic	  target.	  However	  further	  validation	  is	  necessary	  to	  
investigate	  this.	  	  
	   	  






The	  aim	  of	  this	  thesis	  was	  to	  develop	  a	  novel	  3D	   in	  vitro	  model	  system	  to	  use	  as	  an	  assay	  for	  
drug	  screening	   in	   IPF.	  The	  work	  presented	  here	   reports	   the	   finding	   that	  pHLF	  are	  capable	  of	  
spontaneously	  synthesising	  their	  own	  matrix	  (i.e.	  collagen)	  and	  high	  levels	  of	  active	  TGFβ	  when	  
cultured	  as	  spheroids,	  within	  just	  24	  hours	  of	  cell-­‐to-­‐cell	  contact.	  Furthermore,	  the	  results	  also	  
illustrated	   that	   non-­‐IPF	   pHLF	   spontaneously	   produce	   anti-­‐fibrotic	   mediators	   (i.e.	   PGE2)	   to	  
promote	  fibroblast	  apoptosis,	  by	  four	  days	  after	  spheroid	  formation	  (Figure	  4.1);	  however,	  IPF	  
spheroids	  were	  less	  prone	  to	  cell	  death.	  	  
This	   thesis	   also	   illustrated	   some	   intriguing	   findings	  which	   to	   a	   certain	   extent	   contradict	   our	  
current	  understanding	  regarding	  the	  pathogenesis	  of	  IPF:	  
• In	   2D	   in	   vitro	   models	   pHLF	   proliferate,	   however	   in	   this	   3D	   system	   the	   cells	   were	   non-­‐
proliferative	  which	  may	  have	  either	   resulted	   from	   the	   release	  of	   anti-­‐fibrotic	  mediators	  
(i.e.	  PGE2)	  or	  as	  a	  result	  of	  cell-­‐to-­‐cell	  interaction	  leading	  to	  contact	  inhibition.	  
• Reduced	   expression	   of	   both	   COX1	   and	   COX2	   have	   been	   reported	   in	   IPF	   and	   previously	  
published	   data	   have	   primarily	   focused	   on	   the	   role	   of	   COX2-­‐mediated	   PGE2	   synthesis	   in	  
fibroblast	  apoptosis	   (since	  COX2	   is	  considered	  as	  an	   inducible	  enzyme).	  However,	   in	  this	  
thesis	  PGE2	  synthesis	  was	  dependent	  primarily	  on	  the	  activity	  of	  COX1.	  	  
• Although	   several	   studies	   support	   the	   role	   of	   TGFβ	   as	   a	   potent	   cytokine	   involved	   in	  
collagen	  production,	  in	  this	  spheroid	  model	  TGFβ	  does	  not	  appear	  to	  play	  a	  dominant	  role	  
in	  the	  initiation	  of	  collagen	  production.	  	  
These	  findings	  provide	  new	  insight	  to	  the	  way	  pHLF	  behave	  following	  direct	  cell-­‐to-­‐cell	  contact	  
when	  cultured	  as	  a	  3-­‐D	  spheroid.	   It	   is	   important	  to	  note	  however	  that	   in	  vitro	  assay	  systems	  
involving	   the	   use	   of	   a	   single	   cell	   type	   are	   likely	   to	   show	   some	   phenotypical	   differences	   in	  
comparison	  to	  the	  more	  complex	   in	  vivo	  systems	  which	  are	  composed	  of	  multiple	  cells	  types	  
releasing	  several	  mediators.	  In	  fact,	  the	  addition	  of	  another	  cell	  type	  into	  the	  model	  can	  lead	  
to	  dramatic	  phenotypic	  changes.	  For	  instance,	  when	  spheroids	  were	  co-­‐cultured	  with	  epithelial	  
cells	   (see	   Section	   5.2	   for	   preliminary	   data)	   pHLF	   showed	   signs	   of	   proliferation	   and	   non-­‐IPF	  
spheroids	  were	  protected	  from	  apoptosis	  which	  suggests	  an	  epithelial-­‐mesenchymal	  crosstalk.	  
Thus,	   although	   the	   fibroblast	   spheroid	   model	   does	   provide	   some	   convincing	   and	   intriguing	  
results	  it’s	  important	  to	  appreciate	  that	  in	  a	  more	  complex	  system	  the	  results	  may	  be	  different.	  




Medium-­‐throughput	   drug	   screening	   identified	   a	   number	   of	   potential	   therapeutic	   targets	  
including	   EP2/4	   compounds,	   an	   integrin	   αv	   inhibitor,	   Smo	   antagonists,	  MCP-­‐1	   inhibitor,	   and	  
mTORC	   1/2	   inhibitors.	   However,	   since	   these	   compounds	   were	   screened	   at	   a	   relatively	   high	  
concentration,	   it	   is	   feasibly	   that	   some	   of	   the	   effects	   seen	   are	   false	   positives	   as	   a	   result	   of	  
toxicity.	  Determining	  toxic	  effects	  of	  these	  compounds	  was	  one	  of	  the	  major	  challenges	  faced	  
with	  this	  model,	  as	  all	  of	  the	  commercially	  available	  cell	  viability	  assays	  tested,	  failed	  to	  show	  
any	  meaningful	  data;	  TUNEL	  was	  not	  a	  sufficiently	  high-­‐throughput	  approach	  for	  this	  purpose.	  
Therefore,	  in	  order	  to	  fully	  appreciate	  fibroblast	  spheroids	  as	  a	  useful	  assay	  for	  drug	  screening	  
in	  IPF	  the	  optimisation	  of	  a	  spheroid-­‐compatible	  cell	  viability	  assay	  would	  be	  necessary.	   	  One	  
potential	   approach	   could	   involve	   the	  use	  of	   the	   IncuCyte	  which	   captures	   live	   content	   phase	  
contrast	   imaging	  of	  the	  spheroids.	  With	  this	  method	  any	  compounds	  that	   lead	  to	  a	  failure	   in	  
the	  formation	  of	  cell	  aggregates	  may	  possibly	  be	  considered	  as	  toxic.	  An	  additional	  challenge	  
faced	   with	   this	   3D	   model	   was	   determining	   any	   effect	   of	   compounds	   used	   after	   spheroid	  
formation	   (therapeutic	   dosing)	   –	   a	   potential	   reason	   for	   this	   could	   be	   the	   inability	   of	   the	  
compounds	   penetrating	   the	   matrix-­‐rich	   spheroids.	   However,	   further	   investigations	   are	  
necessary	  to	  determine	  this.	  
The	  major	  novelty	  of	   this	  model	   system	   is	   that	   the	   spheroids	  do	  not	   require	   the	  addition	  of	  
exogenous	   mediators	   (e.g.	   FasL	   to	   induce	   apoptosis,	   or	   TGFβ	   as	   a	   pro-­‐fibrotic	   stimulus)	   to	  
show	  the	  effects	  described,	  which	  differs	  from	  all	  other	  in	  vitro	  models	  of	  PF.	  Taken	  together,	  
these	  findings	  support	  that	  this	  3D	  system	  may	  be	  a	  more	  physiological	  model	  in	  comparison	  
to	  2D	  monolayer	  cultures,	  for	  studying	  the	  pathogenesis	  of	  IPF.	  
	  
Figure	  4.	  1:	  Schematic	  summarising	  phenotypic	  differences	  between	  non-­‐IPF	  and	  IPF	  
spheroids.	  
IPF	  spheroids	  have	  a	  myofibroblast-­‐like	  phenotype	  (increased	  expression	  of	  αSMA)	  and	  
are	   resistant	   to	   apoptosis	   in	   comparison	   to	   non-­‐IPF	   spheroids.	   Both	   non-­‐IPF	   and	   IPF	  
spheroids	  spontaneously	  synthesise	  collagen	  and	  active	  TGFβ	  with	  higher	  levels	  seen	  in	  
IPF	  spheroids.	  













CHAPTER	  5:	  FUTURE	  DIRECTIONS	  &	  	  
PRELIMINARY	  WORK	  	  
	  
	   	  




5.1.	  Furture	  work	  
This	   thesis	   has	   investigated	   several	   phenotypic	   characteristics	   of	   primary	   human	   lung	  
fibroblasts	   (pHLF)	   cultured	   as	   spheroids,	   and	   has	   provided	   convincing	   data	   to	   support	   the	  
hypothesis	  that	  fibroblast	  spheroids	  may	  be	  used	  as	  a	  useful	  assay	  for	  compound	  screening	  for	  
drugs	  targeting	  idiopathic	  pulmonary	  fibrosis	  (IPF).	  However,	  further	  studies	  are	  necessary	  to	  
address	  some	  of	  the	  questions	  arising	  from	  the	  current	  data	  (some	  of	  which	  have	  previously	  
been	  mentioned	  in	  the	  Discussion	  section).	  These	  are	  outlined	  below:	  
5.1.1.	  Investigate	  the	  expression	  levels	  of	  collagen	  type	  I	  	  and	  III	  
The	   data	   in	   this	   thesis	   demonstrated	   that	   both	   non-­‐IPF	   and	   IPF	   spheroids	   are	   capable	   of	  
synthesising	  collagen	  within	  just	  24	  hours	  of	  spheroid	  formation,	  with	  elevated	  levels	  seen	  in	  
IPF	   spheroids.	   The	   data	   also	   illustrated	   that	   transcriptionally	   there	   was	   no	   significant	  
difference	   in	   COL1A1	   and	   COL3A1	   mRNA	   levels,	   however	   immunohistochemical	   staining	  
illustrated	  a	  stronger	   immunoreactivity	   for	  both	  types	   in	   IPF	  spheroids,	  plus	  greater	   levels	  of	  
hydroxyproline	   in	   IPF	   spheroids.	   To	   further	   clarify	   these	   data,	   and	   to	   confirm	   the	   post-­‐
transcription	  regulation	  of	  collagen	  production,	  further	  experiments	  are	  required	  to	  measure	  
the	  levels	  of	  procollagen	  carboxy-­‐terminal	  pro-­‐peptides	  PICP	  and	  PIIICP,	  which	  are	  considered	  
as	  surrogate	  markers	  for	  collagen	  type	  I	  and	  type	  III	  respectively.	  
5.1.2.	  Investigate	  EP	  receptor	  expression	  
The	   data	   in	   this	   thesis	   illustrated	   that	   non-­‐IPF	   spheroids	   are	   prone	   to	   apoptosis,	   which	   is	  
dependent	  on	  the	  activity	  of	  COX1	  and	  EP2	  receptor	  signalling.	  However,	  in	  the	  presence	  of	  an	  
EP2	  agonist,	  only	  a	  partial	   increase	   in	   the	  percentage	  of	  apoptotic	   cells	   in	   IPF	   spheroids	  was	  
detected.	  This	  suggests	  that	  even	  in	  the	  presence	  of	  an	  EP2	  agonist	  the	  IPF	  spheroids	  are	  still	  
resistant	   to	   apoptosis.	   One	   possibility	   for	   this	   could	   be	   that	   the	   repertoire	   of	   EP	   receptor	  
expression	   is	   altered	   in	   IPF	   spheroids,	   at	   the	   protein	   level.	   As	   with	   COL1A1/COL3A1	   above,	  
qRT-­‐PCR	  data	  showed	  no	  statistical	  significance	  between	  non-­‐IPF	  and	  IPF	  spheroids	  in	  terms	  of	  
PTGER2	  mRNA	  levels;	  difference	  in	  the	  expression	  of	  these	  receptors	  at	  the	  translational	  level	  
(Larsson	  et	  al.,	  2008)	  should	  therefore	  be	  investigated.	  Approaches	  to	  knock	  down	  EP	  receptor	  
expression	  (using	  sienna),	  followed	  by	  assessment	  of	  spheroid	  formation	  and	  apoptosis	  would	  
also	  be	  of	  interest.	  




5.1.3.	   Determine	   the	   effect	   of	   other	   prostanoids	   on	   the	   phenotype	   of	  
fibroblast	  spheroids	  
As	  well	  as	  PGE2,	  previous	  studies	  have	  also	  demonstrated	  the	  effects	  of	  other	  prostanoids	  on	  
fibroblast	  behaviour,	  such	  as	  the	  anti-­‐fibrotic	  effects	  of	  prostacyclin	  (PGI2)	  in	  vitro	  (Stratton	  et	  
al.,	   2001;	   Kohyama	   et	   al.,	   2002a)	   and	   in	   the	   bleomycin-­‐induced	   pulmonary	   fibrosis	   mouse	  
model	   (Lovgren	   et	   al.,	   2006).	   Therefore,	   the	   effect	   of	   this	   prostanoid	   in	   fibroblast	   spheroids	  
could	   also	  be	  examined	   to	  determine	  whether	   targeting	  PGI2	   receptor	   signalling	  has	   a	  more	  
profound	  effect	  on	  IPF	  spheroid	  apoptosis	  and	  collagen	  synthesis.	  
Furthermore,	  although	  the	  COX	  expression	  in	  IPF	  patients	  is	  low,	  high	  levels	  of	  PGF2α has	  been	  detected	   in	   plasma	   and	   bronchoalveolar	   lavage	   fluid	   (BALF)	   of	   IPF	   patients	   (Aihara	   et	   al.,	  
2013).	  Based	  on	   the	   fibrosis	   toolbox	  data,	  antagonising	   the	   receptor	   for	  PGF2α (FP	   receptor)	  
resulted	  in	  an	  increase	  in	  collagen	  deposition.	  Since	  this	  result	  contrasts	  with	  published	  data,	  
further	   experiments	   on	   this	   should	   be	   performed	   including	   producing	   full-­‐dose	   response	  
curves	  of	  spheroids	  treated	  with	  the	  compound.	  
5.1.4.	  Determine	  the	  role	  of	  αvβ5	  antagonist	  on	  collagen	  synthesis	  and	  TGFβ 	  
activation	  
Spheroids	  are	  capable	  of	  synthesising	  their	  own	  active	  TGFβ,	  which	  appears	  to	  be	  at	  least	  partially	  
dependent	  on	  the	  activity	  of	  β3	  and	  β8	  integrins.	  Since	  a	  compound	  specifically	  targeting	  αvβ5	  was	  
unavailable,	  and	  given	  that	  αvβ5	  mRNA	  levels	  were	  greater	  in	  IPF	  spheroids	  in	  comparison	  to	  non-­‐
IPF,	   the	   effect	   of	   an	  αvβ5-­‐specific	   neutralising	   antibody	   could	   be	   investigated	   (in	   terms	   of	   TGFβ	  
activation).	   In	   addition,	   although	   antagonising	   β3	   and	   β8	   integrins	   had	   no	   effect	   on	   collagen	  
synthesis,	  the	  fibrosis	  toolbox	  identified	  a	  pan-­‐αv	  antagonist	  which	  completely	  abolished	  collagen	  
production	  in	  non-­‐IPF	  and	  IPF	  spheroids;	  further	  validation	  of	  this	  compound	  could	  be	  performed.	  
Taken	   together,	   these	   experiments	   would	   shed	   light	   on	   the	   role	   of	   these	   integrins	   for	   TGFβ	  
activation	  in	  a	  3D	  microenvironment.	  	  
5.1.5.	   Investigate	   the	   effect	   of	   other	   pro-­‐fibrotic	   mediators	   on	   collagen	  
synthesis	  
The	   results	   further	   illustrated	   that	   in	   the	   presence	   of	   a	   potent	   ALK5	   antagonist	   (i.e.	   SB-­‐
525334A),	   collagen	   synthesis	  was	   not	   attenuated	   -­‐	  which	   suggests	   that	   another	  mediator	   is	  
involved	   in	  driving	   the	   initial	   synthesis	   of	   collagen	  within	   these	   spheroids.	   Possibilities	   could	  
include	   platelet-­‐derived	   growth	   factor	   (PDGF),	   epidermal	   growth	   factor	   (EGF),	   and	   insulin	  




growth	  factor	  (IGF)-­‐1,	  all	  of	  which	  have	  previously	  been	  reported	  to	  be	  involved	  in	  promoting	  
myofibroblast	   proliferation,	   chemotaxis,	   cell	   adhesion,	   cell	   survival,	   and	   collagen	   production	  
(Boström	  et	  al.,	  1996;	  Bonner,	  2004;	  Hetzel	  et	  al.,	  2005;	  Hung	  et	  al.,	  2013b).	  An	  investigation	  of	  
expression	   levels	   (mRNA	   and	   protein)	   and	   antagonism	   of	   these	   potentially	   key	   mediators	  
would	  be	  extremely	  interesting.	  
5.1.6.	  Validate	  microarray	  data	  analysis	  
Microarray	  data	  analysis	  identified	  several	  differentially-­‐expressed	  genes	  between	  non-­‐IPF	  and	  
IPF	   spheroids,	   particularly	   those	   involved	   in	   metabolic	   pathways	   and	   those	   involved	   in	   the	  
response	   to	   influenza	   (i.e.	   major	   pro-­‐inflammatory	   mediators,	   such	   as	   IL-­‐1β).	   These	   genes	  
require	   further	  validation	  by	  performing	  qRT-­‐PCR	  and	  western	  blotting.	  Furthermore,	  studies	  
are	  now	  beginning	  to	  realise	  that	  differences	  in	  mRNA	  abundance	  often	  poorly	  correlate	  with	  
protein	   levels	   (Anderson	  and	  Seilhamer,	   1997;	  Gygi	   et	   al.,	   1999;	   Larsson	  et	   al.,	   2008)	  –	   as	   is	  
also	   suggested	   by	   the	   COL1A1/COL3A1	   data	   presented	   in	   this	   thesis.	   Therefore,	   another	  
potential	  future	  study	  could	  involve	  performing	  microarray	  on	  ribosome-­‐bound	  RNA	  samples,	  
which	  is	  a	  method	  previously	  described	  as	  a	  more	  useful	  approach	  to	  understand	  translational	  
regulation	  of	  genes	  (Larsson	  et	  al.,	  2008).	  
In	   addition,	   there	   are	   a	   number	   of	   publically-­‐available	   microarray	   datasets	   which	   have	  
transcriptionally-­‐profiled	   either	   IPF/control	   lung	   tissue,	   or	   cells	   derived	   from	   IPF	   tissue	  
(including	  fibroblasts).	  Alongside	  data	  from	  our	  laboratory,	  which	  is	  currently	  investigating	  the	  
transcriptional	  profile	  of	   IPF	  and	  non-­‐IPF	  fibroblasts	  grown	   in	  monolayer	  culture,	   it	  would	  be	  
highly	  informative	  to	  investigate	  the	  potential	  overlap	  (or	  enrichment)	  of	  genes	  in	  the	  spheroid	  
array	   data,	  with	   these	   other	  microarray	   datasets.	   This	  would	   also	   help	   clarify	  whether	   gene	  
signatures	  present	  in	  the	  IPF	  spheroids	  are	  relevant	  to	  the	  actual	  disease	  process.	  
5.1.7.	   Further	  validation	  of	   some	  key	   compounds	   in	   the	   fibrosis	   toolbox	  and	  
development	  of	  a	  high-­‐throughout	  cell	  viability	  assay	  
The	   fibrosis	   toolbox	   identified	   a	   number	   of	   potential	   targets	   which	   attenuated	   collagen	  
synthesis.	  Such	  compounds	  include	  ALK4/5/7	  receptor	  antagonist,	  MCP1	  receptor	  antagonist,	  
Smoothelin	   (Smo)	   inhibitor,	   and	   mTORC	   1/2	   antagonist.	   In	   addition,	   the	   screening	   also	  
identified	   targets	   which	   exaggerated	   collagen	   production	   including,	   glucocorticosteroid	  
receptor	   (GR)	   antagonist,	   vitamin	   K	   antagonist,	   and	  MMP2	   inhibitor.	   These	   compounds	   also	  
require	  further	  validation.	  




Since	   the	   spheroids	  were	   treated	  with	   the	   compounds	  at	  a	   relatively	  high	   concentration	   (10	  
µM),	  it	  is	  feasible	  that	  some	  of	  the	  effects	  shown	  could	  be	  due	  to	  toxicity.	  Therefore	  it	  is	  also	  
vital	  to	  investigate	  the	  toxicity	  of	  these	  compounds,	  if	  this	  assay	  is	  going	  to	  be	  useful	  for	  pre-­‐
clinical	  compound	  screening.	  The	  TUNEL	  assay	  is	  not	  a	  sufficiently	  high-­‐throughput	  method	  for	  
this,	  so	  another	  cell	  viability	  assay	  is	  necessary.	  Two	  such	  cell	  viability	  assays	  have	  already	  been	  
assessed	  in	  this	  spheroid	  model,	  with	  minimal	  success.	  These	  were	  the	  Alamar	  Blue	  assay	  and	  
the	  acid	  phosphatase	   (APH)	   assay.	  Alamar	  Blue	   is	   a	  blue	  dye	   composed	  of	   resazurin	   (a	  non-­‐
toxic	   cell	   permeable	   compound)	  which	   is	   reduced	   to	   resorufin	   in	   living	   cells.	   This	   reduction	  
reaction	  can	  then	  be	  quantified	  by	  measuring	  the	  fluorescence.	  This	  assay	  has	  previously	  been	  
used	   in	   cancer	   spheroids	   showing	   positive	   results	   (Cheng	   et	   al.,	   2012).	   However	   in	   this	  
fibroblast	  spheroid	  system,	  the	  assay	  failed	  to	  work.	  A	  possible	  reason	  could	  be	  that	  although	  
resazurin	   is	   cell	   permeable,	   it	   may	   not	   be	   able	   to	   penetrate	   through	   the	   matrix-­‐rich	  
environment	  in	  the	  spheroid.	  The	  APH	  assay	  is	  based	  on	  quantifying	  acid	  phosphatase	  activity	  
in	  the	  cell	  cytosol.	  Viable	  cells	  are	  capable	  of	  hydrolysing	  p-­‐nitro	  phenyl	  phosphate	  (pNPP)	  to	  
p-­‐nitrophenol	   and	   its	   absorption	   (at	   405	   nm)	   is	   directly	   proportional	   to	   the	   cell	   number.	  
Previous	  studies	  have	  demonstrated	  that	  this	  assay	   is	  a	  useful	  cell	  viability	  tool	  for	  spheroids	  
(Friedrich	  et	  al.,	  2007).	  However,	  once	  again	  in	  this	  3D	  system	  the	  APH	  assay	  showed	  no	  effect	  
possibly	  due	  to	  the	  same	  reason	  as	  the	  Alamar	  Blue	  assay	  (i.e.	  an	  inability	  of	  pNPP	  penetrating	  
the	  spheroids).	  Therefore,	  a	  more	  reliable	  spheroid	  cell	  viability	  assay	  is	  required	  to	  investigate	  
compound	  toxicity.	  
5.1.8.	   Investigate	   the	   ability	   of	   	   compounds	   to	   penetrate	   spheroids	   for	  
therapeutic	  treatment	  
Current	   data	   involving	   the	   treatment	   of	   spheroids	   with	   antagonists	   and	   agonists	   mainly	  
illustrated	  effects	   shown	  after	  prophylactic	   treatment	  of	   the	  compound.	  However,	  when	   the	  
spheroids	  were	  treated	  24	  hours	  after	  spheroid	  formation,	  no	  such	  effects	  were	  evident.	  This	  
raises	  the	  question	  of	  whether	  the	  compounds	  can	  even	  penetrate	  the	  matrix-­‐rich	  spheroids.	  
Therefore,	  in	  order	  to	  determine	  therapeutic	  targets	  it	  is	  vital	  to	  investigate	  this.	  One	  approach	  
could	   involve	  using	   a	   fluorescent	   label	   tagged	   to	   a	   compound,	  which	   can	  be	  easily	   detected	  
under	  the	  fluorescence	  microscope	  to	  determine	  the	  extent	  of	  diffusion	  into	  the	  spheroid,	  or	  
using	  a	  dye	  such	  as	  Evans	  Blue,	  which	  readily	  associates	  with	  proteins	  and	  again	  can	  be	  easily	  
detected/analysed	  under	  the	  microscope.	  




5.1.9.	  Investigate	  the	  stiffness	  of	  spheroids	  
Mechanical	   cues	   inherent	   to	   stiff	   growth	   substrates	   are	   just	   as	   essential	   as	   chemical	  
compositions	   in	   affecting	   cellular	   behaviour	   (such	   as	   growth,	   differentiation,	   and	   apoptosis)	  
(Tomasek	  et	  al.,	  2002;	  Hinz	  and	  Gabbiani,	  2003a,	  2003b;	  Georges	  and	  Janmey,	  2005;	  Engler	  et	  
al.,	   2006;	   Janmey	  et	  al.,	  2009).	   Studies	  have	   shown	   that	   the	  elastic	  modulus	   in	  most	  normal	  
tissues	  ranges	  from	  0.5-­‐15	  kPa,	  whereas	   in	  a	  fibrotic	  tissue	  the	  stiffness	  can	  be	  10-­‐100	  times	  
greater	  (Discher	  et	  al.,	  2005;	  Georges	  and	  Janmey,	  2005;	  Hinz,	  2010;	  Balestrini	  et	  al.,	  2012).	  In	  
addition,	   several	   studies	   have	   reported	   that	   fibroblasts	   show	   distinct	   functional	   behaviours,	  
dependant	  on	  substrate	  stiffness	   (Goffin	  et	  al.,	  2006;	  Hinz,	  2006).	  Furthermore,	   reducing	  the	  
substrate	  stiffness	  diminishes	  stress	  fibre	  tension	  and	  results	  in	  the	  removal	  of	  αSMA	  from	  the	  
stress	   fibres	   (Goffin	   et	   al.,	   2006).	  	   Since	   IPF	   spheroids	   have	   a	  myofibroblast	   phenotype	   and	  
produce	  high	   levels	  of	  collagen	   in	  comparison	  to	  non-­‐IPF	   it	  could	  be	  hypothesised	  that	  these	  
spheroids	   are	   stiffer	   in	   comparison	   to	   non-­‐IPF.	   It	   would	   be	   highly	   informative	   to	   use	   an	  
approach	  such	  as	  atomic	  force	  microscopy	  to	  investigate	  the	  elastic	  modulus	  (stiffness)	  of	  non-­‐
IPF	  and	  IPF	  spheroids.	  	  
5.1.10.	  The	  feasibility	  of	  co-­‐culturing	  fibroblast	  spheroids	  with	  epithelial	  cells	  
to	  determine	  epithelial-­‐mesenchymal	  crosstalk	  
As	  mentioned	   previously,	   the	  main	   aim	   of	  my	   project	   was	   to	  mimic	   fibrotic	   foci,	   which	   are	  
aggregates	   of	  myofibroblasts	   underlying	   hyperplastic	   epithelial	   cells.	   This	   thesis	   has	   focused	  
solely	  on	  fibroblasts	  cultured	  as	  3D	  spheroids.	  Therefore,	  the	  next	  aim	  of	  this	  project	  would	  be	  
to	   investigate	   whether	   these	   fibroblast	   spheroids	   behave	   differently	   when	   co-­‐cultured	   with	  
epithelial	  cells,	  and	  to	  determine	  the	  epithelial-­‐mesenchymal	  crosstalk.	  The	  next	  section	  in	  this	  
thesis	  will	   illustrate	  some	  preliminary	  results	  of	  non-­‐IPF	  fibroblast	  spheroids	  co-­‐cultured	  with	  
epithelial	   cells	   (in	   submerged	   culture	   and	   at	   air-­‐liquid	   interface),	   and	   this	   should	   be	   further	  
investigated	  to	  improve	  the	  physiological	  relevance	  of	  this	  in	  vitro	  assay	  system.	  
	  
	  




5.2.	  Preliminary	  work:	  Spheroid	  co-­‐culture	  –	  submerged	  
Current	   data	   in	   this	   thesis	   show	   that	   non-­‐IPF	   fibroblast	   spheroids	   are	   more	   apoptotic	   in	  
comparison	   to	   IPF,	  which	   supports	  previously	  published	  studies.	  However,	   to	  date	   it	  has	  not	  
been	   demonstrated	   whether	   co-­‐culture	   of	   epithelial	   cells	   with	   fibroblast	   spheroids	   has	   any	  
effect	  on	  the	  viability	  of	  the	  fibroblasts	   in	  this	  3D	  system,	  or	  vice	  versa.	  Therefore,	  as	  well	  as	  
determining	  the	  feasibility	  of	  co-­‐culturing	  fibroblast	  spheroids	  with	  epithelial	  cells,	  preliminary	  
work	  was	   performed	   to	   address	   this	   issue.	   The	   epithelial	   cells	   line	   used	  were	  A549	   alveolar	  
epithelial	  cells	  and	  primary	  human	  bronchiolar	  epithelial	  cells	  (HBECs).	  A549	  cells	  are	  derived	  
from	  a	   human	   lung	   adenocarcinoma,	   but	   are	   commonly	   used	  by	  many	   researchers	   to	   study	  
ATII	  cell	  function,	  as	  well	  as	  to	  study	  apoptosis,	  adhesion,	  and	  cell	  cycle	  mechanisms	  in	  cancer	  
cells	  (Smith,	  1977).	  
Non-­‐IPF	   (n=1)	   and	   IPF	   (n=1)	   fibroblasts	   were	   cultured	   for	   spheroid	   formation	   for	   24	   hours.	  
Following	   this,	   the	   spheroids	  were	   then	   co-­‐cultured	  with	   5000	   epithelial	   cells	   (A549	   cells	   or	  
HBECs,	   in	   separate	   experiments),	   added	   directly	   to	   the	  well	   containing	   a	   spheroid.	   After	   an	  
additional	   three	   days	   of	   incubation,	   the	   spheroids	  were	   fixed	  with	   4	  %	   PFA	   for	   20	  minutes,	  
processed,	  and	  then	  embedded	   into	  paraffin	  wax.	  Figures	  5.1,	  5.2,	  5.3,	  and	  5.4	  demonstrate	  
that	  in	  the	  presence	  of	  A549s	  or	  HBECs,	  a	  small	  population	  of	  fibroblasts	  within	  the	  spheroids	  
(both	  non-­‐IPF	  and	  IPF)	  were	  positive	  for	  the	  proliferation	  marker	  Ki-­‐67.	  In	  addition,	  Figure	  5.5	  
illustrates	  that	  upon	  co-­‐culturing	  fibroblast	  spheroids	  with	  epithelial	  cells	  (A549s	  or	  HBECs)	  in	  
submerged	   culture,	   non-­‐IPF	   fibroblast	   survival	   is	   supported	   –	   bringing	   the	   rate	   of	   apoptosis	  
down	  to	  the	  level	  seen	  in	  fibrotic	  spheroids.	  Epithelial	  cells	  did	  not	  however	  further	  decrease	  
the	   percentage	   of	   TUNEL	   positive	   cells	   within	   IPF	   spheroids.	   This	   supports	   the	   notion	   that	  
there	   may	   be	   dysregulated	   epithelial-­‐mesenchymal	   crosstalk	   in	   IPF	   patients,	   as	   fibrotic	  
fibroblasts	  seem	  to	  promote	  their	  own	  survival	  and	  therefore	  do	  not	  require	  additional	  factors	  
from	  the	  epithelium,	  in	  contrast	  to	  normal	  spheroids.	  However,	  fibroblasts	  within	  both	  non-­‐IPF	  
and	  IPF	  spheroids	  did	  show	  signs	  of	  proliferation	  in	  the	  presence	  of	  epithelial	  cells.	  Such	  results	  
contrast	  with	  previous	  studies,	  which	  show	  the	  role	  of	  epithelial	  cells	  in	  fibroblast	  apoptosis	  in	  
2D	  culture	  (Lama	  et	  al.,	  2002).	  
Unlike	  most	   cells	  within	   the	   human	   body,	   AECs	   express	   both	   COX1	   and	   COX2	   constitutively	  
(Lama	  et	  al.,	  2002;	  Bozyk	  and	  Moore,	  2011).	  In	  addition,	  previous	  studies	  have	  demonstrated	  
that	  monolayer	   co-­‐culture	   systems	   involving	  both	  AECs	  and	   control	   lung	   fibroblasts	   result	   in	  




fibroblast	   cell	   death,	   a	   decrease	   in	   cell	   proliferation,	   and	   a	   decrease	   in	   collagen	   production	  
(Lama	  et	  al.,	  2002).	  This	  occurs	  downstream	  of	  PGE2	  receptor	  signalling	  (i.e.	  Gαi-­‐coupled	  EP2	  
receptors)	   (Kolodsick	   et	   al.,	   2003;	   Huang	   et	   al.,	   2007,	   2008b).	   However,	   this	   has	   only	   been	  
demonstrated	   in	   2D	   cultures	   and	   as	   mentioned	   above,	   the	   results	   in	   this	   thesis	   provide	  
contrasting	   observations	   of	   increased	   fibroblast	   proliferation	   and	   reduced	   apoptosis	   in	   the	  
presence	  of	  epithelial	  cells.	  	  
A	  possible	  explanation	  is	  that	  if	  the	  epithelial	  cells	  increase	  PGE2	  production,	  then	  PGE2	  could	  
signal	  via	  the	  activation	  of	  other	  PGE2	  receptors	  (i.e.	  EP1	  and	  EP3),	  both	  of	  which	  are	  expressed	  
by	  fibroblasts,	  in	  addition	  to	  EP2.	  EP1	  and	  EP3	  can	  play	  a	  key	  role	  in	  fibroblast	  cell	  survival	  and	  
proliferation	   in	  patients	  with	   acute	   lung	   injury.	   Furthermore,	   it	   has	  been	   suggested	   that	   the	  
activation	   of	   these	   receptors	   occurs	   when	   the	   PGE2	   concentration	   falls	   within	   a	   particular	  
range	   (10-­‐9	   to	   10-­‐7	   M)	   (Bozyk	   and	  Moore,	   2011).	   Thus,	   it	   could	   be	   hypothesised	   that	   in	   3D	  
cultures,	   epithelial	   cells	   inhibit	   apoptosis	   and	   promote	   proliferation	   via	   increased	   PGE2	  
production	   and	   hence	   the	   activation	   of	   additional	   PGE2	   receptors.	   However,	   further	  work	   is	  
required	  to	  investigate	  this	  hypothesis	  and	  understand	  the	  crosstalk	  between	  the	  two	  cells	  in	  
greater	  detail.	  	  
Another	  possible	  reason	  why	  fibroblasts	  in	  3D	  structures	  respond	  differently	  in	  comparison	  to	  
2D	   monolayer	   cultures	   may	   be	   due	   to	   the	   difference	   in	   matrix	   stiffness.	   Culturing	   cells	   on	  
tissue	   culture	   treated	   plastic	   has	   limitations	   for	   understanding	   fibroblast	   cell	   biology,	   as	   the	  
stiffness	   of	   the	   plastic	   is	   approximately	   20,000	   times	   greater	   in	   comparison	   to	   that	  
experienced	  by	  cells	  within	  a	  normal	  lung	  (~2	  kPa),	  1000	  times	  greater	  than	  fibrotic	  lung	  (~40	  
kPa),	   and	   8	   times	   greater	   than	   bone	   (5000	   kPa).	   Thus,	   such	   differences	   in	   results	  may	   have	  
resulted	  due	   to	   the	  difference	   in	   culture	   systems.	  The	   spheroid	  model	  does	   recapitulate	   the	  
proliferation	  feature	  of	   fibroblasts	   in	   fibrotic	   foci.	  Many	  studies	   including	  recent	  unpublished	  
data	   by	  Dr.	   Paul	  Mercer	   (UCL)	   have	   illustrated	   that	   in	   a	   fibrotic	   focus	   a	   small	   population	   of	  
mesenchymal	   cells	   are	   proliferative	   (positive	   for	   Ki-­‐67	   by	   immunohistochemistry),	   lending	  
support	  that	  this	  3D	  spheroid	  model	  may	  be	  a	  useful	  model	  that	  mimics	  a	  fibrotic	  focus.	   	  







































	   	  
A)	  Fibroblast	  spheroid	  
B)	  Fibroblast	  spheroid	  +	  A549	  
Ki-­‐67	   Ki-­‐67	  with	  DAPI	  
Ki-­‐67	   Ki-­‐67	  with	  DAPI	  
Cytokeratin	   Cytokeratin	  with	  DAPI	  
Figure	   5.	   1.	   Proliferation	   of	   non-­‐IPF	   fibroblasts	   within	   the	   3	   dimensional	   spheroid	  
structures	  with	  and	  without	  A549.	  	  
(A)	   Immunofluorescence	   staining	   for	   Ki-­‐67	   (orange)	   with	   DAPI	   (blue)	   as	   the	   nuclear	  
counterstain	   on	   paraffin	   sections	   of	   non-­‐IPF	   fibroblast	   spheroids	   (four	   days	   post	  
spheroid	   formation)	   did	   not	   highlight	   any	   Ki-­‐67+	   cells	   in	   the	   spheroid	   culture	   alone.	  	  
Magnification	   x200.	   (B)	   Spheroids	   co-­‐cultured	   with	   A549s	   (5,000	   epithelial	   cells	   per	  
spheroid)	   had	   a	   positive	   signal	   for	   Ki-­‐67	   (orange	   staining)	   within	   both	   the	   epithelial	  
cytokeratin+	   (green	  staining)	  compartment	   (identified	  on	  serial	   section),	  as	  well	  as	   in	  
fibroblasts	  within	  the	  spheroid.	  Magnification	  x200.	  	  






























A)	  Fibroblast	  spheroid	  
B)	  Fibroblast	  spheroid	  +	  A549	  
Ki-­‐67	   Ki-­‐67	  with	  DAPI	  
Ki-­‐67	   Ki-­‐67	  with	  DAPI	  
Cytokeratin	   Cytokeratin	  with	  DAPI	  
Figure	   5.	   2.	   Proliferation	   of	   IPF	   fibroblasts	   within	   the	   3	   dimensional	   spheroid	  
structures	  with	  and	  without	  A549.	  	  
(A)	   Immunofluorescence	   staining	   for	   Ki-­‐67	   (orange)	   with	   DAPI	   (blue)	   as	   the	   nuclear	  
counterstain	  on	  paraffin	   sections	  of	   IPF	   fibroblast	   spheroids	   (four	  days	  post	   spheroid	  
formation)	   did	   not	   highlight	   any	   Ki-­‐67+	   cells	   in	   the	   spheroid	   culture	   alone.	  	  
Magnification	   x200.	   (B)	   Spheroids	   co-­‐cultured	   with	   A549s	   (5,000	   epithelial	   cells	   per	  
spheroid)	   had	   a	   positive	   signal	   for	   Ki-­‐67	   (orange	   staining)	   within	   both	   the	   epithelial	  
cytokeratin+	   (green	  staining)	  compartment	   (identified	  on	  serial	   section),	  as	  well	  as	   in	  
fibroblasts	  within	  the	  spheroid.	  Magnification	  x200.	  	  


























	   	  
A)	  Fibroblast	  spheroid	  
Ki-­‐67	   Ki-­‐67	  with	  DAPI	  
B)	  Fibroblast	  spheroid	  +	  A549	  
Ki-­‐67	   Cytokeratin	  
Ki-­‐67	  +	  Cytokeratin	  +	  DAPI	  	   Figure	   5.	   3.	   Proliferation	   of	   non-­‐IPF	  
fibroblasts	   within	   the	   3	   dimensional	  
spheroid	   structures	   with	   and	   without	  
HBECs.	  
(A)	  Immunofluorescence	  staining	  for	  Ki-­‐67	  
(orange)	   with	   DAPI	   (blue)	   as	   the	   nuclear	  
counterstain	   on	   paraffin	   sections	   of	   non-­‐
IPF	   fibroblast	   spheroids	   (four	   days	   post	  
spheroid	   formation)	   did	   not	   highlight	   any	  
Ki-­‐67+	   cells	   in	   the	   spheroid	   culture	   alone.	  	  
Magnification	   x200.	   (B)	   Spheroids	   co-­‐
cultured	  with	  HBECs	   (5,000	  epithelial	  cells	  
per	   spheroid)	   had	   a	  positive	   signal	   for	   Ki-­‐
67	   (orange	   staining)	   within	   both	   the	  
epithelial	   cytokeratin+	   (green	   staining)	  
compartment	  (identified	  on	  serial	  section),	  
as	   well	   as	   in	   fibroblasts	   within	   the	  
spheroid.	  Magnification	  x200.	  	  






























A)	  Fibroblast	  spheroid	  
Ki-­‐67	   Ki-­‐67	  with	  DAPI	  
B)	  Fibroblast	  spheroid	  +	  A549	  
Ki-­‐67	   Cytokeratin	  
Ki-­‐67	  +	  Cytokeratin	  +	  DAPI	  	   Figure	  5.	  4.	  Proliferation	  of	  IPF	  fibroblasts	  
within	   the	   3	   dimensional	   spheroid	  
structures	  with	  and	  without	  HBECs.	  
(A)	  Immunofluorescence	  staining	  for	  Ki-­‐67	  
(orange)	   with	   DAPI	   (blue)	   as	   the	   nuclear	  
counterstain	   on	   paraffin	   sections	   of	   IPF	  
fibroblast	   spheroids	   (four	   days	   post	  
spheroid	   formation)	   did	   not	   highlight	   any	  
Ki-­‐67+	   cells	   in	   the	   spheroid	   culture	   alone.	  	  
Magnification	   x200.	   (B)	   Spheroids	   co-­‐
cultured	  with	  HBECs	   (5,000	  epithelial	  cells	  
per	   spheroid)	   had	   a	  positive	   signal	   for	   Ki-­‐
67	   (orange	   staining)	   within	   both	   the	  
epithelial	   cytokeratin+	   (green	   staining)	  
compartment	  (identified	  on	  serial	  section),	  
as	   well	   as	   in	   fibroblasts	   within	   the	  
spheroid.	  Magnification	  x200.	  	  
	  




















































Non-­‐IPF	   IPF	  
Figure	  5.	  5.	  Percentage	  of	  TUNEL	  positive	  cells	  in	  non-­‐IPF	  and	  IPF	  spheroids	  with	  and	  
without	  epithelial	  cell	  co-­‐culture.	  
(A)	   TUNEL	   staining	   of	   paraffin	   embedded	   spheroid	   sections	   four	   days	   post	   spheroid	  
formation.	  Green	  indicates	  cell	  death;	  blue	  is	  DAPI.	  Magnification	  x100.	  Percentage	  of	  
TUNEL	   positive	   cells	   were	   quantified	   in	   spheroids	   co-­‐cultured	   with	   (B)	   A549	   and	   (C)	  





















B)	  	   C)	  	  




5.3.	  Spheroid	  co-­‐culture:	  air-­‐liquid	  interface	  
So	  far	   I	  have	  only	  demonstrated	  the	  effect	  of	  epithelial	  cells	   in	  submerged	  culture.	  To	  better	  
understand	  epithelial-­‐mesenchymal	  crosstalk,	  it	  would	  be	  beneficial	  to	  grow	  epithelial	  cells	  in	  
an	   environment	  which	  more	   closely	   resembles	   the	   normal	   physiological	   situation	  within	   the	  
human	  lung,	  namely	  by	  developing	  a	  model	  in	  which	  the	  epithelial	  cells	  are	  grown	  at	  air-­‐liquid	  
interface	  (ALI).	  
Many	   researchers	   use	   transwells	   to	   grow	  monolayer	   epithelial	   cells	   at	   ALI	   (Lee	   et	   al.,	   2005,	  
2008).	  Thus,	   in	  this	  pilot	  project	  a	  similar	  concept	  was	  applied,	  to	  establish	  a	  model	   in	  which	  
the	   epithelial	   cells	   (at	   air-­‐liquid	   interface)	   coat	   the	   fibroblast	   spheroids.	   Spheroids	   were	  
generated	   as	  previously	   described,	   and	   following	  24	  hours	   incubation	   they	  were	   transferred	  
into	  transwell	  inserts	  containing	  different	  types	  of	  membranes	  (Table	  5.1;	  20	  spheroids	  per	  12	  
well	  insert	  and	  10	  spheroids	  per	  24	  well	  insert).	  Spheroids	  were	  then	  incubated	  for	  another	  24	  
hours	   (10	  %	  CO2,	  37	  oC)	  before	  the	  addition	  of	  epithelial	  cells	   (A549s),	  5x105	  per	  24-­‐well	  and	  
1x106	  cells	  per	  12-­‐well	   insert.	  The	  aim	  then	  was	   to	  allow	  the	  A549s	   to	   reach	  confluence	  and	  
form	   tight	   junctions	   before	   removing	   the	   medium	   from	   the	   upper	   insert	   to	   establish	   ALI	  
(Figure	  5.6).	  
	  





Collagen	  coated	  PTFE	  (equimolar	  
mixture	  types	  I	  and	  III	  collagen)	  
12	  well	   0.4	   VWR	  
Matrigel	  coated	   12	  well	   0.4	   BD	  Bioscience	  









Table	  5.1	  Types	  of	  transwells	  












Figure	   5.7	   illustrates	   the	   appearance	   of	   non-­‐IPF	   spheroids	   cultured	   on	   the	   following	  
membranes:	  polyester,	  collagen-­‐coated,	  and	  matrigel-­‐coated.	  Most	  of	  the	  spheroids	  cultured	  
on	   polyester	   alone	   did	   not	   adhere	   firmly,	   thus	   it	   was	   difficult	   to	   establish	   a	   coating	   of	   co-­‐
cultured	  epithelial	  cells	  (Figure	  5.7A).	  Spheroids	  did	  adhere	  to	  the	  matrigel	  coated	  membrane,	  
however	   within	   24	   hours	   of	   incubation	   the	   spheroids	   degraded	   the	   surrounding	   matrigel	  
(Figure	  5.7B),	  creating	  a	  halo.	  This	  may	  have	  resulted	  from	  significant	  matrix	  metalloproteinase	  
production,	  in	  particular	  MMP2	  (which	  plays	  a	  key	  role	  in	  degrading	  collagen;	  see	  Appendix	  4).	  	  
Figure	   5.7C	   shows	   an	   H&E	   stained	   section	   of	   non-­‐IPF	   spheroids	   co-­‐cultured	   with	   A549s	   on	  
collagen-­‐coated	   transwells.	   As	   shown	   in	   the	   figure,	   the	   spheroids	   firmly	   adhered	   to	   the	  
collagen	  within	  24	  hours,	  in	  comparison	  to	  polyester	  or	  matrigel-­‐coated	  membranes.	  After	  24	  
hours,	   5x105	   A549	   cells	   were	   cultured	   on	   top,	   which	   required	   a	   switch	   from	   their	   routine	  
culture	  in	  F12K/10	  %	  FBS	  at	  37	  oC	  with	  5	  %	  CO2	  into	  DMEM/10	  %	  FBS	  at	  37	  oC	  with	  10	  %	  CO2.	  
The	   cells	   were	   incubated	   for	   6	   days	   to	   reach	   confluence;	   however	   the	   morphology	   of	   the	  
epithelial	   cells	   changed	   (Figure	   5.8)	   and	   they	   also	   failed	   to	   reach	   full	   confluence	   (remaining	  
~50	  %	  confluent),	  so	  ALI	  was	  not	  established.	   It	   is	   important	  to	  note	  that	  5x105	  A549s	  would	  
normally	  be	   sufficient	   for	  an	  epithelial	  monolayer	  ALI	   culture.	  Growth	  of	   the	  A549	  cells	  may	  
have	  been	  impaired	  by	  culture	  in	  DMEM/10	  %	  FBS	  at	  37	  oC	  with	  10	  %	  CO2,	  and	  this	  is	  an	  issue	  
that	   would	   require	   further	   optimisation.	   In	   addition,	   continuing	   this	   work	   using	   primary	  
epithelial	  cells	  (i.e.	  HBECs	  and	  primary	  human	  type	  II	  AECs)	  in	  co-­‐culture	  with	  both	  non-­‐IPF	  and	  
IPF	  spheroids	  would	  be	  highly	  informative.	  	  	  
	   	  
Figure	  5.	  6.	  Schematic	  of	  3D	  spheroid	  model	  at	  ALI.	  	  
Spheroids	   were	   formed	   by	   seeding	   100,000	   fibroblasts	   per	   well	   in	   a	   96-­‐well	   plate	   pre-­‐
coated	  with	  agarose,	  and	  then	  incubating	  for	  24	  hours.	  The	  spheroids	  were	  then	  transferred	  
into	   the	   top	   insert	   of	   a	   transwell.	   After	   24	   hours,	   the	   spheroids	   were	   co-­‐cultured	   with	  
epithelial	  cells.	  Once	  confluence	  was	  reached,	  the	  medium	  from	  the	  top	  insert	  was	  removed	  
to	  establish	  air-­‐liquid	  interface.	  











Figure	  5.	  7.	  Fibroblast	  spheroid	  and	  epithelial	  cell	  co-­‐culture	  system	  in	  transwells.	  
Non-­‐IPF	  spheroids	  were	  formed	  and	  transferred	  into	  transwells	  (polyester,	  matrigel,	  or	  
collagen	  coated).	  A549	  cells	  were	  cultured	  on	  top	  of	  the	  spheroids.	  (A)	  H&E	  staining	  of	  
spheroids	   +	   A549s	   co-­‐cultured	   on	   polyester	   transwells.	   (B)	   Microscopic	   view	   of	  
spheroid	  only,	  cultured	  on	  matrigel-­‐coated	  transwells.	  Arrow	  represents	  the	  margin	  of	  
matrigel	  degradation	  surrounding	  a	  spheroid.	  (C)	  H&E	  stained	  sections	  of	  spheroids	  +	  
A549s	  co-­‐cultured	  on	  collagen-­‐coated	  transwell.	  Scale	  bar,	  100	  μm.	  













5.4.	  Future	  directions	  for	  the	  spheroid	  co-­‐culture	  model	  
	  
	  
In	  these	  preliminary	  studies	  it	  was	  demonstrated	  that	  epithelial	  cells	  appear	  able	  to	  promote	  
fibroblast	   cell	   survival	   and	   proliferation	   within	   the	   spheroids.	   However,	   the	   results	   were	  
obtained	   using	   cells	   from	   only	   one	   patient.	   Therefore,	   the	   future	   work	   would	   involve	  
reproducing	  and	  validating	  these	  results	  using	  more	  non-­‐IPF	  and	  IPF	  fibroblasts	  from	  multiple	  
donors	   in	   co-­‐culture	  with,	  wherever	   possible,	   epithelial	   cells	   derived	   from	   the	   same	   patient	  
(feasible	  for	  HBECs,	  but	  not	  primary	  ATII	  cells).	  
Furthermore,	   previous	   studies	   involving	   2D	  monolayers	   have	   illustrated	   that	   AECs	   from	   IPF	  
patients	  are	  susceptible	  to	  Fas-­‐ligand	  induced	  apoptosis	  (Maher	  et	  al.,	  2010).	  However,	  in	  the	  
preliminary	   work	   above,	   the	   effect	   fibroblasts	   have	   on	   the	   survival	   of	   AECs	   was	   not	  
interrogated;	  thus	  the	  next	  aim	  would	  be	  to	  determine	  whether	  fibroblast	  spheroids	  promote	  
the	   apoptosis	   or	   survival	   of	   AECs.	   In	   addition,	   it	   has	   not	   been	   demonstrated	  whether	   AECs	  
promote	   fibroblast	   spheroid	   survival	   by	   direct	   cell-­‐to-­‐cell	   contact	   or	   via	   a	   soluble	  mediator.	  
Therefore,	  this	  will	  also	  need	  further	  investigation.	  
A	  number	  of	  technical	  challenges	  remain	  regarding	  the	  co-­‐culture	  of	  spheroids	  and	  epithelial	  
cells,	  particularly	  at	  air-­‐liquid	   interface.	   Further	  work	  would	  optimise	   the	   timing	  of	  epithelial	  
A)	   B)	  
Figure	  5.	  8.	  Morphology	  of	  A549s	  on	  collagen	  coated	  membrane.	  	  
A)	  A549	  cells	  cultured	  without	  spheroids	  (control).	  B)	  A549	  cells	  co-­‐cultured	  with	  non-­‐IPF	  
spheroids.	  A549	  cells	  were	  incubated	  for	  six	  days	  in	  DMEM	  +	  10	  %	  FBS	  at	  37	  oC	  with	  10	  %	  
CO2.	  Cells	  appear	  more	  elongated.	  Magnification	  x10	  




cell	  addition	  and	  culture	  conditions,	  and	  subsequent	  transfer	  to	  ALI,	  as	  well	  as	  post-­‐processing	  
for	  analysis	  (including	  fixation	  protocols,	  sectioning	  and	  suchlike).	  	  
Microarray	  data	  analysis	  could	  also	  be	  performed	  to	  determine	  transcriptional	  changes	  of	  the	  
fibroblast	   spheroids	   when	   co-­‐cultured	   with	   epithelial	   cells,	   which	   could	   potentially	   provide	  
vital	  information	  in	  understanding	  key	  pathways	  involved	  in	  epithelial-­‐mesenchymal	  crosstalk,	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1	   45.77	   9.7	  
2	   25.45	   9	  
3	   37.95	   9.2	  
4	   13.84	   9.3	  
5	   20.55	   not	  calc'd	  
6	   22.98	   9	  
7	   15.64	   9	  
8	   20.87	   8.7	  
9	   13.25	   8.9	  
10	   16.84	   9.1	  
11	   11.98	   8.7	  
12	   16.77	   8.6	  
13	   10.46	   9.4	  
14	   16.16	   9.2	  
15	   11.61	   9.2	  
16	   16.07	   9.3	  
17	   14.99	   9.1	  
18	   16.42	   8.5	  
19	   10.11	   9.3	  
20	   19.2	   8.6	  
LB	   4.85	   1.1	  
HT29	   7.91	   9.7	  
	  





























Figure	  A.	  1.	  RNA	  yields	  and	  quality	  control	  	  
	  
RNA	   was	   extracted	   from	   non-­‐IPF	   (n=10)	   and	   IPF	   (n=10)	   spheroids	   using	   RNase	  
aqueous	  kit.	  (A)	  Bioanalyzer	  and	  Nanodrop	  were	  used	  to	  determine	  the	  RNA	  integrity	  
and	  RNA	  concentration,	  respectively.	  (B)	  RNA	  quality	  was	  also	  determined	  by	  running	  
the	  samples	  on	  agarose	  gels.	   (C)	  Samples	  5	  and	  8	  were	   re-­‐run	  on	   the	  agarose	  gel	  at	  
different	   dilutions.	   Lysis	   buffer	   (LB)	   and	   HT29	   were	   used	   as	   negative	   and	   positive	  
controls,	  respectively.	  	  	  	  
	  
A)	   B)	  
C)	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Figure	  A.	  2.	  Poly	  A	  cDNA	  quality	  control	  on	  agarose	  gel	  and	  bioanalyser.	  
A)	   Poly	   A	   cDNA	   samples	   run	   on	   agarose.	   Lysis	   buffer	   (LB)	   and	   HT29	   were	   used	   as	  
controls.	  ES	  =	  empty	  space.	  Sample	  8	  is	  highlighted	  in	  red	  as	  this	  donor	  was	  removed	  
from	   the	   rest	   of	   the	   microarray	   analysis.	   B)	   Bioanalyser	   electrograms	   for	   non-­‐IPF	  
(n=10)	  and	  IPF	  (n=10)	  	  poly	  A	  cDNA	  samples.	  Each	  donor	  is	  labelled	  1-­‐20	  (blue).	  Other	  
than	  sample	  8	  all	  other	  samples	  showed	  good	  quality	  for	  poly	  A	  cDNA.	   	  




















	   	  
17	   	   	   	  	  	  	  	  	  	  	  	  18	   	   	  	  	  	  	  	  	   	  	  	  	  	  19	  
20	   	   	   	  	  	  	  	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  C	  
14	   	   	   	  	  	  	  	  	  	  	  	  15	   	   	  	  	  	  	  	  	   	  	  	  	  	  16	  
11	   	   	   	  	  	  	  	  	  	  	  	  12	   	   	  	  	  	  	  	  	   	  	  	  	  	  13	  
1	   	   	   	  	  	  	  	  	  	  	  	  2	   	   	  	  	  	  	  	  	   	  	  	  	  	  	   	  	  	  	  	  	  3	  
4	   	   	   	  	  	  	  	  	  	  	  	  5	   	   	  	  	  	  	  	  	   	  	  	  	  	  	   	  	  	  	  	  	  6	  
7	   	   	   	  	  	  	  	  	  	  	  	  8	   	   	  	  	  	  	  	  	   	  	  	  	  	  	   	  	  	  	  	  	  9	  
	  10	   	   	   	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	   	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  C	  
Figure	  A.	  3.	  Labelled	  sample	  quality	  control	  on	  bioanalyser	  
	  
Bioanalyser	   electrograms	   for	   non-­‐IPF	   (n=10)	   and	   IPF	   (n=10)	   cRNA	   samples	   following	  
labelling.	   Each	   donor	   is	   labelled	   1-­‐20	   (blue).	   Other	   samples	   showed	   good	   cRNA	  
labelling	  which	  is	  represented	  by	  the	  peak	  shown	  at	  35.	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Figure	  A.	  4.	  Fragmented	  cRNA	  sample	  quality	  control	  on	  bioanalyser	  
Bioanalyser	   electrograms	   for	   non-­‐IPF	   (n=10)	   and	   IPF	   (n=10)	   fragmented	   cRNA	  
samples.	   Each	   donor	   is	   labelled	   1-­‐20	   (blue).	   The	   first	   peak	   (between	   20-­‐25)	   is	   the	  
marker.	   The	   second	  peak	   represent	   the	  quality	   of	   fragmented	   cRNA.	   The	   lower	   the	  
peak	   the	   less	   fragmented	   cRNA	   is	   present.	   In	   general	   all	   samples	   are	   fine	   for	  
hybridisation.	  	  
	  




APPENDIX	  2:	  Microarray	  data	  analysis	  
Table	  A1	  illustrates	  the	  list	  of	  differentially	  expressed	  genes	  following	  microarray	  data	  analysis	  
of	   non-­‐IPF	   and	   IPF	   spheroids	  with	   the	   following	   criteria:	   FDR	  p<0.05,	   fold	   change	   >2	   or	   <-­‐2.	  
Figure	   A5	   illustrates	   protein-­‐protein	   interactions	   of	   the	   seven	   differentially	   expressed	   genes	  
identified	  in	  the	  microarray	  data	  analysis	  belonging	  to	  metabolic	  pathways.	  
	  
Table	  A1:	  Differentially	  expressed	  genes	  following	  microarray	  data	  analysis	  of	  non-­‐IPF	  and	  IPF	  
spheroids	  (FDR	  p<0.05,	  FC	  >2	  or	  <-­‐2)	  




PRR14L	   1558097_at	   proline	  rich	  14-­‐like	   1.35E-­‐06	   2.13452	   Control	  up	  
vs.	  IPF	  
CTSB	   227961_at	   cathepsin	  B	   2.19E-­‐06	   4.35692	   Control	  up	  
vs.	  IPF	  
PTGER3	   213933_at	   prostaglandin	   E	  
receptor	   3	   (subtype	  
EP3)	  
3.60E-­‐06	   -­‐6.97695	   Control	  
down	  vs.	  
IPF	  
ZNF618	   226592_at	   zinc	   finger	   protein	  
618	  
8.55E-­‐06	   2.30699	   Control	  up	  
vs.	  IPF	  
NUDT12	   1562775_at	   nudix	   (nucleoside	  
diphosphate	   linked	  
moiety	  X)-­‐type	  motif	  
12	  





233130_at	   THRB	   intronic	  
transcript	   1	   (non-­‐
protein	   coding)	   ///	  
NULL	  





neuroguidin,	   EIF4E	  
binding	  protein	  





sperm	   associated	  
antigen	  17	  
1.76E-­‐05	   2.34199	   Control	  up	  
vs.	  IPF	  
SULT1C2	   205343_at	   sulfotransferase	  
family,	  cytosolic,	  1C,	  
member	  2	  
2.38E-­‐05	   -­‐2.48374	   Control	  
down	  vs.	  
IPF	  
CS	   208660_at	   citrate	  synthase	   3.06E-­‐05	   2.14768	   Control	  up	  
vs.	  IPF	  
TMEM232	   1568698_at	   transmembrane	  
protein	  232	  
3.12E-­‐05	   -­‐5.62409	   Control	  
down	  vs.	  
IPF	  
ABCB4	   1570505_at	   ATP-­‐binding	  
cassette,	   sub-­‐family	  
B	   (MDR/TAP),	  
member	  4	  







4.03E-­‐05	   2.21755	   Control	  up	  
vs.	  IPF	  
B3GAT2	   239144_at	   beta-­‐1,3-­‐ 4.20E-­‐05	   -­‐7.14623	   Control	  










SCN11A	   210853_at	   sodium	   channel,	  
voltage-­‐gated,	   type	  
XI,	  alpha	  subunit	  
4.22E-­‐05	   -­‐7.98132	   Control	  
down	  vs.	  
IPF	  
XDH	   241994_at	   xanthine	  
dehydrogenase	  








242912_at	   POTE	   ankyrin	  
domain	   family,	  
member	  G	   ///	   POTE	  
ankyrin	   domain	  
family,	  member	  M	  





forkhead	  box	  P1	   5.14E-­‐05	   2.29153	   Control	  up	  
vs.	  IPF	  
C9orf38	   208077_at	   chromosome	  9	  open	  
reading	  frame	  38	  





claudin	  23	   5.82E-­‐05	   -­‐6.87981	   Control	  
down	  vs.	  
IPF	  
ELF4	   31845_at	   E74-­‐like	  factor	  4	  (ets	  
domain	  
transcription	  factor)	  
6.18E-­‐05	   2.40782	   Control	  up	  
vs.	  IPF	  
ADAMDEC1	   206134_at	   ADAM-­‐like,	   decysin	  
1	  
7.23E-­‐05	   -­‐4.44309	   Control	  
down	  vs.	  
IPF	  
GSE1	   212056_at	   Gse1	   coiled-­‐coil	  
protein	  
7.44E-­‐05	   2.0933	   Control	  up	  
vs.	  IPF	  
GLTP	   219267_at	   glycolipid	   transfer	  
protein	  






component	   1,	   s	  
subcomponent	  




chemokine	   (C-­‐C	  
motif)	  ligand	  7	  
8.19E-­‐05	   2.20444	   Control	  up	  
vs.	  IPF	  
CCDC102B	   220301_at	   coiled-­‐coil	   domain	  
containing	  102B	  
8.60E-­‐05	   -­‐2.43441	   Control	  
down	  vs.	  
IPF	  
CHST11	   226368_at	   carbohydrate	  
(chondroitin	   4)	  
sulfotransferase	  11	  





211998_at	   H3	   histone,	   family	  
3A	   /	   H3	   histone,	  
family	   3B	   (H3.3B)	   /	  
microRNA	  4738	  




solute	   carrier	   family	  
16,	   member	   14	  
(monocarboxylic	  
acid	  transporter	  14)	  
0.0001033
14	  
-­‐6.60546	   Control	  
down	  vs.	  
IPF	  




PRKDC	   208694_at	   protein	  kinase,	  DNA-­‐








anoctamin	  4	   0.0001081
34	  





enhancer	   of	   zeste	  











calmodulin	   1	  
(phosphorylase	  
kinase,	   delta)	   /	  





2.33678	   Control	  up	  
vs.	  IPF	  
ARHGEF7	   235412_at	   Rho	   guanine	  
nucleotide	  exchange	  
factor	  (GEF)	  7	  
0.0001423
26	  





myosin	  X	   0.0001426
38	  
2.09371	   Control	  up	  
vs.	  IPF	  




-­‐2.52926	   Control	  
down	  vs.	  
IPF	  
ARHGAP22	   206298_at	   Rho	   GTPase	  
activating	  protein	  22	  
0.0001454
12	  
2.55764	   Control	  up	  
vs.	  IPF	  
MTHFR	   239035_at	   methylenetetrahydr
















SCAN	   domain	  










A	   kinase	   (PRKA)	  
interacting	  protein	  1	  
///	   NUAK	   family,	  
SNF1-­‐like	  kinase,	  2	  
0.0001757
56	  
















3.46477	   Control	  up	  
vs.	  IPF	  
ANKFN1	   1559640_at	   ankyrin-­‐repeat	   and	  
fibronectin	   type	   III	  
domain	  containing	  1	  
0.0001987
11	  





anoctamin	  4	   0.0002115
07	  










2.13772	   Control	  up	  
vs.	  IPF	  






3.18582	   Control	  up	  
vs.	  IPF	  




SLC26A3	   215657_at	   solute	   carrier	   family	  
26,	  member	  3	  
0.0002261
69	  
-­‐4.28905	   Control	  
down	  vs.	  
IPF	  
APCDD1L-­‐AS1	   1559433_at	   APCDD1L	   antisense	  













-­‐2.34506	   Control	  
down	  vs.	  
IPF	  
P4HA1	   243335_at	   prolyl	   4-­‐




-­‐2.34549	   Control	  
down	  vs.	  
IPF	  




2.1688	   Control	  up	  
vs.	  IPF	  
CELF5	   230497_at	   CUGBP,	   Elav-­‐like	  
family	  member	  5	  
0.0002996
44	  
-­‐7.50241	   Control	  
down	  vs.	  
IPF	  




2.1787	   Control	  up	  
vs.	  IPF	  





-­‐3.21016	   Control	  
down	  vs.	  
IPF	  
SCGB2A2	   206378_at	   secretoglobin,	  




-­‐2.37632	   Control	  
down	  vs.	  
IPF	  












2.4936	   Control	  up	  
vs.	  IPF	  
TFAP2C	   205286_at	   transcription	   factor	  
AP-­‐2	   gamma	  
(activating	   enhancer	  




-­‐2.5387	   Control	  
down	  vs.	  
IPF	  
SLC40A1	   223044_at	   solute	   carrier	   family	  





-­‐3.18587	   Control	  
down	  vs.	  
IPF	  
IKZF2	   231929_at	   IKAROS	   family	   zinc	  
finger	  2	  (Helios)	  
0.0003622
99	  
2.78964	   Control	  up	  
vs.	  IPF	  




2.935	   Control	  up	  
vs.	  IPF	  
MCHR1	   230498_at	   melanin-­‐
concentrating	  
hormone	  receptor	  1	  
0.0003709
54	  




ras-­‐related	   C3	  
botulinum	   toxin	  
substrate	   1	   (rho	  
family,	   small	   GTP	  




2.37692	   Control	  up	  
vs.	  IPF	  




2.02342	   Control	  up	  
vs.	  IPF	  
HEATR2	   218460_at	   HEAT	   repeat	   0.0004038 2.27094	   Control	  up	  




containing	  2	   3	   vs.	  IPF	  
IL13RA2	   206172_at	   interleukin	   13	  
receptor,	  alpha	  2	  
0.0004061
64	  









2.02139	   Control	  up	  
vs.	  IPF	  
TOLLIP-­‐AS1	   1555865_at	   TOLLIP	   antisense	  










centromere	   protein	  
A	   ///	   solute	   carrier	  








synuclein,	   alpha	  
(non	   A4	   component	  














2.21428	   Control	  up	  
vs.	  IPF	  
SPTLC2	   225095_at	   serine	  
palmitoyltransferase




2.2132	   Control	  up	  
vs.	  IPF	  
LSM14A	   212131_at	   LSM14A,	   SCD6	  




2.23246	   Control	  up	  
vs.	  IPF	  
	   	  

















in	  list,	  in	  
pathway	  
Phototransduction	   7.33932	   0.000649491	   10.3448	   3	  
Pertussis	   6.88058	   0.00102755	   5.26316	   4	  
Phosphatidylinositol	  
signalling	  system	  
6.64204	   0.00130437	   4.93827	   4	  
Mineral	  absorption	   5.80381	   0.00301604	   6.12245	   3	  
Alcoholism	   5.77681	   0.00309859	   2.95858	   5	  
Oocyte	  meiosis	   5.52153	   0.00399972	   3.63636	   4	  
Neurotrophin	  signalling	  
pathway	  
5.21143	   0.00545389	   3.33333	   4	  
Glioma	   5.00623	   0.00669607	   4.61538	   3	  
Long-­‐term	  potentiation	   4.9221	   0.00728382	   4.47761	   3	  
Amphetamine	  addiction	   4.88108	   0.00758884	   4.41176	   3	  
Gastric	  acid	  secretion	   4.6483	   0.00957784	   4.05405	   3	  
Salivary	  secretion	   4.1489	   0.0157817	   3.37079	   3	  
Alzheimer’s	  disease	   4.09479	   0.0166593	   2.40964	   4	  
GnRH	  signalling	  
pathway	  
4.08964	   0.0167453	   3.2967	   3	  
Circadian	  entrainment	   3.94781	   0.0192969	   3.125	   3	  
Tuberculosis	   3.86399	   0.0209842	   2.24719	   4	  
Melanogenesis	   3.84037	   0.0214857	   3	   3	  
Estrogen	  signalling	  
pathway	  
3.84037	   0.0214857	   3	   3	  
Calcium	  signalling	  
pathway	  
3.80927	   0.0221643	   2.20994	   4	  
Drug	  metabolism	  –	  
other	  enzymes	  
3.61095	   0.0270261	   4.65116	   2	  
Caffeine	  metabolism	   3.51989	   0.0296026	   20	   1	  
Vascular	  smooth	  muscle	  
contraction	  
3.39087	   0.0336794	   2.52101	   3	  
Olfactory	  transduction	   3.36961	   0.0344031	   2.5	   3	  
Rap1	  signaling	  pathway	   3.30307	   0.0367701	   1.88679	   4	  
Systemic	  lupus	  
erythematosus	  
3.28664	   0.0373792	   2.41935	   3	  
Dopaminergic	  synapse	   3.16805	   0.0420855	   2.30769	   3	  
Ras	  signalling	  pathway	   3.13192	   0.0436339	   1.78571	   4	  
Metabolic	  pathways	   0.583509	   0.557937	   0.603448	   7	  
	   	  





Table	  A	  3:	  	  Pathway	  enrichment	  analysis	  (Non-­‐IPF	  vs.	  IPF:	  unadjusted	  p<0.01,	  FC	  >2	  or	  <-­‐2)	  
	  




%	  genes	  in	  
pathway	  that	  
are	  present	  
No.	  of	  genes	  
in	  list,	  in	  
pathway	  
Influenza	  A	   7.21705	   0.000733964	   6.85714	   12	  
Amphetamine	  
addiction	  
6.95352	   0.000955263	   10.2941	   7	  
Circadian	  entrainment	   6.38428	   0.00168788	   8.33333	   8	  
Dopaminergic	  synapse	   5.74976	   0.00318355	   6.92308	   9	  
Phototransduction	   5.45483	   0.00427559	   13.7931	   4	  
GnRH	  signaling	  
pathway	  
5.27537	   0.00511607	   7.69231	   7	  
Vascular	  smooth	  
muscle	  contraction	  
5.05489	   0.00637807	   6.72269	   8	  
Gastric	  acid	  secretion	   4.92094	   0.00729225	   8.10811	   6	  
Pertussis	   4.79315	   0.00828633	   7.89474	   6	  
Estrogen	  signaling	  
pathway	  
4.76635	   0.00851141	   7	   7	  
Phosphatidylinositol	  
signaling	  system	  
4.49249	   0.0111927	   7.40741	   6	  
Ras	  signaling	  pathway	   4.19253	   0.015108	   4.91071	   11	  
Glutamatergic	  
synapse	  
4.09024	   0.0167353	   6.14035	   7	  
Salivary	  secretion	   4.06062	   0.0172384	   6.74157	   6	  
GABAergic	  synapse	   4.06062	   0.0172384	   6.74157	   6	  
Drug	  metabolism	  -­‐	  
other	  enzymes	  
4.05765	   0.0172896	   9.30233	   4	  
Glioma	   4.05677	   0.0173049	   7.69231	   5	  
Fc	  gamma	  R-­‐mediated	  
phagocytosis	  
4.01042	   0.0181258	   6.66667	   6	  
Long-­‐term	  
potentiation	  
3.93719	   0.0195029	   7.46269	   5	  
Morphine	  addiction	   3.91233	   0.0199938	   6.52174	   6	  
Adrenergic	  signaling	  in	  
cardiomyocytes	  
3.78757	   0.0226506	   5.36913	   8	  
Herpes	  simplex	  
infection	  
3.65515	   0.0258576	   4.94505	   9	  
Mineral	  absorption	   3.62375	   0.0266823	   8.16327	   4	  
Melanogenesis	   3.54838	   0.0287712	   6	   6	  
Chemokine	  signaling	  
pathway	  
3.53276	   0.0292242	   4.83871	   9	  
Steroid	  hormone	  
biosynthesis	  
3.31165	   0.0364561	   7.40741	   4	  
Measles	   3.31076	   0.0364884	   5.22388	   7	  
Serotonergic	  synapse	   3.14895	   0.0428971	   5.45455	   6	  
Alcoholism	   3.14121	   0.0432305	   4.73373	   8	  
Glycosphingolipid	  
biosynthesis	  -­‐	  ganglio	  
series	  
3.06899	   0.0464681	   13.3333	   2	  
	  
	  

















	   	  
Figure	  A.	  5.	   Protein-­‐protein	   interactions	  of	   the	  seven	  differentially	  expressed	  genes	  
identified	  in	  the	  microarray	  data	  analysis	  belonging	  to	  metabolic	  pathways	  
Each	   circle	   represents	   an	   individual	   protein	   (not	   differentially	   expressed	   following	  
microarray	   data	   analysis).	   The	   genes	   highlighted	   in	   red	   were	   the	   differentially	  
expressed	  genes	  in	  non-­‐IPF	  and	  IPF	  spheroids	  (fold	  change	  <2	  or	  >-­‐2	  with	  FDR	  p<0.05)	  
all	  of	  which	  belong	  to	  metabolic	  pathways.	  Grey	  lines	  indicate	  co-­‐expression;	  blue	  lines	  
indicate	  protein	  binding.	  	  




APPENDIX	  3:	  Fibrosis	  toolbox	  	  
Figure	  A.6	   illustrates	   compounds	  within	   the	   fibrosis	   toolbox	   targeting	  multiple	  kinases.	  A	  hit	  
was	  considered	  if	  the	  compound	  (at	  10µM)	  resulted	  in	  >50	  %	  change	  in	  collagen	  synthesis	  24	  
hours	  post	  seeding.	  Due	  to	  confidentiality	  the	  precise	  mechanism	  of	  action	  for	  each	  compound	  
is	  unknown.	  Figure	  A.7	   illustrates	  other	  compounds	   in	  the	  fibrosis	  toolbox	  used	  for	  medium-­‐







	   	  
Figure	  A.	  6.	  Effect	  of	  multiple	  kinase	  inhibitors	  on	  collagen	  synthesis	  in	  spheroids.	  	  
Non-­‐IPF	   (green;	   n=1)	   and	   IPF	   (red;	   n=1)	   spheroids	  were	  prophylactically	   treated	  with	  
anti-­‐fibrotic	   compounds	   (10	  µM).	   Spheroids	  were	   collected	   24	   hours	   post-­‐treatment	  
and	  hydrolysed	  in	  6	  M	  HCl	  for	  HPLC.	  	  








Figure	  A.	  7.	  Effect	  of	  potential	  therapeutic	  targets	  on	  collagen	  synthesis	  in	  spheroids.	  	  
Non-­‐IPF	   (green;	   n=1)	   and	   IPF	   (red;	   n=1)	   spheroids	   were	   prophylactically	   treated	   with	   anti-­‐
fibrotic	  compounds	  (10	  µM).	  Spheroids	  were	  collected	  24	  hours	  post-­‐treatment	  and	  hydrolysed	  
in	  6	  M	  HCl	  for	  HPLC.	  	  
































































































































Figure	  A.	  8.	  MMP1,	  MMP2,	  and	  MMP7	  mRNA	  levels.	  	  
	  
Spheroids	   were	   collected	   24-­‐96	   hours	   post	   seeding.	   RNA	   was	   extracted	   from	   the	  
spheroids	   for	   qRT-­‐PCR	   to	   analyse	   the	   mRNA	   levels	   of	   (A)	  MMP1,	   (B)	  MMP2,	   and	   (C)	  
MMP7.	  All	  data	  points	  were	  normalised	  to	  three	  housekeeping	  genes	  based	  on	  GeNorm	  
analysis	  (EIF4A2,	  TOP1,	  and	  UBC).	  Control	  (n=4)	  and	  IPF	  spheroids	  (n=5)	  are	  represented	  
as	  green	  circles	  and	  red	  triangles,	  respectively.	  *p<0.05,	  *p<0.01	  




	  	  	  	  	  	  

















































Figure	  A.	  9.	  MMP2	  levels	  secreted	  into	  the	  conditioned	  media	  of	  spheroids	  
	  
Zymograms	  illustrating	  levels	  of	  MMP2	  present	  in	  the	  supernatants	  of	  (A)	  non-­‐IPF	  and	  
(B)	   IPF	   spheroids,	   which	  were	   collected	   24-­‐96	   hours	   post-­‐seeding.	   Arrow	   illustrates	  
MMP2	  standard	  control.	  (C)	  Average	  MMP2	  levels	  relative	  to	  MMP2	  standard	  control.	  
Non-­‐IPF	   (n=4)	   and	   IPF	   spheroids	   (n=4)	   are	   represented	   as	   green	   circles	   and	   red	  
triangles,	  respectively.	  **	  p<0.01,	  ***p<0.001	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Figure	  A.	  10.	  LOXL2	  qRT-­‐PCR	  data	  for	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
Spheroids	  were	   collected	   24	   hours	   and	   96	   hours	   post	   seeding.	   RNA	  was	   extracted	  
from	  the	  spheroids	  using	  Trizol	  for	  qRT-­‐PCR	  to	  analyse	  the	  mRNA	  levels	  of	  LOXL2.	  All	  
data	  points	  were	  normalised	  to	  three	  housekeeping	  genes	  based	  on	  GeNorm	  analysis	  
(CYC1,	   TOP1,	   and	  UBC).	   Control	  and	   IPF	   spheroids	   are	   represented	   as	   green	   circles	  
and	  red	  triangles,	  respectively.	  (Control,	  n=4;	  IPF,	  n=5).	  *p	  <0.05	  
	  
























































Figure	  A.	  11.	  CCL2	  qRT-­‐PCR	  data	  for	  non-­‐IPF	  and	  IPF	  spheroids.	  	  
Spheroids	  were	   collected	   24	   hours	   and	   96	   hours	   post	   seeding.	   RNA	  was	   extracted	  
from	  the	  spheroids	  using	  Trizol	  for	  qRT-­‐PCR	  to	  analyse	  the	  mRNA	  levels	  of	  CCL2.	  All	  
data	  points	  were	  normalised	  to	  three	  housekeeping	  genes	  based	  on	  GeNorm	  analysis	  
(CYC1,	  TOP1,	  and	  UBC).	  Non-­‐IPF	   and	   IPF	  spheroids	  are	   represented	   as	  green	   circles	  
and	  red	  triangles,	  respectively.	  (Control,	  n=4;	  IPF,	  n=5).	  *p	  <0.05	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